{"b7a3a68738d74df7f16721228803c0c8d6e0811d": [["F eline coronaviruses (FCoVs) are enveloped viruses with a large, capped and polyadenylated RNA genome of about 29, 190 nucleotides.", [["nucleotides", "CHEMICAL", 120, 131], ["F eline coronaviruses", "ORGANISM", 0, 21], ["FCoVs", "GENE_OR_GENE_PRODUCT", 23, 28], ["capped and polyadenylated RNA genome", "RNA", 66, 102], ["F eline coronaviruses", "SPECIES", 0, 21], ["enveloped viruses", "PROBLEM", 34, 51], ["a large, capped and polyadenylated RNA genome", "PROBLEM", 57, 102], ["coronaviruses", "OBSERVATION", 8, 21], ["enveloped", "OBSERVATION_MODIFIER", 34, 43], ["viruses", "OBSERVATION", 44, 51], ["large", "OBSERVATION_MODIFIER", 59, 64], ["polyadenylated RNA genome", "OBSERVATION", 77, 102]]], ["1, 2 The FCoVs are group 1 coronaviruses, recently designated as members of subgroup 1a in the family Coronaviridae.", [["FCoVs", "GENE_OR_GENE_PRODUCT", 9, 14]]], ["Other members of this subgroup include transmissible gastroenteritis virus, canine coronavirus, raccoon dog coronavirus (RDCoV/GZ43/03), and Chinese ferret badger coronavirus (CFBCoV/ DM95/03).", [["transmissible gastroenteritis", "DISEASE", 39, 68], ["canine coronavirus", "DISEASE", 76, 94], ["raccoon dog coronavirus", "DISEASE", 96, 119], ["ferret badger coronavirus", "DISEASE", 149, 174], ["transmissible gastroenteritis virus", "ORGANISM", 39, 74], ["canine coronavirus", "ORGANISM", 76, 94], ["raccoon dog coronavirus", "ORGANISM", 96, 119], ["GZ43/03", "ORGANISM", 127, 134], ["ferret badger coronavirus", "ORGANISM", 149, 174], ["transmissible gastroenteritis virus", "SPECIES", 39, 74], ["canine coronavirus", "SPECIES", 76, 94], ["raccoon dog coronavirus", "SPECIES", 96, 119], ["ferret badger coronavirus", "SPECIES", 149, 174], ["transmissible gastroenteritis virus", "SPECIES", 39, 74], ["canine coronavirus", "SPECIES", 76, 94], ["raccoon dog coronavirus (RDCoV/GZ43/03", "SPECIES", 96, 134], ["Chinese ferret badger coronavirus (CFBCoV/ DM95/03", "SPECIES", 141, 191], ["transmissible gastroenteritis virus", "PROBLEM", 39, 74], ["canine coronavirus", "PROBLEM", 76, 94], ["raccoon dog coronavirus", "TEST", 96, 119]]], ["3 The FCoVs associated with mild enteric infections and infectious peritonitis.", [["enteric infections", "DISEASE", 33, 51], ["peritonitis", "DISEASE", 67, 78], ["The FCoVs", "PROBLEM", 2, 11], ["mild enteric infections", "PROBLEM", 28, 51], ["infectious peritonitis", "PROBLEM", 56, 78], ["mild", "OBSERVATION_MODIFIER", 28, 32], ["enteric", "OBSERVATION_MODIFIER", 33, 40], ["infections", "OBSERVATION", 41, 51], ["infectious", "OBSERVATION_MODIFIER", 56, 66], ["peritonitis", "OBSERVATION", 67, 78]]], ["4 Infection of FCoVs is worldwide; the seroprevalence varies from around 30%, 5e7 to 80%.", [["FCoVs", "DISEASE", 15, 20], ["FCoVs", "CANCER", 15, 20], ["Infection", "OBSERVATION", 2, 11], ["worldwide", "OBSERVATION_MODIFIER", 24, 33]]], ["8, 9 However, among the seropositive cats only a relatively small portion, eg, 5%, 8 11 .8% 10 and 15.4%, 6 develop FIP.", [["FIP", "DISEASE", 116, 119], ["cats", "ORGANISM", 37, 41], ["cats", "SPECIES", 37, 41], ["relatively", "OBSERVATION_MODIFIER", 49, 59], ["small", "OBSERVATION_MODIFIER", 60, 65], ["portion", "OBSERVATION_MODIFIER", 66, 73], ["FIP", "OBSERVATION", 116, 119]]], ["Currently, it is speculated that the key pathogenic feature of FCoV to induce FIP is its ability to replicate to high viral loads in monocytes and macrophages.", [["monocytes", "ANATOMY", 133, 142], ["macrophages", "ANATOMY", 147, 158], ["FCoV", "CHEMICAL", 63, 67], ["FIP", "DISEASE", 78, 81], ["FCoV", "GENE_OR_GENE_PRODUCT", 63, 67], ["monocytes", "CELL", 133, 142], ["macrophages", "CELL", 147, 158], ["monocytes", "CELL_TYPE", 133, 142], ["macrophages", "CELL_TYPE", 147, 158], ["FCoV", "PROBLEM", 63, 67], ["FIP", "PROBLEM", 78, 81], ["high viral loads in monocytes and macrophages", "PROBLEM", 113, 158], ["FCoV", "OBSERVATION", 63, 67], ["viral loads", "OBSERVATION", 118, 129], ["macrophages", "ANATOMY", 147, 158]]], ["Enteric pathotypes are able to circulate in monocytes/macrophages, but that higher rates of replication and dissemination are seen in FIP pathotypes.", [["monocytes", "ANATOMY", 44, 53], ["macrophages", "ANATOMY", 54, 65], ["monocytes", "CELL", 44, 53], ["macrophages", "CELL", 54, 65], ["monocytes", "CELL_TYPE", 44, 53], ["macrophages", "CELL_TYPE", 54, 65], ["Enteric pathotypes", "PROBLEM", 0, 18], ["macrophages", "PROBLEM", 54, 65], ["replication", "PROBLEM", 92, 103], ["dissemination", "PROBLEM", 108, 121], ["FIP pathotypes", "PROBLEM", 134, 148], ["pathotypes", "OBSERVATION", 8, 18], ["monocytes", "OBSERVATION", 44, 53], ["macrophages", "OBSERVATION", 54, 65], ["higher", "OBSERVATION_MODIFIER", 76, 82], ["rates", "OBSERVATION_MODIFIER", 83, 88], ["replication", "OBSERVATION", 92, 103], ["FIP pathotypes", "OBSERVATION", 134, 148]]], ["11e16 The ORF7b is located at the very 3'end of the FCoV genome, which encodes a 26.5-KDa non-structural glycoprotein.", [["ORF7b", "GENE_OR_GENE_PRODUCT", 10, 15], ["FCoV", "GENE_OR_GENE_PRODUCT", 52, 56], ["11e16", "DNA", 0, 5], ["ORF7b", "DNA", 10, 15], ["FCoV genome", "DNA", 52, 63], ["26.5-KDa non-structural glycoprotein", "PROTEIN", 81, 117], ["FCoV genome", "OBSERVATION", 52, 63]]], ["The function of glycoprotein 7b in the life cycle of FCoV is not clear.", [["glycoprotein 7b", "GENE_OR_GENE_PRODUCT", 16, 31], ["FCoV", "CANCER", 53, 57], ["glycoprotein 7b", "PROTEIN", 16, 31], ["glycoprotein 7b", "TREATMENT", 16, 31], ["FCoV", "PROBLEM", 53, 57], ["FCoV", "OBSERVATION", 53, 57], ["not", "UNCERTAINTY", 61, 64], ["clear", "OBSERVATION", 65, 70]]], ["17 It has been speculated that ORF7b plays a determinative role in FCoV virulence as viruses with a truncated gene have been found to be associated with enteric infection only.", [["ORF7b", "CHEMICAL", 31, 36], ["enteric infection", "DISEASE", 153, 170], ["ORF7b", "GENE_OR_GENE_PRODUCT", 31, 36], ["FCoV", "GENE_OR_GENE_PRODUCT", 67, 71], ["ORF7b", "PROTEIN", 31, 36], ["FCoV", "SPECIES", 67, 71], ["FCoV virulence", "PROBLEM", 67, 81], ["enteric infection", "PROBLEM", 153, 170], ["infection", "OBSERVATION", 161, 170]]], ["18 Field FCoV strains of FIP cats analysed thus far all contain intact ORF7b.", [["FIP", "ORGANISM", 25, 28], ["cats", "ORGANISM", 29, 33], ["ORF7b", "GENE_OR_GENE_PRODUCT", 71, 76], ["ORF7b", "PROTEIN", 71, 76], ["cats", "SPECIES", 29, 33], ["FIP cats", "TEST", 25, 33], ["FIP cats", "OBSERVATION", 25, 33], ["intact", "OBSERVATION", 64, 70]]], ["19e24 In order to gain a better understanding of the correlation between ORF7b and the virulence of the virus, we investigated the ORF7b of FCoVs from clinical specimens from 40 cats, half from wet-type FIP animals and half from clinically healthy cats.", [["FCoVs", "ANATOMY", 140, 145], ["specimens", "ANATOMY", 160, 169], ["ORF7b", "GENE_OR_GENE_PRODUCT", 73, 78], ["ORF7b", "GENE_OR_GENE_PRODUCT", 131, 136], ["FCoVs", "GENE_OR_GENE_PRODUCT", 140, 145], ["cats", "ORGANISM", 178, 182], ["FIP", "ORGANISM", 203, 206], ["cats", "ORGANISM", 248, 252], ["ORF7b", "PROTEIN", 73, 78], ["ORF7b", "PROTEIN", 131, 136], ["FCoVs", "PROTEIN", 140, 145], ["cats", "SPECIES", 178, 182], ["cats", "SPECIES", 248, 252], ["ORF7b", "TREATMENT", 73, 78], ["the virus", "PROBLEM", 100, 109], ["clinical specimens", "TEST", 151, 169]]], ["In contrast to the previous finding, short deletions of the 7b gene of FCoVs in body effusions were detected from some of our FIP cats.Specimens collection and FCoV screeningClinical specimens collected from cats presenting at the Animal Hospital of National Taiwan University over a 4-year period (2002e2005) were screened for FCoV by reverse transcriptase-polymerase chain reaction (RT-PCR) as described by Herrewegh et al. 25Sample preparation and reverse transcriptionRectal swab samples were suspended in 1 ml of 0.1% DEPC water.", [["body effusions", "ANATOMY", 80, 94], ["Specimens", "ANATOMY", 135, 144], ["specimens", "ANATOMY", 183, 192], ["swab samples", "ANATOMY", 479, 491], ["effusions", "DISEASE", 85, 94], ["FIP", "DISEASE", 126, 129], ["DEPC", "CHEMICAL", 523, 527], ["DEPC", "CHEMICAL", 523, 527], ["7b", "GENE_OR_GENE_PRODUCT", 60, 62], ["FCoVs", "GENE_OR_GENE_PRODUCT", 71, 76], ["body effusions", "CANCER", 80, 94], ["cats", "ORGANISM", 130, 134], ["cats", "ORGANISM", 208, 212], ["DEPC", "SIMPLE_CHEMICAL", 523, 527], ["7b gene", "DNA", 60, 67], ["FCoVs", "DNA", 71, 76], ["FCoV", "PROTEIN", 328, 332], ["reverse transcriptase", "PROTEIN", 336, 357], ["cats", "SPECIES", 130, 134], ["cats", "SPECIES", 208, 212], ["FCoV", "SPECIES", 328, 332], ["short deletions", "PROBLEM", 37, 52], ["FCoVs in body effusions", "PROBLEM", 71, 94], ["Specimens collection", "TEST", 135, 155], ["FCoV screening", "TEST", 160, 174], ["Clinical specimens", "TEST", 174, 192], ["FCoV", "PROBLEM", 328, 332], ["polymerase chain reaction", "PROBLEM", 358, 383], ["RT-PCR", "TREATMENT", 385, 391], ["25Sample preparation", "TREATMENT", 426, 446], ["reverse transcriptionRectal swab samples", "TREATMENT", 451, 491], ["0.1% DEPC water", "TREATMENT", 518, 533], ["body", "ANATOMY", 80, 84], ["effusions", "OBSERVATION", 85, 94], ["FIP cats", "OBSERVATION", 126, 134]]], ["Total RNA was extracted from 300 ml of the body effusion or suspension of the rectal swab using Trizol.", [["body effusion", "ANATOMY", 43, 56], ["rectal swab", "ANATOMY", 78, 89], ["effusion", "DISEASE", 48, 56], ["body", "ORGANISM_SUBDIVISION", 43, 47], ["rectal swab", "ORGANISM_SUBSTANCE", 78, 89], ["Total RNA", "PROBLEM", 0, 9], ["the body effusion", "PROBLEM", 39, 56], ["the rectal swab", "TEST", 74, 89], ["Trizol", "TREATMENT", 96, 102], ["300 ml", "OBSERVATION_MODIFIER", 29, 35], ["body", "ANATOMY", 43, 47], ["effusion", "OBSERVATION", 48, 56], ["suspension", "OBSERVATION_MODIFIER", 60, 70], ["rectal swab", "ANATOMY", 78, 89]]], ["26 Eleven microlitres of RNA-containing sample was added to the premix, consisting of 4 ml of 5\u00c2 first strand buffer, 2.5 mmol dNTP (GeneTeks, Bioscience, Taipei), 10 pmol primer P211: 5 0 -CACTA-GATCCAGACGTTAGCTC-3 0 , 25 200 mM dithiothreitol and, finally, 1 ml containing 200 unit Moloney murine leukaemia virus reverse transcriptase (Invitrogen, California), were added in a 0.6 ml reaction tube.", [["sample", "ANATOMY", 40, 46], ["NTP", "CHEMICAL", 128, 131], ["dithiothreitol", "CHEMICAL", 230, 244], ["NTP", "CHEMICAL", 128, 131], ["dithiothreitol", "CHEMICAL", 230, 244], ["dithiothreitol", "SIMPLE_CHEMICAL", 230, 244], ["Moloney murine leukaemia virus", "ORGANISM", 284, 314], ["tube", "TISSUE", 395, 399], ["reverse transcriptase", "PROTEIN", 315, 336], ["murine", "SPECIES", 292, 298], ["murine leukaemia virus", "SPECIES", 292, 314], ["Eleven microlitres of RNA", "TREATMENT", 3, 28], ["the premix", "TREATMENT", 60, 70], ["5\u00c2 first strand buffer", "TREATMENT", 94, 116], ["GATCCAGACGTTAGCTC", "TEST", 196, 213], ["dithiothreitol", "TREATMENT", 230, 244], ["Moloney murine leukaemia virus reverse transcriptase", "TREATMENT", 284, 336], ["a 0.6 ml reaction tube", "TREATMENT", 377, 399]]], ["This reaction mixture was then briefly centrifuged and incubated at 37 C for 60 min, then at 72 C for 15 min and finally at 94 C for 5 min.Sample preparation and reverse transcriptionSeminested PCR amplification of the 7b gene Primers for seminested PCR were chosen from a relatively conserved region representation of the FCoV genome and an outline of the primer locations ( Fig 1A) .", [["7b gene Primers", "DNA", 219, 234], ["seminested PCR", "DNA", 239, 253], ["FCoV genome", "DNA", 323, 334], ["primer locations", "DNA", 357, 373], ["Sample preparation", "TREATMENT", 139, 157], ["reverse transcription", "TREATMENT", 162, 183], ["PCR amplification", "TEST", 194, 211], ["the 7b gene Primers", "TEST", 215, 234], ["seminested PCR", "TEST", 239, 253], ["the FCoV genome", "PROBLEM", 319, 334], ["FCoV genome", "OBSERVATION", 323, 334]]], ["Details of the primer sequences are shown in Table 1 .", [["primer sequences", "DNA", 15, 31], ["the primer sequences", "TEST", 11, 31]]], ["Following reverse transcription, 2 ml of the RT reaction mixture was added to 28 ml of the PCR mixture, which consisted of 3 ml 10 \u00c2 Taq buffer, each primer (5 pmol), dNTP (2.5 mmol), 1U of Taq DNA polymerase (Gene-Teks, BioScience, Taipei) and 22.5 ml of 0.1% DEPC water.", [["NTP", "CHEMICAL", 168, 171], ["DEPC", "CHEMICAL", 261, 265], ["NTP", "CHEMICAL", 168, 171], ["DEPC", "CHEMICAL", 261, 265], ["NTP", "SIMPLE_CHEMICAL", 168, 171], ["DNA", "CELLULAR_COMPONENT", 194, 197], ["DEPC", "SIMPLE_CHEMICAL", 261, 265], ["Taq DNA polymerase", "PROTEIN", 190, 208], ["the RT reaction mixture", "TREATMENT", 41, 64], ["the PCR mixture", "TREATMENT", 87, 102], ["dNTP", "TREATMENT", 167, 171], ["Taq DNA polymerase", "TREATMENT", 190, 208], ["0.1% DEPC water", "TREATMENT", 256, 271]]], ["Thermal cycling (Mastercycler Personal, Eppendorf), consisted of 3 min of preheating at 94 C, followed by 35 cycles of denaturation at 94 C for 30 s, annealing at 56 C for 30 s, and extension at 72 C for 1 min with a final extension at 72 C for 5 min.", [["denaturation", "TEST", 119, 131], ["extension", "TEST", 182, 191]]], ["Seminested PCR was performed on 2 ml of the first PCR product using nested primers (7a-F1 and U-R1) under reaction conditions identical to those used in the first amplification.", [["U-R1", "GENE_OR_GENE_PRODUCT", 94, 98], ["R1", "DNA", 96, 98], ["Seminested PCR", "TEST", 0, 14], ["the first PCR product", "TREATMENT", 40, 61], ["nested primers", "TREATMENT", 68, 82], ["reaction conditions", "TREATMENT", 106, 125]]], ["A negative control without DNA template was included to monitor any cross-contamination.Sample preparation and reverse transcriptionAnalysis of PCR-amplified products, sequencing and sequence analysis A 10 ml sample from each PCR mixture was analysed using a 1.5% agarose gel (Viogene, Taipei) for electrophoresis.", [["DNA", "CELLULAR_COMPONENT", 27, 30], ["agarose", "SIMPLE_CHEMICAL", 264, 271], ["DNA template", "DNA", 27, 39], ["PCR-amplified products", "DNA", 144, 166], ["DNA template", "PROBLEM", 27, 39], ["any cross-contamination", "PROBLEM", 64, 87], ["Sample preparation", "TEST", 88, 106], ["reverse transcriptionAnalysis", "TEST", 111, 140], ["PCR", "TEST", 144, 147], ["amplified products", "TREATMENT", 148, 166], ["sequence analysis", "TEST", 183, 200], ["each PCR mixture", "TEST", 221, 237], ["a 1.5% agarose gel", "TREATMENT", 257, 275], ["electrophoresis", "PROBLEM", 298, 313], ["negative", "OBSERVATION", 2, 10]]], ["Amplification products were visualised using UV illumination after ethidium bromide staining.", [["ethidium bromide", "CHEMICAL", 67, 83], ["ethidium bromide", "CHEMICAL", 67, 83], ["ethidium bromide", "SIMPLE_CHEMICAL", 67, 83], ["Amplification products", "TREATMENT", 0, 22], ["UV illumination", "TREATMENT", 45, 60], ["ethidium bromide staining", "TREATMENT", 67, 92]]], ["The nucleotide sequences of the targeted DNA fragments were purified (Geneaid Biotech, Taipei) and determined from both orientations using an auto sequencer (ABI 3730XL, USA).", [["fragments", "ANATOMY", 45, 54], ["nucleotide", "CHEMICAL", 4, 14], ["nucleotide", "CHEMICAL", 4, 14], ["DNA", "CELLULAR_COMPONENT", 41, 44], ["targeted DNA fragments", "DNA", 32, 54], ["The nucleotide sequences", "TEST", 0, 24], ["the targeted DNA fragments", "PROBLEM", 28, 54], ["an auto sequencer", "TEST", 139, 156], ["ABI", "TEST", 158, 161]]], ["The cDNA sequences of ORF7b were then compared with other FCoVs from around the world.", [["ORF7b", "GENE_OR_GENE_PRODUCT", 22, 27], ["cDNA sequences", "DNA", 4, 18], ["ORF7b", "DNA", 22, 27], ["The cDNA sequences", "TEST", 0, 18], ["ORF7b", "TEST", 22, 27]]], ["Multiple alignments of nucleic acid sequences were performed by the Jotun Hein method using the MegAlign program (DNASTAR, Madison, WI).FCoV-infected catsForty cats with positive RT-PCR results were enrolled in this study.", [["nucleic acid", "CHEMICAL", 23, 35], ["FCoV", "CHEMICAL", 136, 140], ["FCoV", "GENE_OR_GENE_PRODUCT", 136, 140], ["cats", "ORGANISM", 150, 154], ["cats", "ORGANISM", 160, 164], ["cats", "SPECIES", 150, 154], ["cats", "SPECIES", 160, 164], ["nucleic acid sequences", "TEST", 23, 45], ["FCoV", "TEST", 136, 140], ["positive RT-PCR", "TEST", 170, 185], ["this study", "TEST", 211, 221], ["infected", "OBSERVATION_MODIFIER", 141, 149]]], ["Based on the clinical manifestation and/ or necropsy findings these cats were further divided into two groups.", [["cats", "ORGANISM", 68, 72]]], ["The first group included 20 clinically healthy cats living in households where there was a history of FIP-related death.", [["FIP", "DISEASE", 102, 105], ["death", "DISEASE", 114, 119], ["cats", "ORGANISM", 47, 51], ["cats", "SPECIES", 47, 51], ["FIP", "PROBLEM", 102, 105], ["related death", "PROBLEM", 106, 119]]], ["Positive RT-PCR results were obtained from the rectal swabs for this group.", [["rectal swabs", "ANATOMY", 47, 59], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 47, 59], ["Positive RT-PCR", "TEST", 0, 15], ["the rectal swabs", "TEST", 43, 59], ["rectal", "ANATOMY", 47, 53]]], ["The age of the cats ranging from 2 month to 8 years (mean 1.49 AE 1.96; n \u00bc 19) and no sex difference (10 animals for each sex) was observed ( Table 2 ).", [["cats", "ORGANISM", 15, 19], ["cats", "SPECIES", 15, 19], ["the cats", "TEST", 11, 19], ["mean", "TEST", 53, 57], ["AE", "TEST", 63, 65], ["sex difference", "PROBLEM", 87, 101]]], ["Another 20 cats that showed a clinical history of anorexia, weight loss, lethargy, icterus, mild antibiotic-unresponsive fever, abdominal distension and/or thoracic effusion with a low albumin to globulin ratio were included in the second group.", [["abdominal", "ANATOMY", 128, 137], ["thoracic", "ANATOMY", 156, 164], ["anorexia", "DISEASE", 50, 58], ["weight loss", "DISEASE", 60, 71], ["lethargy", "DISEASE", 73, 81], ["icterus", "DISEASE", 83, 90], ["fever", "DISEASE", 121, 126], ["abdominal distension", "DISEASE", 128, 148], ["thoracic effusion", "DISEASE", 156, 173], ["cats", "ORGANISM", 11, 15], ["abdominal", "ORGANISM_SUBDIVISION", 128, 137], ["albumin", "GENE_OR_GENE_PRODUCT", 185, 192], ["globulin", "GENE_OR_GENE_PRODUCT", 196, 204], ["globulin", "PROTEIN", 196, 204], ["cats", "SPECIES", 11, 15], ["anorexia", "PROBLEM", 50, 58], ["weight loss", "PROBLEM", 60, 71], ["lethargy", "PROBLEM", 73, 81], ["icterus", "PROBLEM", 83, 90], ["mild antibiotic", "PROBLEM", 92, 107], ["unresponsive fever", "PROBLEM", 108, 126], ["abdominal distension", "PROBLEM", 128, 148], ["thoracic effusion", "PROBLEM", 156, 173], ["a low albumin to globulin ratio", "PROBLEM", 179, 210], ["anorexia", "OBSERVATION", 50, 58], ["icterus", "OBSERVATION", 83, 90], ["mild", "OBSERVATION_MODIFIER", 92, 96], ["antibiotic", "OBSERVATION_MODIFIER", 97, 107], ["unresponsive", "OBSERVATION_MODIFIER", 108, 120], ["fever", "OBSERVATION", 121, 126], ["abdominal", "ANATOMY", 128, 137], ["distension", "OBSERVATION", 138, 148], ["thoracic", "ANATOMY", 156, 164], ["effusion", "OBSERVATION", 165, 173]]], ["These cats subsequently expired or were euthanased with a definite diagnosis of wet-type FIP established from positive RT-PCR for FCoV in body effusions 27, 28 and post-mortem histopathological examination (when available) with typical pyogranulomatous lesions.", [["body effusions", "ANATOMY", 138, 152], ["pyogranulomatous lesions", "ANATOMY", 236, 260], ["FIP", "DISEASE", 89, 92], ["effusions", "DISEASE", 143, 152], ["cats", "ORGANISM", 6, 10], ["body", "ORGANISM_SUBDIVISION", 138, 142], ["pyogranulomatous lesions", "CANCER", 236, 260], ["cats", "SPECIES", 6, 10], ["wet-type FIP", "PROBLEM", 80, 92], ["PCR", "TEST", 122, 125], ["FCoV in body effusions", "PROBLEM", 130, 152], ["post-mortem histopathological examination", "TEST", 164, 205], ["typical pyogranulomatous lesions", "PROBLEM", 228, 260], ["body", "ANATOMY", 138, 142], ["effusions", "OBSERVATION", 143, 152], ["pyogranulomatous", "OBSERVATION_MODIFIER", 236, 252], ["lesions", "OBSERVATION", 253, 260]]], ["In some cases, immunohistochemical staining for FCoV antigen was performed (data not shown).", [["FCoV antigen", "GENE_OR_GENE_PRODUCT", 48, 60], ["FCoV antigen", "PROTEIN", 48, 60], ["immunohistochemical staining", "TEST", 15, 43], ["FCoV antigen", "TEST", 48, 60]]], ["Cats in this group died between 3 months to 4 years (mean 1.15 AE 1.15; n \u00bc 20).", [["mean", "TEST", 53, 57]]], ["Seven of the cats were female, 13 were male ( Table 2) .", [["cats", "ORGANISM", 13, 17], ["cats", "SPECIES", 13, 17]]], ["Details with respect to the clinical history of individual animals are listed in Table 2 .ORF7b deletions detected from both FIP and healthy catsThe second round RT-PCR yielded the expected 766 bp products from the body effusion of the 20 FIP cats ( Fig 1B) and from the rectal swabs of 20 clinically healthy cats ( Fig 1C) .", [["body effusion", "ANATOMY", 215, 228], ["rectal swabs", "ANATOMY", 271, 283], ["FIP", "DISEASE", 125, 128], ["cats", "ORGANISM", 141, 145], ["body", "ORGANISM_SUBDIVISION", 215, 219], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 271, 283], ["cats", "ORGANISM", 309, 313], [".ORF7b deletions", "DNA", 89, 105], ["cats", "SPECIES", 141, 145], ["cats", "SPECIES", 243, 247], ["cats", "SPECIES", 309, 313], ["The second round RT-PCR", "TEST", 145, 168], ["the body effusion", "PROBLEM", 211, 228], ["the rectal swabs", "TEST", 267, 283], ["body", "ANATOMY", 215, 219], ["effusion", "OBSERVATION", 220, 228], ["rectal", "ANATOMY", 271, 277]]], ["The complete ORF7b (621 bp) sequences for the 40 viruses were submitted to GenBank under accession numbers DQ648122 and DQ675414eDQ675452.", [["ORF7b", "GENE_OR_GENE_PRODUCT", 13, 18], ["ORF7b", "DNA", 13, 18], ["bp) sequences", "TEST", 24, 37]]], ["Specimen type (P \u00bc pleural effusion, A \u00bc ascites, R \u00bc rectal swab) for virus derivation is incorporated into the viral denomination (Table 2 ).", [["pleural", "ANATOMY", 19, 26], ["ascites", "ANATOMY", 41, 48], ["rectal swab", "ANATOMY", 54, 65], ["pleural effusion", "DISEASE", 19, 35], ["ascites", "DISEASE", 41, 48], ["Specimen type (P \u00bc pleural effusion", "PROBLEM", 0, 35], ["A \u00bc ascites", "PROBLEM", 37, 48], ["R \u00bc rectal swab", "TREATMENT", 50, 65], ["virus derivation", "PROBLEM", 71, 87], ["pleural", "ANATOMY", 19, 26], ["effusion", "OBSERVATION", 27, 35], ["ascites", "OBSERVATION", 41, 48], ["rectal", "ANATOMY", 54, 60]]], ["Sequence analysis revealed that the ORF7b of the naturally occurring FCoVs was mostly intact (32/40).", [["FCoVs", "ANATOMY", 69, 74], ["ORF7b", "GENE_OR_GENE_PRODUCT", 36, 41], ["FCoVs", "CANCER", 69, 74], ["ORF7b", "DNA", 36, 41], ["FCoVs", "DNA", 69, 74], ["Sequence analysis", "TEST", 0, 17], ["mostly", "OBSERVATION_MODIFIER", 79, 85], ["intact", "OBSERVATION", 86, 92]]], ["However, three-and 12-nucleotide deletions were found in one (NTU37A) and seven (NTU4P, NTU5A, NTU13R, NTU14R, NTU15R, NTU16R, NTU25R) FCoVs, respectively.", [["NTU25R", "DNA", 127, 133], ["FCoVs", "DNA", 135, 140], ["12-nucleotide deletions", "PROBLEM", 19, 42], ["NTU5A", "TEST", 88, 93]]], ["Four isolates with the 12-nucleotide deletion originated from the same household, whereas remaining isolates had an unrelated origin (Fig 2A) .", [["nucleotide", "CHEMICAL", 26, 36], ["12-nucleotide deletion", "DNA", 23, 45], ["Four isolates", "TEST", 0, 13], ["nucleotide deletion", "PROBLEM", 26, 45]]], ["The two deletions are both located near the 5 0 terminus, covering positions 30e32 and 53e64, respectively; both are in-frame deletions resulting in loss of either one or four amino acids in the ORF7 protein.ORF7b deletions detected from both FIP and healthy catsOf the eight FCoVs with deletions, five originated from the rectal swabs of clinically healthy cats (NTU13R, NTU14R, NTU15R, NTU16R and NTU25R), and three from the body effusions of FIP cats (NTU4P, NTU5A and NTU37A) (Fig 2A) .", [["rectal swabs", "ANATOMY", 323, 335], ["body effusions", "ANATOMY", 427, 441], ["amino acids", "CHEMICAL", 176, 187], ["FIP", "DISEASE", 243, 246], ["effusions", "DISEASE", 432, 441], ["amino acids", "CHEMICAL", 176, 187], ["amino acids", "AMINO_ACID", 176, 187], ["ORF7", "GENE_OR_GENE_PRODUCT", 195, 199], ["ORF7b", "GENE_OR_GENE_PRODUCT", 208, 213], ["cats", "ORGANISM", 259, 263], ["FCoVs", "CANCER", 276, 281], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 323, 335], ["cats", "ORGANISM", 358, 362], ["NTU25R", "GENE_OR_GENE_PRODUCT", 399, 405], ["body", "ORGANISM_SUBDIVISION", 427, 431], ["cats", "ORGANISM", 449, 453], ["5 0 terminus", "DNA", 44, 56], ["ORF7 protein", "PROTEIN", 195, 207], ["ORF7b", "PROTEIN", 208, 213], ["FCoVs", "DNA", 276, 281], ["cats", "SPECIES", 259, 263], ["cats", "SPECIES", 358, 362], ["The two deletions", "PROBLEM", 0, 17], ["loss of either one", "PROBLEM", 149, 167], ["four amino acids", "TEST", 171, 187], ["ORF7b deletions", "PROBLEM", 208, 223], ["FIP cats", "TREATMENT", 445, 453], ["two", "OBSERVATION_MODIFIER", 4, 7], ["deletions", "OBSERVATION", 8, 17], ["5 0", "ANATOMY_MODIFIER", 44, 47], ["terminus", "OBSERVATION_MODIFIER", 48, 56], ["loss", "OBSERVATION_MODIFIER", 149, 153], ["rectal", "ANATOMY", 323, 329], ["body", "ANATOMY", 427, 431], ["effusions", "OBSERVATION", 432, 441], ["FIP cats", "OBSERVATION", 445, 453]]], ["Regardless of the clinical status of the cats, viruses originating from the same household were similar to one another (NTU9R, NTU10R, NTU11R, NTU12R and NTU8P; NTU27R, NTU28R, NTU29R and NTU26A).", [["cats", "ORGANISM", 41, 45], ["NTU9R", "DNA", 120, 125], ["NTU10R", "DNA", 127, 133], ["NTU11R", "PROTEIN", 135, 141], ["NTU12R", "PROTEIN", 143, 149], ["NTU8P", "PROTEIN", 154, 159], ["NTU27R", "PROTEIN", 161, 167], ["NTU28R", "PROTEIN", 169, 175], ["NTU29R", "DNA", 177, 183], ["NTU26A", "DNA", 188, 194], ["cats", "SPECIES", 41, 45], ["viruses", "PROBLEM", 47, 54]]], ["No sequence specificity related to the FIP occurrence could be identified throughout the ORF7b from the 40 FCoVs isolated from the FIP and clinically healthy cats (Fig 2A) .Genetic comparison of FCoV ORF7bAn overall nucleotide sequence identity of 87.6e100% was demonstrated for the 40 local FCoVs analysed.", [["FIP", "DISEASE", 39, 42], ["nucleotide", "CHEMICAL", 216, 226], ["FIP", "GENE_OR_GENE_PRODUCT", 39, 42], ["ORF7b", "GENE_OR_GENE_PRODUCT", 89, 94], ["cats", "ORGANISM", 158, 162], ["FCoV", "GENE_OR_GENE_PRODUCT", 195, 199], ["FCoVs", "CANCER", 292, 297], ["ORF7b", "DNA", 89, 94], ["FCoV ORF7bAn", "DNA", 195, 207], ["cats", "SPECIES", 158, 162], ["sequence specificity", "TEST", 3, 23], ["the FIP occurrence", "PROBLEM", 35, 53], ["nucleotide sequence identity", "TEST", 216, 244], ["FIP", "OBSERVATION", 39, 42], ["FIP", "OBSERVATION", 131, 134]]], ["Figure 2B shows the phylogenic relationship of the local (n \u00bc 13), American (n \u00bc 6), British (n \u00bc 1) and Dutch (n \u00bc 1) strains.", [["American (n \u00bc", "TEST", 67, 80], ["strains", "PROBLEM", 119, 126], ["phylogenic relationship", "OBSERVATION_MODIFIER", 20, 43], ["local", "OBSERVATION_MODIFIER", 51, 56]]], ["Except for NTU33R, all the local FCoVs fall into two clusters genetically separated from foreign strains (Fig 2B) .", [["NTU33R", "GENE_OR_GENE_PRODUCT", 11, 17], ["FCoVs", "GENE_OR_GENE_PRODUCT", 33, 38], ["NTU33R", "PROTEIN", 11, 17], ["FCoVs", "DNA", 33, 38], ["NTU33R", "TREATMENT", 11, 17], ["all the local FCoVs fall", "PROBLEM", 19, 43], ["foreign strains", "PROBLEM", 89, 104], ["foreign strains", "OBSERVATION", 89, 104]]], ["The NTU33R strain shows a relatively high sequence homology with two American strains, 79-1146 (91.5%) and NOR15 (91.3%).", [["NTU33R", "GENE_OR_GENE_PRODUCT", 4, 10], ["The NTU33R strain", "TEST", 0, 17], ["American strains", "TEST", 69, 85]]], ["This virus originated from a clinically healthy feline.", [["feline", "ORGANISM", 48, 54], ["This virus", "PROBLEM", 0, 10]]], ["Two other cats (NTU34R & NTU35R) in the same household as NTU33R harboured viruses with nearly identical ORF7b sequences (Fig 2A) .DiscussionIn 1995, Herrewegh et al, first demonstrated the association between ORF7b gene integrity and FCoV virulence in a comparative sequence analysis.", [["cats", "ORGANISM", 10, 14], ["ORF7b", "GENE_OR_GENE_PRODUCT", 210, 215], ["NTU33R", "DNA", 58, 64], ["ORF7b sequences", "DNA", 105, 120], ["ORF7b gene", "DNA", 210, 220], ["cats", "SPECIES", 10, 14], ["FCoV virulence", "PROBLEM", 235, 249], ["a comparative sequence analysis", "TEST", 253, 284], ["FCoV virulence", "OBSERVATION", 235, 249]]], ["20 The gene became the focus of attention, with studies of viruses from different geographical areas of the world.", [["viruses", "PROBLEM", 59, 66]]], ["The sequence findings analysed thus far, together with those from the present study, are summarised in Table 3 .", [["The sequence findings", "TEST", 0, 21], ["the present study", "TEST", 66, 83]]], ["The full-length ORF7b gene consists of 621 nt, however, only partial sequences are available for comparison of some viruses.", [["ORF7b", "GENE_OR_GENE_PRODUCT", 16, 21], ["full-length ORF7b gene", "DNA", 4, 26], ["partial sequences", "TEST", 61, 78], ["some viruses", "PROBLEM", 111, 123], ["viruses", "OBSERVATION", 116, 123]]], ["Of the total of 92 FCoVs analysed, deletions were identified in 13.", [["FCoVs", "CANCER", 19, 24], ["FCoVs", "DNA", 19, 24], ["deletions", "PROBLEM", 35, 44]]], ["Five of the 13 deleted viruses were laboratory strains, with eight from clinical specimens obtained in this study.", [["specimens", "ANATOMY", 81, 90], ["the 13 deleted viruses", "PROBLEM", 8, 30], ["laboratory strains", "PROBLEM", 36, 54], ["clinical specimens", "TEST", 72, 90], ["this study", "TEST", 103, 113]]], ["On further examination, the length range of the deletions was 3e406 nt for these ORF7b-deleted FCoVs (Table 4 ).", [["ORF7b", "GENE_OR_GENE_PRODUCT", 81, 86], ["ORF7b-deleted FCoVs", "DNA", 81, 100], ["further examination", "TEST", 3, 22]]], ["Five isolates with rather large deletions (56e406 nt) were all laboratory passage strains.", [["56e406 nt", "DNA", 43, 52], ["rather large deletions", "PROBLEM", 19, 41], ["all laboratory passage strains", "PROBLEM", 59, 89]]], ["20 The only field viruses originating from FIP cats with deletions were the three identified in this study.", [["FIP cats", "ORGANISM", 43, 51], ["deletions", "PROBLEM", 57, 66], ["this study", "TEST", 96, 106], ["field", "OBSERVATION_MODIFIER", 12, 17], ["viruses", "OBSERVATION", 18, 25], ["FIP cats", "OBSERVATION", 43, 51]]], ["The characteristics of our deletions are: (i) they are relatively short, eg, either 3 nt (NTU37A) or 12 nt (NTU4P, NTU5A); (ii) they are all in-frame deletions; and, (iii) in comparison to the downstream location for the major deletions in the laboratory strains, our deletions are all located near the 5 0 terminus of the gene, eg, nt 30e32 (NTU37A) and nt 53e64 (NTU4P, NTU5A).DiscussionRestriction fragment polymorphism analysis to monitor the presence of small deletions in FCoVs originating from naturally infected cats (12 FIP and four healthy cats), did not detect any deletions.", [["FCoVs", "GENE_OR_GENE_PRODUCT", 478, 483], ["cats", "ORGANISM", 520, 524], ["cats", "ORGANISM", 550, 554], ["NTU4P", "DNA", 108, 113], ["NTU5A", "DNA", 115, 120], ["5 0 terminus", "DNA", 303, 315], ["nt 30e32", "DNA", 333, 341], ["NTU37A", "DNA", 343, 349], ["nt 53e64", "DNA", 355, 363], ["NTU4P", "DNA", 365, 370], ["NTU5A", "DNA", 372, 377], ["FCoVs", "DNA", 478, 483], ["cats", "SPECIES", 520, 524], ["cats", "SPECIES", 550, 554], ["the major deletions", "PROBLEM", 217, 236], ["the laboratory strains", "PROBLEM", 240, 262], ["our deletions", "PROBLEM", 264, 277], ["nt", "TEST", 355, 357], ["fragment polymorphism analysis", "TEST", 401, 431], ["small deletions in FCoVs", "PROBLEM", 459, 483], ["any deletions", "PROBLEM", 572, 585], ["small", "OBSERVATION_MODIFIER", 459, 464], ["deletions", "OBSERVATION", 465, 474]]], ["20 The data strongly suggest that ORF7b is maintained, however, the presence of nonsense codons or very small deletions (<10 bp) cannot be excluded as addressed by the authors.", [["ORF7b", "GENE_OR_GENE_PRODUCT", 34, 39], ["ORF7b", "PROTEIN", 34, 39], ["nonsense codons", "PROBLEM", 80, 95], ["very small deletions", "PROBLEM", 99, 119], ["bp", "TEST", 125, 127], ["nonsense codons", "OBSERVATION", 80, 95], ["very", "OBSERVATION_MODIFIER", 99, 103], ["small", "OBSERVATION_MODIFIER", 104, 109]]], ["Our data revealed small deletions do associated with field strains.", [["Our data", "TEST", 0, 8], ["small deletions", "PROBLEM", 18, 33], ["field strains", "PROBLEM", 53, 66], ["small", "OBSERVATION_MODIFIER", 18, 23], ["deletions", "OBSERVATION", 24, 33]]], ["Moreover, the deletions were observed in FCoV not only from healthy cats, but also from some of the FIP animals.DiscussionThe current understanding with respect to ORF7b includes the following: (i) the gene can only be found in feline and canine, but not in porcine, coronaviruses 18,29 ; (ii) the gene encodes a non-structural, soluble, secretory 20 The phylogenetic trees were generated using the DNASTAR MegAlign program.", [["FIP", "DISEASE", 100, 103], ["FCoV", "CANCER", 41, 45], ["cats", "ORGANISM", 68, 72], ["ORF7b", "GENE_OR_GENE_PRODUCT", 164, 169], ["feline", "ORGANISM", 228, 234], ["canine", "ORGANISM", 239, 245], ["porcine", "ORGANISM", 258, 265], ["coronaviruses 18,29", "ORGANISM", 267, 286], ["ORF7b", "DNA", 164, 169], ["feline", "SPECIES", 228, 234], ["porcine", "SPECIES", 258, 265], ["canine", "SPECIES", 239, 245], ["the deletions", "PROBLEM", 10, 23], ["the DNASTAR MegAlign program", "TREATMENT", 395, 423], ["FIP", "OBSERVATION", 100, 103]]], ["The scale beneath the tree measures the distance between sequences, and the units at the bottom of the tree indicates the number of substitution events.", [["substitution events", "PROBLEM", 132, 151], ["tree", "ANATOMY_MODIFIER", 22, 26], ["bottom", "ANATOMY_MODIFIER", 89, 95], ["tree", "ANATOMY_MODIFIER", 103, 107], ["substitution events", "OBSERVATION", 132, 151]]], ["The dotted lines indicate a negative length introduced by averaging the tree. glycoprotein 17 ; (iii) the glycoprotein 7b is dispensable for viral replication in tissue culture; 17 and, (iv) the gene is readily lost during in vitro propagation.", [["tissue culture", "ANATOMY", 162, 176], ["lines", "CELL", 11, 16], ["glycoprotein 17", "GENE_OR_GENE_PRODUCT", 78, 93], ["(iii) the glycoprotein 7b", "GENE_OR_GENE_PRODUCT", 96, 121], ["dotted lines", "CELL_LINE", 4, 16], ["glycoprotein 17", "PROTEIN", 78, 93], ["glycoprotein 7b", "PROTEIN", 106, 121], ["The dotted lines", "TREATMENT", 0, 16], ["glycoprotein", "TEST", 78, 90], ["the glycoprotein 7b", "TREATMENT", 102, 121], ["viral replication", "PROBLEM", 141, 158], ["tissue culture", "TEST", 162, 176], ["negative", "OBSERVATION_MODIFIER", 28, 36], ["length", "OBSERVATION_MODIFIER", 37, 43], ["tree", "ANATOMY_MODIFIER", 72, 76]]], ["20 Herein, we report identification of three FIP-related viruses with deletions in the 5 0 terminus of their ORF7b gene.", [["FIP", "GENE_OR_GENE_PRODUCT", 45, 48], ["ORF7b", "GENE_OR_GENE_PRODUCT", 109, 114], ["5 0 terminus", "DNA", 87, 99], ["ORF7b gene", "DNA", 109, 119], ["three FIP-related viruses", "PROBLEM", 39, 64], ["viruses", "OBSERVATION", 57, 64]]], ["These deletions are very small and result in no change in the reading frame, thus, the function of the deleted gp 7b is very likely to be intact in these viruses.", [["gp 7b", "GENE_OR_GENE_PRODUCT", 111, 116], ["reading frame", "DNA", 62, 75], ["gp 7b", "PROTEIN", 111, 116], ["These deletions", "PROBLEM", 0, 15], ["the deleted gp 7b", "PROBLEM", 99, 116], ["very", "OBSERVATION_MODIFIER", 20, 24], ["small", "OBSERVATION_MODIFIER", 25, 30], ["no", "UNCERTAINTY", 45, 47], ["change", "OBSERVATION_MODIFIER", 48, 54], ["very likely to be", "UNCERTAINTY", 120, 137], ["intact", "OBSERVATION", 138, 144], ["viruses", "OBSERVATION", 154, 161]]], ["In this study, we found that amplification of ORF7b from some FIP cats was difficult.", [["ORF7b", "GENE_OR_GENE_PRODUCT", 46, 51], ["cats", "ORGANISM", 66, 70], ["ORF7b", "PROTEIN", 46, 51], ["this study", "TEST", 3, 13], ["amplification of ORF7b", "PROBLEM", 29, 51], ["some FIP cats", "TEST", 57, 70]]], ["Alteration of primer sets to target specific gene regions (data not shown), has not solved the problem of effective amplification.", [["gene regions", "DNA", 45, 57], ["Alteration of primer sets", "PROBLEM", 0, 25], ["effective amplification", "TREATMENT", 106, 129]]], ["Is gp 7b truly indispensable in the natural FIP infection?", [["FIP infection", "DISEASE", 44, 57], ["gp 7b", "GENE_OR_GENE_PRODUCT", 3, 8], ["FIP", "ORGANISM", 44, 47], ["gp 7b", "PROTEIN", 3, 8], ["the natural FIP infection", "PROBLEM", 32, 57], ["natural", "OBSERVATION_MODIFIER", 36, 43], ["FIP", "OBSERVATION_MODIFIER", 44, 47], ["infection", "OBSERVATION", 48, 57]]], ["Clarification of the presence or absence of ORF7b in FCoVs difficult to amplify may elucidate the role of gp7b in FIP pathogenesis.DiscussionIn conclusion, deletion in ORF7b were previously identified in laboratory strains of variable passage number and were considered to be associated with avirulence.", [["FIP", "DISEASE", 114, 117], ["ORF7b", "GENE_OR_GENE_PRODUCT", 44, 49], ["FCoVs", "CANCER", 53, 58], ["gp7b", "GENE_OR_GENE_PRODUCT", 106, 110], ["FIP", "GENE_OR_GENE_PRODUCT", 114, 117], ["ORF7b", "GENE_OR_GENE_PRODUCT", 168, 173], ["ORF7b", "PROTEIN", 44, 49], ["gp7b", "PROTEIN", 106, 110], ["ORF7b", "DNA", 168, 173], ["ORF7b in FCoVs", "PROBLEM", 44, 58], ["FIP pathogenesis", "PROBLEM", 114, 130], ["avirulence", "PROBLEM", 292, 302], ["FIP", "OBSERVATION", 114, 117]]], ["20 In this study, field isolates showed small in-frame deletions in the 3 0 region of ORF7b in both virulent and avirulent FCoV strains.", [["ORF7b", "GENE_OR_GENE_PRODUCT", 86, 91], ["FCoV strains", "ORGANISM", 123, 135], ["3 0 region", "DNA", 72, 82], ["ORF7b", "DNA", 86, 91], ["FCoV", "SPECIES", 123, 127], ["this study", "TEST", 6, 16], ["field isolates", "TEST", 18, 32], ["small in-frame deletions", "PROBLEM", 40, 64], ["ORF7b", "PROBLEM", 86, 91], ["small", "OBSERVATION_MODIFIER", 40, 45], ["both", "OBSERVATION_MODIFIER", 95, 99], ["virulent", "OBSERVATION_MODIFIER", 100, 108], ["avirulent FCoV strains", "OBSERVATION", 113, 135]]], ["Deletions had not previously been observed in FIP pathotypes.", [["Deletions", "PROBLEM", 0, 9], ["FIP pathotypes", "OBSERVATION", 46, 60]]], ["However, no deletions were seen in the majority of field strains.", [["deletions", "PROBLEM", 12, 21], ["no", "UNCERTAINTY", 9, 11], ["deletions", "OBSERVATION", 12, 21]]], ["This implies that the presence of this deletion is not correlated with pathogenicity. x UCD4 is a virulent strain, 30 however, the virulence of this deleted mutant generated in the sixth passage during in vitro culture hasn't yet been tested.", [["UCD4", "GENE_OR_GENE_PRODUCT", 88, 92], ["this deletion", "PROBLEM", 34, 47], ["pathogenicity", "PROBLEM", 71, 84], ["a virulent strain", "PROBLEM", 96, 113], ["vitro culture", "TEST", 205, 218], ["deletion", "OBSERVATION", 39, 47], ["not correlated with", "UNCERTAINTY", 51, 70], ["pathogenicity", "OBSERVATION", 71, 84], ["virulent", "OBSERVATION_MODIFIER", 98, 106]]]], "bf1e6dfd9c9d59920881e64aebe30638cdfa1c0d": [["JEFFREY N. RUBINHospitals are an essential component of community preparedness for terrorism and other hazards, both natural and manmade.", [["essential", "OBSERVATION_MODIFIER", 33, 42], ["component", "OBSERVATION_MODIFIER", 43, 52]]], ["Despite general preparedness requirements within the industry, hospitals typically are a weak link with respect to community disaster preparedness, particularly for those incidents involving contaminated patients.", [["patients", "ORGANISM", 204, 212], ["patients", "SPECIES", 204, 212]]], ["Significant systemic constraints make most hospitals reluctant partners in preparedness and generate ineffective response; this condition has been highlighted by the antiterrorism training and preparedness programs in the past few years.", [["Significant systemic constraints", "PROBLEM", 0, 32], ["the antiterrorism training", "TREATMENT", 162, 188], ["preparedness programs", "TREATMENT", 193, 214]]], ["Results of numerous exercises and actual responses across the United States indicate a predictable list of pitfalls, most of them related to inherent system limitations that continue to hinder effective disaster operations in hospitals:JEFFREY N. RUBIN\u2022 Communications \u2022 Hospital security \u2022 Decontamination procedures, equipment, and training \u2022 Hospital staff management \u2022 Exercise realism, content, follow-upIntroductionRecent events have focused attention on the ability of communities to respond to acts of terrorism.", [["numerous exercises", "TREATMENT", 11, 29]]], ["Public safety and emergency management personnel have developed and tested response plans, and considerable federal resources have been expended toward the same end-albeit with inconsistent results.", [["emergency management", "TREATMENT", 18, 38]]], ["Hospitals face increasing operating costs coupled with decreasing reimbursement rates.", [["decreasing reimbursement rates", "TREATMENT", 55, 85]]], ["Healthcare facilities are hardly exempt from government regulations (a recent example is the Health Insurance Portability and Accountability Act [6]-HIPAA) and are strongly affected by changes in Medicare reimbursement patterns, but accredited hospitals also deal with the non-governmental Joint Commission for the Accreditation of Healthcare Organizations (JCAHO).", [["Joint", "ANATOMY", 290, 295]]], ["Standards are diverse in scope and generally derived from clinical, ethical, technological, environmental, or occupational indications.", [["diverse", "OBSERVATION_MODIFIER", 14, 21]]], ["More than most corporations or government agencies, a healthcare facility that suffers a crisis of public confidence stands to lose both funding and patients along with its reputation.", [["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157]]], ["With respect to disasters, this includes:Hospital Challenges and Constraints\u2022 Managing medical assessment, treatment, and continuing care for acute incidents involving large numbers of patients \u2022 Effectively managing contaminated patients \u2022 Recognizing, identifying, and managing consequences of bioterrorism \u2022 Protecting employees, patients and their families, and anyone else within the facility \u2022 Dealing with all of these while continuing to provide everyday emergency careHospital Challenges and ConstraintsPublic agencies responsible for preparedness and response have little direct control over public hospitals and none over private facilities (which are not accountable to public officials).", [["patients", "ORGANISM", 185, 193], ["patients", "ORGANISM", 230, 238], ["patients", "ORGANISM", 333, 341], ["patients", "SPECIES", 185, 193], ["patients", "SPECIES", 230, 238], ["patients", "SPECIES", 333, 341], ["medical assessment", "TEST", 87, 105], ["treatment", "TREATMENT", 107, 116], ["everyday emergency careHospital Challenges", "TREATMENT", 454, 496], ["ConstraintsPublic agencies", "TREATMENT", 501, 527]]], ["There is no suitable alternative to engaged hospitals when trying to plan for or manage a mass-casualty incident or other type of large-scale disaster affecting a community.", [["a mass", "PROBLEM", 88, 94], ["no", "UNCERTAINTY", 9, 11], ["mass", "OBSERVATION", 90, 94], ["large", "OBSERVATION_MODIFIER", 130, 135]]], ["Should the incident be at the hospital itself (such as a fire or hazardous material release) or involve the hospital (for example, a flood or hurricane), a prepared facility and staff may be the difference between minimal loss of life and a true catastrophe.Hospital RequirementsHospitals have been required to have and exercise emergency preparedness plans (formerly known as \"disaster plans\") for many years.", [["minimal loss of life", "PROBLEM", 214, 234], ["a true catastrophe", "PROBLEM", 239, 257], ["catastrophe", "OBSERVATION", 246, 257]]], ["As of January 2001, hospitals wishing to achieve or retain JCAHO accreditation had to have a comprehensive plan in place, covering the four traditional phases of emergency management (mitigation, preparedness, response, and recovery) [7] .", [["emergency management", "TREATMENT", 162, 182]]], ["A hazard vulnerability analysis, part of the new standards, not only determines both the most likely and the most catastrophic incidents, but also identifies the range of hazards for a given hospital.", [["A hazard vulnerability analysis", "TEST", 0, 31], ["most likely", "UNCERTAINTY", 89, 100]]], ["The standards also establish requirements for staff training and familiarization with the plan.Hospital RequirementsThe wave of training and other preparedness programs, accompanied by requirements and expectations regarding preparedness for acts of terrorism, has not ignored hospitals.", [["staff training", "TREATMENT", 46, 60], ["The wave of training", "TREATMENT", 116, 136]]], ["The Defense Department's Domestic Preparedness Program (continued by the Justice Department) in the late 1990s provided basic training on medical management of casualties affected by chemical, biological, and radiological warfare agents.", [["casualties", "DISEASE", 160, 170], ["basic training", "TREATMENT", 120, 134], ["medical management", "TREATMENT", 138, 156], ["radiological warfare agents", "TREATMENT", 209, 236]]], ["Curriculum and training were limited by design: it was largely military in origin, focused on the response phase, and did not contain much depth in hospital preparedness.", [["military", "OBSERVATION", 63, 71]]], ["The Metropolitan Medical Response System (MMRS) [8], initially overseen by the Department of Health and Human Services and now part of the Department of Homeland Security, was the first large-scale federal program to focus on improving the ability of healthcare systems to detect, identify, and manage incidents involving large numbers of potentially contaminated casualties.", [["Human", "ORGANISM", 104, 109], ["Human", "SPECIES", 104, 109]]], ["The goal of incorporating first responders (public safety agencies), public health agencies, hospitals, and emergency management and linking local, state, and federal agencies was an innovative global approach to a healthcare system that is commonly approached via its components.", [["emergency management", "TREATMENT", 108, 128], ["a healthcare system", "TREATMENT", 213, 232]]], ["The challenges faced by MMRS participants and administrators in the program's initial incarnation were less a result of the philosophy than of the style and method of administration.", [["participants", "SPECIES", 29, 41], ["method of administration", "TREATMENT", 157, 181]]], ["The MMRS is now part of the multi-faceted Homeland Security Grant Program [8A], addressing key issues of medical surge capacity in the community.Hospital RequirementsSurge capacity, the ability to handle a large influx of ill or injured people beyond standard community resources, is a critical component of hospital preparedness.", [["ill", "DISEASE", 222, 225], ["people", "SPECIES", 237, 243], ["The MMRS", "TEST", 0, 8]]], ["Realistically, solutions must involve alternative assessment and treatment centers rather than physically expanding hospitals-and most do (either via adapting existing alternate facilities or setting up temporary ones).", [["alternative assessment", "TEST", 38, 60], ["treatment centers", "TREATMENT", 65, 82]]], ["Providing adequate staffing for these alternative centers is the greater challenge.Hospital RequirementsIn addition to preparedness requirements, hospitals fall under regulations of the Occupational Safety & Health Administration (OSHA) and the Environmental Protection Agency (EPA).", [["these alternative centers", "TREATMENT", 32, 57], ["preparedness requirements", "TREATMENT", 119, 144]]], ["The lack of a clear and consistent application of OSHA regulations has been an obstacle to developing consistency, although progress appears to be in the making when this was written.Hospital RequirementsPlan development, staff training, and equipment maintenance are non-reimbursable costs in terms of billing, but some financial support has developed.", [["OSHA regulations", "TREATMENT", 50, 66], ["clear", "OBSERVATION", 14, 19]]], ["The grants were supposed to assist states in achieving \"critical benchmarks for bioterrorism preparedness planning,\" promulgated by the Department of Health and Human Services.", [["Human", "ORGANISM", 161, 166], ["Human", "SPECIES", 161, 166]]], ["Three of the initial benchmarks were to designate a bioterrorism preparedness coordinator, establish a hospital preparedness planning committee to advise the state health department, and develop a plan for managing epidemics, regardless of origin [13] .", [["managing epidemics", "PROBLEM", 206, 224]]], ["States have some discretion on disbursement (provided that funds are directed toward fulfillment of primary grant goals), with many aiming for general hospital preparedness as a first step in bioterrorism preparedness.", [["general hospital preparedness", "TREATMENT", 143, 172]]], ["Subsequent and planned grants from HRSA have allowed expansion of preparedness funding from hospitals to health systems and encourage regional and statewide coordination.", [["expansion", "OBSERVATION_MODIFIER", 53, 62]]], ["In combination with public health preparedness grants from the CDC and the MMRS component of the Homeland Security Grant Program, the HRSA National Bioterrorism Hospital Preparedness Program [13A] is addressing local, regional, and state aspects of health-system surge capacity and capability.Hospital RequirementsDespite requirements, some standards, and best intentions, significant obstacles remain, including the combination of staff and equipment shortages, lack of surge capacity, and minimal funding.", [["lack of surge capacity", "PROBLEM", 463, 485], ["minimal", "OBSERVATION_MODIFIER", 491, 498]]], ["Although there have been (and likely will continue to be) substantial improvements, most hospitals are still unprepared to effectively manage the results of a major incident-whether due to mishap, terrorism, natural disaster, or infectious disease outbreak-requiring treatment of mass casualties, staff protection, or facility evacuation [14, 15] .", [["mishap", "PROBLEM", 189, 195], ["terrorism", "PROBLEM", 197, 206], ["infectious disease outbreak", "PROBLEM", 229, 256], ["mass casualties", "PROBLEM", 280, 295], ["evacuation", "TREATMENT", 327, 337], ["infectious", "OBSERVATION_MODIFIER", 229, 239]]], ["An incident contemporaneous with local or regional infrastructure disruption will not only magnify hospital shortcomings, it will further hamper effective hospital response and hospital and community recovery.ObservationsMilsten [16] surveyed 22 years of incidents in the United States and abroad, identifying a broad list of hospital challenges (communications and power failures, water shortages and contamination, structural damage, hazardous materials exposure, facility evacuation, and resource allocation), accompanied by general suggestions (such as developing plans and procedures for disasters).ObservationsThe observations on which the discussion and conclusions in this chapter are based on multiple sources:Observations\u2022 Direct personal observation (generally as controller or evaluator) of tabletop, functional, and full-scale exercises, along with actual incidents such as tornadoes, ice storms, floods, hazardous materials spills, and multiplecasualty events. \u2022 Personal communications and written afteraction reports from local exercises and actual incidents elsewhere. \u2022 Published observations and after-action reports from three large-scale exercises: TOPOFF (May 2000) [17] , Dark Winter (June 2001) [18] , and TOPOFF 2 (May 2003) [19] [20] [21] .ObservationsHospitals consistently encountered challenges in the following areas: communications, security, decontamination, staff training, staff protection, and exercise design and conduct.", [["local or regional infrastructure disruption", "PROBLEM", 33, 76], ["hospital challenges", "TREATMENT", 326, 345], ["power failures", "PROBLEM", 366, 380], ["water shortages", "PROBLEM", 382, 397], ["structural damage", "PROBLEM", 417, 434], ["evacuation", "TREATMENT", 475, 485], ["full-scale exercises", "TREATMENT", 829, 849], ["staff protection", "TREATMENT", 1407, 1423], ["local", "OBSERVATION_MODIFIER", 33, 38], ["infrastructure disruption", "OBSERVATION", 51, 76]]], ["The most significant aspect of these observations may be their consistency: the challenges and pitfalls encountered by hospitals and the agencies supporting them are definable and reproducible-and thus predictable.", [["most significant", "OBSERVATION_MODIFIER", 4, 20]]], ["As such, there is value in their description, discussion, and analysis.CommunicationsIntrafacility communications during exercises and actual events have been described as \"difficult,\" \"inconsistent,\" \"marginal,\" and \"nonexistent.\"", [["analysis", "TEST", 62, 70]]], ["Phones are overloaded, radios-when availableare insufficient in number, range, and frequency options (or a combination of those), and staff commonly lack adequate training in communications procedures or equipment operation.", [["overloaded", "PROBLEM", 11, 21], ["communications procedures", "TREATMENT", 175, 200], ["equipment operation", "TREATMENT", 204, 223], ["overloaded", "OBSERVATION", 11, 21]]], ["Many hospitals host licensed amateur radio operators during disasters; the ham networks provide an important communications resource, allowing voice, data, and even video transmissions among incident scenes, hospitals, emergency operations centers, and other critical facilities.SecuritySecurity staff in most hospitals that have them are private guards, either hospital or contract employees.", [["ham networks", "MULTI-TISSUE_STRUCTURE", 75, 87]]], ["Most are unarmed and have no powers of arrest.", [["arrest", "PROBLEM", 39, 45], ["arrest", "OBSERVATION", 39, 45]]], ["Although their responsibilities vary considerably, most are there as deterrents and to restrain violent patients or visitors.", [["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112]]], ["Hospital security is an important part of JCAHO's \"secure environment,\" protecting patients, staff, visitors, information, and the physical infrastructure [22, 23] .", [["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91]]], ["Some hospitals, particularly large ones in urban areas, employ sworn law enforcement officers, either on contract or as employees.", [["large", "OBSERVATION_MODIFIER", 29, 34]]], ["Recurrent securityrelated challenges have internal and external foci: lockdown and the role of local law enforcement.", [["Recurrent securityrelated challenges", "PROBLEM", 0, 36], ["internal", "OBSERVATION_MODIFIER", 42, 50], ["external", "OBSERVATION_MODIFIER", 55, 63], ["foci", "OBSERVATION", 64, 68]]], ["Lockdown is analogous to cardiopulmonary resuscitation (CPR): it is a short-term step intended for use early in the incident to buy time for more definitive measures.", [["cardiopulmonary", "ANATOMY", 25, 40], ["cardiopulmonary resuscitation", "TREATMENT", 25, 54]]], ["In securing all or part of the facility against additional entry, staff implementing lockdown can gain some breathing room while providing short-term protection to themselves and their patients.", [["patients", "ORGANISM", 185, 193], ["patients", "SPECIES", 185, 193], ["short-term protection", "TREATMENT", 139, 160]]], ["Also, as with CPR, lockdown can make the difference between success and failure in implementation of an emergency plan but is rarely effective on its own; a plan that ends with lockdown is doomed to fail.SecurityIn most exercises simulating a terrorist incident, naturally occurring disease outbreak, or unintentional hazardous material release, the hospital in question has been \"overrun,\" meaning that a portion (generally the ED) or all of the facility is no longer able to function cohesively, protect its staff, or provide organized care to current and prospective patients.", [["patients", "ORGANISM", 570, 578], ["patients", "SPECIES", 570, 578], ["CPR", "TREATMENT", 14, 17], ["lockdown", "TREATMENT", 19, 27], ["an emergency plan", "TREATMENT", 101, 118], ["naturally occurring disease outbreak", "PROBLEM", 263, 299]]], ["This can be due to contamination of the area, an unmanageable crush of incoming patients, perceived threat of violence, or loss of infrastructure.", [["violence", "DISEASE", 110, 118], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["contamination of the area", "PROBLEM", 19, 44], ["violence", "PROBLEM", 110, 118], ["loss of infrastructure", "PROBLEM", 123, 145], ["unmanageable", "OBSERVATION_MODIFIER", 49, 61], ["crush", "OBSERVATION", 62, 67]]], ["In many of these exercises, hospital staff recognized impending failure and requested assistance from law enforcement agencies for facility security and crowd control.", [["impending failure", "PROBLEM", 54, 71]]], ["With few exceptions these requests were not met (or were met too late), although it eventually became apparent to most participants that these needs were indeed urgent and the loss of hospitals disastrous.", [["participants", "SPECIES", 119, 131], ["the loss of hospitals disastrous", "PROBLEM", 172, 204]]], ["Although it is not an exaggeration to say that law enforcement was not an eager player in hospital security, this was not due to laxity on the part of police.", [["laxity", "PROBLEM", 129, 135]]], ["As they were given little to no external guidance on how to rank request urgency, they found themselves with too many priorities.", [["urgency", "PROBLEM", 73, 80]]], ["This issue offers a compelling example of the need to consider hospital preparedness within the context of community resources.DecontaminationMass decontamination has been a common focus since antiterrorism training became a mass-market product in the late 1990s.", [["community resources", "TREATMENT", 107, 126], ["DecontaminationMass decontamination", "PROBLEM", 127, 162], ["antiterrorism training", "TREATMENT", 193, 215], ["a mass", "PROBLEM", 223, 229], ["Mass", "OBSERVATION", 142, 146], ["mass", "OBSERVATION", 225, 229]]], ["Considerable sums have been spent on extensive training and equipment designed to decontaminate thousands of people at an incident scene and hundreds at a hospital.", [["people", "ORGANISM", 109, 115], ["people", "SPECIES", 109, 115], ["extensive training", "TREATMENT", 37, 55], ["equipment", "TREATMENT", 60, 69]]], ["Common goals in cities participating in MMRS contracts were for hospitals to be able to decontaminate at least 100 ambulatory patients without relying on external assistance (i.e., a fire service hazmat team).", [["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134]]], ["Both MMRS and HRSA goals represent significant expectations, and to date they have proved largely fanciful.", [["Both MMRS", "TEST", 0, 9], ["significant", "OBSERVATION_MODIFIER", 35, 46]]], ["Terrorism aside, all acute-care hospitals should be able to successfully manage a single contaminated patient without external resources [25] .", [["patient", "ORGANISM", 102, 109], ["patient", "SPECIES", 102, 109], ["external resources", "TREATMENT", 118, 136]]], ["A 2002 American Hospital Association survey [26] reported that a majority of hospitals had plans in place for managing chemical and biological attacks; this is a marked increase relative to surveys taken before 11 September 2001 [27] .", [["managing chemical and biological attacks", "PROBLEM", 110, 150]]], ["The great majority still find singlepatient decontamination an elusive goal.Staff TrainingAs with the public-safety sector, there is no shortage of training and equipment for hospital preparedness; there is also little in the way of functional standards, guidelines, or quality control among programs and their purveyors.", [["singlepatient decontamination", "TREATMENT", 30, 59], ["great", "OBSERVATION_MODIFIER", 4, 9], ["no", "UNCERTAINTY", 133, 135]]], ["The lack of standardization and the vast range of executive support almost guarantee that each facility or hospital market will go through its own set of decisions, all driven at least as much by financial considerations as by need.What Type of Training Should be Provided?There are many training options, but the most common (and the most applicable) include the HEICS (currently being updated) [29] , terrorism and weapons of mass destruction, and general and medical management of hazardous materials.", [["terrorism", "PROBLEM", 403, 412], ["mass destruction", "PROBLEM", 428, 444], ["mass", "OBSERVATION", 428, 432]]], ["HEICS is a standardized incident management system adapted from incident command system variants used by local, state, and federal publicsafety and emergency-management personnel.", [["a standardized incident management system", "TREATMENT", 9, 50]]], ["What will an individual hospital, hospital group, or regional consortium support?", [["regional consortium support", "TREATMENT", 53, 80]]], ["To add to the mix, sweeping (and verging on the arbitrary) training requirements related to compliance with the National Incident Management System and other federal homeland security initiatives consume substantial staff resources while yielding little apparent benefit.Who Should be Trained?Principal distinctions include clinical vs. nonclinical, executive vs. managerial vs. labor, determining which departments should be included, the number of trained staff needed to provide adequate coverage on all shifts, frequency of initial and refresher training, and how much effort should be made to include physicians, particularly those who contract with hospitals (a common arrangement, especially in the ED).", [["the arbitrary) training requirements", "TREATMENT", 44, 80], ["labor", "PROBLEM", 379, 384], ["refresher training", "TREATMENT", 540, 558]]], ["High turnover rates can quickly deprive a facility of trained employees.", [["High turnover rates", "PROBLEM", 0, 19]]], ["Insufficient or ineffective refresher training can produce the same effect as high turnover, as hard-won skills deteriorate due to lack of use.", [["ineffective refresher training", "TREATMENT", 16, 46]]], ["Many preparedness and decontamination training programs are provided in \"trainthe-trainer\" format-that is, a small group of employees is trained and expected to cascade the training down to fellow employees, even though their newly acquired \"expertise\" is unac-companied by experience, additional knowledge, or implementation capability.", [["decontamination training programs", "TREATMENT", 22, 55]]], ["Lack of effective follow-up creates the all-too-common phenomenon of \"trainers\" who teach few if any classes and soon lose whatever competencies they may have acquired-particularly if there is no executive support for continued training.Staff ProtectionEssential components of staff protection include personal protective equipment (PPE) for common tasks and decontamination, chemoprophylaxis and immunization, and sufficient training, education, and policy development to ensure that they are available and appropriately used.", [["continued training", "TREATMENT", 218, 236], ["staff protection", "TREATMENT", 277, 293], ["personal protective equipment", "TREATMENT", 302, 331], ["common tasks", "TREATMENT", 342, 354], ["decontamination", "TREATMENT", 359, 374], ["chemoprophylaxis", "TREATMENT", 376, 392], ["immunization", "TREATMENT", 397, 409]]], ["Common PPE pitfalls include inadequate training for existing equipment, inadequate equipment itself, and ineffective policies and procedures governing PPE use.", [["Common PPE pitfalls", "TREATMENT", 0, 19], ["inadequate training", "TREATMENT", 28, 47], ["existing equipment", "TREATMENT", 52, 70]]], ["The SARS outbreak of 2003 and the effect it had on hospitals and EMS staff is an excellent example: insufficient and inappropriate PPE contributed to the disruptive effect on health systems and exposure among healthcare workers [30, 31] .", [["SARS", "DISEASE", 4, 8], ["inappropriate PPE", "PROBLEM", 117, 134], ["the disruptive effect on health systems", "PROBLEM", 150, 189]]], ["The safety net that chemoprophylaxis (for example, antibiotics for possible anthrax exposures) and immunization (for example, smallpox vaccine for healthcare workers) can provide will fail if it is not made available promptly and to all affected and potentially affected employees.", [["anthrax", "DISEASE", 76, 83], ["chemoprophylaxis", "TREATMENT", 20, 36], ["antibiotics", "TREATMENT", 51, 62], ["anthrax exposures", "TREATMENT", 76, 93], ["immunization", "TREATMENT", 99, 111], ["smallpox vaccine", "TREATMENT", 126, 142]]], ["Employees who are not confident that their employer will offer appropriate protection are unlikely to show up for work during a crisis.", [["a crisis", "PROBLEM", 126, 134]]], ["This is by no means limited to issues of terrorism, but extends to all potentially catastrophic events.Exercise Design and ConductSo far we have examined common pitfalls that relate to staffing, equipment, training, and procedures.", [["terrorism", "PROBLEM", 41, 50], ["all potentially catastrophic events", "PROBLEM", 67, 102], ["Exercise Design", "TEST", 103, 118], ["terrorism", "OBSERVATION", 41, 50], ["catastrophic", "OBSERVATION", 83, 95]]], ["Given the longstanding JCAHO requirement of at least two exercises per year, hospitals should house considerable expertise in exercise design, conduct, and evaluation.", [["evaluation", "TEST", 156, 166]]], ["In fact, a most significant recurring pitfall in hospital exercises is a distorted picture.", [["a distorted picture", "PROBLEM", 71, 90], ["significant", "OBSERVATION_MODIFIER", 16, 27], ["recurring", "OBSERVATION_MODIFIER", 28, 37], ["pitfall", "OBSERVATION", 38, 45]]], ["An exercise, like a written plan, may meet JCAHO standards without conferring significant benefit in terms of actual preparedness or response capability on the hospital(s) in question.Exercise Design and ConductThe most common types of exercises (tabletop and functional) do not involve hands-on operations but rather focus on decision making and plan evaluation.", [["Exercise Design", "TEST", 184, 199], ["operations", "TREATMENT", 296, 306], ["evaluation", "TEST", 352, 362], ["most common", "OBSERVATION_MODIFIER", 215, 226]]], ["Hospitals must be able to receive and manage actual patients during exercises, requiring either additional staffing to allow exercise operations to go on alongside everyday operations or limiting the scope and duration of play.", [["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["exercise operations", "TREATMENT", 125, 144], ["everyday operations", "TREATMENT", 164, 183]]], ["Additional staffing for exercises means additional cost and staff scheduling challenges.Exercise Design and ConductBecause of the need for advance scheduling of personnel and simply having sufficient personnel on hand, two common exercise deficiencies ensue: lack of surprise and preferential testing of the most populated shifts.", [["hand", "ANATOMY", 213, 217], ["hand", "ORGANISM_SUBDIVISION", 213, 217], ["Exercise Design", "TREATMENT", 88, 103], ["two common exercise deficiencies", "PROBLEM", 219, 251], ["preferential testing", "TEST", 280, 300]]], ["Examples include ED physicians immediately diagnosing rare conditions that are part of the exercise scenario, with equally rarely used medications being immediately available in the ED or pharmacy and, in more than one exercise, a large ED having a full decontamination station set up, with staff wearing full PPE, before play even began.", [["medications", "TREATMENT", 135, 146], ["large", "OBSERVATION_MODIFIER", 231, 236]]], ["Any exercise scenario induces a certain degree of artificiality, but effective exercises are designed so that artificiality does not interfere with evaluation of identified objectives.", [["Any exercise scenario", "PROBLEM", 0, 21], ["artificiality", "PROBLEM", 50, 63], ["evaluation", "TEST", 148, 158]]], ["Untoward, artificial, staff preparation for an exercise adds artificiality that directly compromises effective evaluation.", [["effective evaluation", "TEST", 101, 121]]], ["In addition, the overwhelming lack of exercises on evening and night shifts tests capabilities only when a hospital is at its highest staffing levels.", [["night shifts tests capabilities", "TEST", 63, 94]]], ["This not only deprives some staff of exercise experience, but also deprives the facility of evaluating performance during off-shifts.Exercise Design and ConductThe combination of insufficient training and ineffective exercises deprives staff of experience in improvisation and decision making, thus increasing the likelihood that a single significant obstacle (for example, difficulty setting up decontamination equipment, or even presentation of a contaminated patient) can derail the exercise or actual response.SuggestionsThere are multiple potential solutions for the challenges herein identified.", [["patient", "ORGANISM", 462, 469], ["patient", "SPECIES", 462, 469], ["Exercise Design", "TEST", 133, 148], ["insufficient training", "TREATMENT", 179, 200], ["ineffective exercises", "TREATMENT", 205, 226], ["decontamination equipment", "TREATMENT", 396, 421], ["multiple potential solutions", "TREATMENT", 535, 563], ["the challenges herein", "TREATMENT", 568, 589], ["multiple", "OBSERVATION_MODIFIER", 535, 543]]], ["Clearly, fundamental changes are needed, either in the expectations of hospitals (unlikely) or the resources made available to them to further the cause of preparedness (more likely and currently improving).", [["fundamental changes", "PROBLEM", 9, 28]]], ["There is no question that hospital preparedness must be part of a regional approach to health systems and general preparedness across agency, jurisdictional, and corporate boundaries.", [["no question", "UNCERTAINTY", 9, 20]]], ["Hospitals are part of a greater whole, but each hospital must also have a degree of self-sufficiency to enable independent operations should regional assistance be unavailable.", [["self-sufficiency", "PROBLEM", 84, 100], ["enable independent operations", "TREATMENT", 104, 133]]], ["Realistic expectations for communications systems in disasters are essential for effective implementation of an emergency operations plan.", [["an emergency operations plan", "TREATMENT", 109, 137]]], ["Redundancy is an obvious and desirable solution; simple lowtech equipment can be effective.", [["simple lowtech equipment", "TREATMENT", 49, 73]]], ["These are similar to the popular family radios but are intended (and required) for business use. \u2022 Phone/intercom systems: An internal communications system that is powered by emergency generators and does not require functioning external equipment (such as remote switching stations).", [["An internal communications system", "TREATMENT", 123, 156], ["functioning external equipment", "TREATMENT", 218, 248], ["internal communications", "OBSERVATION", 126, 149]]], ["These systems can be surprisingly robust, even if communications into and out of the facility are disrupted.", [["disrupted", "OBSERVATION", 98, 107]]], ["A facility that owns its own phone switch (that is, switching is done by an internal rather than an external computer) is more likely to retain internal function than one relying on a service provider's switch.", [["more likely", "UNCERTAINTY", 122, 133]]], ["This is even more important for large campuses comprising multiple buildings.", [["multiple", "OBSERVATION_MODIFIER", 58, 66]]], ["Most hospitals have such boards in place, but they are not necessarily used during emergency operations.", [["emergency operations", "TREATMENT", 83, 103]]], ["Status boards serve an important function away from patient-care areas as well: information management in hospital emergency operations centers (also known as command centers, coordination centers, and facility command posts).", [["patient", "ORGANISM", 52, 59], ["patient", "SPECIES", 52, 59]]], ["Combining runners, status boards, and digital cameras creates the opportunity to receive quick, non-intrusive status reports from various parts of a hospital: literally a snapshot of status that may be delivered to the hospital's emergency operations center and displayed there. \u2022 Self-initiation: This is more a training than a communications issue, but the point is that the better trained and exercised employees are, the more capable they will be of independent implementation of an emergency operations plan when activation is initiated.", [["an emergency operations", "TREATMENT", 484, 507]]], ["Many potential solutions to security issues require hospitals to increase their level of interaction with local emergency management and public safety agencies and may require substantial revision of those agencies' existing policies, procedures, and mutual aid agreements:Security\u2022 Meet with local law enforcement agencies: Hospitals are essential resources during disasters and may be targets of terrorism.", [["local emergency management", "TREATMENT", 106, 132], ["substantial revision", "TREATMENT", 176, 196], ["terrorism", "PROBLEM", 398, 407], ["terrorism", "OBSERVATION", 398, 407]]], ["Everyday security resources, where present, are likely to be insufficient during disasters, particularly those involving terrorism.", [["likely to be", "UNCERTAINTY", 48, 60]]], ["If possible, special units may be identified and preassigned to hospitals; this ideal arrangement removes a decision step during an incident. \u2022 Consider private security to provide or augment protection: Although private security guards do not have powers of arrest, they can provide substantial numbers for securing facility access.", [["arrest", "PROBLEM", 259, 265], ["securing facility access", "TREATMENT", 308, 332]]], ["If numerous self-referred patients arrive at a hospital and are met with clear information and directions, they will likely comply.", [["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34]]], ["Incorporation of private security personnel into emergency plans should include specifications of available staff, callup procedures, and consultation with local law enforcement regarding policies and procedures for disasters. \u2022 Make lockdown a realistic part of the plan:SecurityFacilities in a multi-hospital region should reach consensus on a functional definition and share it with local emergency management and public safety providers.", [["disasters", "PROBLEM", 216, 225], ["SecurityFacilities", "TREATMENT", 272, 290], ["local emergency management", "TREATMENT", 386, 412]]], ["Internal training and resources should include readily understandable designation for building entrances and exits.", [["Internal training", "TREATMENT", 0, 17]]], ["Prepositioned, or readily available, signage and pre-scripted messages (both for public address systems and local media broadcast as needed)Securityto direct patients and families to appropriate entrances will speed emergency implementation and improve compliance.", [["patients", "ORGANISM", 158, 166], ["patients", "SPECIES", 158, 166], ["local media broadcast", "TREATMENT", 108, 129]]], ["The biggest step is to be able to decontaminate a single patient without endangering staff, patients, or visitors and without rendering the ED unavailable to incoming traffic [36] .", [["patient", "ORGANISM", 57, 64], ["patients", "ORGANISM", 92, 100], ["patient", "SPECIES", 57, 64], ["patients", "SPECIES", 92, 100]]], ["Industrial incidents can contaminate several patients, making multi-patient capability particularly important for hospitals in industrial areas.", [["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53]]], ["Most incidents resulting in contaminated patients occur at fixed facilities or in agricultural applications [37] , but they can happen anywhere there is a transportation route; moreover, contaminated patients do not always go to the nearest hospital.", [["patients", "ORGANISM", 41, 49], ["patients", "ORGANISM", 200, 208], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 200, 208]]], ["The leap from multi-patient to mass decontamination is expensive, requires far more extensive training and drilling, and may be unrealistic (both in capabilities and likelihood) for smaller facilities.", [["multi-patient to mass decontamination", "TREATMENT", 14, 51], ["extensive training", "TREATMENT", 84, 102], ["drilling", "TREATMENT", 107, 115], ["mass", "OBSERVATION", 31, 35]]], ["For facilities where mass decontamination is considered a legitimate potential need, temporary facilities will likely need to be established; either \"dry\" decontamination or self-disrobement and decontamination (\"strip and shower\") [38] should be seriously considered.", [["mass decontamination", "PROBLEM", 21, 41], ["temporary facilities", "TREATMENT", 85, 105], ["dry\" decontamination", "PROBLEM", 150, 170], ["self-disrobement", "PROBLEM", 174, 190], ["decontamination (\"strip", "TREATMENT", 195, 218]]], ["Whether in the form of trailers, tents, canopies, or large open areas, equipment (and training) must be provided with the foreknowledge that it will be used rarely if at all.", [["tents", "TREATMENT", 33, 38], ["large", "OBSERVATION_MODIFIER", 53, 58]]], ["This is an important consideration: the greatest likelihood is that employees' only exposure to the knowledge, skills, abilities, and decision-making processes involved in mass decontamination will be gained and applied only in training and exercises.DecontaminationThe Agency for Healthcare Research and Quality (AHRQ) has produced numerous useful references and guidelines for hospital preparedness [38A], including models for decontamination, PPE, and isolation and quarantine [38B], and California's Emergency Medical Services Authority has updated their Patient Decontamination Recommendations for Hospitals [38C].", [["mass decontamination", "TREATMENT", 172, 192], ["decontamination", "TREATMENT", 429, 444], ["PPE", "TREATMENT", 446, 449]]], ["These and similar references represent substantial resources in planning an training for single-patient and mass decontamination.Staff TrainingHospital training staff tend to be overloaded with a wide variety of responsibilities, including clinical competencies, continuing education, community education, and non-clinical staff training.", [["patient", "ORGANISM", 96, 103], ["patient", "SPECIES", 96, 103], ["an training", "TREATMENT", 73, 84], ["single-patient and mass decontamination", "TREATMENT", 89, 128], ["substantial", "OBSERVATION_MODIFIER", 39, 50], ["resources", "OBSERVATION", 51, 60], ["mass", "OBSERVATION", 108, 112]]], ["Most hospital staff have little expertise in developing and providing training for disaster procedures, particularly patient and facility decontamination.", [["patient", "ORGANISM", 117, 124], ["patient", "SPECIES", 117, 124], ["disaster procedures", "TREATMENT", 83, 102], ["decontamination", "TREATMENT", 138, 153]]], ["Although \"train-the-trainer\" classes are popular and readily available, newly minted trainers commonly find themselves with few resources and little or no experience, with a resultant dearth of cascaded training.", [["cascaded training", "TREATMENT", 194, 211]]], ["The following steps can help compensate:Staff Training\u2022 An effective training program requires executive support: A directive, backed up by appropriate resource allocation, is the basis on which a successful program progresses. \u2022 Contract for specialized training: Rather than attempting to develop and maintain such expertise, hospitals, hospital groups, or-even better-communities should strongly consider contracting for expertise.", [["An effective training program", "TREATMENT", 56, 85]]], ["Contracts should include follow-up services (refresher training and assistance with exercise development as needed) and provide the option of developing internal capability for conducting informal training and drills within individual units.", [["refresher training", "TREATMENT", 45, 63], ["exercise development", "TREATMENT", 84, 104], ["developing internal capability", "PROBLEM", 142, 172], ["conducting informal training", "TREATMENT", 177, 205]]], ["Hick et al. [39] effectively summarized healthcarespecific needs and goals for decontamination training that incorporate recent OSHA interpretations [40] [41] [42] [43] . \u2022 Let clinicians be clinicians: There are a few positions within a HEICS organization that should be filled by physicians, but in general the most important function for physicians in a disaster is that of a clinician.", [["[40] [41] [42", "SIMPLE_CHEMICAL", 149, 162], ["decontamination training", "TREATMENT", 79, 103], ["few", "OBSERVATION_MODIFIER", 215, 218], ["positions", "OBSERVATION_MODIFIER", 219, 228]]], ["Therefore, hospitals should include select staff physicians in HEICS and other disaster training and provide brief orientations to the bulk of physicians, so that they understand the roles, responsibilities, and function of the emergency organization. \u2022 Move some training to the schools: New guidelines from the Association of American Medical Colleges [44] suggest a curriculum for future physicians in medical schools.", [["disaster training", "TREATMENT", 79, 96]]], ["The most important provision for staff protection is irrespective of specific issues, procedures, or equipment.", [["staff protection", "TREATMENT", 33, 49]]], ["To enable operations to continue under emergency conditions, staff protection measures must be designed with the intent of demonstrating an institutional commitment to employee safety.", [["staff protection measures", "TREATMENT", 61, 86]]], ["This is as much an exercise in trust as in deed; facilities with strained labor-management relations will face greater difficulty in this pursuit than those with smooth partnerships.Staff Protection\u2022 PPE must meet realistic needs: There is no consistent standard for PPE for incidents involving hazmat or weapons of mass destruction.", [["strained labor", "PROBLEM", 65, 79], ["face greater difficulty", "PROBLEM", 106, 129], ["PPE", "PROBLEM", 267, 270], ["incidents", "PROBLEM", 275, 284], ["hazmat", "PROBLEM", 295, 301], ["mass destruction", "PROBLEM", 316, 332], ["no consistent", "UNCERTAINTY", 240, 253], ["mass", "OBSERVATION", 316, 320]]], ["These incidents would send potentially contaminated patients to hospitals.", [["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60]]], ["Level B ensembles (splash protection with self-contained or supplied-air breathing apparatus) offer substantial respiratory protection, but there is little evidence that it is necessary in this setting, and the additional equipment weight, maintenance, and potential claustrophobic reaction of its users may make it deleterious.", [["respiratory", "ANATOMY", 112, 123], ["splash protection", "TREATMENT", 19, 36], ["air breathing apparatus", "TREATMENT", 69, 92], ["substantial respiratory protection", "TREATMENT", 100, 134], ["the additional equipment weight", "TREATMENT", 207, 238], ["potential claustrophobic reaction", "PROBLEM", 257, 290], ["respiratory protection", "OBSERVATION", 112, 134]]], ["In addition, regulatory, financial, and training requirements for Level B are likely to render it both prohibitive and ineffective. , internal and community plans and policies and must specify priority distribution for critical staff and must include procedures for doing so.", [["Level B", "PROBLEM", 66, 73]]], ["Cities participating in a Metropolitan Medical Response System contract are required to incorporate caches and SNS deliveries into their plan, but they must specify priority recipients. \u2022 Consider staff families in plans: It is the unusual healthcare employee who will be satisfied with individual protection that does not cover the family.", [["SNS", "ANATOMICAL_SYSTEM", 111, 114], ["recipients", "ORGANISM", 174, 184]]], ["Plans providing for employee chemoprophylaxis and/or immunizations should include distribution to employee families; this will complicate planning and implementation but will help achieve the goal of having staff available to perform critical functions.ExercisesExercises, traditionally (and still) a JCAHO requirement, are now part of the HRSA National Bioterrorism Hospital Preparedness Plan as well.ExercisesBeyond compliance issues, exercise are an excellent method of testing plans, training, and equipment-but only if the exercises are designed and conducted with that intent.", [["employee chemoprophylaxis", "TREATMENT", 20, 45], ["immunizations", "TREATMENT", 53, 66], ["a JCAHO requirement", "PROBLEM", 299, 318]]], ["This requires that hospitals:Exercises\u2022 Base exercises on realistic plans and models: Start at manageable scales and build on demonstrated principles and procedures.", [["principles and procedures", "TREATMENT", 139, 164]]], ["External evaluators will enhance objectivity and help keep employees out of difficult situations (such as evaluating their supervisors).", [["External evaluators", "TEST", 0, 19]]], ["Focused exercise design and competent controllers can prevent or minimize distractions arising from obstacles encountered during play.", [["Focused exercise design", "TREATMENT", 0, 23], ["competent controllers", "TREATMENT", 28, 49], ["distractions", "PROBLEM", 74, 86]]], ["Local and state emergency management and public safety agencies are excellent resources. \u2022 Use realistic staffing patterns for exercises:ExercisesIn addition to the need for covering all shifts on training and exercises, it is essential to employ staffing patterns that are likely to be in effect when a real incident happens.", [["exercises", "TREATMENT", 210, 219]]], ["Taskbased drills may not need scenarios, but largerscale exercises do.", [["Taskbased drills", "TREATMENT", 0, 16], ["scenarios", "TREATMENT", 30, 39]]], ["Exercises for off-peak shifts should use off-peak staffing; incidents that would require callbacks to provide additional staffing or specialized skills should not assume that those assets are present at the outset. \u2022 Recognize that success has multiple definitions:ExercisesAn exercise that evaluates its intended objectives and yields action items is a success, but only if there is action.", [["callbacks", "TREATMENT", 89, 98]]], ["It is appropriate to determine whether a plan or procedure was successful, particularly regarding specific tasks or functions.", [["procedure", "TREATMENT", 49, 58]]], ["Failure requires corrective action, but the objective determination of success or failure has value as well-not everything is relative.", [["corrective action", "TREATMENT", 17, 34], ["failure", "PROBLEM", 82, 89], ["corrective", "OBSERVATION", 17, 27], ["failure", "OBSERVATION", 82, 89]]], ["An effective preparedness program can use successes and failures as motivators for continued improvement.Critical StepsTo facilitate hospital and community preparedness, there are some essential needs that require action on the federal level (and in some cases require not just a federal but a national approach):Critical Steps\u2022 Financial incentives and support for hospital preparedness: As long as preparedness is competing with everyday essential needs, it will fail to thrive.", [["An effective preparedness program", "TREATMENT", 0, 33]]], ["Whether by grant, reimbursement, or other means, hospitals must have some type of dedicated (and internally immutable) funding stream to cover not just equipment but planning, initial training, refresher training, and exercises.", [["refresher training", "TREATMENT", 194, 212]]], ["Preparedness is an ongoing process and must have ongoing support.", [["ongoing support", "TREATMENT", 49, 64]]], ["The current multi-year cycle of HRSA preparedness grants is an important step in the right direction (albeit already reduced from in its initial funding levels), but it needs to evolve into a secure funding stream and be tied to measurable, sustainable improvements in broad-spectrum (as opposed to bioterrorism-dominant) preparedness.", [["HRSA preparedness grants", "TREATMENT", 32, 56], ["right", "ANATOMY_MODIFIER", 85, 90]]], ["For now and the foreseeable future, NIMS compliance is a necessary price to pay for maintaining access to federal preparedness grants. \u2022 Realistic consensus standards: Hospitals and public safety agencies still rely on unproven tenets, many incorporating military models that have little application in the civilian world.Critical StepsIn the absence of national standards, states and even localities have been developing their own.", [["unproven tenets", "TREATMENT", 219, 234]]], ["In many areas and individual facilities, equipment and training are determined in the absence of standards or even an identified strategy.", [["equipment and training", "TREATMENT", 41, 63], ["many", "OBSERVATION_MODIFIER", 3, 7], ["areas", "OBSERVATION_MODIFIER", 8, 13]]], ["Such standards are most important with respect to PPE, mass decontamination (including \"no decontamination\"), and dealing with mass illness.", [["mass illness", "DISEASE", 127, 139], ["mass decontamination", "PROBLEM", 55, 75], ["mass illness", "PROBLEM", 127, 139], ["mass", "OBSERVATION", 55, 59], ["mass", "OBSERVATION", 127, 131]]], ["The EMSA and AHRQ best practices and models are substantial resources, but they are not yet standards. \u2022 Ethics and liability: As discussed by Pesik et al.Critical Steps[52], triage following use of a weapon of mass destruction on the U.S. civilian population will not fit familiar models.", [["mass destruction", "PROBLEM", 211, 227], ["mass", "OBSERVATION", 211, 215]]], ["In particular, mass illness related to bioterrorism could create a paradox in which the sickest patients receive palliative care only.", [["illness", "DISEASE", 20, 27], ["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["mass illness", "PROBLEM", 15, 27], ["bioterrorism", "PROBLEM", 39, 51], ["palliative care", "TREATMENT", 113, 128], ["mass", "OBSERVATION", 15, 19]]], ["Effective, ethical planning is as essential as the legal protection to conduct it.", [["ethical planning", "TREATMENT", 11, 27]]]], "PMC7450219": [["Beds were sectioned into 8 pods with 30-32 beds each, all separated by partitions (Figure 1).", [["pods", "ANATOMY", 27, 31], ["Beds", "TREATMENT", 0, 4]]], ["Medical providers were to be stationed at the patient intake area to receive patients from ambulances.", [["patient", "ORGANISM", 46, 53], ["patients", "ORGANISM", 77, 85], ["patient", "SPECIES", 46, 53], ["patients", "SPECIES", 77, 85]]], ["Designated areas for doffing and donning of PPE are described in the following diagrams.DESCRIPTION OF FACILITY", [["doffing and donning of PPE", "TREATMENT", 21, 47]]]], "PMC7285131": [], "cce60a30c188469627670870f9ce53e6fa33850a": [["2 on available studies, aimed to evidence the potential survival of novel Coronavirus, and evidencing the 29 appropriate application of disinfection protocols, as a containment measure to viral spread.", [["available studies", "TEST", 5, 22], ["novel Coronavirus", "PROBLEM", 68, 85], ["disinfection protocols", "TREATMENT", 136, 158], ["viral spread", "PROBLEM", 188, 200], ["viral spread", "OBSERVATION", 188, 200]]], ["We have no conflict of interests for the paper titled \"Persistance of SARS-CoV-2 in the environment and 306 COVID-19 transmission from animate and inanimate matrices\" 307", [["SARS", "DISEASE", 70, 74], ["SARS", "PROBLEM", 70, 74], ["CoV", "TEST", 75, 78], ["COVID", "TEST", 108, 113]]]], "PMC7436072": [["IntroductionThe whole world, including India, is facing the Coronavirus pandemic which was started in Wuhan provenance of China in December 2019.", [["the Coronavirus pandemic", "PROBLEM", 56, 80]]], ["In India, the first case of coronavirus was detected on January 30, 2020, in Kerala, and till June 1, 2020, 8:00 am 19,0648 cases have been confirmed.", [["coronavirus", "DISEASE", 28, 39], ["coronavirus", "ORGANISM", 28, 39], ["coronavirus", "PROBLEM", 28, 39]]], ["The Indian government has taken stringent action to fight against the COVID-19 by timely lockdown throughout the country and taking various measures like increasing the testing capability and increasing the number of beds for the management of COVID-19 patients.", [["patients", "ORGANISM", 253, 261], ["patients", "SPECIES", 253, 261], ["various measures", "TREATMENT", 132, 148], ["the testing capability", "TEST", 165, 187], ["COVID", "TEST", 244, 249]]], ["The 5 most populous cities in India are Mumbai, Maharashtra (18.4 million people),IntroductionDelhi, Delhi (16.3 million people), Bangalore, Karnataka (8.44 million people), Hyderabad, Telangana (6.73 million people), and Ahmedabad, Gujarat (5.57 million people).IntroductionThe spread of novel SARS CoV- 2 between people, seems to be primarily via respiratory droplets and aerosols and fomites; however, transmission through the feco-oral route is also a possibility [1].", [["respiratory droplets", "ANATOMY", 349, 369], ["people", "ORGANISM", 255, 261], ["CoV- 2", "ORGANISM", 300, 306], ["people", "ORGANISM", 315, 321], ["people", "SPECIES", 74, 80], ["people", "SPECIES", 121, 127], ["people", "SPECIES", 165, 171], ["people", "SPECIES", 209, 215], ["people", "SPECIES", 255, 261], ["people", "SPECIES", 315, 321], ["SARS CoV", "SPECIES", 295, 303], ["novel SARS CoV", "TREATMENT", 289, 303]]], ["Environmental factors such as temperature and humidity influence the spread of coronavirus transmission [2].", [["coronavirus", "DISEASE", 79, 90], ["coronavirus", "ORGANISM", 79, 90], ["Environmental factors", "PROBLEM", 0, 21], ["temperature and humidity", "TREATMENT", 30, 54]]], ["The other viruses of coronavirus family including SARS CoV-1 and Middle East respiratory syndrome coronavirus (MERS-CoV) showed temporal association with temperature and humidity [3, 4].", [["respiratory syndrome coronavirus", "DISEASE", 77, 109], ["coronavirus", "ORGANISM", 21, 32], ["SARS CoV-1", "ORGANISM", 50, 60], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 65, 109], ["MERS-CoV", "ORGANISM", 111, 119], ["coronavirus", "SPECIES", 21, 32], ["SARS CoV-1", "SPECIES", 50, 60], ["coronavirus", "SPECIES", 98, 109], ["SARS CoV-1", "SPECIES", 50, 60], ["Middle East respiratory syndrome coronavirus", "SPECIES", 65, 109], ["MERS-CoV", "SPECIES", 111, 119], ["SARS CoV", "TEST", 50, 58], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 65, 109], ["viruses", "OBSERVATION", 10, 17], ["coronavirus", "OBSERVATION", 21, 32], ["Middle", "ANATOMY_MODIFIER", 65, 71], ["respiratory syndrome", "ANATOMY", 77, 97]]], ["The previous research from China showed a negative correlation between relative humidity and SARS CoV-1 and a positive relationship with temperature [5].", [["CoV-1", "GENE_OR_GENE_PRODUCT", 98, 103], ["SARS CoV-1", "SPECIES", 93, 103], ["relative humidity", "TEST", 71, 88], ["SARS CoV", "TEST", 93, 101]]], ["Though, a study from Saudi Arabia on MERS-CoV found a significant positive association of cases with low humidity and temperature [3].", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 37, 45], ["MERS-CoV", "SPECIES", 37, 45], ["a study", "TEST", 8, 15], ["low humidity", "PROBLEM", 101, 113], ["significant", "OBSERVATION_MODIFIER", 54, 65], ["positive", "OBSERVATION", 66, 74], ["low humidity", "OBSERVATION_MODIFIER", 101, 113]]], ["However, another study demonstrated high temperature and low humidity as a significant contributor to MERS-CoV infection [6].", [["infection", "DISEASE", 111, 120], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 102, 110], ["MERS-CoV", "SPECIES", 102, 110], ["another study", "TEST", 9, 22], ["high temperature", "PROBLEM", 36, 52], ["low humidity", "PROBLEM", 57, 69], ["CoV infection", "PROBLEM", 107, 120], ["high temperature", "OBSERVATION_MODIFIER", 36, 52], ["low humidity", "OBSERVATION_MODIFIER", 57, 69], ["infection", "OBSERVATION", 111, 120]]], ["Therefore, temperature and humidity play an essential role in the transmission of both SARS-1 and MERS-CoV infection.IntroductionRecent evidence suggested that COVID-19 infection is more common in cold and temperate climate as compared to a warm climate, similar to the influenza virus which tends to disappear when the weather becomes warm.", [["SARS", "DISEASE", 87, 91], ["infection", "DISEASE", 107, 116], ["COVID-19", "CHEMICAL", 160, 168], ["infection", "DISEASE", 169, 178], ["influenza", "DISEASE", 270, 279], ["SARS-1", "GENE_OR_GENE_PRODUCT", 87, 93], ["MERS-CoV", "ORGANISM", 98, 106], ["COVID-19", "ORGANISM", 160, 168], ["influenza virus", "ORGANISM", 270, 285], ["SARS-1", "SPECIES", 87, 93], ["MERS-CoV", "SPECIES", 98, 106], ["influenza virus", "SPECIES", 270, 285], ["humidity", "TREATMENT", 27, 35], ["MERS", "PROBLEM", 98, 102], ["CoV infection", "PROBLEM", 103, 116], ["COVID-19 infection", "PROBLEM", 160, 178], ["a warm climate", "PROBLEM", 239, 253], ["the influenza virus", "PROBLEM", 266, 285], ["CoV", "ANATOMY", 103, 106], ["infection", "OBSERVATION", 107, 116], ["infection", "OBSERVATION", 169, 178], ["influenza virus", "OBSERVATION", 270, 285], ["warm", "OBSERVATION", 336, 340]]], ["The first of its kind study from China on COVID-19 and environmental factors demonstrated the significant negative association between COVID-19 cases with temperature and humidity [7].", [["COVID", "TEST", 42, 47], ["COVID", "TEST", 135, 140]]], ["It was observed that average daily confirmed cases decreased by 11\u201312% when there was an increase in average humidity of 1% with a temperature range of 5\u20138 \u00b0C. It was also suggested that the novel COVID-19 pandemic had affected more seriously in countries within a temperature range of 3 to 17 \u00b0C with absolute humidity between 3 and 9 g/m2.", [["COVID-19", "ORGANISM", 197, 205], ["a temperature range", "TEST", 129, 148], ["the novel COVID", "TEST", 187, 202], ["absolute humidity", "TEST", 302, 319], ["increase", "OBSERVATION_MODIFIER", 89, 97], ["average", "OBSERVATION_MODIFIER", 101, 108], ["humidity", "OBSERVATION_MODIFIER", 109, 117]]], ["Therefore, it has been proposed that dry and moderately cold environment is the most convenient state for transmission of COVID-19 [8].IntroductionSince India has the second largest population in the world and weather conditions are extreme and different from the countries severely affected by COVID-19; therefore it is essential to know the association of temperature and humidity on COVID-19.", [["COVID-19", "CHEMICAL", 122, 130], ["COVID-19", "CHEMICAL", 295, 303], ["dry and moderately cold environment", "PROBLEM", 37, 72], ["COVID", "TEST", 122, 127], ["COVID", "TEST", 295, 300], ["COVID", "TEST", 386, 391], ["moderately", "OBSERVATION_MODIFIER", 45, 55], ["largest", "OBSERVATION_MODIFIER", 174, 181], ["population", "OBSERVATION", 182, 192]]], ["Moreover, the data on environmental factors and COVID-19 is still limited.", [["environmental factors", "TEST", 22, 43], ["COVID", "TEST", 48, 53]]], ["Thus, this study will contribute to predict the factors for COVID-19 and better pandemic response to policymakers regarding additional public health measures.Study Area ::: MethodsDelhi is one of the most crowded cities in the world, is the capital of India and is the largest city in the country as well.", [["MethodsDelhi", "CHEMICAL", 173, 185], ["this study", "TEST", 6, 16], ["COVID", "TEST", 60, 65], ["additional public health measures", "TREATMENT", 124, 157], ["capital", "OBSERVATION_MODIFIER", 241, 248], ["largest", "OBSERVATION_MODIFIER", 269, 276]]], ["The population of Delhi as per census 2011, was 16,368,899 inhabitants with a population growth rate of 1.39% per year.Data Collection and Analysis ::: MethodsThe dependent variable was the number of COVID-19 cases in Delhi from April 1 to May 31, 2020.", [["a population growth rate", "TEST", 76, 100], ["Methods", "TREATMENT", 152, 159], ["COVID", "TEST", 200, 205], ["population", "OBSERVATION_MODIFIER", 4, 14], ["dependent", "OBSERVATION_MODIFIER", 163, 172], ["variable", "OBSERVATION_MODIFIER", 173, 181]]], ["Independent variables were the number of COVID-19 tests performed, daily temperature, and daily relative humidity.", [["COVID", "TEST", 41, 46], ["temperature", "TEST", 73, 84]]], ["For a number of COVID-19 tests, a crowdsource platform was used which captures data from different sources ranging from media reports to official twitter handles of state authorities (www.covid19india.org).", [["COVID", "DNA", 16, 21], ["COVID", "TEST", 16, 21], ["a crowdsource platform", "TREATMENT", 32, 54]]], ["For meteorological data, an online weather forecasting website (www.worldweatheronline.com) was used which uses satellite-based imagery for predication and has a record of previous data.", [["meteorological data", "TEST", 4, 23], ["previous data", "TEST", 172, 185]]], ["From here past data of daily maximum temperature, average temperature and average relative humidity was taken.", [["average temperature", "TEST", 50, 69]]], ["SPSS ver 21 was used to model this data with the help of linear regression.ResultA total of two-month data were used.", [["linear regression", "PROBLEM", 57, 74]]], ["The mean maximum temperature was 40.4 \u00b1 3.6 \u00b0C ranging from 33 to 48 \u00b0C. The mean average temperature was 35.6 \u00b1 3.6 \u00b0C ranging from 28.5 to 43 \u00b0C. In the same way, average relative humidity % was 21.2 \u00b1 7.6 ranging from 8 to 39.5% (Fig. 1).ResultLinear regression was run to understand the effect of the number of tests, temperature, and relative humidity on the number of COVID-19 cases in Delhi.", [["The mean maximum temperature", "TEST", 0, 28], ["\u00b0C", "TEST", 44, 46], ["The mean average temperature", "TEST", 73, 101], ["\u00b0C", "TEST", 117, 119], ["average relative humidity", "TEST", 165, 190], ["ResultLinear regression", "PROBLEM", 241, 264], ["tests", "TEST", 315, 320], ["temperature", "TEST", 322, 333], ["humidity", "OBSERVATION_MODIFIER", 182, 190]]], ["To assess linearity, a scatterplot of the number of COVID-19 cases against the number of tests, maximum temperature, average temperature, and average relative humidity with a superimposed regression line was plotted.", [["COVID", "TEST", 52, 57], ["tests", "TEST", 89, 94], ["maximum temperature", "TEST", 96, 115], ["average temperature", "TEST", 117, 136], ["a superimposed regression line", "TREATMENT", 173, 203], ["regression line", "OBSERVATION", 188, 203]]], ["Visual inspection of these plots indicated an approx.", [["Visual inspection", "TEST", 0, 17], ["these plots", "TEST", 21, 32]]], ["A linear relationship between the variables (Fig. 2).ResultThe model was significantly able to predict number of COVID-19 cases, F (4,56) = 1213.61, p < 0.001, accounting for 99.4% of the variation in COVID-19 cases with adjusted R2 = 98.8%.", [["COVID", "TEST", 113, 118], ["p", "TEST", 149, 150], ["the variation", "TEST", 184, 197], ["COVID", "TEST", 201, 206], ["R2", "TEST", 230, 232], ["linear", "OBSERVATION_MODIFIER", 2, 8]]], ["As shown in Table 1, the only number of tests significantly affects COVID cases.", [["tests", "TEST", 40, 45]]], ["With every 100 extra tests performed leads to approx.", [["extra tests", "TEST", 15, 26]]], ["Maximum Temperature, average temperature and average relative humidity did not show statistical significance.DiscussionThis study pattern of temperature and humidity change provides a depiction of the occurrence of COVID-19 cases in Delhi, India.", [["Maximum Temperature", "TEST", 0, 19], ["average temperature", "TEST", 21, 40], ["average relative humidity", "TEST", 45, 70], ["This study", "TEST", 119, 129], ["temperature and humidity change", "PROBLEM", 141, 172], ["COVID", "TEST", 215, 220]]], ["We did not find a significant association of temperature and humidity with COVID-19 cases after regression.", [["COVID", "TREATMENT", 75, 80]]], ["Our findings are consistent with results of previous research which also showed no relationship of COVID-19 with temperature [9, 10].", [["COVID-19", "CHEMICAL", 99, 107], ["previous research", "TEST", 44, 61], ["COVID", "TEST", 99, 104], ["temperature", "TEST", 113, 124], ["consistent with", "UNCERTAINTY", 17, 32]]], ["The study from Indonesia showed a positive correlation of average temperature with COVID-19; however, they did not adjust the variable by regression analysis [11].", [["The study", "TEST", 0, 9], ["average temperature", "TEST", 58, 77], ["COVID", "TEST", 83, 88]]], ["The research from Brazil also suggested that higher mean temperatures and average relative humidity favored the COVID-19 transmission, finding different from coldest countries or periods under cool temperatures [12].", [["COVID-19", "SPECIES", 112, 120], ["higher mean temperatures", "PROBLEM", 45, 69], ["the COVID", "TEST", 108, 117]]], ["The study on the effects of temperature and humidity on the daily new cases and new deaths of COVID-19 in 166 countries demonstrated that temperature and relative humidity were both negatively related to daily new cases and deaths.", [["deaths", "DISEASE", 84, 90], ["COVID-19", "CHEMICAL", 94, 102], ["deaths", "DISEASE", 224, 230], ["The study", "TEST", 0, 9], ["COVID", "TEST", 94, 99], ["temperature and relative humidity", "PROBLEM", 138, 171]]], ["It was observed that each 1 \u00b0C increase in temperature is associated with 3.08% (95% CI 1.53%, 4.63%) reduction in daily new cases after adjusting with all other variables.", [["temperature", "TEST", 43, 54], ["CI", "TEST", 85, 87]]], ["Similarly, a 1% increase in relative humidity was associated with a 0.85% (95% CI 0.51%, 1.19%) reduction in the daily new case [13].", [["relative humidity", "PROBLEM", 28, 45], ["CI", "TEST", 79, 81], ["increase", "OBSERVATION_MODIFIER", 16, 24], ["humidity", "OBSERVATION_MODIFIER", 37, 45]]], ["However, the countries included in this study had temperatures ranged from \u2212 5.28 to 34.30 \u00b0C. The average temperature in our study ranged 28.5\u201343 \u00b0C which was quite warm and different from this study.", [["this study", "TEST", 35, 45], ["temperatures", "TEST", 50, 62], ["The average temperature", "TEST", 95, 118], ["our study", "TEST", 122, 131], ["this study", "TEST", 190, 200], ["average", "OBSERVATION_MODIFIER", 99, 106], ["temperature", "OBSERVATION_MODIFIER", 107, 118], ["warm", "OBSERVATION", 166, 170]]], ["Moreover, there are certain factors like migrant workers, high density of population, poor health hygiene etc. that might also contribute to an increasing number of cases besides metrological parameters.", [["metrological parameters", "TEST", 179, 202], ["high density", "OBSERVATION_MODIFIER", 58, 70], ["increasing", "OBSERVATION_MODIFIER", 144, 154]]], ["The difference in results in the various study may also be due to different statistical methods.DiscussionThe important findings in our study were a statistically significant association of COVID-19 cases with an increase in the total number of tests.", [["the various study", "TEST", 29, 46], ["our study", "TEST", 132, 141], ["COVID", "TEST", 190, 195], ["tests", "TEST", 245, 250], ["difference", "OBSERVATION_MODIFIER", 4, 14], ["may also be due to", "UNCERTAINTY", 47, 65], ["increase", "OBSERVATION_MODIFIER", 213, 221]]], ["This is also being reflected in the country as cases have rampantly increased after increase COVID-19 testing capacity.", [["increase COVID", "TREATMENT", 84, 98]]], ["The experts suggested that testing capacity in India still needs to increase by tenfold or more to estimate the exact number of cases [14].DiscussionThe major strength of our study is that we used data set from one of the most populous cities with extreme weather conditions in the World.", [["testing capacity", "TEST", 27, 43], ["our study", "TEST", 171, 180]]], ["However, our research has a few limitations.", [["few", "OBSERVATION_MODIFIER", 28, 31]]], ["Firstly, India has a large geographic area; therefore, the result of this study might not be represented by the whole country.", [["a large geographic area", "PROBLEM", 19, 42], ["this study", "TEST", 69, 79], ["large", "OBSERVATION_MODIFIER", 21, 26], ["geographic", "OBSERVATION_MODIFIER", 27, 37], ["area", "OBSERVATION_MODIFIER", 38, 42]]], ["Secondly, there are certain factors like social distancing, hand hygiene, universal masking, migration of population etc. which may affect COVID-19 cases and need to be explored in large scale study.ConclusionThe findings of our study provide preliminary evidence that the COVID-19 pandemic may not be suppressed with an increase in temperature and humidity.", [["hand", "ANATOMY", 60, 64], ["hand", "ORGANISM_SUBDIVISION", 60, 64], ["universal masking", "TREATMENT", 74, 91], ["COVID", "TEST", 139, 144], ["large scale study", "TEST", 181, 198], ["our study", "TEST", 225, 234], ["the COVID", "TEST", 269, 278], ["increase", "OBSERVATION_MODIFIER", 321, 329]]], ["However, it is crucial to increase the testing capacity to achieve a meaningful epidemiologic understanding of the prevalence and to guide policy measures for COVID-19.", [["the testing capacity", "TEST", 35, 55], ["COVID", "TEST", 159, 164]]]], "18c0b4d11ea665dcc1f4571ff6bfa5a54fdd958c": [["Henan J a n 2 9 F e b 0 8 F e b 1 8 F e b 2 8 M a r 0 9 M a r 1 9", [["r 1 9", "DNA", 60, 65], ["Henan J", "TEST", 0, 7], ["b", "TEST", 40, 41], ["a r", "TEST", 58, 61]]]], "PMC7127316": [["IntroductionHotels are designed to provide high overall comfort and multi-faceted services to guests frequently accustomed to, and willing to pay for exclusive amenities, treatment, and entertainment.", [["treatment", "TREATMENT", 171, 180]]], ["On the other hand, state-of-the-art technical infrastructure is typically utilized in hotels to provide high levels of comfort, especially thermal comfort.", [["thermal comfort", "TREATMENT", 139, 154]]], ["Nevertheless, using energy-intensive space-conditioning systems does not warrant absolute guest\u2019s satisfaction [1], [3].", [["energy-intensive space-conditioning systems", "TREATMENT", 20, 63]]], ["Guests frequently complain about thermal discomfort, even where expensive and sophisticated systems are operated.", [["thermal discomfort", "PROBLEM", 33, 51]]], ["Complaints in hotels are most commonly related to uncomfortable air temperatures (too high or too low), and to the difficulty or impossibility of individual adjustment [3].", [["uncomfortable air temperatures", "PROBLEM", 50, 80]]], ["Moreover, space conditioning (heating, cooling, and ventilation for the purpose of maintaining high standards of air quality and thermal comfort) typically accounts for about half the total energy consumed in hotels [4], [5].", [["space conditioning", "TREATMENT", 10, 28], ["cooling", "TREATMENT", 39, 46], ["ventilation", "TREATMENT", 52, 63], ["space conditioning", "OBSERVATION", 10, 28]]], ["Nevertheless, hotels are public places accommodating a vast variety of international travellers; therefore the demand for good IAQ may be higher than for other types of buildings [6].IntroductionTeeters et al. [6] claimed that facility managers in the hospitality sector have only reacted to those IAQ problems that have caused immediate irritation to guests or employees.", [["immediate irritation", "PROBLEM", 328, 348]]], ["However, inadequate air quality as well as the lack of air circulation is another frequent complaint.", [["inadequate air quality", "PROBLEM", 9, 31], ["inadequate", "OBSERVATION_MODIFIER", 9, 19], ["air quality", "OBSERVATION", 20, 31], ["air circulation", "OBSERVATION", 55, 70]]], ["In addition, the IAQ of hotel buildings affects the health of guests especially in terms of bacterial contamination.", [["bacterial contamination", "PROBLEM", 92, 115], ["bacterial contamination", "OBSERVATION", 92, 115]]], ["For example, Legionnaire\u2019s disease broke out in one USA hotel (182 people illness and 29 deaths in 1976) and more than 60 outbreaks worldwide in hotels, hospitals and offices were reported [7], [8], [9].", [["Legionnaire\u2019s disease", "DISEASE", 13, 34], ["illness", "DISEASE", 74, 81], ["deaths", "DISEASE", 89, 95], ["people", "SPECIES", 67, 73], ["Legionnaire\u2019s disease", "PROBLEM", 13, 34], ["disease", "OBSERVATION", 27, 34]]], ["Furthermore, the severe acute respiratory syndrome (SARS) broke out in \u201cM\u201d hotel in Hong Kong has increased the public awareness to indoor air quality of hotels [8].IntroductionOn the other hand, the European Parliament and Council approved in December 2002 a directive on the energy performance of buildings 2002/91/EC (EPBD) [10], which introduced the obligation of energy certification of buildings.", [["acute respiratory syndrome", "DISEASE", 24, 50], ["SARS", "DISEASE", 52, 56], ["the severe acute respiratory syndrome", "PROBLEM", 13, 50], ["severe", "OBSERVATION_MODIFIER", 17, 23], ["acute", "OBSERVATION_MODIFIER", 24, 29], ["respiratory syndrome", "OBSERVATION", 30, 50], ["increased", "OBSERVATION_MODIFIER", 98, 107]]], ["One of these is the \u2018\u2018Indoor environmental input parameters for design and assessment of energy performance of buildings\u201d, addressing IAQ, thermal environment, lighting and acoustics [11].", [["assessment", "TEST", 75, 85]]], ["Portugal, as one of the European Union member states, approved a series of national laws to implement the EPBD [13], [14], [15], stating simultaneously that IAQ monitoring of the existing non residential buildings is mandatory, under the rules of RSECE [14].", [["the EPBD", "TEST", 102, 110]]], ["However, it is not the case for most of the member countries.IntroductionIn this scope, a comprehensive IAQ audit methodology along with energy audit of buildings should be established in order to identify the indoor air problems.", [["energy audit of buildings", "TREATMENT", 137, 162]]], ["Although, some IAQ monitoring methods have been developed in different countries, most of them are applied to office and hospital buildings [e.g. Ref.", [["some IAQ monitoring methods", "TEST", 10, 37]]], ["However, the IAQ monitoring approach that is suitable for the hotel building has not yet been developed [1].IntroductionHence, the purpose of this study is to develop and demonstrate a comprehensive IAQ audit methodology for hotel buildings.", [["the IAQ monitoring approach", "TEST", 9, 36], ["this study", "TEST", 142, 152]]], ["The data collected from this approach can be used to assess the air quality in hotel buildings and to identify the indoor air problems.", [["The data", "TEST", 0, 8], ["this approach", "TREATMENT", 24, 37], ["the indoor air problems", "PROBLEM", 111, 134]]], ["Furthermore, the result from IAQ audit shows the necessity of having IAQ audit along with energy audit of buildings.", [["IAQ audit", "TEST", 29, 38]]], ["In fact, if just energy parameters are considered, as in the last decades, people\u2019s comfort and health can be significantly sacrificed.IAQ audit methodology ::: Indoor air quality auditThe proposed IAQ audit follows a systematic approach with portable equipment, involving the measurement of physical parameters (temperature (dry bulb), relative humidity and the concentration of the suspended particulate matter (PM10)), the monitoring of the concentrations of selected chemical indicators (carbon dioxide (CO2), carbon monoxide (CO), formaldehyde (HCHO), and total volatile organic compounds (TVOCs)), and the measurements of biological indicators (bacteria, fungi, Legionella).", [["carbon dioxide", "CHEMICAL", 492, 506], ["CO2", "CHEMICAL", 508, 511], ["carbon monoxide", "CHEMICAL", 514, 529], ["formaldehyde", "CHEMICAL", 536, 548], ["HCHO", "CHEMICAL", 550, 554], ["carbon dioxide", "CHEMICAL", 492, 506], ["CO2", "CHEMICAL", 508, 511], ["carbon monoxide", "CHEMICAL", 514, 529], ["CO", "CHEMICAL", 531, 533], ["formaldehyde", "CHEMICAL", 536, 548], ["HCHO", "CHEMICAL", 550, 554], ["people", "ORGANISM", 75, 81], ["carbon dioxide", "SIMPLE_CHEMICAL", 492, 506], ["CO2", "SIMPLE_CHEMICAL", 508, 511], ["carbon monoxide", "SIMPLE_CHEMICAL", 514, 529], ["CO", "SIMPLE_CHEMICAL", 531, 533], ["formaldehyde", "SIMPLE_CHEMICAL", 536, 548], ["HCHO", "SIMPLE_CHEMICAL", 550, 554], ["volatile organic compounds", "SIMPLE_CHEMICAL", 567, 593], ["people", "SPECIES", 75, 81], ["portable equipment", "TEST", 243, 261], ["carbon dioxide (CO2", "TREATMENT", 492, 511], ["carbon monoxide (CO", "TREATMENT", 514, 533], ["formaldehyde (HCHO)", "TREATMENT", 536, 555], ["total volatile organic compounds", "TREATMENT", 561, 593], ["bacteria", "PROBLEM", 651, 659], ["fungi", "PROBLEM", 661, 666], ["Legionella", "PROBLEM", 668, 678]]], ["In the reported case, air exchange rates (AERs) were measured by the concentration-decay method using metabolic CO2 as the tracer gas.", [["CO2", "CHEMICAL", 112, 115], ["CO2", "CHEMICAL", 112, 115], ["CO2", "SIMPLE_CHEMICAL", 112, 115], ["metabolic CO2", "TEST", 102, 115], ["the tracer gas", "TEST", 119, 133], ["air", "OBSERVATION", 22, 25]]], ["The IAQ audit commences with the collection and analysis of the available architectural, mechanical and electrical drawings follows by the walkthrough inspection in order to verify and update the information provided by the building owner or responsible agent, as well as observation for any apparent or potential pollutant sources, occupant\u2019s activities and complaints, swift verification of CO2 levels in the building, pre-evaluation of the hygienic and maintenance conditions of the HVAC systems, and collection of additional information which is deemed necessary for an adequate audit planning.IAQ audit methodology ::: Indoor air quality auditAll collected information on the building and its HVAC systems, including during the walkthrough inspection, is considered to determine the quantity and locations of the required sampling points, a crucial task for the suitable planning of the measuring campaign.", [["CO2", "CHEMICAL", 393, 396], ["CO2", "CHEMICAL", 393, 396], ["CO2", "SIMPLE_CHEMICAL", 393, 396], ["the walkthrough inspection", "TEST", 135, 161], ["CO2 levels", "TEST", 393, 403], ["the HVAC systems", "TREATMENT", 482, 498], ["the walkthrough inspection", "TEST", 729, 755]]], ["The next stage of the audit involves the measurement of the specified indicators, followed by the evaluation phase.", [["the evaluation phase", "TEST", 94, 114]]], ["In this phase, the measured data will be analyzed and compared with standards/regulations specified limits and the sources of IAQ problems will be identified, with the help of an integral correlation between all indicators measured and information acquired.", [["IAQ problems", "PROBLEM", 126, 138], ["an integral correlation", "TEST", 176, 199]]], ["Finally a set of corrective actions will be recommended to the building owner/manager.Building characteristics ::: Indoor air quality auditTo better illustrate the proposed IAQ audit methodology of hotel buildings, a 4-star hotel building in a city at the central region of Portugal was selected as a case study.", [["corrective actions", "TREATMENT", 17, 35], ["a case study", "TEST", 299, 311], ["central", "ANATOMY_MODIFIER", 256, 263]]], ["The underground levels are mainly the car parking areas, with the exception of \u22121 level, in which a restaurant, kitchen and 2 conference rooms are situated.", [["The underground levels", "TEST", 0, 22], ["underground", "OBSERVATION_MODIFIER", 4, 15], ["levels", "OBSERVATION_MODIFIER", 16, 22], ["mainly", "OBSERVATION_MODIFIER", 27, 33]]], ["The hotel has 120 rooms and 13 suites distributed by 7 floors with a similar architecture, from 1st level to 7th level.Building characteristics ::: Indoor air quality auditThe HVAC system for the whole building is based in a centralized hot/chilled water production system, with a two-pipe distribution and a fan coil unit (FCU) in each guest room.", [["The HVAC system", "TREATMENT", 172, 187], ["a centralized hot/chilled water production system", "TREATMENT", 223, 272], ["a fan coil unit", "TREATMENT", 307, 322]]], ["The guest rooms are naturally ventilated: the sole mechanical ventilation element in each one is the exhaust fan at the respective adjacent bathroom.", [["the sole mechanical ventilation element", "TREATMENT", 42, 81], ["naturally ventilated", "OBSERVATION", 20, 40], ["mechanical", "OBSERVATION", 51, 61], ["ventilation element", "OBSERVATION", 62, 81]]], ["By this way, the fresh air supplied to the rooms and suites comes in by infiltration through the window frames and from the corridor through the door slits, strongly promoted by the bathroom mechanical exhaust fan.", [["the fresh air", "PROBLEM", 13, 26], ["air", "OBSERVATION", 23, 26], ["infiltration", "OBSERVATION", 72, 84]]], ["The ground level (lobby, reception, etc.) is served by a specific air handling unit (AHU) with a fraction of air recirculation.", [["air recirculation", "OBSERVATION", 109, 126]]], ["The air renewal and thermal conditioning for conference and meeting rooms, as well as for the restaurant is provided by all-fresh AHUs.Preliminary visit ::: Preliminary visit and measurements ::: Indoor air quality auditA walkthrough inspection and checklist was completed for the hotel to document HVAC system operation and hygiene, air intake location, sources of contaminants, building drainage, roof and interior inspection, maintenance, combustion appliances, room area and volume, carpets, special facilities, space usage and other factors.", [["checklist", "TEST", 249, 258], ["HVAC system operation", "TREATMENT", 299, 320], ["building drainage", "TREATMENT", 380, 397], ["roof and interior inspection", "TREATMENT", 399, 427], ["combustion appliances", "TREATMENT", 442, 463], ["space usage", "TREATMENT", 516, 527], ["air renewal", "OBSERVATION", 4, 15], ["drainage", "OBSERVATION", 389, 397], ["combustion appliances", "OBSERVATION", 442, 463]]], ["Floor plans and other information regarding the hotel were obtained.Number and location of sampling points ::: Preliminary visit and measurements ::: Indoor air quality auditAfter the collection of all the mentioned data, an integrated analysis of the hotel building was done to determine the quantity and locations of the sampling points.", [["an integrated analysis", "TEST", 222, 244]]], ["All spaces of the building with human occupancy were grouped by zones.", [["human", "ORGANISM", 32, 37], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 32, 37], ["human occupancy", "TREATMENT", 32, 47]]], ["Accordingly, the hotel building was divided into 7 different zones based on the ventilation system supplying each zone, the type of activity in the zone, thermal loads, and source of emissions.Number and location of sampling points ::: Preliminary visit and measurements ::: Indoor air quality auditBrief overview of the zones and number of measuring points, as well as their corresponding HVAC system are presented in Table 1.Number and location of sampling points ::: Preliminary visit and measurements ::: Indoor air quality auditThe minimum number of sampling points to be considered in each zone was estimated as suggested in the national IAQ guideline (technical note NT-SCE-02, 2009 [17]):(1)Ni=0.15\u00d7Ai,where Ni is the minimum number of sampling points in zone i (Ni\u2265 1), and Ai is the area of zone i in m2.Number and location of sampling points ::: Preliminary visit and measurements ::: Indoor air quality auditTherefore, for this project the mentioned indicators were measured in 7 zones which encompass 27 points in total.", [["Ni", "CHEMICAL", 716, 718], ["Ni", "CHEMICAL", 699, 701], ["Ni", "CHEMICAL", 716, 718], ["the ventilation system", "TREATMENT", 76, 98], ["Ni", "TEST", 699, 701], ["zone", "OBSERVATION_MODIFIER", 114, 118], ["activity", "OBSERVATION_MODIFIER", 132, 140], ["zone", "OBSERVATION_MODIFIER", 148, 152], ["thermal loads", "OBSERVATION", 154, 167], ["zones", "ANATOMY_MODIFIER", 321, 326], ["minimum", "OBSERVATION_MODIFIER", 537, 544], ["zone", "ANATOMY_MODIFIER", 801, 805], ["m2", "ANATOMY", 811, 813], ["27 points", "OBSERVATION_MODIFIER", 1014, 1023]]], ["Nevertheless the main area of concern for this IAQ audit is the set of guest rooms, as they are naturally ventilated and lack of good IAQ was much probable.", [["IAQ", "GENE_OR_GENE_PRODUCT", 134, 137], ["main", "OBSERVATION_MODIFIER", 17, 21], ["area", "OBSERVATION_MODIFIER", 22, 26]]], ["Spatial position of sampling points are specified in accordance to the international guideline EN ISO 16000-1 [19]: at least 1 m away from walls in the room, and about 1 m above the floor, since this is the approximate height of the average breathing zone.Physical indicators ::: Preliminary visit and measurements ::: Indoor air quality auditThe thermal comfort level of the indoor environment is measured using an indoor climate analyzer DirectSense IAQ (Model IQ610, Graywolf), which allowed measuring the room ambient temperature (dry bulb) and relative humidity, besides the concentration of several chemical pollutants referred in the next section.", [["bulb", "ORGANISM_SUBDIVISION", 539, 543], ["relative humidity", "TREATMENT", 549, 566], ["several chemical pollutants", "PROBLEM", 597, 624], ["position", "OBSERVATION_MODIFIER", 8, 16], ["chemical pollutants", "OBSERVATION", 605, 624]]], ["The concentration of airborne particulate matter (PM10: for particles of size \u226410 \u03bcm) was measured using an airborne particle counter (Model Handheld 3016 IAQ, LIGHTHOUSE).Physical indicators ::: Preliminary visit and measurements ::: Indoor air quality auditSince it was found very probable during preliminary visit that the ventilation rate in the guest rooms was insufficient, AER measurement became inevitable.", [["an airborne particle counter", "TREATMENT", 105, 133], ["the ventilation rate", "TEST", 322, 342], ["AER measurement", "TEST", 380, 395], ["concentration", "OBSERVATION_MODIFIER", 4, 17]]], ["The AER in the room was measured using the concentration-decay method, in which metabolic CO2 was selected as the tracer gas [20], [21], [22], [23], [24].", [["CO2", "CHEMICAL", 90, 93], ["CO2", "CHEMICAL", 90, 93], ["CO2", "SIMPLE_CHEMICAL", 90, 93], ["[21]", "SIMPLE_CHEMICAL", 131, 135], ["[22]", "SIMPLE_CHEMICAL", 137, 141], ["[23]", "SIMPLE_CHEMICAL", 143, 147], ["AER", "PROTEIN", 4, 7], ["metabolic CO2", "TEST", 80, 93], ["the tracer gas", "TEST", 110, 124]]], ["The IAQ monitor (Model PS32, SENSOTRON) was used for three days CO2 measurements.Chemical indicators ::: Preliminary visit and measurements ::: Indoor air quality auditContinuous real-time chemical monitoring of carbon dioxide (CO2), carbon monoxide (CO), formaldehyde (HCHO), and total volatile organic compounds (TVOCs) was carried out at the pre-determined indoor sampling points of each specified zone or group of spaces, at about 1 m above floor level and an outdoor point in close proximity to the fresh air intake point of the AHU, for a period of 15 min at each point.", [["carbon dioxide", "CHEMICAL", 212, 226], ["CO2", "CHEMICAL", 228, 231], ["carbon monoxide", "CHEMICAL", 234, 249], ["formaldehyde", "CHEMICAL", 256, 268], ["HCHO", "CHEMICAL", 270, 274], ["CO2", "CHEMICAL", 64, 67], ["carbon dioxide", "CHEMICAL", 212, 226], ["CO2", "CHEMICAL", 228, 231], ["carbon monoxide", "CHEMICAL", 234, 249], ["CO", "CHEMICAL", 251, 253], ["formaldehyde", "CHEMICAL", 256, 268], ["HCHO", "CHEMICAL", 270, 274], ["CO2", "SIMPLE_CHEMICAL", 64, 67], ["carbon dioxide", "SIMPLE_CHEMICAL", 212, 226], ["CO2", "SIMPLE_CHEMICAL", 228, 231], ["carbon monoxide", "SIMPLE_CHEMICAL", 234, 249], ["CO", "SIMPLE_CHEMICAL", 251, 253], ["formaldehyde", "SIMPLE_CHEMICAL", 256, 268], ["HCHO", "SIMPLE_CHEMICAL", 270, 274], ["volatile organic compounds", "SIMPLE_CHEMICAL", 287, 313], ["The IAQ monitor", "TEST", 0, 15], ["Model PS32, SENSOTRON)", "TREATMENT", 17, 39], ["CO2 measurements", "TEST", 64, 80], ["Indoor air quality", "TEST", 144, 162], ["carbon dioxide (CO2", "TREATMENT", 212, 231], ["carbon monoxide", "TEST", 234, 249], ["formaldehyde (HCHO", "TREATMENT", 256, 274], ["zone", "OBSERVATION_MODIFIER", 401, 405], ["fresh air", "OBSERVATION", 504, 513]]], ["All the above chemical indicators were measured with DirectSense IAQ (Model IQ610, Graywolf), with the exception of formaldehyde (HCHO) which was measured with Formaldehyde Gas Detector (Model FP-30, RIKEN KEIKI Co., Ltd.).Biological indicators ::: Preliminary visit and measurements ::: Indoor air quality auditA portable air sampler (SAS Super IAQ, pb international CO.) for semi-solid medium (Agar plates) with a constant air flow rate of 100 L/min was used to carry out the biological sampling for determining the concentration of bacteria and fungi in the air.", [["formaldehyde", "CHEMICAL", 116, 128], ["HCHO", "CHEMICAL", 130, 134], ["formaldehyde", "CHEMICAL", 116, 128], ["HCHO", "CHEMICAL", 130, 134], ["Formaldehyde", "CHEMICAL", 160, 172], ["formaldehyde", "SIMPLE_CHEMICAL", 116, 128], ["HCHO", "SIMPLE_CHEMICAL", 130, 134], ["Formaldehyde Gas Detector", "TEST", 160, 185], ["Model FP", "TEST", 187, 195], ["Indoor air quality", "TEST", 288, 306], ["semi-solid medium (Agar plates", "TREATMENT", 377, 407], ["a constant air flow rate", "TEST", 414, 438], ["the biological sampling", "TEST", 474, 497], ["bacteria", "PROBLEM", 535, 543], ["fungi in the air", "PROBLEM", 548, 564], ["air flow", "OBSERVATION", 425, 433], ["bacteria", "OBSERVATION", 535, 543], ["fungi", "OBSERVATION", 548, 553], ["air", "OBSERVATION", 561, 564]]], ["The medium used for the collection and further laboratorial culture of bacteria was tryptic soy agar (TSA), while the collection of fungi was made on malt extract agar (MEA).", [["TSA", "CHEMICAL", 102, 105], ["malt extract", "CHEMICAL", 150, 162], ["the collection", "PROBLEM", 20, 34], ["further laboratorial culture", "TEST", 39, 67], ["bacteria", "PROBLEM", 71, 79], ["fungi", "PROBLEM", 132, 137]]], ["Each of these measurements was taken over a period of 2.5 min to get an air sample of 250 L. After incubation in laboratory under specific temperature conditions, each plate is analyzed and the results of counting are expressed in colony-forming units per cubic meter of air (CFU/m3).", [["colony", "ANATOMY", 231, 237], ["these measurements", "TEST", 8, 26], ["an air sample", "TEST", 69, 82], ["air", "ANATOMY", 271, 274]]], ["Legionella is another biological indicator which should be monitored.", [["Legionella", "PROBLEM", 0, 10]]], ["An effective sampling of Legionella depends upon a correct water sampling, considering relevant factors such as the choice of sampling location, presence of water treatment products or the need to disinfect the sampling point.", [["Legionella", "PROBLEM", 25, 35], ["a correct water sampling", "TREATMENT", 49, 73], ["water treatment products", "TREATMENT", 157, 181], ["effective", "OBSERVATION_MODIFIER", 3, 12], ["Legionella", "OBSERVATION", 25, 35], ["water treatment", "OBSERVATION_MODIFIER", 157, 172]]], ["The sampling criteria are defined in the national IAQ guideline (technical note NT-SCE-02 [17]), regarding namely the minimum number of samples and the typically recommended collection points in the hot-water ductwork.Biological indicators ::: Preliminary visit and measurements ::: Indoor air quality auditIn order to ensure the suitability of the measuring equipment, the ranges and accuracy of the measurement instruments used in this study are summarized in Table 2.Assessment of the air exchange rate ::: Physical indicators ::: Results and discussionSince the rooms have no dedicated supply of outdoor air, it was decided to perform a monitoring campaign of CO2 measurements to assess the adequacy of the AER by infiltration and, if it is the case, find an appropriate remediation action.", [["CO2", "CHEMICAL", 664, 667], ["CO2", "CHEMICAL", 664, 667], ["CO2", "SIMPLE_CHEMICAL", 664, 667], ["AER", "SIMPLE_CHEMICAL", 711, 714], ["The sampling criteria", "TEST", 0, 21], ["collection points", "TEST", 174, 191], ["the measurement instruments", "TEST", 397, 424], ["this study", "TEST", 433, 443], ["the air exchange rate", "TEST", 484, 505], ["a monitoring campaign", "TEST", 639, 660], ["CO2 measurements", "TEST", 664, 680], ["infiltration", "PROBLEM", 718, 730], ["air exchange", "OBSERVATION", 488, 500], ["infiltration", "OBSERVATION", 718, 730]]], ["The IAQ monitor PS32, configured to a sampling interval of 1 min, was left during three days in suite #620.Assessment of the air exchange rate ::: Physical indicators ::: Results and discussionThe fresh air flow rate through a room is usually evaluated using one of the three tracer-gas methods: concentration decay, constant emission or constant concentration method [23].", [["PS32", "CHEMICAL", 16, 20], ["The IAQ monitor PS32", "TEST", 0, 20], ["the air exchange rate", "TEST", 121, 142], ["The fresh air flow rate", "TEST", 193, 216], ["left", "ANATOMY_MODIFIER", 70, 74], ["air", "OBSERVATION", 125, 128], ["fresh", "OBSERVATION_MODIFIER", 197, 202], ["air flow", "OBSERVATION", 203, 211]]], ["In this project, the tracer gas concentration-decay method was selected.", [["the tracer gas concentration", "TEST", 17, 45]]], ["In this method a certain amount of tracer gas is introduced to the room and then it is mixed with the indoor air to get its uniform concentration in the whole room.", [["tracer gas", "PROBLEM", 35, 45], ["tracer gas", "OBSERVATION", 35, 45]]], ["Then the gradually decreasing concentration of tracer gas in the air is recorded.", [["tracer gas", "TEST", 47, 57], ["gradually", "OBSERVATION_MODIFIER", 9, 18], ["decreasing", "OBSERVATION_MODIFIER", 19, 29], ["concentration", "OBSERVATION_MODIFIER", 30, 43], ["tracer gas", "OBSERVATION", 47, 57], ["air", "OBSERVATION", 65, 68]]], ["In the simplest case the tracer gas may be carbon dioxide introduced in the room in a natural way, through the air exhaled by people staying in that room \u2013 metabolic carbon dioxide [20], [21], [22], [23], [24].", [["carbon dioxide", "CHEMICAL", 43, 57], ["carbon dioxide", "CHEMICAL", 166, 180], ["carbon dioxide", "CHEMICAL", 43, 57], ["carbon dioxide", "CHEMICAL", 166, 180], ["carbon dioxide", "SIMPLE_CHEMICAL", 43, 57], ["carbon dioxide", "SIMPLE_CHEMICAL", 166, 180], ["[21], [22], [23]", "SIMPLE_CHEMICAL", 187, 203], ["people", "SPECIES", 126, 132], ["the tracer gas", "TEST", 21, 35], ["carbon dioxide", "TREATMENT", 43, 57], ["metabolic carbon dioxide", "TEST", 156, 180]]], ["This was the case in the present study.Assessment of the air exchange rate ::: Physical indicators ::: Results and discussionThe AER (h\u22121) in this method is determined through the analysis of the decay of CO2 concentration in the room, after the source of such gas has been stopped, i.e., after the occupants have left the room.", [["CO2", "CHEMICAL", 205, 208], ["CO2", "CHEMICAL", 205, 208], ["CO2", "SIMPLE_CHEMICAL", 205, 208], ["the present study", "TEST", 21, 38], ["the air exchange rate", "TEST", 53, 74], ["CO2 concentration", "TREATMENT", 205, 222], ["such gas", "PROBLEM", 256, 264], ["air", "OBSERVATION", 57, 60]]], ["So, for a decay period (t\u2212t0) starting from an assumed uniform CO2 concentration C0 in the room, the integration of an overall mass balance leads to(2)C(t)\u2212Cext=(C0\u2212Cext)\u00b7exp[\u2212AER(t\u2212t0)]where C(t) is the observed CO2 concentration at time t, and Cext is the CO2 concentration in the outdoor air.", [["CO2", "CHEMICAL", 63, 66], ["CO2", "CHEMICAL", 213, 216], ["CO2", "CHEMICAL", 258, 261], ["CO2", "CHEMICAL", 63, 66], ["(C0\u2212Cext)\u00b7exp[\u2212AER(t\u2212t0)]", "CHEMICAL", 161, 186], ["C", "CHEMICAL", 192, 193], ["CO2", "CHEMICAL", 213, 216], ["CO2", "CHEMICAL", 258, 261], ["CO2", "SIMPLE_CHEMICAL", 63, 66], ["C0\u2212Cext)\u00b7exp[\u2212AER(t\u2212t0)", "SIMPLE_CHEMICAL", 162, 185], ["C(t)", "SIMPLE_CHEMICAL", 192, 196], ["CO2", "SIMPLE_CHEMICAL", 213, 216], ["CO2", "SIMPLE_CHEMICAL", 258, 261], ["an overall mass balance leads", "PROBLEM", 116, 145], ["t", "TEST", 153, 154], ["Cext", "TEST", 156, 160], ["C0", "TEST", 162, 164], ["Cext", "TEST", 165, 169], ["\u00b7exp", "TEST", 170, 174], ["AER", "TEST", 176, 179], ["t\u2212t0", "TEST", 180, 184], ["CO2 concentration", "TEST", 213, 230], ["Cext", "TEST", 246, 250], ["the CO2 concentration", "PROBLEM", 254, 275], ["mass", "OBSERVATION", 127, 131], ["CO2 concentration", "OBSERVATION", 258, 275], ["outdoor air", "OBSERVATION", 283, 294]]], ["All the CO2 concentrations are expressed in ppm.Assessment of the air exchange rate ::: Physical indicators ::: Results and discussionEquation (2) can be made explicit for AER (h\u22121):(3)AER=\u22121t\u2212t0\u00b7ln(C(t)\u2212CextC0\u2212Cext)The direct estimation of the AER through equation (3) is easy when conditions are stable regarding the fresh air flow rate, the CO2 concentration in outdoor air and the flow pattern inside the room.", [["CO2", "CHEMICAL", 8, 11], ["CO2", "CHEMICAL", 344, 347], ["CO2", "CHEMICAL", 8, 11], ["CO2", "CHEMICAL", 344, 347], ["CO2", "SIMPLE_CHEMICAL", 8, 11], ["CO2", "SIMPLE_CHEMICAL", 344, 347], ["the air exchange rate", "TEST", 62, 83], ["AER", "TEST", 172, 175], ["AER", "TEST", 185, 188], ["the fresh air flow rate", "TEST", 315, 338], ["the CO2 concentration", "TEST", 340, 361], ["CO2 concentrations", "OBSERVATION", 8, 26], ["air", "OBSERVATION", 66, 69], ["air flow", "OBSERVATION", 325, 333], ["flow pattern", "OBSERVATION", 385, 397]]], ["However equations (2), (3) apply to the case of a uni-zone room having air exchanges only with outdoor environment.", [["air exchanges", "TREATMENT", 71, 84], ["air exchanges", "OBSERVATION", 71, 84]]], ["In the present case, as the room door is very tight and the corridor is most of the time unoccupied, it was concluded that the studied room could be considered a uni-zone compartment.", [["uni-zone compartment", "ANATOMY", 162, 182], ["very", "OBSERVATION_MODIFIER", 41, 45], ["tight", "OBSERVATION", 46, 51]]], ["Regarding the uniformity of the distribution of the CO2 concentration inside the room, it was not possible to put in practice, previous to the decay phase, the recommended procedure of using a fan during a short period to promote a good dilution, on account of the hotel guests privacy issues.", [["CO2", "CHEMICAL", 52, 55], ["CO2", "CHEMICAL", 52, 55], ["CO2", "SIMPLE_CHEMICAL", 52, 55], ["procedure", "TREATMENT", 172, 181], ["a fan", "TREATMENT", 191, 196], ["uniformity", "OBSERVATION_MODIFIER", 14, 24], ["distribution", "OBSERVATION_MODIFIER", 32, 44], ["CO2 concentration", "OBSERVATION", 52, 69]]], ["Nevertheless, it was latter checked that in a similar room where an equilibrium concentration of 1100 ppm had been achieved after the sleeping period, the spatial variability of CO2 concentration was in the order of \u00b115 ppm.", [["CO2", "CHEMICAL", 178, 181], ["CO2", "CHEMICAL", 178, 181], ["CO2", "SIMPLE_CHEMICAL", 178, 181], ["CO2 concentration", "TEST", 178, 195], ["CO2 concentration", "OBSERVATION", 178, 195]]], ["In rooms where there is not a strong ventilation flow, spatial non-uniformities of CO2 concentrations tend to be lower.Assessment of the air exchange rate ::: Physical indicators ::: Results and discussionA previous smoothing procedure may be recommended to minimize the disturbing influence of imprecision due to the fluctuating feature of the recorded C(t) data, as it is the case of gas analyzers with imprecision higher than \u00b130 ppm.", [["CO2", "CHEMICAL", 83, 86], ["CO2", "CHEMICAL", 83, 86], ["CO2", "SIMPLE_CHEMICAL", 83, 86], ["CO2 concentrations", "PROBLEM", 83, 101], ["the air exchange rate", "TEST", 133, 154], ["discussionA previous smoothing procedure", "TREATMENT", 195, 235], ["gas analyzers", "TEST", 386, 399], ["strong", "OBSERVATION_MODIFIER", 30, 36], ["ventilation flow", "OBSERVATION", 37, 53], ["air", "OBSERVATION", 137, 140]]], ["Fig. 2shows the first day evolution of CO2 concentration in suite #620, before any remediation action.", [["CO2", "CHEMICAL", 39, 42], ["CO2", "CHEMICAL", 39, 42], ["CO2", "SIMPLE_CHEMICAL", 39, 42], ["CO2 concentration", "TEST", 39, 56], ["any remediation action", "TREATMENT", 79, 101]]], ["A curve fitting, with a linear law for a chosen concentration-decay period is shown in Fig. 3, indicating an AER of 0.429 h\u22121.", [["A curve fitting", "TREATMENT", 0, 15], ["a linear law", "TREATMENT", 22, 34], ["an AER", "TEST", 106, 112]]], ["The value of AER estimated by this method was robust, i.e., regression achieved a correlation coefficient R= 0.9978, which means that conditions were quite stable.", [["AER", "PROTEIN", 13, 16], ["stable", "OBSERVATION_MODIFIER", 156, 162]]], ["The represented decay period corresponds to a calm day with low wind velocity (v< 2 m/s), thus it represents the worst case regarding AER conditions in the studied room.Assessment of the air exchange rate ::: Physical indicators ::: Results and discussionIt is seen from Table 3that by the 0.429 h\u22121 AER, the amount of fresh air (coming into the room by infiltration) provided to suite #620 in the considered decay period was 20 m3/h/person, which is lower than the minimum requirement stated by national IAQ regulation (RSECE [14]) for design project of hotel rooms in new buildings which is 30 m3/h/occupant.Assessment of the air exchange rate ::: Physical indicators ::: Results and discussionConsequently, it was suggested to the hotel technical management to keep the bathroom mechanical exhaust fan working during the night period.", [["low wind velocity", "PROBLEM", 60, 77], ["AER conditions", "PROBLEM", 134, 148], ["the air exchange rate", "TEST", 183, 204], ["fresh air", "PROBLEM", 319, 328], ["the air exchange rate", "TEST", 624, 645], ["air", "OBSERVATION", 187, 190], ["amount", "OBSERVATION_MODIFIER", 309, 315], ["fresh air", "OBSERVATION", 319, 328], ["infiltration", "OBSERVATION", 354, 366], ["lower", "OBSERVATION_MODIFIER", 451, 456], ["30 m3", "OBSERVATION_MODIFIER", 593, 598], ["air", "OBSERVATION", 628, 631]]], ["In Fig. 4the time evolution of CO2 concentration during a day after prescribing the new control policy for bathroom mechanical exhaust fan is presented.", [["CO2", "CHEMICAL", 31, 34], ["CO2", "CHEMICAL", 31, 34], ["CO2", "SIMPLE_CHEMICAL", 31, 34], ["CO2 concentration", "PROBLEM", 31, 48], ["the new control policy", "TREATMENT", 80, 102], ["bathroom mechanical exhaust fan", "TREATMENT", 107, 138]]], ["Accordingly, the fresh air flow rate raised enough to keep the CO2 concentration within an acceptable level during the whole period with the total occupancy of the room, regarding the second compliance criterion for CO2 in existing building, based on national IAQ guideline [17], which indicates an average CO2 value lower than 1500 ppm, during the whole occupancy period (see Section 3.2.1 for further details).Evaluation of thermal comfort ::: Physical indicators ::: Results and discussionThe measured thermal comfort parameters during 2 days measurement campaign (28\u201329 March 2009) are listed in Table 4.", [["CO2", "CHEMICAL", 63, 66], ["CO2", "CHEMICAL", 216, 219], ["CO2", "CHEMICAL", 307, 310], ["CO2", "CHEMICAL", 63, 66], ["CO2", "CHEMICAL", 216, 219], ["CO2", "CHEMICAL", 307, 310], ["CO2", "SIMPLE_CHEMICAL", 63, 66], ["CO2", "SIMPLE_CHEMICAL", 216, 219], ["CO2", "SIMPLE_CHEMICAL", 307, 310], ["the fresh air flow rate", "TEST", 13, 36], ["the CO2 concentration", "TEST", 59, 80], ["an average CO2 value", "TEST", 296, 316], ["air flow", "OBSERVATION", 23, 31]]], ["The average air temperature recorded in each guest room ranged from 23 to 24.0 \u00b0C. This is within the recommended range according to ASHRAE design criteria [18].", [["The average air temperature", "TEST", 0, 27], ["average", "OBSERVATION_MODIFIER", 4, 11], ["air temperature", "OBSERVATION", 12, 27]]], ["The temperature in the cold season (winter) should vary between 23 \u00b0C and 24 \u00b0C, in the hot season (summer) between 23 \u00b0C and 26 \u00b0C, relative humidity should be between 30% and 35% in winter, 50% and 60% during summer and air velocity should not exceed 0.2 m/s in the guest room.", [["air velocity", "TEST", 222, 234], ["air velocity", "OBSERVATION", 222, 234]]], ["Too cold temperature will not only make guests uncomfortable, it will also result in more energy consumption in air-conditioning.", [["Too cold temperature", "PROBLEM", 0, 20]]], ["The average relative humidity of each room ranged from 31.5% to 35%, which is within the recommended range (30\u201335%).", [["average", "OBSERVATION_MODIFIER", 4, 11], ["relative", "OBSERVATION_MODIFIER", 12, 20], ["humidity", "OBSERVATION_MODIFIER", 21, 29]]], ["The mean air velocity in the rooms was not measured because it was clearly found unnecessary.Evaluation of particulate pollution ::: Physical indicators ::: Results and discussionThe recommended threshold level for the concentration of suspended particulate matter (PM10) in indoor air is 150 \u03bcg/m3 in Portugal [14].", [["PM10", "CHEMICAL", 266, 270], ["The mean air velocity", "TEST", 0, 21], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["air velocity", "OBSERVATION", 9, 21]]], ["Table 5shows the measured values of indoor concentration of PM10, which overcome the threshold level in two of the monitored rooms of the 6th floor.", [["PM10", "CHEMICAL", 60, 64], ["PM10", "SIMPLE_CHEMICAL", 60, 64]]], ["It should be mentioned that these measurements were conducted shortly after the cleaning operation of the rooms.", [["these measurements", "TEST", 28, 46], ["the cleaning operation", "TREATMENT", 76, 98]]], ["Further tests proved an increase of the PM10 concentration after vigorous walking in the rooms, which suggested that the detected suspended particulate matter originated from the floor carpet, where it was somehow deposited.", [["PM10", "CHEMICAL", 40, 44], ["PM10", "CHEMICAL", 40, 44], ["PM10", "SIMPLE_CHEMICAL", 40, 44], ["Further tests", "TEST", 0, 13], ["the PM10 concentration", "TREATMENT", 36, 58], ["increase", "OBSERVATION_MODIFIER", 24, 32]]], ["A recommendation for implementing an improved technique and more frequent cleaning was given to the hotel management.Carbon dioxide (CO2) ::: Chemical indicators ::: Results and discussionThe concentration of carbon dioxide in the specified sample points varied between locations, and reached values as high as 1710 ppm.", [["Carbon dioxide", "CHEMICAL", 117, 131], ["CO2", "CHEMICAL", 133, 136], ["carbon dioxide", "CHEMICAL", 209, 223], ["Carbon dioxide", "CHEMICAL", 117, 131], ["CO2", "CHEMICAL", 133, 136], ["carbon dioxide", "CHEMICAL", 209, 223], ["Carbon dioxide", "SIMPLE_CHEMICAL", 117, 131], ["CO2", "SIMPLE_CHEMICAL", 133, 136], ["carbon dioxide", "SIMPLE_CHEMICAL", 209, 223], ["an improved technique", "TREATMENT", 34, 55], ["more frequent cleaning", "TREATMENT", 60, 82], ["the hotel management", "TREATMENT", 96, 116], ["Carbon dioxide", "TEST", 117, 131], ["The concentration of carbon dioxide", "TREATMENT", 188, 223], ["concentration", "OBSERVATION_MODIFIER", 192, 205], ["carbon dioxide", "OBSERVATION", 209, 223]]], ["During night hours, the concentration level of CO2 increased due to the constant metabolic emission by the guests in the rooms and the AER revealed to be insufficient.", [["CO2", "CHEMICAL", 47, 50], ["CO2", "CHEMICAL", 47, 50], ["CO2", "SIMPLE_CHEMICAL", 47, 50], ["the concentration level of CO2", "TEST", 20, 50], ["the constant metabolic emission", "PROBLEM", 68, 99], ["the AER", "TEST", 131, 138], ["metabolic emission", "OBSERVATION", 81, 99], ["insufficient", "OBSERVATION", 154, 166]]], ["Regarding the CO2 concentration, the verification of compliance with the national regulation limit value (1000 ppm) must take into account the actual occupancy of the room.", [["CO2", "CHEMICAL", 14, 17], ["CO2", "CHEMICAL", 14, 17], ["CO2", "SIMPLE_CHEMICAL", 14, 17], ["the CO2 concentration", "PROBLEM", 10, 31]]], ["For this purpose, the technical note NT-SCE-02, 2009 [17] suggests the following criterion:(4)([CO2]MedT\u2212[CO2]Ext)\u00d7Nocup.maxNocup.+[CO2]Ext\u2264[CO2]MRwhere [CO2]MR is reference limit value of CO2 concentration, 1800 mg/m3 (corresponding to 1000 ppm at standard pressure and 25 \u00b0C [10]), [CO2]Ext is the CO2 concentration in the outdoor air (400 ppm for this case), [CO2]MedT is time-averaged concentration of CO2 in each sampling point in ppm, Nocup.max. is maximum allowed number of occupants in the room or space, Nocup is the actual number of occupants during the measurements.Carbon dioxide (CO2) ::: Chemical indicators ::: Results and discussionFor the case of existing buildings, if this first criterion is not fulfilled, a second one is recommended that allows an increase of 50% of the threshold level, but implies measuring and averaging the CO2 over the full period of occupancy.", [["CO2", "CHEMICAL", 106, 109], ["CO2", "CHEMICAL", 132, 135], ["CO2", "CHEMICAL", 141, 144], ["CO2", "CHEMICAL", 154, 157], ["CO2", "CHEMICAL", 189, 192], ["CO2", "CHEMICAL", 285, 288], ["CO2", "CHEMICAL", 300, 303], ["CO2", "CHEMICAL", 363, 366], ["CO2", "CHEMICAL", 406, 409], ["Carbon dioxide", "CHEMICAL", 577, 591], ["CO2", "CHEMICAL", 593, 596], ["CO2", "CHEMICAL", 849, 852], ["[CO2]MedT\u2212[CO2]Ext", "CHEMICAL", 95, 113], ["[CO2]Ext\u2264", "CHEMICAL", 131, 140], ["CO2", "CHEMICAL", 141, 144], ["CO2", "CHEMICAL", 154, 157], ["CO2", "CHEMICAL", 189, 192], ["CO2", "CHEMICAL", 285, 288], ["CO2", "CHEMICAL", 300, 303], ["[CO2]MedT", "CHEMICAL", 362, 371], ["CO2", "CHEMICAL", 406, 409], ["Carbon dioxide", "CHEMICAL", 577, 591], ["CO2", "CHEMICAL", 593, 596], ["CO2", "CHEMICAL", 849, 852], ["[CO2]MedT\u2212[CO2]Ext", "SIMPLE_CHEMICAL", 95, 113], ["+[CO2]Ext\u2264[CO2]MRwhere [CO2]MR", "SIMPLE_CHEMICAL", 130, 160], ["CO2", "SIMPLE_CHEMICAL", 189, 192], ["[CO2]Ext", "SIMPLE_CHEMICAL", 284, 292], ["CO2", "SIMPLE_CHEMICAL", 300, 303], ["[CO2]MedT", "SIMPLE_CHEMICAL", 362, 371], ["CO2", "SIMPLE_CHEMICAL", 406, 409], ["Carbon dioxide", "SIMPLE_CHEMICAL", 577, 591], ["CO2", "SIMPLE_CHEMICAL", 593, 596], ["CO2", "SIMPLE_CHEMICAL", 849, 852], ["MR", "PROTEIN", 158, 160], ["CO2", "TEST", 96, 99], ["MedT", "TEST", 100, 104], ["CO2", "TEST", 106, 109], ["Ext", "TEST", 110, 113], ["\u00d7", "TEST", 114, 115], ["Nocup.maxNocup", "TEST", 115, 129], ["CO2", "TEST", 132, 135], ["Ext\u2264", "TEST", 136, 140], ["CO2", "TEST", 141, 144], ["MRwhere", "TEST", 145, 152], ["CO2]MR", "TEST", 154, 160], ["CO2 concentration", "TEST", 189, 206], ["standard pressure", "TEST", 249, 266], ["CO2", "TEST", 285, 288], ["the CO2 concentration", "TEST", 296, 317], ["CO2", "TEST", 363, 366], ["CO2", "TEST", 406, 409], ["Carbon dioxide", "TEST", 577, 591], ["increase", "OBSERVATION_MODIFIER", 769, 777], ["CO2", "OBSERVATION_MODIFIER", 849, 852]]], ["This second criterion may be expressed as:(5)([CO2]MedT\u2212[CO2]Ext)\u00d7Nocup.maxNocup.+[CO2]Ext\u2264[CO2]MR\u00d71.5where [CO2]MedT is now the time-averaged CO2 concentration for the extended period.Carbon dioxide (CO2) ::: Chemical indicators ::: Results and discussionThe time-averaged concentration of CO2 is calculated by the following expression:(6)[CO2]MedT=CT=\u2211\u0394ti\u00d7CiTwhere Ci in ppm is the pollutant concentration at time ti, \u0394ti is the sampling measurement period, and T is the total measurement period.Carbon dioxide (CO2) ::: Chemical indicators ::: Results and discussion", [["CO2", "CHEMICAL", 57, 60], ["CO2", "CHEMICAL", 83, 86], ["CO2", "CHEMICAL", 92, 95], ["CO2", "CHEMICAL", 109, 112], ["CO2", "CHEMICAL", 143, 146], ["Carbon dioxide", "CHEMICAL", 185, 199], ["CO2", "CHEMICAL", 201, 204], ["CO2", "CHEMICAL", 291, 294], ["CO2", "CHEMICAL", 341, 344], ["Carbon dioxide", "CHEMICAL", 498, 512], ["CO2", "CHEMICAL", 514, 517], ["[CO2]MedT\u2212[CO2]Ext", "CHEMICAL", 46, 64], ["[CO2]Ext\u2264[CO2]MR", "CHEMICAL", 82, 98], ["[CO2]MedT", "CHEMICAL", 108, 117], ["CO2", "CHEMICAL", 143, 146], ["Carbon dioxide", "CHEMICAL", 185, 199], ["CO2", "CHEMICAL", 201, 204], ["CO2", "CHEMICAL", 291, 294], ["CO2", "CHEMICAL", 341, 344], ["Carbon dioxide", "CHEMICAL", 498, 512], ["CO2", "CHEMICAL", 514, 517], ["[CO2]MedT\u2212[CO2]Ext", "SIMPLE_CHEMICAL", 46, 64], ["[CO2]Ext\u2264[CO2]MR", "SIMPLE_CHEMICAL", 82, 98], ["[CO2]MedT", "SIMPLE_CHEMICAL", 108, 117], ["CO2", "SIMPLE_CHEMICAL", 143, 146], ["Carbon dioxide", "SIMPLE_CHEMICAL", 185, 199], ["CO2", "SIMPLE_CHEMICAL", 201, 204], ["CO2", "SIMPLE_CHEMICAL", 291, 294], ["[CO2]MedT", "SIMPLE_CHEMICAL", 340, 349], ["Carbon dioxide", "SIMPLE_CHEMICAL", 498, 512], ["CO2", "SIMPLE_CHEMICAL", 514, 517], ["CO2", "TEST", 47, 50], ["MedT", "TEST", 51, 55], ["CO2", "TEST", 57, 60], ["Ext", "TEST", 61, 64], ["\u00d7", "TEST", 65, 66], ["Nocup.maxNocup", "TEST", 66, 80], ["CO2", "TEST", 83, 86], ["Ext\u2264", "TEST", 87, 91], ["CO2", "TEST", 92, 95], ["MR\u00d7", "TEST", 96, 99], ["CO2", "TEST", 109, 112], ["CO2 concentration", "TEST", 143, 160], ["Carbon dioxide", "TEST", 185, 199], ["CO2", "TEST", 291, 294], ["CO2", "TEST", 341, 344], ["MedT", "TEST", 345, 349], ["CT", "TEST", 350, 352], ["Carbon dioxide", "TEST", 498, 512]]]], "efcdcf807d33027878f4a6acc1412924a15b657b": [["IntroductionEnveloped viruses are well adapted pathogens infecting a great variety of hosts from protozoans to mammals that hijack the host cell's molecular machinery for reproduction (International Committee on Taxonomy of Viruses 2012; Buchmann and Holmes 2015) .", [["cell", "ANATOMY", 140, 144], ["Enveloped viruses", "ORGANISM", 12, 29], ["host cell", "CELL", 135, 144], ["viruses", "OBSERVATION", 22, 29], ["great variety", "OBSERVATION_MODIFIER", 69, 82]]], ["A characteristic feature of these viruses is a cell membrane-derived envelope modified with virally encoded proteins glycosylated by the host glycosylation apparatus as they pass through the secretory pathway.", [["cell membrane", "ANATOMY", 47, 60], ["cell membrane", "CELLULAR_COMPONENT", 47, 60], ["virally encoded proteins", "PROTEIN", 92, 116], ["these viruses", "PROBLEM", 28, 41], ["a cell membrane", "TREATMENT", 45, 60], ["virally encoded proteins glycosylated", "TREATMENT", 92, 129], ["viruses", "OBSERVATION", 34, 41]]], ["While some viral glycoproteins are glycosylated at relatively few sites, others are densely glycosylated with N-linked and O-linked glycans.", [["N", "CHEMICAL", 110, 111], ["O", "CHEMICAL", 123, 124], ["O-linked glycans", "SIMPLE_CHEMICAL", 123, 139], ["viral glycoproteins", "PROTEIN", 11, 30], ["N-linked and O-linked glycans", "PROTEIN", 110, 139], ["some viral glycoproteins", "PROBLEM", 6, 30], ["viral glycoproteins", "OBSERVATION", 11, 30]]], ["Prominent examples include the Ebola virus glycoprotein modified by a very high content of O-linked glycans, and the HIV-1 glycoprotein gp160 that is glycosylated by the addition of multiple N-linked glycans (Jeffers et al. 2002; Pabst et al. 2012; Yang W et al. 2014) .", [["O", "CHEMICAL", 91, 92], ["N", "CHEMICAL", 191, 192], ["Ebola virus", "ORGANISM", 31, 42], ["HIV-1", "ORGANISM", 117, 122], ["gp160", "GENE_OR_GENE_PRODUCT", 136, 141], ["Ebola virus glycoprotein", "PROTEIN", 31, 55], ["O-linked glycans", "PROTEIN", 91, 107], ["HIV-1 glycoprotein gp160", "PROTEIN", 117, 141], ["Ebola virus", "SPECIES", 31, 42], ["HIV-1", "SPECIES", 117, 122], ["Ebola virus", "SPECIES", 31, 42], ["HIV-1", "SPECIES", 117, 122], ["the Ebola virus glycoprotein", "PROBLEM", 27, 55], ["the HIV", "TEST", 113, 120], ["glycoprotein gp160", "TREATMENT", 123, 141], ["multiple N-linked glycans", "TREATMENT", 182, 207], ["Ebola", "OBSERVATION", 31, 36], ["very", "OBSERVATION_MODIFIER", 70, 74], ["high content", "OBSERVATION_MODIFIER", 75, 87]]], ["Although specific functional roles have been assigned to distinct glycosites of multiple viruses (Goffard et al. 2005; Falkowska et al. 2007; Helle et al. 2010; Wang et al. 2013 Wang et al. , 2017 Lennemann et al. 2014; Bradel-Tretheway et al. 2015; Luo et al. 2015; Orlova et al. 2015; Suenaga et al. 2015; Stone et al. 2016; Wu et al. 2017) , it is generally believed that the high levels of glycosylation serve as a protective shield from the host's immune system (Francica et al. 2010; Helle et al. 2011; Sommerstein et al. 2015; Behrens et al. 2016; Gram et al. 2016; Walls et al. 2016) .", [["immune system", "ANATOMICAL_SYSTEM", 453, 466], ["multiple viruses", "PROBLEM", 80, 96], ["the high levels of glycosylation", "PROBLEM", 375, 407], ["a protective shield", "TREATMENT", 417, 436], ["multiple", "OBSERVATION_MODIFIER", 80, 88], ["viruses", "OBSERVATION", 89, 96]]], ["The other major role of glycosylation occurs during virus entry where glycans on the host cell represent viral receptors interacting with carbohydrate binding proteins on the viral surface.", [["cell", "ANATOMY", 90, 94], ["surface", "ANATOMY", 181, 188], ["carbohydrate", "CHEMICAL", 138, 150], ["host cell", "CELL", 85, 94], ["carbohydrate binding proteins", "GENE_OR_GENE_PRODUCT", 138, 167], ["viral receptors", "PROTEIN", 105, 120], ["carbohydrate binding proteins", "PROTEIN", 138, 167], ["glycosylation", "TREATMENT", 24, 37], ["viral receptors", "PROBLEM", 105, 120], ["carbohydrate binding proteins", "PROBLEM", 138, 167], ["glycosylation", "OBSERVATION", 24, 37], ["host cell", "OBSERVATION_MODIFIER", 85, 94], ["viral receptors", "OBSERVATION", 105, 120], ["viral surface", "OBSERVATION_MODIFIER", 175, 188]]], ["A prominent example is the influenza viruses that attach to surface glycans residing on cellular glycoproteins (Air 2014) .", [["surface", "ANATOMY", 60, 67], ["cellular", "ANATOMY", 88, 96], ["influenza viruses", "ORGANISM", 27, 44], ["cellular", "CELL", 88, 96], ["cellular glycoproteins", "PROTEIN", 88, 110], ["the influenza viruses", "PROBLEM", 23, 44], ["prominent", "OBSERVATION_MODIFIER", 2, 11], ["influenza viruses", "OBSERVATION", 27, 44], ["cellular glycoproteins", "OBSERVATION", 88, 110]]], ["Hemagglutinins (HA) of human influenza viruses use \u03b12,6-linked sialic acid moieties, while those of avian viruses bind preferentially to \u03b12,3-linked sialic acids (Air 2014) .", [["Hemagglutinins", "CHEMICAL", 0, 14], ["influenza viruses", "DISEASE", 29, 46], ["\u03b12,6-linked sialic acid", "CHEMICAL", 51, 74], ["\u03b12,3-linked sialic acids", "CHEMICAL", 137, 161], ["sialic acid", "CHEMICAL", 63, 74], ["sialic acids", "CHEMICAL", 149, 161], ["Hemagglutinins", "GENE_OR_GENE_PRODUCT", 0, 14], ["human", "ORGANISM", 23, 28], ["influenza viruses", "ORGANISM", 29, 46], ["\u03b12,6-linked sialic acid", "SIMPLE_CHEMICAL", 51, 74], ["avian viruses", "ORGANISM", 100, 113], ["\u03b12,3-linked sialic acids", "SIMPLE_CHEMICAL", 137, 161], ["\u03b12,3", "PROTEIN", 137, 141], ["human", "SPECIES", 23, 28], ["human influenza viruses", "SPECIES", 23, 46], ["Hemagglutinins (HA)", "PROBLEM", 0, 19], ["human influenza viruses", "PROBLEM", 23, 46], ["sialic acid moieties", "TREATMENT", 63, 83], ["avian viruses bind", "TREATMENT", 100, 118]]], ["Apart from influenza virus, several other nonenveloped human viruses, including adenoviruses, reoviruses and rotaviruses, use sialic acidcontaining oligosaccharides as cell receptors (Stencel-Baerenwald et al. 2014 ).", [["cell", "ANATOMY", 168, 172], ["influenza virus", "DISEASE", 11, 26], ["influenza virus", "ORGANISM", 11, 26], ["human", "ORGANISM", 55, 60], ["adenoviruses", "ORGANISM", 80, 92], ["reoviruses", "GENE_OR_GENE_PRODUCT", 94, 104], ["sialic acidcontaining oligosaccharides", "GENE_OR_GENE_PRODUCT", 126, 164], ["cell", "CELL", 168, 172], ["cell receptors", "PROTEIN", 168, 182], ["influenza virus", "SPECIES", 11, 26], ["human", "SPECIES", 55, 60], ["influenza virus", "SPECIES", 11, 26], ["human", "SPECIES", 55, 60], ["influenza virus", "PROBLEM", 11, 26], ["several other nonenveloped human viruses", "PROBLEM", 28, 68], ["adenoviruses", "PROBLEM", 80, 92], ["reoviruses", "PROBLEM", 94, 104], ["rotaviruses", "PROBLEM", 109, 120], ["sialic acidcontaining oligosaccharides", "TREATMENT", 126, 164], ["cell receptors", "TREATMENT", 168, 182], ["influenza virus", "OBSERVATION", 11, 26], ["human viruses", "OBSERVATION", 55, 68]]], ["Sialic acid is not the only glycan that can be used by viruses for cell attachment.", [["cell", "ANATOMY", 67, 71], ["Sialic acid", "CHEMICAL", 0, 11], ["Sialic acid", "CHEMICAL", 0, 11], ["Sialic acid", "SIMPLE_CHEMICAL", 0, 11], ["cell", "CELL", 67, 71], ["Sialic acid", "TREATMENT", 0, 11], ["cell attachment", "PROBLEM", 67, 82]]], ["For example, flaviviruses, human respiratory syncytial virus and some of the herpesviruses use proteoglycans as a point of attachment to cells, whereas core fucosylation is suggested to play a role in HBV entry into hepatoma cells (Jolly and Sattentau 2013; Takamatsu et al. 2016) .", [["cells", "ANATOMY", 137, 142], ["hepatoma cells", "ANATOMY", 216, 230], ["respiratory syncytial virus", "DISEASE", 33, 60], ["human", "ORGANISM", 27, 32], ["respiratory syncytial virus", "ORGANISM", 33, 60], ["herpesviruses", "ORGANISM", 77, 90], ["proteoglycans", "GENE_OR_GENE_PRODUCT", 95, 108], ["cells", "CELL", 137, 142], ["HBV", "ORGANISM", 201, 204], ["hepatoma cells", "CELL", 216, 230], ["hepatoma cells", "CELL_TYPE", 216, 230], ["human", "SPECIES", 27, 32], ["respiratory syncytial virus", "SPECIES", 33, 60], ["human respiratory syncytial virus", "SPECIES", 27, 60], ["HBV", "SPECIES", 201, 204], ["flaviviruses", "PROBLEM", 13, 25], ["human respiratory syncytial virus", "PROBLEM", 27, 60], ["proteoglycans", "TREATMENT", 95, 108], ["attachment to cells", "PROBLEM", 123, 142], ["flaviviruses", "OBSERVATION", 13, 25], ["respiratory syncytial virus", "OBSERVATION", 33, 60], ["hepatoma", "ANATOMY", 216, 224]]], ["The important aspects of host glycans as receptors for viral infectivity will not be reviewed here as they are covered elsewhere (Jolly and Sattentau 2013; Stencel-Baerenwald et al. 2014; Kim et al. 2017 ).", [["host glycans", "TREATMENT", 25, 37], ["viral infectivity", "PROBLEM", 55, 72]]], ["Instead, we will present the available information on glycosylation of human enveloped viruses.", [["human", "ORGANISM", 71, 76], ["enveloped viruses", "ORGANISM", 77, 94], ["human", "SPECIES", 71, 76], ["human enveloped viruses", "SPECIES", 71, 94], ["glycosylation of human enveloped viruses", "TREATMENT", 54, 94]]], ["We will discuss general functions of glycosylation in various aspects of the viral life cycle and interaction with the immune system.", [["immune system", "ANATOMY", 119, 132], ["glycosylation", "TREATMENT", 37, 50], ["the viral life cycle", "TREATMENT", 73, 93]]], ["In addition, we will discuss human herpesvirus glycosylation in more detail and include conclusions emerging from our recent global O-glycoproteomic analyses.N-and O-linked glycosylation of proteinsGlycosylation of viral envelope glycoproteins depends on the host glycosylation machinery.", [["N", "CHEMICAL", 158, 159], ["O", "CHEMICAL", 164, 165], ["human", "ORGANISM", 29, 34], ["herpesvirus", "ORGANISM", 35, 46], ["viral envelope glycoproteins", "PROTEIN", 215, 243], ["human", "SPECIES", 29, 34], ["human herpesvirus", "SPECIES", 29, 46], ["human herpesvirus glycosylation", "TREATMENT", 29, 60], ["proteinsGlycosylation", "TREATMENT", 190, 211], ["viral envelope glycoproteins", "TREATMENT", 215, 243], ["the host glycosylation machinery", "TREATMENT", 255, 287]]], ["Viral glycoproteins, like cellular proteins, possess signal peptides directing them to the secretory pathway.", [["cellular", "ANATOMY", 26, 34], ["cellular", "CELL", 26, 34], ["Viral glycoproteins", "PROTEIN", 0, 19], ["cellular proteins", "PROTEIN", 26, 43], ["Viral glycoproteins", "PROBLEM", 0, 19], ["cellular proteins", "OBSERVATION", 26, 43]]], ["Proteins targeted to the secretory pathway can be decorated with different kinds of post-translational modifications en route to the cell surface or another cellular compartment.", [["cell surface", "ANATOMY", 133, 145], ["cellular compartment", "ANATOMY", 157, 177], ["cell surface", "CELLULAR_COMPONENT", 133, 145], ["cellular compartment", "CELLULAR_COMPONENT", 157, 177], ["Proteins", "TEST", 0, 8], ["post-translational modifications", "TREATMENT", 84, 116], ["different kinds", "OBSERVATION_MODIFIER", 65, 80], ["post-translational modifications", "OBSERVATION", 84, 116], ["cellular compartment", "OBSERVATION", 157, 177]]], ["Glycosylation is one of the most widespread and versatile modifications of proteins and is classified as N-, O-and C-linked, named after the acceptor amino acid atom to which the sugar moiety is attached.", [["amino acid", "CHEMICAL", 150, 160], ["N", "CHEMICAL", 105, 106], ["O-", "CHEMICAL", 109, 111], ["C", "CHEMICAL", 115, 116], ["amino acid", "CHEMICAL", 150, 160], ["sugar", "CHEMICAL", 179, 184], ["C", "SIMPLE_CHEMICAL", 115, 116], ["amino acid", "AMINO_ACID", 150, 160], ["sugar", "SIMPLE_CHEMICAL", 179, 184], ["Glycosylation", "TREATMENT", 0, 13], ["the acceptor amino acid atom", "TREATMENT", 137, 165], ["the sugar moiety", "TREATMENT", 175, 191], ["one of the most widespread", "OBSERVATION_MODIFIER", 17, 43]]], ["While there is only one type of N-linked glycosylation in terms of initiation, many types of O-glycosylation exist, classified based on the identity of initiating monosaccharides (Stanley 2011; Moremen et al. 2012) .", [["N", "CHEMICAL", 32, 33], ["O", "CHEMICAL", 93, 94], ["monosaccharides", "CHEMICAL", 163, 178], ["monosaccharides", "SIMPLE_CHEMICAL", 163, 178], ["N-linked glycosylation", "TREATMENT", 32, 54], ["one type", "OBSERVATION_MODIFIER", 20, 28]]], ["Most types of O-glycosylation are carried out in the secretory pathway, but cytosolic and nuclear proteins can also be glycosylated with N-acetylglucosamine (GlcNAc) by a cytosolic glycosyltransferase (Moremen et al. 2012; Yang and Qian 2017) .", [["cytosolic", "ANATOMY", 76, 85], ["nuclear", "ANATOMY", 90, 97], ["cytosolic", "ANATOMY", 171, 180], ["O", "CHEMICAL", 14, 15], ["N-acetylglucosamine", "CHEMICAL", 137, 156], ["GlcNAc", "CHEMICAL", 158, 164], ["cytosolic", "CELLULAR_COMPONENT", 76, 85], ["nuclear", "CELLULAR_COMPONENT", 90, 97], ["N-acetylglucosamine", "SIMPLE_CHEMICAL", 137, 156], ["GlcNAc", "GENE_OR_GENE_PRODUCT", 158, 164], ["cytosolic and nuclear proteins", "PROTEIN", 76, 106], ["N-acetylglucosamine", "PROTEIN", 137, 156], ["cytosolic glycosyltransferase", "PROTEIN", 171, 200], ["glycosylation", "TREATMENT", 16, 29], ["cytosolic and nuclear proteins", "PROBLEM", 76, 106], ["N-acetylglucosamine (GlcNAc", "TREATMENT", 137, 164], ["a cytosolic glycosyltransferase", "TREATMENT", 169, 200]]], ["Some types of O-glycosylation are specific to distinct classes of proteins or domains (Moremen et al. 2012; Haltom and Jafar-Nejad 2015; Larsen et al. 2017) .", [["O", "CHEMICAL", 14, 15], ["glycosylation", "TREATMENT", 16, 29]]], ["In this review the term O-glycosylation will refer to GalNAc-or mucin-type O-glycosylation, which is one of the most widespread forms of protein O-glycosylation (Bennett et al. 2012) .", [["O", "CHEMICAL", 24, 25], ["GalNAc", "CHEMICAL", 54, 60], ["O", "CHEMICAL", 75, 76], ["O", "CHEMICAL", 145, 146], ["GalNAc", "GENE_OR_GENE_PRODUCT", 54, 60], ["mucin", "GENE_OR_GENE_PRODUCT", 64, 69], ["GalNAc", "TEST", 54, 60], ["glycosylation", "TREATMENT", 77, 90]]], ["N-linked glycosylation of proteins is acquired cotranslationally as they fold in the endoplasmic reticulum (Rothman and Lodish 1977) .", [["endoplasmic reticulum", "ANATOMY", 85, 106], ["N", "CHEMICAL", 0, 1], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 85, 106], ["linked glycosylation of proteins", "PROBLEM", 2, 34], ["endoplasmic reticulum", "ANATOMY", 85, 106]]], ["The initial glycan moiety is comprised of nine mannose (Man), three glucose (Glc) and two GlcNAc residues that are transferred on proteins from a dolicholphosphate-linked precursor to asparagine residues within NXS/T consensus sequons (X-all amino acids except P) (Robbins et al. 1977; Bause 1983; Kornfeld and Kornfeld 1985) .", [["glucose", "CHEMICAL", 68, 75], ["Glc", "CHEMICAL", 77, 80], ["dolicholphosphate", "CHEMICAL", 146, 163], ["asparagine", "CHEMICAL", 184, 194], ["amino acids", "CHEMICAL", 242, 253], ["mannose", "CHEMICAL", 47, 54], ["glucose", "CHEMICAL", 68, 75], ["Glc", "CHEMICAL", 77, 80], ["GlcNAc", "CHEMICAL", 90, 96], ["dolicholphosphate", "CHEMICAL", 146, 163], ["asparagine", "CHEMICAL", 184, 194], ["amino acids", "CHEMICAL", 242, 253], ["mannose", "SIMPLE_CHEMICAL", 47, 54], ["Man", "SIMPLE_CHEMICAL", 56, 59], ["glucose", "SIMPLE_CHEMICAL", 68, 75], ["Glc", "SIMPLE_CHEMICAL", 77, 80], ["dolicholphosphate", "SIMPLE_CHEMICAL", 146, 163], ["asparagine", "AMINO_ACID", 184, 194], ["amino acids", "AMINO_ACID", 242, 253], ["dolicholphosphate-linked precursor", "PROTEIN", 146, 180], ["NXS", "PROTEIN", 211, 214], ["The initial glycan moiety", "TREATMENT", 0, 25], ["three glucose (Glc", "TEST", 62, 80], ["two GlcNAc residues", "PROBLEM", 86, 105], ["a dolicholphosphate", "TREATMENT", 144, 163], ["asparagine residues", "PROBLEM", 184, 203], ["all amino acids", "TREATMENT", 238, 253], ["GlcNAc residues", "OBSERVATION", 90, 105]]], ["The initial glycan structure is trimmed to Man 8 GlcNAc 2 in the endoplasmic reticulum, with intermediates assisting in protein quality control (Hammond et al. 1994; Helenius and Aebi 2004) .", [["endoplasmic reticulum", "ANATOMY", 65, 86], ["GlcNAc", "CHEMICAL", 49, 55], ["Man 8 GlcNAc 2", "GENE_OR_GENE_PRODUCT", 43, 57], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 65, 86], ["Man 8 GlcNAc 2", "PROTEIN", 43, 57], ["The initial glycan structure", "PROBLEM", 0, 28], ["glycan structure", "OBSERVATION", 12, 28], ["endoplasmic reticulum", "ANATOMY", 65, 86]]], ["In the Golgi apparatus, the glycans can be further trimmed, elongated and branched by a differentially expressed set of glycosidases and glycosyltransferases to yield hybrid or complex-type N-glycans (Hunt et al. 1978; Rabouille et al. 1995; Schachter 2000) .", [["Golgi apparatus", "ANATOMY", 7, 22], ["Golgi apparatus", "CELLULAR_COMPONENT", 7, 22], ["glycosidases", "GENE_OR_GENE_PRODUCT", 120, 132], ["glycosidases", "PROTEIN", 120, 132], ["glycosyltransferases", "PROTEIN", 137, 157], ["glycosidases", "TREATMENT", 120, 132], ["glycosyltransferases", "TREATMENT", 137, 157], ["Golgi", "ANATOMY_MODIFIER", 7, 12], ["elongated", "OBSERVATION_MODIFIER", 60, 69], ["branched", "OBSERVATION_MODIFIER", 74, 82]]], ["As proteins pass through the Golgi apparatus, they can also be modified with mucin-type O-glycans, initiated by a family of 20 GalNAc-transferases that add the initial GalNAc monosaccharide to Ser, Thr and possibly Tyr residues (Rottger et al. 1998; Halim et al. 2011; Bennett et al. 2012) .", [["Golgi apparatus", "ANATOMY", 29, 44], ["GalNAc", "CHEMICAL", 127, 133], ["GalNAc monosaccharide", "CHEMICAL", 168, 189], ["Ser", "CHEMICAL", 193, 196], ["Thr", "CHEMICAL", 198, 201], ["Tyr", "CHEMICAL", 215, 218], ["Golgi apparatus", "CELLULAR_COMPONENT", 29, 44], ["mucin", "GENE_OR_GENE_PRODUCT", 77, 82], ["O-glycans", "GENE_OR_GENE_PRODUCT", 88, 97], ["GalNAc-transferases", "GENE_OR_GENE_PRODUCT", 127, 146], ["GalNAc monosaccharide", "GENE_OR_GENE_PRODUCT", 168, 189], ["Ser", "AMINO_ACID", 193, 196], ["Thr", "AMINO_ACID", 198, 201], ["Tyr", "AMINO_ACID", 215, 218], ["mucin", "PROTEIN", 77, 82], ["20 GalNAc-transferases", "PROTEIN", 124, 146], ["the initial GalNAc monosaccharide", "TREATMENT", 156, 189], ["Tyr residues", "PROBLEM", 215, 227]]], ["The GalNAc-transferases exhibit somewhat overlapping, but also distinct substrate specificities and the expression of the isoenzymes is regulated in a tissue-and differentiation-specific manner (Sutherlin et al. 1997; Wandall et al. 1997 Wandall et al. , 2007 Mandel et al. 1999; Young et al. 2003; Tian and Ten Hagen 2006) .", [["tissue", "ANATOMY", 151, 157], ["GalNAc", "CHEMICAL", 4, 10], ["GalNAc-transferases", "GENE_OR_GENE_PRODUCT", 4, 23], ["tissue", "TISSUE", 151, 157], ["GalNAc-transferases", "PROTEIN", 4, 23], ["isoenzymes", "PROTEIN", 122, 132], ["somewhat overlapping", "PROBLEM", 32, 52], ["the isoenzymes", "PROBLEM", 118, 132], ["GalNAc", "ANATOMY_MODIFIER", 4, 10], ["somewhat", "OBSERVATION_MODIFIER", 32, 40], ["overlapping", "OBSERVATION", 41, 52]]], ["Since there are no conserved protein sequence motifs for general or isoformspecific O-glycosylation, it is much more difficult to predict this modification (Gerken et al. 2011) .", [["O", "CHEMICAL", 84, 85], ["conserved protein sequence motifs", "DNA", 19, 52], ["conserved protein sequence motifs", "PROBLEM", 19, 52], ["glycosylation", "TREATMENT", 86, 99], ["no", "UNCERTAINTY", 16, 18]]], ["However, prediction algorithms exist and are rapidly improving due to the vast increase in the number of identified O-glycosites using proteome-wide strategies.", [["O", "CHEMICAL", 116, 117], ["O-glycosites", "SIMPLE_CHEMICAL", 116, 128], ["O-glycosites", "PROTEIN", 116, 128], ["prediction algorithms", "TEST", 9, 30], ["proteome-wide strategies", "TREATMENT", 135, 159], ["vast", "OBSERVATION_MODIFIER", 74, 78], ["increase", "OBSERVATION_MODIFIER", 79, 87]]], ["O-linked glycans can be further elongated by competing glycosyltransferases to form up to eight core structures, which adds to the heterogeneity of O-glycosylation and impedes its analysis (Brockhausen et al. 1990; Yeh et al. 1999; Dalziel et al. 2001; Schachter 2000) .", [["O", "CHEMICAL", 0, 1], ["O", "CHEMICAL", 148, 149], ["O-linked glycans", "SIMPLE_CHEMICAL", 0, 16], ["glycosyltransferases", "PROTEIN", 55, 75], ["further elongated", "PROBLEM", 24, 41], ["competing glycosyltransferases", "TREATMENT", 45, 75], ["elongated", "OBSERVATION_MODIFIER", 32, 41]]], ["Although many types of protein glycosylation exist, N-and mucin-type O-linked glycosylation are the most studied in viral research.", [["N", "CHEMICAL", 52, 53], ["O", "CHEMICAL", 69, 70], ["mucin", "GENE_OR_GENE_PRODUCT", 58, 63], ["protein glycosylation exist", "TEST", 23, 50], ["N", "TEST", 52, 53], ["mucin", "TEST", 58, 63], ["linked glycosylation", "PROBLEM", 71, 91]]], ["These types of glycosylation will also be the focus in the following sections.Methods for analysis of viral glycosylationHistorically, herpesviruses and togaviruses were some of the first viruses investigated for modification with carbohydrates, which led to important findings regarding general aspects of viral glycosylation.", [["sections", "ANATOMY", 69, 77], ["carbohydrates", "CHEMICAL", 231, 244], ["herpesviruses", "ORGANISM", 135, 148], ["togaviruses", "CANCER", 153, 164], ["glycosylation", "TREATMENT", 15, 28], ["analysis", "TEST", 90, 98], ["viral glycosylation", "TREATMENT", 102, 121], ["herpesviruses", "PROBLEM", 135, 148], ["togaviruses", "TREATMENT", 153, 164], ["carbohydrates", "TREATMENT", 231, 244], ["viral glycosylation", "TREATMENT", 307, 326], ["glycosylation", "OBSERVATION", 15, 28], ["viral glycosylation", "OBSERVATION", 307, 326]]], ["Early methods of analysis were based on monitoring the incorporation of radioactively labeled monosaccharides and amino acids into newly synthesized viral proteins during infection (Keller et al. 1970; Spear and Roizman 1970; Kim et al. 1976) .", [["amino acids", "CHEMICAL", 114, 125], ["infection", "DISEASE", 171, 180], ["monosaccharides", "CHEMICAL", 94, 109], ["amino acids", "CHEMICAL", 114, 125], ["monosaccharides", "SIMPLE_CHEMICAL", 94, 109], ["amino acids", "AMINO_ACID", 114, 125], ["viral proteins", "PROTEIN", 149, 163], ["analysis", "TEST", 17, 25], ["radioactively labeled monosaccharides", "TREATMENT", 72, 109], ["amino acids", "TREATMENT", 114, 125], ["newly synthesized viral proteins during infection", "PROBLEM", 131, 180], ["viral proteins", "OBSERVATION", 149, 163]]], ["It was thereby established that viral protein glycosylation took place at the cellular membranes and not the cytoplasmic compartment .", [["cellular membranes", "ANATOMY", 78, 96], ["cytoplasmic compartment", "ANATOMY", 109, 132], ["cellular membranes", "CELLULAR_COMPONENT", 78, 96], ["cytoplasmic compartment", "CELLULAR_COMPONENT", 109, 132], ["viral protein glycosylation", "TREATMENT", 32, 59], ["cellular membranes", "ANATOMY", 78, 96], ["cytoplasmic compartment", "OBSERVATION", 109, 132]]], ["Early glycoprofiling experiments utilized pronase digestion of labeled glycoproteins followed by gel filtration, which allowed separation of the short glycopeptides, bearing different glycan moieties (Honess and Roizman 1975; Schwarz et al. 1977) .", [["pronase", "SIMPLE_CHEMICAL", 42, 49], ["labeled glycoproteins", "PROTEIN", 63, 84], ["Early glycoprofiling experiments", "TREATMENT", 0, 32], ["pronase digestion", "TREATMENT", 42, 59], ["labeled glycoproteins", "TREATMENT", 63, 84], ["gel filtration", "TREATMENT", 97, 111], ["the short glycopeptides", "TREATMENT", 141, 164]]], ["Moreover, differentially labeled sugars were used to provide insight into the putative composition of individual glycan structures (Sefton 1975 ).", [["sugars", "CHEMICAL", 33, 39], ["sugars", "SIMPLE_CHEMICAL", 33, 39], ["sugars", "TEST", 33, 39]]], ["An important conclusion based on such experiments was that the extent of sugar incorporation into individual viral proteins differed depending on the infected cell type (Keller et al. 1970) , establishing that viruses are dependent on the host glycosylation machinery.", [["cell", "ANATOMY", 159, 163], ["sugar", "CHEMICAL", 73, 78], ["sugar", "SIMPLE_CHEMICAL", 73, 78], ["cell type", "CELL", 159, 168], ["viral proteins", "PROTEIN", 109, 123], ["sugar incorporation", "PROBLEM", 73, 92], ["individual viral proteins", "PROBLEM", 98, 123], ["infected cell type", "OBSERVATION", 150, 168], ["viruses", "OBSERVATION", 210, 217]]], ["Use of glycosylation inhibitors, such as tunicamycin, 2-deoxy-D-glucose and glucosamine, provided additional insights into regulation of glycan synthesis, its impact on viral replication, and showed that glycosylation of viral proteins is critical for infectivity and cell-cell fusion (Knowles and Person 1976; Leavitt et al. 1977; Olofsson and Lycke 1980; Herrler and Compans 1983; Lambert and Pons 1983; Mann et al. 1983 ).", [["cell", "ANATOMY", 268, 272], ["cell", "ANATOMY", 273, 277], ["tunicamycin", "CHEMICAL", 41, 52], ["2-deoxy-D-glucose", "CHEMICAL", 54, 71], ["glucosamine", "CHEMICAL", 76, 87], ["tunicamycin", "CHEMICAL", 41, 52], ["2-deoxy-D-glucose", "CHEMICAL", 54, 71], ["glucosamine", "CHEMICAL", 76, 87], ["tunicamycin", "SIMPLE_CHEMICAL", 41, 52], ["2-deoxy-D-glucose", "SIMPLE_CHEMICAL", 54, 71], ["glucosamine", "SIMPLE_CHEMICAL", 76, 87], ["glycan", "GENE_OR_GENE_PRODUCT", 137, 143], ["cell", "CELL", 268, 272], ["cell", "CELL", 273, 277], ["viral proteins", "PROTEIN", 221, 235], ["glycosylation inhibitors", "TREATMENT", 7, 31], ["tunicamycin", "TREATMENT", 41, 52], ["deoxy", "TREATMENT", 56, 61], ["D-glucose", "TREATMENT", 62, 71], ["glucosamine", "TREATMENT", 76, 87], ["glycan synthesis", "TREATMENT", 137, 153], ["viral replication", "TREATMENT", 169, 186], ["glycosylation of viral proteins", "PROBLEM", 204, 235], ["infectivity", "PROBLEM", 252, 263], ["cell-cell fusion", "TREATMENT", 268, 284], ["cell fusion", "OBSERVATION", 273, 284]]], ["Studies in cell lines deficient for specific glycosyltransferases or intracellular transport inhibitors provided additional means for investigating biological consequences of disrupted glycan synthesis and maturation, respectively (Campadelli-Fiume et al. 1982; Edwardson 1984) .Methods for analysis of viral glycosylationAlongside numerous studies addressing viral N-glycan composition and function, it was discovered that viral envelope glycoproteins could also be modified with O-linked glycans (Olofsson et al. 1981; Shida and Dales 1981; Niemann et al. 1982; Gruber and Levine 1985; Montalvo et al. 1985; Gong et al. 1987; Lundstrom et al. 1991) .", [["cell lines", "ANATOMY", 11, 21], ["intracellular", "ANATOMY", 69, 82], ["N", "CHEMICAL", 366, 367], ["O", "CHEMICAL", 481, 482], ["cell lines", "CELL", 11, 21], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 69, 82], ["glycan", "SIMPLE_CHEMICAL", 185, 191], ["O-linked glycans", "SIMPLE_CHEMICAL", 481, 497], ["cell lines", "CELL_LINE", 11, 21], ["viral envelope glycoproteins", "PROTEIN", 424, 452], ["specific glycosyltransferases", "TREATMENT", 36, 65], ["intracellular transport inhibitors", "TREATMENT", 69, 103], ["disrupted glycan synthesis", "PROBLEM", 175, 201], ["viral glycosylation", "TREATMENT", 303, 322], ["numerous studies", "TEST", 332, 348], ["viral N-glycan composition", "TREATMENT", 360, 386], ["viral envelope glycoproteins", "TREATMENT", 424, 452], ["cell lines", "OBSERVATION", 11, 21]]], ["As for human proteins, the Golgi apparatus was identified as the site of viral O-glycosylation (Johnson and Spear 1983; Locker et al. 1992) .", [["Golgi apparatus", "ANATOMY", 27, 42], ["O", "CHEMICAL", 79, 80], ["human", "ORGANISM", 7, 12], ["Golgi", "CELLULAR_COMPONENT", 27, 32], ["human proteins", "PROTEIN", 7, 21], ["human", "SPECIES", 7, 12], ["human", "SPECIES", 7, 12], ["human proteins", "TEST", 7, 21], ["the Golgi apparatus", "TEST", 23, 42]]], ["Historically it was presumed that few viruses were O-glycosylated and the function of this modification remained undetermined for some time (Feldmann et al. 1991; Bernstein et al. 1994) .", [["O", "CHEMICAL", 51, 52], ["few viruses", "PROBLEM", 34, 45], ["few", "OBSERVATION_MODIFIER", 34, 37], ["viruses", "OBSERVATION", 38, 45]]], ["One of the first functions of viral O-glycosylation was discovered in vaccinia virus, where it has been demonstrated that the hemagglutinating activity of glycoprotein HA was entirely dependent on O-linked glycans (Shida and Dales 1981) .", [["O", "CHEMICAL", 197, 198], ["vaccinia virus", "ORGANISM", 70, 84], ["glycoprotein HA", "GENE_OR_GENE_PRODUCT", 155, 170], ["O-linked glycans", "SIMPLE_CHEMICAL", 197, 213], ["glycoprotein HA", "PROTEIN", 155, 170], ["vaccinia virus", "SPECIES", 70, 84], ["viral O-glycosylation", "PROBLEM", 30, 51], ["vaccinia virus", "PROBLEM", 70, 84], ["the hemagglutinating activity of glycoprotein HA", "PROBLEM", 122, 170], ["viral O-glycosylation", "OBSERVATION", 30, 51], ["hemagglutinating", "OBSERVATION_MODIFIER", 126, 142], ["activity", "OBSERVATION_MODIFIER", 143, 151]]], ["A similar carbohydratedependent function was described for rubella virus, where treatment with a mix of glycosidases removing all glycans resulted in inhibition of hemagglutination (Ho-Terry and Cohen 1984) .Methods for analysis of viral glycosylationDevelopment of new biochemical methods facilitated the isolation and analysis of viral glycoproteins and glycans.", [["rubella virus", "DISEASE", 59, 72], ["rubella virus", "ORGANISM", 59, 72], ["viral glycoproteins", "PROTEIN", 332, 351], ["rubella virus", "SPECIES", 59, 72], ["A similar carbohydratedependent function", "PROBLEM", 0, 40], ["rubella virus", "PROBLEM", 59, 72], ["treatment", "TREATMENT", 80, 89], ["a mix of glycosidases", "TREATMENT", 95, 116], ["all glycans", "TREATMENT", 126, 137], ["hemagglutination", "PROBLEM", 164, 180], ["analysis", "TEST", 220, 228], ["viral glycosylation", "TREATMENT", 232, 251], ["new biochemical methods", "PROBLEM", 266, 289], ["the isolation", "TEST", 302, 315], ["viral glycoproteins and glycans", "PROBLEM", 332, 363], ["new", "OBSERVATION_MODIFIER", 266, 269]]], ["Use of plant lectins or sera from immunized animals as well as vaccinated patients facilitated purification of viral envelope proteins and enabled analysis of glycans at the individual protein level (Eisenberg et al. 1979; Wenske et al. 1982; Friedrichs and Grose 1984; Respess et al. 1984; Montalvo et al. 1985) .", [["sera", "ANATOMY", 24, 28], ["sera", "ORGANISM_SUBSTANCE", 24, 28], ["patients", "ORGANISM", 74, 82], ["viral envelope proteins", "PROTEIN", 111, 134], ["patients", "SPECIES", 74, 82], ["plant lectins", "TREATMENT", 7, 20], ["sera", "TREATMENT", 24, 28], ["viral envelope proteins", "PROBLEM", 111, 134], ["glycans", "TEST", 159, 166]]], ["Introduction of chemical glycan release from the peptides or sequential enzymatic deglycosylation enabled more precise characterization of viral glycan size and composition compared to pronase digests (Burke and Keegstra 1979; Rasilo and Renkonen 1979) , and led to determination of type and structure of N-and O-linked glycans for many viruses (Pesonen 1979; Pesonen, Ronnholm et al. 1982; Niemann et al. 1984) .", [["N", "CHEMICAL", 305, 306], ["O", "CHEMICAL", 311, 312], ["O-linked glycans", "SIMPLE_CHEMICAL", 311, 327], ["chemical glycan release", "TREATMENT", 16, 39], ["the peptides", "TREATMENT", 45, 57], ["sequential enzymatic deglycosylation", "TREATMENT", 61, 97], ["viral glycan size", "PROBLEM", 139, 156], ["N", "TEST", 305, 306], ["many viruses", "PROBLEM", 332, 344], ["viral glycan", "OBSERVATION_MODIFIER", 139, 151], ["size", "OBSERVATION_MODIFIER", 152, 156]]], ["The subsequent introduction of reverse phase HPLC further facilitated glycopeptide analysis, allowing separation of larger glycopeptides, generated by digestion of proteins with proteases of defined specificity, such as trypsin.", [["trypsin", "GENE_OR_GENE_PRODUCT", 220, 227], ["proteases", "PROTEIN", 178, 187], ["trypsin", "PROTEIN", 220, 227], ["reverse phase HPLC", "TEST", 31, 49], ["glycopeptide analysis", "TEST", 70, 91], ["larger glycopeptides", "TREATMENT", 116, 136]]], ["Subsequent enzymatic glycan release enabled N-glycan analysis on isolated glycopeptides (Rosner and Robbins 1982; Cohen et al. 1983; Hsieh et al. 1983) , and demonstrated site-specific glycan microheterogeneity in different hosts (Hsieh et al. 1983) .", [["Subsequent enzymatic glycan release", "TEST", 0, 35], ["glycan analysis", "TEST", 46, 61], ["isolated glycopeptides", "TREATMENT", 65, 87], ["glycan microheterogeneity", "OBSERVATION", 185, 210]]], ["Development and advancement of mass spectrometry-based applications had a large impact on the analysis of glycans, which was quickly adopted in the virology field.", [["advancement of mass spectrometry", "TREATMENT", 16, 48], ["the analysis of glycans", "TEST", 90, 113], ["mass", "OBSERVATION", 31, 35], ["large", "OBSERVATION_MODIFIER", 74, 79]]], ["More recent advances in mass spectrometry-based glycoprofiling and glycoproteomics of enveloped viruses are discussed in the following sections.Glycoprofiling of viruses using mass spectrometryModern mass spectrometry-based methods of analysis enable robust characterization of N-or O-linked glycans in complex biological samples with unprecedented sensitivity and resolution.", [["sections", "ANATOMY", 135, 143], ["samples", "ANATOMY", 322, 329], ["O", "CHEMICAL", 283, 284], ["N-or O-linked glycans", "SIMPLE_CHEMICAL", 278, 299], ["samples", "CANCER", 322, 329], ["N-or O-linked glycans", "PROTEIN", 278, 299], ["mass spectrometry", "TEST", 24, 41], ["based glycoprofiling", "TREATMENT", 42, 62], ["glycoproteomics", "TREATMENT", 67, 82], ["enveloped viruses", "PROBLEM", 86, 103], ["Glycoprofiling of viruses", "PROBLEM", 144, 169], ["mass spectrometry", "TEST", 176, 193], ["Modern mass spectrometry", "TEST", 193, 217], ["analysis", "TEST", 235, 243], ["robust characterization", "TEST", 251, 274], ["linked glycans", "PROBLEM", 285, 299], ["unprecedented sensitivity", "TEST", 335, 360], ["mass", "OBSERVATION", 24, 28], ["enveloped", "OBSERVATION_MODIFIER", 86, 95], ["viruses", "OBSERVATION", 96, 103]]], ["It has become routine practice in the characterization of recombinant therapeutics as well as vaccine candidates (Xie et al. 2011; Dubayle et al. 2015; Jacob et al. 2015) .", [["routine practice", "TREATMENT", 14, 30], ["recombinant therapeutics", "TREATMENT", 58, 82], ["vaccine candidates", "TREATMENT", 94, 112]]], ["Matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) is one of the most commonly used tools in modern day glycan analysis.", [["Matrix-assisted laser desorption/ionization mass spectrometry", "TREATMENT", 0, 61], ["glycan analysis", "TEST", 126, 141]]], ["Combining MALDI-MS with lectin microarray enables more reliable characterization of glycan structures, where lectin binding profiles can provide additional information on the glycosidic linkage (Mechref et al. 2003; Lei et al. 2015) .", [["lectin", "GENE_OR_GENE_PRODUCT", 109, 115], ["lectin", "PROTEIN", 24, 30], ["lectin", "PROTEIN", 109, 115], ["lectin microarray", "TEST", 24, 41]]], ["Moreover, tandem MALDI-MS or tandem electrospray ionization MS allows fragmentation of selected precursor ions, enabling more detailed characterization of structures of a given composition (Mechref et al. 2003; Ritchie et al. 2010) .", [["tandem MALDI", "TEST", 10, 22], ["MS", "PROBLEM", 23, 25], ["tandem electrospray ionization", "TREATMENT", 29, 59], ["selected precursor ions", "PROBLEM", 87, 110]]], ["The techniques were soon adapted for analysis of N-glycans on recombinant viral proteins and mature viral particles.Glycoprofiling of viruses using mass spectrometryApplying mass spectrometry-based analysis to viral glycans released from mature viral particles illustrated the heterogeneity of N-glycan structures present on a single protein.", [["N", "CHEMICAL", 294, 295], ["N-glycans", "GENE_OR_GENE_PRODUCT", 49, 58], ["recombinant viral proteins", "PROTEIN", 62, 88], ["analysis", "TEST", 37, 45], ["N-glycans", "TREATMENT", 49, 58], ["recombinant viral proteins", "TREATMENT", 62, 88], ["mature viral particles", "PROBLEM", 93, 115], ["Glycoprofiling of viruses", "PROBLEM", 116, 141], ["mass spectrometry", "PROBLEM", 148, 165], ["Applying mass spectrometry", "TEST", 165, 191], ["viral glycans", "PROBLEM", 210, 223], ["mature viral particles", "PROBLEM", 238, 260], ["the heterogeneity of N-glycan structures", "PROBLEM", 273, 313], ["viral particles", "OBSERVATION", 100, 115], ["viruses", "OBSERVATION", 134, 141], ["mass", "OBSERVATION", 174, 178], ["viral particles", "OBSERVATION", 245, 260]]], ["For example, detailed studies on Dengue virions revealed enormous heterogeneity of N-glycan structures modifying two putative sites of Dengue virus glycoprotein, with 19 distinct structures identified (Lei et al. 2015) .", [["Dengue", "DISEASE", 33, 39], ["N", "CHEMICAL", 83, 84], ["Dengue virions", "ORGANISM", 33, 47], ["Dengue virus", "ORGANISM", 135, 147], ["Dengue virus glycoprotein", "PROTEIN", 135, 160], ["Dengue virus", "SPECIES", 135, 147], ["Dengue virus", "SPECIES", 135, 147], ["detailed studies", "TEST", 13, 29], ["Dengue virions", "TEST", 33, 47], ["enormous heterogeneity of N-glycan structures", "PROBLEM", 57, 102], ["Dengue virus glycoprotein", "PROBLEM", 135, 160], ["19 distinct structures", "PROBLEM", 167, 189], ["enormous", "OBSERVATION_MODIFIER", 57, 65], ["heterogeneity", "OBSERVATION_MODIFIER", 66, 79], ["Dengue virus glycoprotein", "OBSERVATION", 135, 160], ["19 distinct", "OBSERVATION_MODIFIER", 167, 178]]], ["In addition, MS-based glycoprofiling demonstrated distinct glycosylation patterns in different host species for Chikungunya virus (Lancaster et al. 2016) , confirming earlier observations on togaviruses (Hsieh et al. 1983) .Glycoprofiling of viruses using mass spectrometryMALDI-MS has also been used to compare glycan profiles of recombinantly expressed viral proteins and proteins isolated from native viruses.", [["Chikungunya", "DISEASE", 112, 123], ["Chikungunya virus", "ORGANISM", 112, 129], ["recombinantly expressed viral proteins", "PROTEIN", 331, 369], ["Chikungunya virus", "SPECIES", 112, 129], ["Chikungunya virus", "SPECIES", 112, 129], ["MS", "TEST", 13, 15], ["distinct glycosylation patterns", "PROBLEM", 50, 81], ["Chikungunya virus", "PROBLEM", 112, 129], ["Glycoprofiling of viruses", "PROBLEM", 224, 249], ["mass spectrometryMALDI", "PROBLEM", 256, 278], ["MS", "PROBLEM", 279, 281], ["glycan profiles", "TEST", 312, 327], ["recombinantly expressed viral proteins", "PROBLEM", 331, 369], ["native viruses", "PROBLEM", 397, 411], ["distinct", "OBSERVATION_MODIFIER", 50, 58], ["glycosylation patterns", "OBSERVATION", 59, 81], ["different host species", "OBSERVATION", 85, 107], ["viruses", "OBSERVATION", 242, 249], ["viral proteins", "OBSERVATION", 355, 369], ["native viruses", "OBSERVATION", 397, 411]]], ["Comparison of N-glycan profiles on recombinant HIV-1 gp120 monomers and gp120/gp41 trimers, present on native viruses, revealed that while monomeric recombinant protein contained a high proportion of complex-type glycans, native trimers with preserved protein quaternary structure predominantly contained high-mannose type carbohydrates (Doores, Bonomelli et al. 2010; Bonomelli et al. 2011) .", [["mannose", "CHEMICAL", 310, 317], ["carbohydrates", "CHEMICAL", 323, 336], ["HIV-1", "ORGANISM", 47, 52], ["gp120", "ORGANISM", 53, 58], ["gp120", "GENE_OR_GENE_PRODUCT", 72, 77], ["recombinant HIV-1 gp120 monomers", "PROTEIN", 35, 67], ["gp120", "PROTEIN", 72, 77], ["gp41 trimers", "PROTEIN", 78, 90], ["monomeric recombinant protein", "PROTEIN", 139, 168], ["complex-type glycans", "PROTEIN", 200, 220], ["native trimers", "PROTEIN", 222, 236], ["HIV-1", "SPECIES", 47, 52], ["HIV-1", "SPECIES", 47, 52], ["N-glycan profiles", "TEST", 14, 31], ["recombinant HIV", "TEST", 35, 50], ["gp120/gp41 trimers", "TREATMENT", 72, 90], ["native viruses", "PROBLEM", 103, 117], ["monomeric recombinant protein", "TEST", 139, 168], ["preserved protein quaternary structure", "PROBLEM", 242, 280], ["protein", "OBSERVATION", 252, 259], ["quaternary structure", "OBSERVATION", 260, 280], ["high", "OBSERVATION_MODIFIER", 305, 309], ["mannose type", "OBSERVATION_MODIFIER", 310, 322]]], ["The high-mannose type glycans consistently found in monomeric and trimeric formulations are part of the intrinsic mannose patch that contains densely spaced underprocessed glycans (Bonomelli et al. 2011) .", [["mannose", "CHEMICAL", 9, 16], ["mannose", "CHEMICAL", 114, 121], ["mannose", "SIMPLE_CHEMICAL", 114, 121], ["The high-mannose type glycans", "PROBLEM", 0, 29], ["monomeric and trimeric formulations", "TREATMENT", 52, 87], ["the intrinsic mannose patch", "TREATMENT", 100, 127], ["densely spaced underprocessed glycans", "PROBLEM", 142, 179], ["high", "OBSERVATION_MODIFIER", 4, 8], ["mannose patch", "OBSERVATION", 114, 127], ["densely", "OBSERVATION_MODIFIER", 142, 149]]], ["In contrast, analysis of dimeric viral glycoprotein of Hendra virus suggests that oligomerization does not always impede glycan processing (Bowden et al. 2010 ).", [["Hendra virus", "ORGANISM", 55, 67], ["dimeric viral glycoprotein", "PROTEIN", 25, 51], ["Hendra virus", "SPECIES", 55, 67], ["Hendra virus", "SPECIES", 55, 67], ["dimeric viral glycoprotein of Hendra virus", "PROBLEM", 25, 67]]], ["Viral protein architecture, however, is not the only requirement for recapitulation of physiologically relevant glycosylation, as the repertoire of glycosyltransferases naturally also plays an important role.", [["glycosyltransferases", "PROTEIN", 148, 168], ["Viral protein architecture", "TEST", 0, 26], ["physiologically relevant glycosylation", "PROBLEM", 87, 125], ["the repertoire of glycosyltransferases", "TREATMENT", 130, 168], ["protein architecture", "OBSERVATION", 6, 26]]], ["For example, N-glycans on gp120 on pseudovirions from the cell line HEK293T mainly carried \u03b12,3-linked sialic acids, while N-glycans on gp120 from virions derived from peripheral blood mononuclear cells predominantly carried \u03b12,6-linked sialic acids (Pritchard, Harvey et al. 2015) .", [["cell line HEK293T", "ANATOMY", 58, 75], ["virions", "ANATOMY", 147, 154], ["peripheral blood mononuclear cells", "ANATOMY", 168, 202], ["sialic acids", "CHEMICAL", 103, 115], ["sialic acids", "CHEMICAL", 237, 249], ["sialic acids", "CHEMICAL", 103, 115], ["sialic acids", "CHEMICAL", 237, 249], ["N-glycans", "GENE_OR_GENE_PRODUCT", 13, 22], ["gp120", "GENE_OR_GENE_PRODUCT", 26, 31], ["cell line HEK293T", "CELL", 58, 75], ["\u03b12,3-linked sialic acids", "SIMPLE_CHEMICAL", 91, 115], ["N-glycans", "GENE_OR_GENE_PRODUCT", 123, 132], ["gp120", "GENE_OR_GENE_PRODUCT", 136, 141], ["peripheral blood mononuclear cells", "CELL", 168, 202], ["\u03b12,6-linked sialic acids", "SIMPLE_CHEMICAL", 225, 249], ["gp120", "PROTEIN", 26, 31], ["cell line HEK293T", "CELL_LINE", 58, 75], ["\u03b12,3", "PROTEIN", 91, 95], ["gp120", "PROTEIN", 136, 141], ["peripheral blood mononuclear cells", "CELL_TYPE", 168, 202], ["\u03b12,6", "PROTEIN", 225, 229], ["pseudovirions", "TREATMENT", 35, 48], ["the cell line HEK293T", "TEST", 54, 75], ["sialic acids", "TEST", 103, 115], ["peripheral blood mononuclear cells", "TEST", 168, 202], ["peripheral", "ANATOMY_MODIFIER", 168, 178], ["blood", "ANATOMY", 179, 184], ["mononuclear cells", "OBSERVATION", 185, 202]]], ["Such differences might have huge implications on immunogenicity of recombinant vaccine antigens, given that some broadly neutralizing antibodies to HIV-1 recognize glycan-containing epitopes Mouquet et al. 2012; McCoy and Burton 2017) .", [["HIV-1", "ORGANISM", 148, 153], ["glycan-", "SIMPLE_CHEMICAL", 164, 171], ["recombinant vaccine antigens", "PROTEIN", 67, 95], ["neutralizing antibodies", "PROTEIN", 121, 144], ["epitopes", "PROTEIN", 182, 190], ["HIV-1", "SPECIES", 148, 153], ["HIV-1", "SPECIES", 148, 153], ["immunogenicity of recombinant vaccine antigens", "TREATMENT", 49, 95], ["some broadly neutralizing antibodies to HIV", "PROBLEM", 108, 151]]], ["Therefore, both antigen formulations and production cell lines must be considered very carefully.Glycoprofiling of viruses using mass spectrometryAnother concern when analyzing recombinant viral proteins as the source of information for viral glycosylation, is the occasional need for artificial formulations of recombinant viral proteins that often lack natural processing and oligomerization signals when not assembled and presented in the viral context (Bowden et al. 2008; Ritchie et al. 2010) .", [["cell lines", "ANATOMY", 52, 62], ["cell lines", "CELL", 52, 62], ["production cell lines", "CELL_LINE", 41, 62], ["recombinant viral proteins", "PROTEIN", 177, 203], ["recombinant viral proteins", "PROTEIN", 312, 338], ["both antigen formulations", "TREATMENT", 11, 36], ["production cell lines", "TREATMENT", 41, 62], ["Glycoprofiling of viruses", "PROBLEM", 97, 122], ["mass spectrometry", "PROBLEM", 129, 146], ["analyzing recombinant viral proteins", "PROBLEM", 167, 203], ["viral glycosylation", "PROBLEM", 237, 256], ["artificial formulations", "TREATMENT", 285, 308], ["recombinant viral proteins", "TREATMENT", 312, 338], ["cell lines", "OBSERVATION", 52, 62], ["viruses", "OBSERVATION", 115, 122]]], ["For example, it has been shown that lack of proteolytic cleavage of the membrane-truncated soluble HIV-1 envelope glycoprotein (gp140) resulted in aberrant glycosylation that altered the conformation of the trimer (AlSalmi et al. 2015) .", [["membrane", "ANATOMY", 72, 80], ["gp140", "CHEMICAL", 128, 133], ["membrane", "CELLULAR_COMPONENT", 72, 80], ["HIV-1 envelope glycoprotein", "GENE_OR_GENE_PRODUCT", 99, 126], ["gp140", "GENE_OR_GENE_PRODUCT", 128, 133], ["membrane-truncated soluble HIV-1 envelope glycoprotein", "PROTEIN", 72, 126], ["gp140", "PROTEIN", 128, 133], ["HIV-1", "SPECIES", 99, 104], ["HIV-1", "SPECIES", 99, 104], ["proteolytic cleavage of the membrane", "PROBLEM", 44, 80], ["aberrant glycosylation", "PROBLEM", 147, 169], ["aberrant glycosylation", "OBSERVATION", 147, 169]]], ["Ebola virus glycoprotein represents another example of a highly elaborate protein complex assembly.", [["Ebola virus", "ORGANISM", 0, 11], ["Ebola virus glycoprotein", "PROTEIN", 0, 24], ["protein complex", "PROTEIN", 74, 89], ["Ebola virus", "SPECIES", 0, 11], ["Ebola virus", "SPECIES", 0, 11], ["Ebola virus glycoprotein", "PROBLEM", 0, 24], ["protein complex", "OBSERVATION", 74, 89]]], ["It exists as three distinct species due to transcriptional stuttering-sGP, GP and ssGP-two of which are secreted (Lee and Saphire 2009) .", [["sGP", "GENE_OR_GENE_PRODUCT", 70, 73], ["ssGP", "GENE_OR_GENE_PRODUCT", 82, 86], ["sGP", "PROTEIN", 70, 73], ["GP", "PROTEIN", 75, 77], ["ssGP", "DNA", 82, 86], ["three distinct species", "PROBLEM", 13, 35], ["transcriptional stuttering", "PROBLEM", 43, 69], ["sGP", "PROBLEM", 70, 73], ["GP", "TEST", 75, 77], ["ssGP", "TEST", 82, 86], ["three distinct", "OBSERVATION_MODIFIER", 13, 27], ["species", "OBSERVATION", 28, 35], ["transcriptional", "OBSERVATION_MODIFIER", 43, 58], ["stuttering", "OBSERVATION", 59, 69], ["sGP", "OBSERVATION_MODIFIER", 70, 73], ["GP", "OBSERVATION_MODIFIER", 75, 77]]], ["The membrane bound GP is proteolytically processed to GP1 and GP2, and forms a trimer at the cell surface (Lee and Saphire 2009) .", [["membrane", "ANATOMY", 4, 12], ["cell surface", "ANATOMY", 93, 105], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["GP", "GENE_OR_GENE_PRODUCT", 19, 21], ["GP1", "GENE_OR_GENE_PRODUCT", 54, 57], ["GP2", "GENE_OR_GENE_PRODUCT", 62, 65], ["cell surface", "CELLULAR_COMPONENT", 93, 105], ["GP", "PROTEIN", 19, 21], ["GP1", "PROTEIN", 54, 57], ["GP2", "PROTEIN", 62, 65], ["GP2", "TEST", 62, 65]]], ["Nevertheless, formulations of GPs that differ from the natural viral context have been pursued for glycoanalysis.", [["GPs", "TEST", 30, 33], ["glycoanalysis", "TREATMENT", 99, 112]]], ["N-glycan analysis was performed for soluble fragment of GP1 and sGP.", [["GP1", "GENE_OR_GENE_PRODUCT", 56, 59], ["sGP", "GENE_OR_GENE_PRODUCT", 64, 67], ["GP1", "PROTEIN", 56, 59], ["sGP", "PROTEIN", 64, 67], ["glycan analysis", "TEST", 2, 17], ["soluble fragment of GP1 and sGP", "PROBLEM", 36, 67]]], ["The GP1 exhibited a mix of complex, hybrid and high-mannose structures, while sGP carried a higher proportion of processed structures (Ritchie et al. 2010) .", [["mannose", "CHEMICAL", 52, 59], ["GP1", "GENE_OR_GENE_PRODUCT", 4, 7], ["sGP", "SIMPLE_CHEMICAL", 78, 81], ["GP1", "PROTEIN", 4, 7], ["sGP", "PROTEIN", 78, 81], ["The GP1", "TEST", 0, 7], ["a mix of complex, hybrid and high-mannose structures", "PROBLEM", 18, 70], ["mix", "OBSERVATION_MODIFIER", 20, 23], ["complex", "OBSERVATION_MODIFIER", 27, 34], ["hybrid", "OBSERVATION_MODIFIER", 36, 42], ["high", "OBSERVATION_MODIFIER", 47, 51], ["mannose structures", "OBSERVATION", 52, 70]]], ["A more recent glycoprofiling of stabilized monomeric GP1,2 constructs from five different strains of Ebola virus confirmed the presence of heterogeneous and mostly complex-type N-glycans (Collar et al. 2016) .", [["Ebola virus", "DISEASE", 101, 112], ["GP1", "GENE_OR_GENE_PRODUCT", 53, 56], ["Ebola virus", "ORGANISM", 101, 112], ["monomeric GP1,2 constructs", "DNA", 43, 69], ["Ebola virus", "SPECIES", 101, 112], ["Ebola virus", "SPECIES", 101, 112], ["A more recent glycoprofiling of stabilized monomeric GP1,2 constructs", "PROBLEM", 0, 69], ["Ebola virus", "PROBLEM", 101, 112], ["Ebola virus", "OBSERVATION", 101, 112], ["heterogeneous", "OBSERVATION_MODIFIER", 139, 152], ["mostly", "OBSERVATION_MODIFIER", 157, 163], ["complex", "OBSERVATION_MODIFIER", 164, 171]]], ["This is in contrast to a highly variable O-glycan pattern in the different strains (Collar et al. 2016) .", [["O", "CHEMICAL", 41, 42]]], ["A few other recombinant glycoproteins from Nipah virus and Machupo virus were expressed in their monomeric forms and reported to predominantly carry complex-type N-glycans (Bowden et al. 2008 (Bowden et al. , 2009 ).", [["Nipah virus", "ORGANISM", 43, 54], ["Machupo virus", "ORGANISM", 59, 72], ["recombinant glycoproteins", "PROTEIN", 12, 37], ["Nipah virus", "SPECIES", 43, 54], ["Machupo virus", "SPECIES", 59, 72], ["Nipah virus", "SPECIES", 43, 54], ["Machupo virus", "SPECIES", 59, 72], ["A few other recombinant glycoproteins", "PROBLEM", 0, 37], ["Nipah virus", "TREATMENT", 43, 54], ["Machupo virus", "TREATMENT", 59, 72], ["few", "OBSERVATION_MODIFIER", 2, 5], ["recombinant", "OBSERVATION_MODIFIER", 12, 23], ["glycoproteins", "OBSERVATION", 24, 37], ["Nipah virus", "OBSERVATION", 43, 54]]], ["In conclusion, it is difficult to predict glycosylation patterns of native oligomeric protein complexes based on studies of recombinant monomeric proteins.", [["native oligomeric protein complexes", "PROTEIN", 68, 103], ["recombinant monomeric proteins", "PROTEIN", 124, 154], ["native oligomeric protein complexes", "PROBLEM", 68, 103], ["recombinant monomeric proteins", "PROBLEM", 124, 154], ["oligomeric protein complexes", "OBSERVATION", 75, 103]]], ["It is, however, sometimes the only solution because of difficulties in expression of correctly folded and authentic protein complexes.Glycoprofiling of viruses using mass spectrometryMALDI-MS can also be applied for O-glycan analysis (Canis et al. 2010; Franc et al. 2013) ; however, it has not been widely used in the virology field and only a few examples of O-glycoprofiling of viral glycoproteins using MALDI-MS exist Collar et al. 2016) .", [["O", "CHEMICAL", 361, 362], ["protein complexes", "PROTEIN", 116, 133], ["viral glycoproteins", "PROTEIN", 381, 400], ["Glycoprofiling of viruses", "PROBLEM", 134, 159], ["mass spectrometryMALDI", "PROBLEM", 166, 188], ["MS", "PROBLEM", 189, 191], ["glycan analysis", "TEST", 218, 233], ["viral glycoproteins", "TREATMENT", 381, 400], ["protein complexes", "OBSERVATION", 116, 133], ["viruses", "OBSERVATION", 152, 159]]], ["It can probably be explained by lower interest in viral O-glycosylation as opposed to N-glycosylation, primarily due to poorly characterized functions of viral O-glycans and the presumption that most viral glycoproteins are not heavily O-glycosylated.", [["O", "CHEMICAL", 56, 57], ["N", "CHEMICAL", 86, 87], ["O", "CHEMICAL", 236, 237], ["O-glycans", "GENE_OR_GENE_PRODUCT", 160, 169], ["viral O-glycans", "PROTEIN", 154, 169], ["viral glycoproteins", "PROTEIN", 200, 219], ["viral O-glycosylation", "TREATMENT", 50, 71], ["N-glycosylation", "TREATMENT", 86, 101], ["viral O-glycans", "PROBLEM", 154, 169], ["most viral glycoproteins", "PROBLEM", 195, 219], ["probably be explained", "UNCERTAINTY", 7, 28]]], ["In addition, more sophisticated methods allowing simultaneous determination of modified amino acids have rapidly taken over, which have in the recent years been widely used for analysis of viral O-glycosylation.Glycoproteomics of virusesWhile glycoprofiling studies provide important information on distribution and composition of different glycan structures present on a given protein, it lacks the information on individual glycosite location, occupancy and glycan structure heterogeneity.", [["amino acids", "CHEMICAL", 88, 99], ["amino acids", "CHEMICAL", 88, 99], ["amino acids", "AMINO_ACID", 88, 99], ["glycosite", "SIMPLE_CHEMICAL", 426, 435], ["modified amino acids", "TREATMENT", 79, 99], ["viral O-glycosylation", "PROBLEM", 189, 210], ["Glycoproteomics of viruses", "TREATMENT", 211, 237], ["glycoprofiling studies", "TEST", 243, 265], ["different glycan structures", "PROBLEM", 331, 358], ["glycan structure heterogeneity", "PROBLEM", 460, 490], ["viral O-glycosylation", "OBSERVATION", 189, 210], ["viruses", "OBSERVATION", 230, 237], ["glycan structure", "OBSERVATION", 460, 476]]], ["The recent development of instruments equipped with ECD or ETD MS2 fragmentation has allowed for simultaneous determination of the peptide sequence and the position to which the carbohydrate moiety is attached (Levery et al. 2015) .", [["carbohydrate", "CHEMICAL", 178, 190], ["ECD", "TREATMENT", 52, 55], ["ETD MS2 fragmentation", "PROBLEM", 59, 80], ["simultaneous determination of the peptide sequence", "TEST", 97, 147], ["the carbohydrate moiety", "TREATMENT", 174, 197], ["instruments", "OBSERVATION", 26, 37]]], ["When relevant reporter glycan oxonium ions are present and it is easy to predict the glycosylation position within peptides, HCD MS2 fragmentation can also be used (Wuhrer et al. 2007 ).", [["oxonium", "CHEMICAL", 30, 37], ["oxonium", "CHEMICAL", 30, 37], ["relevant reporter glycan oxonium ions", "TREATMENT", 5, 42], ["HCD MS2 fragmentation", "PROBLEM", 125, 146]]], ["Interfacing the mass spectrometer with capillary liquid chromatography enables separation of complex proteome-scale glycopeptide mixtures and allows identification of thousands of glycopeptides in a single run.", [["capillary liquid chromatography", "TEST", 39, 70], ["complex proteome-scale glycopeptide mixtures", "TREATMENT", 93, 137], ["glycopeptides", "TREATMENT", 180, 193], ["mass", "OBSERVATION", 16, 20], ["capillary", "ANATOMY_MODIFIER", 39, 48]]], ["At the single protein level, it is now possible to determine the exact position, structure heterogeneity, and site occupancy for each individual glycosite (Wuhrer et al. 2007) .", [["structure", "OBSERVATION_MODIFIER", 81, 90], ["heterogeneity", "OBSERVATION_MODIFIER", 91, 104]]], ["Both N-and O-glycosylation can be analyzed by tandem MS. Biosynthetic features of N-glycosylation enable relatively easy identification and quantification of deglycosylated sites by MS2 sequencing.", [["N", "CHEMICAL", 5, 6], ["O", "CHEMICAL", 11, 12], ["N", "CHEMICAL", 82, 83], ["glycosylation", "TREATMENT", 13, 26], ["N-glycosylation", "TREATMENT", 82, 97], ["deglycosylated sites", "PROBLEM", 158, 178]]], ["Due to asparagine deamidation during enzymatic N-glycan removal, the site occupancy can be determined by calculating the intensity ratio of naked (Asn) and deglycosylated (Asp) peptides (Pabst et al. 2012; An et al. 2015) .", [["asparagine", "CHEMICAL", 7, 17], ["N-glycan", "CHEMICAL", 47, 55], ["asparagine", "CHEMICAL", 7, 17], ["N", "CHEMICAL", 47, 48], ["Asn", "CHEMICAL", 147, 150], ["Asp", "CHEMICAL", 172, 175], ["asparagine", "AMINO_ACID", 7, 17], ["asparagine deamidation", "PROBLEM", 7, 29], ["enzymatic N-glycan removal", "TREATMENT", 37, 63], ["the site occupancy", "PROBLEM", 65, 83], ["deglycosylated (Asp) peptides", "TREATMENT", 156, 185]]], ["However, the more appropriate methodology includes carrying out the reaction using heavy-oxygen water (O 18 -H 2 O), which discriminates deglycosylated sites from spontaneous Asn deamidation (Palmisano et al. 2012; Cao et al. 2017) .", [["oxygen", "CHEMICAL", 89, 95], ["O 18 -H 2 O", "CHEMICAL", 103, 114], ["Asn", "CHEMICAL", 175, 178], ["oxygen", "CHEMICAL", 89, 95], ["O 18 -H 2 O", "CHEMICAL", 103, 114], ["Asn", "CHEMICAL", 175, 178], ["heavy-oxygen water", "SIMPLE_CHEMICAL", 83, 101], ["O 18 -H 2 O", "SIMPLE_CHEMICAL", 103, 114], ["Asn", "AMINO_ACID", 175, 178], ["the reaction", "PROBLEM", 64, 76], ["heavy-oxygen water", "TREATMENT", 83, 101], ["spontaneous Asn deamidation", "PROBLEM", 163, 190]]], ["It is also possible to evaluate the overall distribution of N-glycosite occupancy on intact glycoproteins by metabolically simplifying the glycans to homogeneous structures (Struwe et al. 2017) .", [["N-glycosite", "CHEMICAL", 60, 71], ["N", "CHEMICAL", 60, 61], ["N-glycosite occupancy", "PROBLEM", 60, 81], ["intact glycoproteins", "TREATMENT", 85, 105]]], ["For O-linked glycans, complete O-glycan removal does not result in chemical peptide modification and cannot be used for identification of glycosylated amino acid positions (Levery et al. 2015) .", [["amino acid", "CHEMICAL", 151, 161], ["O", "CHEMICAL", 4, 5], ["O", "CHEMICAL", 31, 32], ["amino acid", "CHEMICAL", 151, 161], ["O-linked glycans", "SIMPLE_CHEMICAL", 4, 20], ["O-glycan", "SIMPLE_CHEMICAL", 31, 39], ["amino acid", "AMINO_ACID", 151, 161], ["complete O-glycan removal", "TREATMENT", 22, 47], ["chemical peptide modification", "TREATMENT", 67, 96], ["glycosylated amino acid positions", "TREATMENT", 138, 171]]], ["ETD and ECD MS2 techniques allow analysis of intact O-glycopeptides by fragmentation of the peptide backbone without the loss of O-glycan modification, however, it is of limited use for determining site occupancy (Wuhrer et al. 2007; Sihlbom et al. 2009; Zauner et al. 2012) .", [["O", "CHEMICAL", 52, 53], ["O", "CHEMICAL", 129, 130], ["O-glycopeptides", "SIMPLE_CHEMICAL", 52, 67], ["ETD", "TEST", 0, 3], ["ECD MS2 techniques", "TEST", 8, 26], ["glycopeptides", "TREATMENT", 54, 67], ["the peptide backbone", "TREATMENT", 88, 108]]], ["Approximations are yet often made by comparing intensities of nonmodified and glycosylated peptides (Brautigam et al. 2013; Stansell et al. 2015) .", [["nonmodified and glycosylated peptides", "TREATMENT", 62, 99]]], ["The relative quantitation of both N-and O-glycosylated peptides is not as accurate due to different ionization efficiencies of nonglycosylated peptides and peptides carrying complex glycans.", [["N", "CHEMICAL", 34, 35], ["O", "CHEMICAL", 40, 41], ["nonglycosylated peptides", "TREATMENT", 127, 151], ["quantitation", "OBSERVATION_MODIFIER", 13, 25], ["ionization efficiencies", "OBSERVATION", 100, 123]]], ["Dependent on the complexity of the glycans, glycopeptides generally exhibit poorer ionization compared to peptides (Stavenhagen et al. 2013 ).", [["glycopeptides", "TREATMENT", 44, 57], ["poorer ionization", "PROBLEM", 76, 93]]], ["The analysis of complex proteins therefore often requires enrichment with hydrophilic interaction chromatography or specific lectins, which is particularly relevant for proteome-wide applications (Bunkenborg et al. 2004; Zielinska et al. 2010; Khatri et al. 2014; Levery et al. 2015) .", [["complex proteins", "PROTEIN", 16, 32], ["The analysis", "TEST", 0, 12], ["complex proteins", "PROBLEM", 16, 32], ["hydrophilic interaction chromatography", "TREATMENT", 74, 112]]], ["However, information regarding site occupancy needs to be sacrificed.N-glycoproteomicsTandem mass spectrometry has been widely used for characterization of N-glycosylation sites on viral proteins, with respect to individual site occupancy status (macroheterogeneity) and site-specific structural diversity (microheterogeneity), as these are important features that can affect protein-protein interactions and immunogenicity.", [["N", "CHEMICAL", 156, 157], ["N-glycosylation sites", "PROTEIN", 156, 177], ["viral proteins", "PROTEIN", 181, 195], ["site occupancy", "PROBLEM", 31, 45], ["glycoproteomicsTandem mass spectrometry", "TREATMENT", 71, 110], ["glycosylation sites", "PROBLEM", 158, 177], ["viral proteins", "PROBLEM", 181, 195]]], ["Comprehensive glycoproteomic analysis has, for example, mapped N-linked glycosylation of seasonal influenza A virus H3N2 HA, identifying more than 90 % site occupancy of all putative N-linked glycan sites .", [["N", "CHEMICAL", 63, 64], ["N", "CHEMICAL", 183, 184], ["seasonal influenza A virus H3N2 HA", "ORGANISM", 89, 123], ["N-linked glycan sites", "PROTEIN", 183, 204], ["influenza A virus H3N2", "SPECIES", 98, 120], ["seasonal influenza A virus H3N2", "SPECIES", 89, 120], ["Comprehensive glycoproteomic analysis", "TEST", 0, 37], ["seasonal influenza A virus H3N2 HA", "PROBLEM", 89, 123], ["glycan sites", "OBSERVATION", 192, 204]]], ["Moreover, the globular head glycosites, associated with host immune receptor interaction, were strictly high-mannose type .", [["head", "ANATOMY", 23, 27], ["mannose", "CHEMICAL", 109, 116], ["globular head glycosites", "PROTEIN", 14, 38], ["the globular head glycosites", "PROBLEM", 10, 38], ["globular", "OBSERVATION_MODIFIER", 14, 22], ["head", "ANATOMY", 23, 27], ["glycosites", "OBSERVATION", 28, 38], ["mannose type", "OBSERVATION", 109, 121]]], ["In a separate study on the highly pathogenic H5N1 influenza A virus, it was also shown that all potential N-glycosites were consistently occupied between several different strains (Blake et al. 2009 ), suggesting that N-glycosylation of HA is conserved between the different isolates of the same virus subtype, with a high occupancy of potential N-glycosites.", [["influenza A virus", "DISEASE", 50, 67], ["N", "CHEMICAL", 346, 347], ["H5N1 influenza A virus", "ORGANISM", 45, 67], ["HA", "GENE_OR_GENE_PRODUCT", 237, 239], ["N-glycosites", "PROTEIN", 346, 358], ["H5N1 influenza A virus", "SPECIES", 45, 67], ["H5N1 influenza A virus", "SPECIES", 45, 67], ["a separate study", "TEST", 3, 19], ["the highly pathogenic H5N1 influenza A virus", "PROBLEM", 23, 67], ["all potential N-glycosites", "PROBLEM", 92, 118], ["several different strains", "PROBLEM", 154, 179], ["N-glycosylation of HA", "PROBLEM", 218, 239], ["the same virus subtype", "PROBLEM", 287, 309]]], ["In a similar way, it has been demonstrated that all predicted N-glycan sequons were utilized in Hepatitis C virus E2 and Murray Valley encephalitis virus NS1 (Blitvich et al. 2001; Iacob et al. 2008) , where the majority of HCV E2 glycosites were modified with high-mannose type glycans (Iacob et al. 2008 ).", [["Hepatitis C virus E2", "CHEMICAL", 96, 116], ["Murray Valley encephalitis", "DISEASE", 121, 147], ["E2", "CHEMICAL", 228, 230], ["mannose", "CHEMICAL", 266, 273], ["Hepatitis C virus E2", "ORGANISM", 96, 116], ["Murray Valley encephalitis virus", "ORGANISM", 121, 153], ["NS1", "ORGANISM", 154, 157], ["HCV", "ORGANISM", 224, 227], ["N-glycan sequons", "PROTEIN", 62, 78], ["Hepatitis C virus", "SPECIES", 96, 113], ["Murray Valley encephalitis virus", "SPECIES", 121, 153], ["Hepatitis C virus", "SPECIES", 96, 113], ["Murray Valley encephalitis virus", "SPECIES", 121, 153], ["HCV", "SPECIES", 224, 227], ["all predicted N-glycan sequons", "TREATMENT", 48, 78], ["Hepatitis C virus E2", "TREATMENT", 96, 116], ["Murray Valley encephalitis virus NS1", "PROBLEM", 121, 157], ["HCV E2 glycosites", "TREATMENT", 224, 241]]], ["On the densely glycosylated HIV-1 envelope glycoprotein several strategies have been employed to characterize the nature and location of the many glycans, with up to 27 mostly highly occupied N-glycosites identified, some of which were exclusively highmannose type (Pabst et al. 2012; Go et al. 2013; Yang W et al. 2014) .", [["N", "CHEMICAL", 192, 193], ["highmannose", "CHEMICAL", 248, 259], ["HIV-1", "ORGANISM", 28, 33], ["densely glycosylated HIV-1 envelope glycoprotein", "PROTEIN", 7, 55], ["N-glycosites", "PROTEIN", 192, 204], ["HIV-1", "SPECIES", 28, 33], ["HIV-1", "SPECIES", 28, 33], ["the densely glycosylated HIV", "PROBLEM", 3, 31], ["1 envelope glycoprotein", "TREATMENT", 32, 55]]], ["Tandem mass spectrometry has also been used for addressing differences in cell-type specific glycosylation and influence of protein conformation.", [["cell", "ANATOMY", 74, 78], ["cell", "CELL", 74, 78], ["Tandem mass spectrometry", "PROBLEM", 0, 24], ["cell-type specific glycosylation", "TREATMENT", 74, 106], ["mass", "OBSERVATION", 7, 11]]], ["Out of convenience, soluble HIV-1 gp120 or gp140 preparations are often analyzed.", [["HIV-1 gp120", "GENE_OR_GENE_PRODUCT", 28, 39], ["gp140", "GENE_OR_GENE_PRODUCT", 43, 48], ["gp120", "PROTEIN", 34, 39], ["gp140", "PROTEIN", 43, 48], ["HIV-1", "SPECIES", 28, 33], ["HIV-1", "SPECIES", 28, 33], ["soluble HIV-1 gp120 or gp140 preparations", "TREATMENT", 20, 61]]], ["HIV-1 gp120 produced in CHO and 293 T cells had very similar occupancy, degree of fucosylation, sialylation, and glycan maturation, with a larger share of glycosites predominantly carrying hybrid and complex-type N-glycans (Go et al. 2013 ).", [["CHO", "ANATOMY", 24, 27], ["293 T cells", "ANATOMY", 32, 43], ["HIV-1", "ORGANISM", 0, 5], ["gp120", "ORGANISM", 6, 11], ["CHO", "CELL", 24, 27], ["293 T cells", "CELL", 32, 43], ["glycosites", "GENE_OR_GENE_PRODUCT", 155, 165], ["HIV-1 gp120", "PROTEIN", 0, 11], ["CHO", "CELL_LINE", 24, 27], ["293 T cells", "CELL_LINE", 32, 43], ["glycosites", "PROTEIN", 155, 165], ["HIV-1", "SPECIES", 0, 5], ["HIV-1", "SPECIES", 0, 5], ["HIV", "TEST", 0, 3], ["fucosylation, sialylation", "PROBLEM", 82, 107], ["glycan maturation", "PROBLEM", 113, 130], ["a larger share of glycosites", "PROBLEM", 137, 165], ["fucosylation", "OBSERVATION", 82, 94], ["glycan maturation", "OBSERVATION", 113, 130]]], ["The positions of some of the exclusively high-mannose N-glycans were located within the intrinsic mannose patch of gp120 (Go et al. 2013; Behrens et al. 2016) .", [["mannose", "CHEMICAL", 46, 53], ["mannose", "CHEMICAL", 98, 105], ["gp120", "PROTEIN", 115, 120], ["the exclusively high-mannose N-glycans", "TREATMENT", 25, 63], ["positions", "OBSERVATION_MODIFIER", 4, 13], ["mannose patch", "OBSERVATION", 98, 111]]], ["In contrast, a much higher proportion of the N-glycosites on gp140 expressed in CHO, recombinant trimers, or those on gp120 purified from native virions were modified with highmannose type N-glycans (Pabst et al. 2012; Behrens et al. 2016; Panico et al. 2016; Go et al. 2017) .", [["CHO", "ANATOMY", 80, 83], ["virions", "ANATOMY", 145, 152], ["highmannose", "CHEMICAL", 172, 183], ["gp140", "GENE_OR_GENE_PRODUCT", 61, 66], ["CHO", "CELL", 80, 83], ["gp120", "GENE_OR_GENE_PRODUCT", 118, 123], ["N-glycosites", "PROTEIN", 45, 57], ["gp140", "PROTEIN", 61, 66], ["CHO", "CELL_LINE", 80, 83], ["recombinant trimers", "PROTEIN", 85, 104], ["gp120", "PROTEIN", 118, 123], ["highmannose type N-glycans", "PROTEIN", 172, 198], ["native virions", "TREATMENT", 138, 152]]], ["This again signifies the importance of analyzing the native protein conformation for generation of relevant glycosylation patterns.", [["relevant glycosylation patterns", "PROBLEM", 99, 130]]], ["Glycosylation in different cell lines was also investigated for Hendra virus recombinant glycoprotein G, where all seven potential N-glycan sites were occupied in HeLa cells (Colgrave et al. 2012) .", [["cell lines", "ANATOMY", 27, 37], ["HeLa cells", "ANATOMY", 163, 173], ["cell lines", "CELL", 27, 37], ["Hendra virus", "ORGANISM", 64, 76], ["glycoprotein G", "GENE_OR_GENE_PRODUCT", 89, 103], ["HeLa cells", "CELL", 163, 173], ["cell lines", "CELL_LINE", 27, 37], ["Hendra virus recombinant glycoprotein G", "PROTEIN", 64, 103], ["N-glycan sites", "PROTEIN", 131, 145], ["HeLa cells", "CELL_LINE", 163, 173], ["Hendra virus", "SPECIES", 64, 76], ["Hendra virus", "SPECIES", 64, 76], ["Glycosylation in different cell lines", "TREATMENT", 0, 37], ["Hendra virus recombinant glycoprotein G", "TREATMENT", 64, 103], ["glycan sites", "PROBLEM", 133, 145], ["different cell lines", "OBSERVATION", 17, 37], ["HeLa cells", "OBSERVATION", 163, 173]]], ["In contrast, only four sites were N-glycosylated in HEK293, although the degree of glycan maturation was similar in both cell lines (Colgrave et al. 2012) .", [["HEK293", "ANATOMY", 52, 58], ["cell lines", "ANATOMY", 121, 131], ["N", "CHEMICAL", 34, 35], ["HEK293", "CELL", 52, 58], ["glycan", "GENE_OR_GENE_PRODUCT", 83, 89], ["cell lines", "CELL", 121, 131], ["HEK293", "CELL_LINE", 52, 58], ["cell lines", "CELL_LINE", 121, 131], ["glycan maturation", "PROBLEM", 83, 100], ["glycan maturation", "OBSERVATION", 83, 100], ["both cell lines", "OBSERVATION", 116, 131]]], ["To summarize the results obtained from various N-glycoprofiling and glycoproteomic studies, it seems that most of the putative N-glycosylation sequons are glycosylated with high occupancy on viral proteins.", [["N", "CHEMICAL", 127, 128], ["N-glycosylation sequons", "PROTEIN", 127, 150], ["viral proteins", "PROTEIN", 191, 205], ["glycoproteomic studies", "TEST", 68, 90], ["high occupancy on viral proteins", "PROBLEM", 173, 205], ["viral proteins", "OBSERVATION", 191, 205]]], ["However, the site occupancy of viral protein N-glycosylation can vary in different producer cell lines.", [["cell lines", "ANATOMY", 92, 102], ["N", "CHEMICAL", 45, 46], ["cell lines", "CELL", 92, 102], ["viral protein N", "PROTEIN", 31, 46], ["producer cell lines", "CELL_LINE", 83, 102], ["viral protein N", "TREATMENT", 31, 46], ["glycosylation", "TREATMENT", 47, 60], ["viral protein", "OBSERVATION", 31, 44], ["producer cell lines", "OBSERVATION", 83, 102]]], ["Moreover, high-mannose type N-glycans may constitute a substantial, if not the major, proportion of viral N-glycosites, particularly when native protein structure and oligomerization is taken into account.", [["mannose", "CHEMICAL", 15, 22], ["N", "CHEMICAL", 106, 107], ["high-mannose type N-glycans", "TREATMENT", 10, 37], ["viral N-glycosites", "PROBLEM", 100, 118]]], ["Thus, results obtained from analysis of recombinant monomeric proteins should be interpreted with caution also when considering the occupancy of individual N-glycosylation sites as well as complexity of glycan structures as discussed above.O-glycoproteomicsFor decades very little information has been available regarding sitespecific O-glycosylation of viral proteins.", [["N", "CHEMICAL", 156, 157], ["O", "CHEMICAL", 335, 336], ["recombinant monomeric proteins", "PROTEIN", 40, 70], ["N-glycosylation sites", "PROTEIN", 156, 177], ["viral proteins", "PROTEIN", 354, 368], ["recombinant monomeric proteins", "TREATMENT", 40, 70], ["individual N-glycosylation sites", "TREATMENT", 145, 177], ["glycoproteomics", "TREATMENT", 242, 257], ["viral proteins", "PROBLEM", 354, 368], ["viral proteins", "OBSERVATION", 354, 368]]], ["Some of the first described virus-derived site-specific O-glycans were on isoform M of HBV surface antigen purified from patient-derived viral particles ).", [["surface", "ANATOMY", 91, 98], ["O-glycans", "GENE_OR_GENE_PRODUCT", 56, 65], ["HBV surface antigen", "GENE_OR_GENE_PRODUCT", 87, 106], ["patient", "ORGANISM", 121, 128], ["O-glycans", "PROTEIN", 56, 65], ["isoform M", "PROTEIN", 74, 83], ["HBV surface antigen", "PROTEIN", 87, 106], ["patient", "SPECIES", 121, 128], ["HBV", "SPECIES", 87, 90], ["HBV surface antigen", "TEST", 87, 106]]], ["The O-glycosylation site was identified by combining MALDI analysis of exoglycosidase-treated glycopeptide and Edman sequencing of the underlying peptide.", [["exoglycosidase", "CHEMICAL", 71, 85], ["exoglycosidase", "SIMPLE_CHEMICAL", 71, 85], ["O-glycosylation site", "DNA", 4, 24], ["exoglycosidase", "PROTEIN", 71, 85], ["The O-glycosylation site", "PROBLEM", 0, 24], ["combining MALDI analysis", "TEST", 43, 67], ["exoglycosidase", "TEST", 71, 85], ["glycopeptide", "TREATMENT", 94, 106], ["Edman", "TREATMENT", 111, 116], ["the underlying peptide", "PROBLEM", 131, 153]]], ["The position of the glycan attachment site was deduced by carboxypeptidase digestion and confirmed by collision-induced dissociation tandem mass spectrometry, representing some of the early glycoproteomic experiments of viral proteins ).", [["carboxypeptidase", "GENE_OR_GENE_PRODUCT", 58, 74], ["glycan attachment site", "PROTEIN", 20, 42], ["carboxypeptidase", "PROTEIN", 58, 74], ["viral proteins", "PROTEIN", 220, 234], ["the glycan attachment site", "PROBLEM", 16, 42], ["carboxypeptidase digestion", "TREATMENT", 58, 84], ["induced dissociation tandem mass spectrometry", "PROBLEM", 112, 157], ["viral proteins", "PROBLEM", 220, 234], ["viral proteins", "OBSERVATION", 220, 234]]], ["The recent advances in mass spectrometry-based proteomics have resulted in numerous studies addressing O-glycosylation of individual viral glycoproteins.", [["O", "CHEMICAL", 103, 104], ["viral glycoproteins", "PROTEIN", 133, 152], ["mass spectrometry", "TEST", 23, 40], ["individual viral glycoproteins", "PROBLEM", 122, 152], ["viral glycoproteins", "OBSERVATION", 133, 152]]], ["O-glycoproteomic analyses have been performed for several recombinant or isolated viral glycoproteins, including HIV-1 gp120, influenza A virus HA1, HCV E2, HSV-1 gC and Hendra virus glycoprotein G (Colgrave et al. 2012; Brautigam et al. 2013; Go et al. 2013; Yang W et al. 2014; Norden et al. 2015; Stansell et al. 2015) .", [["HIV-1 gp120", "ORGANISM", 113, 124], ["influenza A virus HA1", "ORGANISM", 126, 147], ["HCV E2", "ORGANISM", 149, 155], ["HSV-1 gC", "ORGANISM", 157, 165], ["Hendra virus", "ORGANISM", 170, 182], ["glycoprotein G", "GENE_OR_GENE_PRODUCT", 183, 197], ["viral glycoproteins", "PROTEIN", 82, 101], ["gp120", "PROTEIN", 119, 124], ["gC", "PROTEIN", 163, 165], ["Hendra virus glycoprotein G", "PROTEIN", 170, 197], ["HIV-1", "SPECIES", 113, 118], ["influenza A virus", "SPECIES", 126, 143], ["HSV-1", "SPECIES", 157, 162], ["Hendra virus", "SPECIES", 170, 182], ["HIV-1", "SPECIES", 113, 118], ["influenza A virus", "SPECIES", 126, 143], ["HCV", "SPECIES", 149, 152], ["HSV-1", "SPECIES", 157, 162], ["Hendra virus", "SPECIES", 170, 182], ["glycoproteomic analyses", "TEST", 2, 25], ["isolated viral glycoproteins", "PROBLEM", 73, 101], ["HIV", "TEST", 113, 116], ["influenza A virus HA1", "PROBLEM", 126, 147], ["HCV E2", "TEST", 149, 155], ["HSV", "TEST", 157, 160], ["Hendra virus glycoprotein G", "TREATMENT", 170, 197], ["viral glycoproteins", "OBSERVATION", 82, 101]]], ["Recombinantly expressed gp120 and HA1 were glycosylated at a single position each, which in both cases was modified with core 1 or core 2 elongated O-glycans (Stansell et al. 2015) .", [["O", "CHEMICAL", 148, 149], ["gp120", "GENE_OR_GENE_PRODUCT", 24, 29], ["HA1", "GENE_OR_GENE_PRODUCT", 34, 37], ["O-glycans", "SIMPLE_CHEMICAL", 148, 157], ["gp120", "PROTEIN", 24, 29], ["HA1", "PROTEIN", 34, 37]]], ["Interestingly, site occupancy was much lower in recombinant gp140 undergoing proteolytic cleavage to gp120, assuming equivalent ionization efficiencies of nonmodified and glycosylated peptides.", [["gp140", "GENE_OR_GENE_PRODUCT", 60, 65], ["gp120", "GENE_OR_GENE_PRODUCT", 101, 106], ["recombinant gp140", "PROTEIN", 48, 65], ["gp120", "PROTEIN", 101, 106], ["proteolytic cleavage", "TREATMENT", 77, 97], ["nonmodified and glycosylated peptides", "TREATMENT", 155, 192], ["ionization efficiencies", "OBSERVATION", 128, 151]]], ["Recombinant gp140 possessed shorter less sialylated, predominantly core 1 O-glycans, again underlining the importance of native protein conformation for analogous studies (Stansell et al. 2015) .", [["gp140", "GENE_OR_GENE_PRODUCT", 12, 17], ["gp140", "PROTEIN", 12, 17], ["analogous studies", "TEST", 153, 170]]], ["In contrast, gp120 purified from T-cell derived virions was devoid of the single site found glycosylated in recombinantly expressed gp120 (Stansell et al. 2015) .", [["T-cell", "ANATOMY", 33, 39], ["virions", "ANATOMY", 48, 55], ["gp120", "GENE_OR_GENE_PRODUCT", 13, 18], ["T-cell", "CELL", 33, 39], ["gp120", "GENE_OR_GENE_PRODUCT", 132, 137], ["gp120", "PROTEIN", 13, 18], ["gp120", "PROTEIN", 132, 137], ["T-cell derived virions", "TREATMENT", 33, 55]]], ["This, however, might be related to the viral strain used, as the single site was reported to be glycosylated in a separate study using virions from a different HIV-1 strain (Yang W et al. 2014 ).", [["HIV-1", "ORGANISM", 160, 165], ["HIV-1", "SPECIES", 160, 165], ["HIV-1", "SPECIES", 160, 165], ["the viral strain", "PROBLEM", 35, 51], ["a separate study", "TEST", 112, 128], ["virions", "TREATMENT", 135, 142], ["a different HIV", "PROBLEM", 148, 163], ["might be related to", "UNCERTAINTY", 15, 34], ["viral strain", "OBSERVATION", 39, 51]]], ["In addition, treatment of passaged or plasma-derived HIV-1 virions with antibodies against O-linked carbohydrate structures resulted in inhibition of cell entry, and virus neutralization (Hansen et al. 1990 (Hansen et al. , 1991 , suggesting that HIV-1 gp120 can indeed be O-glycosylated in vivo.", [["plasma", "ANATOMY", 38, 44], ["cell", "ANATOMY", 150, 154], ["O", "CHEMICAL", 91, 92], ["carbohydrate", "CHEMICAL", 100, 112], ["O", "CHEMICAL", 273, 274], ["plasma", "ORGANISM_SUBSTANCE", 38, 44], ["HIV-1 virions", "ORGANISM", 53, 66], ["cell", "CELL", 150, 154], ["HIV-1", "ORGANISM", 247, 252], ["gp120", "ORGANISM", 253, 258], ["antibodies", "PROTEIN", 72, 82], ["gp120", "PROTEIN", 253, 258], ["HIV-1", "SPECIES", 53, 58], ["HIV-1", "SPECIES", 247, 252], ["HIV-1", "SPECIES", 53, 58], ["HIV-1", "SPECIES", 247, 252], ["plasma", "TEST", 38, 44], ["antibodies", "TEST", 72, 82], ["linked carbohydrate structures", "PROBLEM", 93, 123], ["inhibition of cell entry", "PROBLEM", 136, 160], ["glycosylated in vivo", "TREATMENT", 275, 295], ["cell entry", "OBSERVATION", 150, 160]]], ["Comparison of recombinant gp120 O-glycosylation in two different cell lines revealed predominant core 1 O-glycosylation in CHO cells, compared to core 1, core 2 and core 4 in 293 T cells (Go et al. 2013) .", [["cell lines", "ANATOMY", 65, 75], ["CHO cells", "ANATOMY", 123, 132], ["293 T cells", "ANATOMY", 175, 186], ["O", "CHEMICAL", 104, 105], ["cell lines", "CELL", 65, 75], ["CHO cells", "CELL", 123, 132], ["293 T cells", "CELL", 175, 186], ["gp120", "PROTEIN", 26, 31], ["cell lines", "CELL_LINE", 65, 75], ["CHO cells", "CELL_LINE", 123, 132], ["293 T cells", "CELL_LINE", 175, 186], ["recombinant gp120 O-glycosylation", "TREATMENT", 14, 47], ["glycosylation in CHO cells", "PROBLEM", 106, 132], ["cell lines", "OBSERVATION", 65, 75], ["predominant", "OBSERVATION_MODIFIER", 85, 96], ["core", "OBSERVATION_MODIFIER", 97, 101], ["CHO cells", "OBSERVATION", 123, 132]]], ["In a similar manner, Hendra virus glycoprotein G expressed in HeLa and HEK293 cells, differed considerably with different numbers of O-glycosites identified and carrying different core structures (Colgrave et al. 2012) .", [["HeLa", "ANATOMY", 62, 66], ["HEK293 cells", "ANATOMY", 71, 83], ["Hendra virus", "ORGANISM", 21, 33], ["glycoprotein G", "GENE_OR_GENE_PRODUCT", 34, 48], ["HeLa", "CELL", 62, 66], ["HEK293 cells", "CELL", 71, 83], ["O-glycosites", "SIMPLE_CHEMICAL", 133, 145], ["Hendra virus glycoprotein G", "PROTEIN", 21, 48], ["HeLa", "CELL_LINE", 62, 66], ["HEK293 cells", "CELL_LINE", 71, 83], ["O-glycosites", "PROTEIN", 133, 145], ["Hendra virus", "SPECIES", 21, 33], ["Hendra virus", "SPECIES", 21, 33], ["Hendra virus glycoprotein G", "TREATMENT", 21, 48], ["HEK293 cells", "OBSERVATION", 71, 83]]], ["Recombinant HCV E2 was O-glycosylated at six positions, with predominantly core 1 and core 2 O-glycan structures (Brautigam et al. 2013 ).", [["E2", "CHEMICAL", 16, 18], ["O", "CHEMICAL", 23, 24], ["O", "CHEMICAL", 93, 94], ["HCV E2", "ORGANISM", 12, 18], ["HCV", "SPECIES", 12, 15], ["Recombinant HCV E2", "TEST", 0, 18], ["HCV", "OBSERVATION", 12, 15]]], ["More than 80 % occupancy was estimated for five of the six sites, whereas one site had very low occupancy.", [["very low occupancy", "PROBLEM", 87, 105], ["very", "OBSERVATION_MODIFIER", 87, 91], ["low occupancy", "OBSERVATION", 92, 105]]], ["Moreover, a high level of structural heterogeneity was observed for the O-glycans localized at the individual sites, with up to 14 different structures identified (Brautigam et al. 2013) .", [["O", "CHEMICAL", 72, 73], ["O-glycans", "GENE_OR_GENE_PRODUCT", 72, 81], ["O-glycans", "PROTEIN", 72, 81], ["a high level of structural heterogeneity", "PROBLEM", 10, 50], ["structural heterogeneity", "OBSERVATION", 26, 50]]], ["A recent study on O-linked glycosylation of HSV-1 mucin-like protein gC provided some insight into O-glycan synthesis, suggesting that the eleven O-glycosites were added in an orderly fashion, before elongation took place .", [["O", "CHEMICAL", 18, 19], ["O", "CHEMICAL", 99, 100], ["O", "CHEMICAL", 146, 147], ["HSV-1", "ORGANISM", 44, 49], ["mucin", "GENE_OR_GENE_PRODUCT", 50, 55], ["O-glycan", "SIMPLE_CHEMICAL", 99, 107], ["O-glycosites", "SIMPLE_CHEMICAL", 146, 158], ["HSV-1 mucin-like protein gC", "PROTEIN", 44, 71], ["HSV-1", "SPECIES", 44, 49], ["HSV-1", "SPECIES", 44, 49], ["A recent study", "TEST", 0, 14], ["HSV", "TEST", 44, 47], ["protein gC", "TEST", 61, 71], ["the eleven O-glycosites", "TREATMENT", 135, 158]]], ["These studies underscore the high heterogeneity of O-glycan structures, which are both cell type and protein specific, and the need for careful selection of candidates and expression cell lines for clinical applications.", [["cell", "ANATOMY", 87, 91], ["cell lines", "ANATOMY", 183, 193], ["O", "CHEMICAL", 51, 52], ["cell", "CELL", 87, 91], ["cell lines", "CELL", 183, 193], ["expression cell lines", "CELL_LINE", 172, 193], ["These studies", "TEST", 0, 13], ["the high heterogeneity of O-glycan structures", "PROBLEM", 25, 70], ["careful selection of candidates", "TREATMENT", 136, 167], ["expression cell lines", "TREATMENT", 172, 193], ["clinical applications", "TREATMENT", 198, 219], ["high", "OBSERVATION_MODIFIER", 29, 33], ["heterogeneity", "OBSERVATION_MODIFIER", 34, 47], ["cell type", "OBSERVATION", 87, 96]]], ["Moreover, comprehensive analysis of immune responses mounted by these different structures would be highly beneficial.Global O-glycoproteomicsWhile it is clear that single protein-targeted mass spectrometry approaches can provide comprehensive information on single site occupancy and structure heterogeneity, we lack robust methods of analysis for site-specific O-glycosylation in complex or proteome-wide samples.", [["samples", "ANATOMY", 407, 414], ["O", "CHEMICAL", 363, 364], ["samples", "CANCER", 407, 414], ["comprehensive analysis", "TEST", 10, 32], ["immune responses", "PROBLEM", 36, 52], ["Global O-glycoproteomics", "PROBLEM", 118, 142], ["single protein", "TEST", 165, 179], ["targeted mass spectrometry approaches", "TREATMENT", 180, 217], ["single site occupancy", "PROBLEM", 259, 280], ["structure heterogeneity", "PROBLEM", 285, 308], ["analysis", "TEST", 336, 344], ["glycosylation", "TREATMENT", 365, 378], ["O-glycoproteomics", "OBSERVATION", 125, 142]]], ["To solve this problem, we recently introduced a method for globally mapping O-glycosylation sites in glycoengineered cell lines lacking O-linked glycan elongation, which is based on Vicia villosa lectin (VVA) affinity enrichment of simple glycopeptides coupled to tandem mass spectrometry (Steentoft et al. 2011 ).", [["cell lines", "ANATOMY", 117, 127], ["O", "CHEMICAL", 76, 77], ["O", "CHEMICAL", 136, 137], ["glycoengineered cell lines", "CELL", 101, 127], ["Vicia villosa", "ORGANISM", 182, 195], ["lectin", "GENE_OR_GENE_PRODUCT", 196, 202], ["VVA", "SIMPLE_CHEMICAL", 204, 207], ["O-glycosylation sites", "PROTEIN", 76, 97], ["glycoengineered cell lines", "CELL_LINE", 101, 127], ["Vicia villosa lectin", "PROTEIN", 182, 202], ["VVA", "PROTEIN", 204, 207], ["Vicia villosa", "SPECIES", 182, 195], ["Vicia villosa", "SPECIES", 182, 195], ["a method", "TREATMENT", 46, 54], ["globally mapping O", "TREATMENT", 59, 77], ["glycosylation sites", "TREATMENT", 78, 97], ["glycoengineered cell lines", "TREATMENT", 101, 127], ["linked glycan elongation", "PROBLEM", 138, 162], ["Vicia villosa lectin (VVA)", "TREATMENT", 182, 208], ["simple glycopeptides", "TREATMENT", 232, 252], ["tandem mass spectrometry", "PROBLEM", 264, 288], ["cell lines", "OBSERVATION", 117, 127], ["glycan elongation", "OBSERVATION", 145, 162]]], ["The method is also applicable for analysis of wild type cells, predominantly expressing core 1 O-glycans, by using peanut agglutinin (PNA) enrichment of desialylated glycopeptides (Yang Z et al. 2014) .", [["cells", "ANATOMY", 56, 61], ["cells", "CELL", 56, 61], ["O-glycans", "GENE_OR_GENE_PRODUCT", 95, 104], ["peanut agglutinin", "SIMPLE_CHEMICAL", 115, 132], ["PNA", "SIMPLE_CHEMICAL", 134, 137], ["wild type cells", "CELL_TYPE", 46, 61], ["peanut agglutinin", "PROTEIN", 115, 132], ["analysis", "TEST", 34, 42], ["wild type cells", "PROBLEM", 46, 61], ["peanut agglutinin", "TREATMENT", 115, 132], ["desialylated glycopeptides", "TREATMENT", 153, 179]]], ["We have applied these methods in the analysis of O-glycosylation of HSV-1 infected human fibroblasts by performing a sequential enrichment with PNA and VVA, thus reporting the first comprehensive viral O-glycoproteome (Bagdonaite et al. 2015) .", [["fibroblasts", "ANATOMY", 89, 100], ["O", "CHEMICAL", 49, 50], ["HSV-1", "ORGANISM", 68, 73], ["human", "ORGANISM", 83, 88], ["fibroblasts", "CELL", 89, 100], ["PNA", "SIMPLE_CHEMICAL", 144, 147], ["VVA", "SIMPLE_CHEMICAL", 152, 155], ["human fibroblasts", "CELL_TYPE", 83, 100], ["HSV-1", "SPECIES", 68, 73], ["human", "SPECIES", 83, 88], ["HSV-1", "SPECIES", 68, 73], ["human", "SPECIES", 83, 88], ["these methods", "TREATMENT", 16, 29], ["the analysis", "TEST", 33, 45], ["HSV", "PROBLEM", 68, 71], ["infected human fibroblasts", "PROBLEM", 74, 100], ["a sequential enrichment", "TREATMENT", 115, 138], ["PNA", "PROBLEM", 144, 147], ["VVA", "PROBLEM", 152, 155], ["PNA", "OBSERVATION", 144, 147]]], ["This approach provides several clear advantages: first of all, it allows simultaneous analysis of all viral glycoproteins expressed in an infected cell.", [["cell", "ANATOMY", 147, 151], ["cell", "CELL", 147, 151], ["viral glycoproteins", "PROTEIN", 102, 121], ["simultaneous analysis", "TEST", 73, 94], ["all viral glycoproteins", "PROBLEM", 98, 121], ["an infected cell", "PROBLEM", 135, 151], ["infected cell", "OBSERVATION", 138, 151]]], ["Secondly, the strategy takes into account the endogenous glycosylation of a permissive cell, dictated by the repertoire of glycosyltransferases, as well as native conformations of proteins and the cytopathic effects of viral infection.", [["cell", "ANATOMY", 87, 91], ["viral infection", "DISEASE", 219, 234], ["cell", "CELL", 87, 91], ["glycosyltransferases", "PROTEIN", 123, 143], ["glycosyltransferases", "TREATMENT", 123, 143], ["native conformations of proteins", "PROBLEM", 156, 188], ["the cytopathic effects", "PROBLEM", 193, 215], ["viral infection", "PROBLEM", 219, 234], ["permissive cell", "OBSERVATION", 76, 91], ["cytopathic", "OBSERVATION_MODIFIER", 197, 207], ["viral", "OBSERVATION_MODIFIER", 219, 224], ["infection", "OBSERVATION", 225, 234]]], ["Irrelevant cell lines are often chosen for recombinant expression of viral proteins.", [["cell lines", "ANATOMY", 11, 21], ["cell lines", "CELL", 11, 21], ["Irrelevant cell lines", "CELL_LINE", 0, 21], ["viral proteins", "PROTEIN", 69, 83], ["Irrelevant cell lines", "TREATMENT", 0, 21], ["viral proteins", "PROBLEM", 69, 83], ["cell lines", "OBSERVATION", 11, 21], ["viral proteins", "OBSERVATION", 69, 83]]], ["The glycosylation obtained in these cells lines does not always reflect the glycosylation pattern in a natural host.Global O-glycoproteomicsUsing herpesviruses as a model system, we have applied the same method for defining the O-glycoproteomes of other members of Herpesviridae family-HSV-2, VZV, HCMV and EBV Iversen et al. 2016) .", [["cells lines", "ANATOMY", 36, 47], ["cells lines", "CELL", 36, 47], ["herpesviruses", "ORGANISM", 146, 159], ["Herpesviridae", "GENE_OR_GENE_PRODUCT", 265, 278], ["HSV-2", "ORGANISM", 286, 291], ["VZV", "ORGANISM", 293, 296], ["HCMV", "ORGANISM", 298, 302], ["EBV", "ORGANISM", 307, 310], ["cells lines", "CELL_LINE", 36, 47], ["VZV", "SPECIES", 293, 296], ["HCMV", "SPECIES", 298, 302], ["The glycosylation", "TREATMENT", 0, 17], ["these cells lines", "TREATMENT", 30, 47], ["Global O-glycoproteomics", "PROBLEM", 116, 140], ["HSV", "TEST", 286, 289], ["VZV", "PROBLEM", 293, 296], ["HCMV", "PROBLEM", 298, 302], ["glycosylation pattern", "OBSERVATION", 76, 97], ["O-glycoproteomics", "OBSERVATION", 123, 140]]], ["The wide occurrence, associated complications and shortage of prophylactic measures make herpesviruses a relevant model system to analyze O-glycans and their importance in viral life cycle (Vazquez et al. 2001; Cohen et al. 2006; Adjei et al. 2008; Kramer et al. 2008; Oxman 2010; Shiley and Blumberg 2010; Lopo et al. 2011; Sauerbrei et al. 2011; Levine et al. 2012; van Rijckevorsel et al. 2012; Astuto et al. 2013; Conde-Glez et al. 2013; Fishman 2013; Gorfinkel et al. 2013; Odland et al. 2013; Pembrey et al. 2013; Rowe et al. 2013 Shaiegan et al. 2015) .", [["herpesviruses", "ORGANISM", 89, 102], ["O-glycans", "GENE_OR_GENE_PRODUCT", 138, 147], ["associated complications", "PROBLEM", 21, 45], ["prophylactic measures", "TREATMENT", 62, 83], ["Shiley", "TREATMENT", 281, 287], ["wide", "OBSERVATION_MODIFIER", 4, 8], ["complications", "OBSERVATION", 32, 45]]], ["In addition, the large proteomes of herpesviruses highlight the benefits of global viral O-glycoproteomics.", [["herpesviruses", "ORGANISM", 36, 49], ["the large proteomes of herpesviruses", "PROBLEM", 13, 49], ["global viral O-glycoproteomics", "TREATMENT", 76, 106], ["large", "OBSERVATION_MODIFIER", 17, 22]]], ["Human herpesviruses encode seven to 12 glycoproteins associated with the viral particle; however, many more viral proteins possess signal peptides and transit through the host secretory pathway.", [["Human", "ORGANISM", 0, 5], ["viral proteins", "PROTEIN", 108, 122], ["Human", "SPECIES", 0, 5], ["Human herpesviruses", "SPECIES", 0, 19], ["Human herpesviruses encode", "TREATMENT", 0, 26], ["the viral particle", "PROBLEM", 69, 87], ["many more viral proteins possess signal peptides", "PROBLEM", 98, 146], ["viral particle", "OBSERVATION", 73, 87]]], ["Some of them have previously been investigated for glycan modifications in focused studies.", [["glycan modifications", "TREATMENT", 51, 71], ["focused studies", "TEST", 75, 90]]], ["N-linked glycans have been identified on viral envelope glycoproteins from all 8 human herpesviruses (Wenske et al. 1982; Edson and Thorley-Lawson 1983; Friedrichs and Grose 1984; Serafini-Cessi et al. 1984 Montalvo et al. 1985; Grose 1986, 1987; Gong et al. 1987; Britt and Vugler 1989; Gong and Kieff 1990; Okuno et al. 1990 Okuno et al. , 1992 Foa-Tomasi et al. 1992; Nolan and Morgan 1995; Pfeiffer et al. 1995; Hata et al. 1996; Mukai et al. 1997; Chandran et al. 1998; Pertel et al. 1998; Huber and Compton 1999; Li et al. 1999; Zhu et al. 1999; Baghian et al. 2000; Skrincosky et al. 2000; Wu et al. 2000; Maresova et al. 2000; Theiler and Compton 2002; Koyano et al. 2003; Paulsen et al. 2005; Yamagishi et al. 2008; Gore and Hutt-Fletcher 2009; Luo et al. 2015) , where individual glycoproteins have been demonstrated to exhibit variable extent and pattern of glycan chain maturation (Wenske et al. 1982; Edson and Thorley-Lawson 1983; Friedrichs and Grose 1984; Serafini-Cessi et al. 1984 Montalvo et al. 1985; Grose 1986, 1987; Britt and Vugler 1989; Gong and Kieff 1990; Okuno et al. 1990 Okuno et al. , 1992 Huber and Compton 1999; Maresova et al. 2000; Theiler and Compton 2002; Yamagishi et al. 2008) .", [["N", "CHEMICAL", 0, 1], ["human", "ORGANISM", 81, 86], ["herpesviruses", "ORGANISM", 87, 100], ["Theiler", "ORGANISM", 635, 642], ["Theiler", "ORGANISM", 1167, 1174], ["N-linked glycans", "PROTEIN", 0, 16], ["viral envelope glycoproteins", "PROTEIN", 41, 69], ["human", "SPECIES", 81, 86], ["Theiler", "SPECIES", 635, 642], ["Theiler", "SPECIES", 1167, 1174], ["human", "SPECIES", 81, 86], ["linked glycans", "PROBLEM", 2, 16], ["viral envelope glycoproteins", "TREATMENT", 41, 69], ["Serafini", "TREATMENT", 180, 188], ["Britt", "TEST", 265, 270], ["Serafini", "TREATMENT", 972, 980]]], ["A relatively smaller proportion of envelope glycoproteins of herpesviruses have been investigated in terms of O-glycosylation, and in some of these envelope proteins O-glycans have been detected by biochemical assays (Serafini-Cessi, Dall'Olio, Scannavini, Costanzo et al. 1983; Montalvo et al. 1985; Gong et al. 1987; Montalvo and Grose 1987; Serafini-Cessi et al. 1988 Britt and Vugler 1989; Kari et al. 1992; Yao et al. 1993; Nolan and Morgan 1995; Borza and Hutt-Fletcher 1998; Cardinali et al. 1998; Lake et al. 1998; Peng et al. 1998; Torrisi et al. 1999; Zhu et al. 1999; Wu et al. 2000; Theiler and Compton 2002; Xiao et al. 2007) .", [["O", "CHEMICAL", 110, 111], ["herpesviruses", "ORGANISM", 61, 74], ["O-glycans", "GENE_OR_GENE_PRODUCT", 166, 175], ["Theiler", "ORGANISM", 595, 602], ["envelope glycoproteins", "PROTEIN", 35, 57], ["envelope proteins", "PROTEIN", 148, 165], ["Theiler", "SPECIES", 595, 602], ["envelope glycoproteins of herpesviruses", "PROBLEM", 35, 74], ["glycosylation", "TREATMENT", 112, 125], ["biochemical assays", "TEST", 198, 216], ["Serafini", "TEST", 218, 226], ["Dall'Olio", "TREATMENT", 234, 243], ["Scannavini", "TREATMENT", 245, 255], ["Serafini", "TEST", 344, 352], ["relatively", "OBSERVATION_MODIFIER", 2, 12], ["smaller", "OBSERVATION_MODIFIER", 13, 20], ["envelope glycoproteins", "OBSERVATION", 35, 57]]], ["Only a few of these proteins have merited more thorough investigation with most attention devoted to proteins containing mucin-like domains.", [["mucin", "GENE_OR_GENE_PRODUCT", 121, 126], ["mucin-like domains", "PROTEIN", 121, 139], ["thorough investigation", "TEST", 47, 69], ["few", "OBSERVATION_MODIFIER", 7, 10]]], ["HSV-1 attachment factor gC was the first envelope glycoprotein described to carry O-glycans, acquiring distinct structures in different cell types (Olofsson et al. 1981 (Olofsson et al. , 1983 Dall'Olio et al. 1985; Lundstrom et al. 1987) , and specific O-glycosites have recently been mapped to the mucin-like region (Bagdonaite et al. 2015; Norden et al. 2015) .", [["cell", "ANATOMY", 136, 140], ["HSV-1", "ORGANISM", 0, 5], ["gC", "GENE_OR_GENE_PRODUCT", 24, 26], ["O-glycans", "GENE_OR_GENE_PRODUCT", 82, 91], ["cell", "CELL", 136, 140], ["O-glycosites", "SIMPLE_CHEMICAL", 254, 266], ["mucin", "GENE_OR_GENE_PRODUCT", 300, 305], ["HSV-1 attachment factor gC", "PROTEIN", 0, 26], ["envelope glycoprotein", "PROTEIN", 41, 62], ["O-glycans", "PROTEIN", 82, 91], ["O-glycosites", "PROTEIN", 254, 266], ["mucin", "PROTEIN", 300, 305], ["HSV-1", "SPECIES", 0, 5], ["HSV-1", "SPECIES", 0, 5], ["HSV", "TEST", 0, 3], ["attachment factor gC", "TEST", 6, 26], ["the first envelope glycoprotein", "PROBLEM", 31, 62], ["different cell types", "OBSERVATION", 126, 146]]], ["Furthermore, the HSV-2 and VZV orthologs were also found to be O-glycosylated (Zezulak and Spear 1983; Bagdonaite et al. 2016) .", [["O", "CHEMICAL", 63, 64], ["HSV-2", "ORGANISM", 17, 22], ["VZV", "ORGANISM", 27, 30], ["HSV-2 and VZV orthologs", "DNA", 17, 40], ["HSV-2", "SPECIES", 17, 22], ["VZV", "SPECIES", 27, 30], ["the HSV", "TEST", 13, 20], ["VZV orthologs", "TEST", 27, 40]]], ["Similarly, other mucin-like region-containing proteins such as HSV-1 gI, HSV-2 gG, EBV gp150 and gp350 have been shown to accommodate high density of O-glycosylation, and the types of O-glycan structures were identified for some of these proteins Nolan and Morgan 1995; Borza and Hutt-Fletcher 1998; Norberg et al. 2007 ).", [["O", "CHEMICAL", 150, 151], ["O", "CHEMICAL", 184, 185], ["mucin", "GENE_OR_GENE_PRODUCT", 17, 22], ["HSV-1 gI", "ORGANISM", 63, 71], ["HSV-2 gG", "ORGANISM", 73, 81], ["EBV", "ORGANISM", 83, 86], ["gp150", "GENE_OR_GENE_PRODUCT", 87, 92], ["gp350", "GENE_OR_GENE_PRODUCT", 97, 102], ["mucin", "PROTEIN", 17, 22], ["HSV-1 gI, HSV-2 gG", "PROTEIN", 63, 81], ["EBV gp150", "PROTEIN", 83, 92], ["gp350", "PROTEIN", 97, 102], ["HSV-1", "SPECIES", 63, 68], ["HSV-1", "SPECIES", 63, 68], ["other mucin-like region", "PROBLEM", 11, 34], ["HSV", "TEST", 63, 66], ["gI", "TEST", 69, 71], ["HSV", "TEST", 73, 76], ["EBV gp150", "TEST", 83, 92]]], ["The conserved viral fusion effector gB has been shown or predicted to be O-glycosylated in all herpesvirus subfamilies (Serafini-Cessi, Dall'Olio, Scannavini, Costanzo et al. 1983; Gong et al. 1987; Montalvo and Grose 1987; Britt and Vugler 1989) .", [["O", "CHEMICAL", 73, 74], ["gB", "GENE_OR_GENE_PRODUCT", 36, 38], ["herpesvirus", "ORGANISM", 95, 106], ["conserved viral fusion effector gB", "PROTEIN", 4, 38], ["O-glycosylated", "PROTEIN", 73, 87], ["The conserved viral fusion effector gB", "PROBLEM", 0, 38], ["glycosylated", "TREATMENT", 75, 87], ["all herpesvirus subfamilies", "TREATMENT", 91, 118], ["Serafini", "TEST", 120, 128], ["Cessi", "TREATMENT", 129, 134], ["Dall'Olio", "TREATMENT", 136, 145], ["Scannavini", "TREATMENT", 147, 157], ["viral fusion", "OBSERVATION", 14, 26]]], ["The era of proteome-wide mass spectrometry-based applications allowed robust characterization of viral O-glycoproteomes (Bagdonaite et al. 2015 Iversen et al. 2016) .", [["proteome", "TEST", 11, 19], ["wide mass spectrometry", "TREATMENT", 20, 42], ["wide", "OBSERVATION_MODIFIER", 20, 24], ["mass", "OBSERVATION", 25, 29]]], ["The characterizations confirmed the identity of the majority of previously described O-glycoproteins of herpesviruses, and provided a tremendous expansion of site-specific O-glycosylation (Bagdonaite et al. 2015 Iversen et al. 2016) .", [["O", "CHEMICAL", 172, 173], ["herpesviruses", "ORGANISM", 104, 117], ["O-glycoproteins", "PROTEIN", 85, 100], ["The characterizations", "TEST", 0, 21], ["herpesviruses", "PROBLEM", 104, 117], ["a tremendous expansion of site", "TREATMENT", 132, 162]]], ["While GalNActype O-glycosylation is often associated with dense glycosylation in mucin-like regions, it is also abundantly found in isolation or small clusters in human proteins (Steentoft et al. 2013) , which is more difficult to predict.", [["GalNActype", "CHEMICAL", 6, 16], ["GalNActype", "CHEMICAL", 6, 16], ["GalNActype", "GENE_OR_GENE_PRODUCT", 6, 16], ["mucin", "GENE_OR_GENE_PRODUCT", 81, 86], ["human", "ORGANISM", 163, 168], ["mucin", "PROTEIN", 81, 86], ["human proteins", "PROTEIN", 163, 177], ["human", "SPECIES", 163, 168], ["human", "SPECIES", 163, 168], ["GalNActype O-glycosylation", "PROBLEM", 6, 32], ["dense glycosylation in mucin-like regions", "PROBLEM", 58, 99], ["small clusters in human proteins", "PROBLEM", 145, 177], ["dense", "OBSERVATION_MODIFIER", 58, 63], ["glycosylation", "OBSERVATION", 64, 77], ["isolation", "OBSERVATION", 132, 141], ["small", "OBSERVATION_MODIFIER", 145, 150], ["clusters", "OBSERVATION_MODIFIER", 151, 159]]], ["In agreement with this, we have demonstrated ample presence of isolated O-glycan sites on viral glycoproteins of HSV-1, HSV-2, VZV, HCMV and EBV by glycoproteomic approaches (Bagdonaite et al. 2015 Iversen et al. 2016 ).", [["O", "CHEMICAL", 72, 73], ["HSV-1", "ORGANISM", 113, 118], ["HSV-2", "ORGANISM", 120, 125], ["VZV", "ORGANISM", 127, 130], ["HCMV", "ORGANISM", 132, 136], ["EBV", "ORGANISM", 141, 144], ["O-glycan sites", "PROTEIN", 72, 86], ["viral glycoproteins", "PROTEIN", 90, 109], ["HSV-1", "SPECIES", 113, 118], ["HSV-1", "SPECIES", 113, 118], ["HSV-2", "SPECIES", 120, 125], ["VZV", "SPECIES", 127, 130], ["HCMV", "SPECIES", 132, 136], ["EBV", "SPECIES", 141, 144], ["isolated O-glycan sites", "PROBLEM", 63, 86], ["viral glycoproteins", "TEST", 90, 109], ["HSV", "TEST", 113, 116], ["HSV", "TEST", 120, 123], ["VZV", "PROBLEM", 127, 130], ["HCMV", "PROBLEM", 132, 136]]], ["Location of O-glycosites identified via proteome-wide MS/MS approaches with respect to protein structural features suggests possible involvement in the protein-protein interactions (Bagdonaite et al. 2015 , as exemplified in subsequent sections.", [["sections", "ANATOMY", 236, 244], ["O", "CHEMICAL", 12, 13], ["O-glycosites", "PROTEIN", 12, 24], ["glycosites", "TEST", 14, 24], ["proteome", "TEST", 40, 48], ["wide MS", "PROBLEM", 49, 56], ["MS approaches", "PROBLEM", 57, 70], ["protein structural features", "PROBLEM", 87, 114], ["suggests possible", "UNCERTAINTY", 115, 132]]], ["Large scale glycoproteomic analyses of human herpesviruses of varying phylogeny (HSV-1, HSV-2, VZV, HCMV and EBV) have made it possible to compare the O-glycosite patterns in homologous proteins (Bagdonaite et al. 2015 Iversen et al. 2016 ).", [["O", "CHEMICAL", 151, 152], ["human", "ORGANISM", 39, 44], ["HSV-1", "ORGANISM", 81, 86], ["HSV-2", "ORGANISM", 88, 93], ["VZV", "ORGANISM", 95, 98], ["HCMV", "ORGANISM", 100, 104], ["EBV", "ORGANISM", 109, 112], ["homologous proteins", "PROTEIN", 175, 194], ["human", "SPECIES", 39, 44], ["HSV-1", "SPECIES", 81, 86], ["human herpesviruses", "SPECIES", 39, 58], ["HSV-1", "SPECIES", 81, 86], ["HSV-2", "SPECIES", 88, 93], ["VZV", "SPECIES", 95, 98], ["HCMV", "SPECIES", 100, 104], ["EBV", "SPECIES", 109, 112], ["Large scale glycoproteomic analyses", "PROBLEM", 0, 35], ["human herpesviruses", "PROBLEM", 39, 58], ["varying phylogeny", "TEST", 62, 79], ["HSV", "TEST", 81, 84], ["HSV", "TEST", 88, 91], ["VZV", "PROBLEM", 95, 98], ["HCMV", "PROBLEM", 100, 104], ["human herpesviruses", "OBSERVATION_MODIFIER", 39, 58]]], ["Comparison of O-glycosite conservation between alphaherpesviruses HSV-1 and HSV-2 suggests that sequence homology is an important determinant for O-glycosylation in closely related viruses ( Figure 1A and F).", [["O", "CHEMICAL", 146, 147], ["O-glycosite", "SIMPLE_CHEMICAL", 14, 25], ["alphaherpesviruses", "ORGANISM", 47, 65], ["HSV-1", "ORGANISM", 66, 71], ["HSV-2", "ORGANISM", 76, 81], ["HSV-1", "SPECIES", 66, 71], ["HSV-1", "SPECIES", 66, 71], ["HSV-2", "SPECIES", 76, 81], ["alphaherpesviruses HSV", "TEST", 47, 69], ["HSV", "TEST", 76, 79], ["glycosylation", "PROBLEM", 148, 161]]], ["Isolated homologous glycosites were mainly situated on highly homologous peptide stretches, whereas densely spaced glycosites in Pro/Ser/Thr-rich regions were glycosylated irrespective of low sequence identity, as expected .", [["Pro", "CHEMICAL", 129, 132], ["Ser", "CHEMICAL", 133, 136], ["Thr", "CHEMICAL", 137, 140], ["glycosites", "GENE_OR_GENE_PRODUCT", 20, 30], ["glycosites", "GENE_OR_GENE_PRODUCT", 115, 125], ["Ser", "AMINO_ACID", 133, 136], ["Thr", "AMINO_ACID", 137, 140], ["Pro/Ser/Thr-rich regions", "DNA", 129, 153], ["Isolated homologous glycosites", "PROBLEM", 0, 30], ["densely spaced glycosites", "PROBLEM", 100, 125], ["Pro/Ser/Thr-rich regions", "TREATMENT", 129, 153], ["homologous glycosites", "OBSERVATION", 9, 30], ["Thr", "ANATOMY", 137, 140]]], ["Several glycoproteins are homologous between all herpesviruses, including gB, gH, gL, gM and gN, of which gB, gH and gL comprise the conserved cell entry machinery (McGeoch et al. 2006) .", [["cell", "ANATOMY", 143, 147], ["herpesviruses", "ORGANISM", 49, 62], ["gB", "GENE_OR_GENE_PRODUCT", 74, 76], ["gH", "GENE_OR_GENE_PRODUCT", 78, 80], ["gL", "GENE_OR_GENE_PRODUCT", 82, 84], ["gM", "GENE_OR_GENE_PRODUCT", 86, 88], ["gN", "GENE_OR_GENE_PRODUCT", 93, 95], ["gB", "GENE_OR_GENE_PRODUCT", 106, 108], ["gH", "GENE_OR_GENE_PRODUCT", 110, 112], ["gL", "GENE_OR_GENE_PRODUCT", 117, 119], ["cell", "CELL", 143, 147], ["gB", "PROTEIN", 74, 76], ["gH", "PROTEIN", 78, 80], ["gL", "PROTEIN", 82, 84], ["gM", "PROTEIN", 86, 88], ["gN", "PROTEIN", 93, 95], ["gB", "PROTEIN", 106, 108], ["gH", "PROTEIN", 110, 112], ["gL", "PROTEIN", 117, 119], ["Several glycoproteins", "TREATMENT", 0, 21], ["glycoproteins", "OBSERVATION", 8, 21], ["gB", "ANATOMY", 74, 76], ["gN", "OBSERVATION", 93, 95], ["gB", "ANATOMY", 106, 108]]], ["We identified a large number of O-glycosites on HSV-1 fusogenic effector gB, and predicted that a number of O-glycosites could be conserved in most, if not all, human herpesviruses ( Figure 1A -C) .", [["HSV-1", "ORGANISM", 48, 53], ["gB", "GENE_OR_GENE_PRODUCT", 73, 75], ["O-glycosites", "SIMPLE_CHEMICAL", 108, 120], ["human", "ORGANISM", 161, 166], ["Figure 1A -C", "CELL", 183, 195], ["O-glycosites", "PROTEIN", 32, 44], ["HSV-1 fusogenic effector gB", "PROTEIN", 48, 75], ["O-glycosites", "PROTEIN", 108, 120], ["human", "SPECIES", 161, 166], ["HSV-1", "SPECIES", 48, 53], ["human", "SPECIES", 161, 166], ["glycosites", "PROBLEM", 34, 44], ["HSV", "PROBLEM", 48, 51], ["large", "OBSERVATION_MODIFIER", 16, 21], ["number", "OBSERVATION_MODIFIER", 22, 28], ["gB", "ANATOMY", 73, 75]]], ["Based on multiple sequence alignments across investigated herpesvirus family members, enrichment of Oglycosylation was found in the extreme N-terminus of gB regardless of the underlying considerable sequence variation between different herpesviruses.", [["N", "CHEMICAL", 140, 141], ["herpesvirus", "ORGANISM", 58, 69], ["gB", "GENE_OR_GENE_PRODUCT", 154, 156], ["herpesviruses", "ORGANISM", 236, 249], ["extreme N-terminus", "PROTEIN", 132, 150], ["gB", "PROTEIN", 154, 156], ["Oglycosylation", "TREATMENT", 100, 114], ["different herpesviruses", "PROBLEM", 226, 249], ["gB", "ANATOMY", 154, 156], ["different herpesviruses", "OBSERVATION", 226, 249]]], ["This suggests that glycosylation patches are less dependent on the underlying sequence, and might serve a glycan specific function, such as protection of the N-terminal exposed region of gB from proteolytic degradation or immune recognition.", [["N", "CHEMICAL", 158, 159], ["gB", "GENE_OR_GENE_PRODUCT", 187, 189], ["N-terminal exposed region", "PROTEIN", 158, 183], ["gB", "PROTEIN", 187, 189], ["glycosylation patches", "PROBLEM", 19, 40], ["the underlying sequence", "TEST", 63, 86], ["the N-terminal exposed region of gB", "PROBLEM", 154, 189], ["proteolytic degradation", "PROBLEM", 195, 218], ["immune recognition", "PROBLEM", 222, 240], ["glycosylation patches", "OBSERVATION", 19, 40], ["less dependent", "OBSERVATION_MODIFIER", 45, 59], ["gB", "ANATOMY", 187, 189]]], ["In contrast, conserved single glycosites were predominantly found between HSV-1, HSV-2, and, to a smaller extent, VZV, and suggest that they mainly exert subfamily-specific functions.", [["HSV-1", "ORGANISM", 74, 79], ["HSV-2", "ORGANISM", 81, 86], ["VZV", "ORGANISM", 114, 117], ["HSV-1", "SPECIES", 74, 79], ["HSV-1", "SPECIES", 74, 79], ["HSV-2", "SPECIES", 81, 86], ["VZV", "SPECIES", 114, 117], ["HSV", "TEST", 74, 77], ["HSV", "TEST", 81, 84], ["VZV", "PROBLEM", 114, 117], ["smaller extent", "OBSERVATION_MODIFIER", 98, 112], ["VZV", "OBSERVATION", 114, 117]]], ["The conserved protein gH, which is another essential component of the fusion machinery, was found glycosylated in four out of five investigated viruses.", [["gH", "GENE_OR_GENE_PRODUCT", 22, 24], ["gH", "PROTEIN", 22, 24], ["The conserved protein gH", "TEST", 0, 24], ["the fusion machinery", "TREATMENT", 66, 86], ["protein gH", "OBSERVATION", 14, 24], ["essential", "OBSERVATION_MODIFIER", 43, 52], ["component", "OBSERVATION_MODIFIER", 53, 62], ["fusion", "OBSERVATION", 70, 76], ["viruses", "OBSERVATION", 144, 151]]], ["Although no clear conserved pattern of glycosylation was observed, the O-glycosites were predominantly localized to the two exposed N-terminal domains involved in interaction with other viral proteins ( Figure 1D and E) .Global O-glycoproteomicsIn summary, global O-glycoproteomics of viruses open up possibilities to rapidly \"scan\" the proteome of viruses for O-glycan modifications.", [["O", "CHEMICAL", 71, 72], ["N", "CHEMICAL", 132, 133], ["O", "CHEMICAL", 361, 362], ["O-glycan", "SIMPLE_CHEMICAL", 361, 369], ["O-glycosites", "PROTEIN", 71, 83], ["N-terminal domains", "PROTEIN", 132, 150], ["viral proteins", "PROTEIN", 186, 200], ["Figure 1D and E", "PROTEIN", 203, 218], ["glycosylation", "PROBLEM", 39, 52], ["other viral proteins", "TEST", 180, 200], ["viruses", "PROBLEM", 285, 292], ["no", "UNCERTAINTY", 9, 11], ["viruses", "OBSERVATION", 349, 356]]], ["Although the occupancy and the relevance of the individual glycan sites are still unknown, the information can be used to follow up by complimentary techniques at individual protein and glycosite level.", [["the occupancy", "PROBLEM", 9, 22]]], ["It can be applied to any human virus of interest; given relevant propagation systems are available.", [["human", "ORGANISM", 25, 30], ["human", "SPECIES", 25, 30], ["human virus", "SPECIES", 25, 36]]], ["The method, of course, has its limitations, such as a limited number of glycoforms that can be captured, as well as the availability of protein sequences in the databases, which is challenging when analyzing emerging or poorly annotated viruses, as well as clinical isolates.", [["protein sequences", "TEST", 136, 153], ["the databases", "TEST", 157, 170], ["poorly annotated viruses", "PROBLEM", 220, 244]]], ["Ideally, a virus database compiling structural data, sequence variability, available glycomic and glycoproteomic data as well as antigenic sites could be created to advance basic and applied research in virology.", [["a virus database", "TEST", 9, 25], ["sequence variability", "TEST", 53, 73], ["glycomic and glycoproteomic data", "TEST", 85, 117], ["antigenic sites", "TREATMENT", 129, 144]]], ["If sufficient experimental data is compiled, machine learning bioinformatic techniques could be applied to predict glycosylation patterns of emerging viral strains within distinct virus species or even families.Roles of glycosylation in virus biologyGlycans on viral envelope glycoproteins play important roles in virus biology, with specific functions identified in various stages of viral infection (Table I and Figure 2 ).", [["viral infection", "DISEASE", 385, 400], ["Glycans", "GENE_OR_GENE_PRODUCT", 250, 257], ["Glycans", "PROTEIN", 250, 257], ["viral envelope glycoproteins", "PROTEIN", 261, 289], ["bioinformatic techniques", "TREATMENT", 62, 86], ["emerging viral strains", "PROBLEM", 141, 163], ["distinct virus species", "PROBLEM", 171, 193], ["glycosylation in virus biology", "TREATMENT", 220, 250], ["Glycans", "TREATMENT", 250, 257], ["viral envelope glycoproteins", "TREATMENT", 261, 289], ["viral infection", "PROBLEM", 385, 400], ["various stages", "OBSERVATION_MODIFIER", 367, 381], ["viral", "OBSERVATION_MODIFIER", 385, 390], ["infection", "OBSERVATION", 391, 400]]], ["As previously mentioned, glycosylation is generally required for progeny formation and infectivity for many viruses (Knowles and Person 1976; Leavitt et al. 1977; Olofsson and Lycke 1980; Herrler and Compans 1983; Lambert and Pons 1983; Mann et al. 1983; Kuhn et al. 1988; Li et al. 2006; Reszka et al. 2010; Mathys and Balzarini 2015; Shrivastava-Ranjan et al. 2016; Mossenta et al. 2017) .", [["progeny", "ANATOMY", 65, 72], ["glycosylation", "TREATMENT", 25, 38], ["progeny formation", "PROBLEM", 65, 82]]], ["In some cases, mature N-glycans in particular are necessary for proper viral particle formation and release (Datema et al. 1984) .", [["particle", "ANATOMY", 77, 85], ["N-glycans", "GENE_OR_GENE_PRODUCT", 22, 31], ["proper viral particle formation", "PROBLEM", 64, 95], ["viral particle", "OBSERVATION", 71, 85]]], ["As in human proteins, N-linked glycosylation is critical for proper folding of viral proteins (Land and Braakman 2001; Zai et al. 2013; Wu et al. 2017) , and, in some cases, viral protein secretion (Hu et al. 1995; Lu et al. 1997; Yoshii et al. 2013; Mossenta et al. 2017) .", [["N", "CHEMICAL", 22, 23], ["human", "ORGANISM", 6, 11], ["human proteins", "PROTEIN", 6, 20], ["viral proteins", "PROTEIN", 79, 93], ["human", "SPECIES", 6, 11], ["human", "SPECIES", 6, 11], ["viral proteins", "PROBLEM", 79, 93], ["viral protein secretion", "PROBLEM", 174, 197]]], ["Drugs targeting glycoprotein maturation and exhibiting a favorable therapeutic ratio can therefore be used to combat viral infections, where no other therapeutics are available (Miller et al. 2012 ).", [["viral infections", "DISEASE", 117, 133], ["Drugs", "TREATMENT", 0, 5], ["glycoprotein maturation", "PROBLEM", 16, 39], ["a favorable therapeutic ratio", "PROBLEM", 55, 84], ["viral infections", "PROBLEM", 117, 133], ["glycoprotein maturation", "OBSERVATION", 16, 39]]], ["Most importantly, N-and Olinked glycans shield immunodominant epitopes from immune recognition (Francica et al. 2010; Helle et al. 2011; Sommerstein et al. 2015; Behrens et al. 2016; Gram et al. 2016; Walls et al. 2016 ).", [["N", "CHEMICAL", 18, 19], ["immunodominant epitopes", "PROTEIN", 47, 70], ["Olinked glycans shield immunodominant epitopes", "TREATMENT", 24, 70], ["immune recognition", "PROBLEM", 76, 94]]], ["In addition to general functions, specific types of glycans on viral glycoproteins often affect receptor binding and cell fusion (Lin et al. 2003; Lozach et al. 2003; Gramberg et al. 2005; Davis et al. 2006; Miller et al. 2008; Chen et al. 2014; Phoenix et al. 2016; Wang et al. 2016) .", [["cell", "ANATOMY", 117, 121], ["cell", "CELL", 117, 121], ["viral glycoproteins", "PROTEIN", 63, 82], ["viral glycoproteins", "TREATMENT", 63, 82], ["receptor binding", "PROBLEM", 96, 112], ["cell fusion", "TREATMENT", 117, 128], ["cell fusion", "OBSERVATION", 117, 128]]], ["Moreover, it is becoming increasingly clear that distinct glycans play separate roles in various stages of the viral cycle (Goffard et al. 2005; Falkowska et al. 2007; Helle et al. 2010; Wang et al. 2013 Wang et al. , 2017 Lennemann et al. 2014; Bradel-Tretheway et al. 2015; Luo et al. 2015; Orlova et al. 2015; Wu et al. 2017) .", [["increasingly", "OBSERVATION_MODIFIER", 25, 37], ["clear", "OBSERVATION", 38, 43], ["distinct", "OBSERVATION_MODIFIER", 49, 57], ["glycans", "OBSERVATION", 58, 65]]], ["Some site-specific functions of viral glycosylation have been assigned for both N-and O-linked glycans mostly by site-directed mutagenesis studies.", [["N", "CHEMICAL", 80, 81], ["O", "CHEMICAL", 86, 87], ["O-linked glycans", "SIMPLE_CHEMICAL", 86, 102], ["Some site", "PROBLEM", 0, 9], ["viral glycosylation", "TREATMENT", 32, 51], ["linked glycans", "PROBLEM", 88, 102], ["directed mutagenesis studies", "TEST", 118, 146]]], ["Identified roles of glycans within various stages of the viral cycle will be discussed in the following sections.Attachment and entryA number of viruses, such as HCV, Dengue virus, Ebola virus, SARS coronavirus, West Nile virus, Rift Valley fever virus and Japanese encephalitis virus use N-linked glycans as attachment and entry receptors by interacting with cellular lectins DC-SIGN, L-SIGN, LSECtin, ASGP-R or mannose receptor (Becker et al. 1995; Lin et al. 2003; Lozach et al. 2003; Gramberg et al. 2005; Davis et al. 2006; Miller et al. 2008; Chen et al. 2014; Phoenix et al. 2016; Wang et al. 2016) .", [["sections", "ANATOMY", 104, 112], ["cellular", "ANATOMY", 360, 368], ["Dengue virus", "DISEASE", 167, 179], ["Ebola virus", "DISEASE", 181, 192], ["SARS coronavirus", "DISEASE", 194, 210], ["Rift Valley fever", "DISEASE", 229, 246], ["Japanese encephalitis", "DISEASE", 257, 278], ["N", "CHEMICAL", 289, 290], ["mannose", "CHEMICAL", 413, 420], ["HCV", "ORGANISM", 162, 165], ["Dengue virus", "ORGANISM", 167, 179], ["Ebola virus", "ORGANISM", 181, 192], ["SARS coronavirus", "ORGANISM", 194, 210], ["West Nile virus", "ORGANISM", 212, 227], ["Rift Valley fever virus", "ORGANISM", 229, 252], ["Japanese encephalitis virus", "ORGANISM", 257, 284], ["cellular", "CELL", 360, 368], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 377, 384], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 386, 392], ["LSECtin", "GENE_OR_GENE_PRODUCT", 394, 401], ["ASGP-R", "GENE_OR_GENE_PRODUCT", 403, 409], ["mannose receptor", "GENE_OR_GENE_PRODUCT", 413, 429], ["attachment and entry receptors", "PROTEIN", 309, 339], ["cellular lectins", "PROTEIN", 360, 376], ["DC", "PROTEIN", 377, 379], ["SIGN", "PROTEIN", 380, 384], ["L", "PROTEIN", 386, 387], ["SIGN", "PROTEIN", 388, 392], ["LSECtin", "PROTEIN", 394, 401], ["ASGP", "PROTEIN", 403, 407], ["R", "PROTEIN", 408, 409], ["mannose receptor", "PROTEIN", 413, 429], ["Dengue virus", "SPECIES", 167, 179], ["Ebola virus", "SPECIES", 181, 192], ["SARS coronavirus", "SPECIES", 194, 210], ["West Nile virus", "SPECIES", 212, 227], ["Rift Valley fever virus", "SPECIES", 229, 252], ["Japanese encephalitis virus", "SPECIES", 257, 284], ["HCV", "SPECIES", 162, 165], ["Dengue virus", "SPECIES", 167, 179], ["Ebola virus", "SPECIES", 181, 192], ["SARS coronavirus", "SPECIES", 194, 210], ["West Nile virus", "SPECIES", 212, 227], ["Rift Valley fever virus", "SPECIES", 229, 252], ["Japanese encephalitis virus", "SPECIES", 257, 284], ["the viral cycle", "TREATMENT", 53, 68], ["Attachment", "PROBLEM", 113, 123], ["viruses", "PROBLEM", 145, 152], ["HCV", "PROBLEM", 162, 165], ["Dengue virus", "PROBLEM", 167, 179], ["Ebola virus", "PROBLEM", 181, 192], ["SARS coronavirus", "PROBLEM", 194, 210], ["West Nile virus", "PROBLEM", 212, 227], ["Rift Valley fever virus", "PROBLEM", 229, 252], ["Japanese encephalitis virus", "PROBLEM", 257, 284], ["SIGN", "TEST", 380, 384], ["LSECtin", "TEST", 394, 401], ["glycans", "ANATOMY_MODIFIER", 20, 27], ["viral cycle", "OBSERVATION", 57, 68], ["viruses", "OBSERVATION", 145, 152]]], ["Mature N-glycans have been suggested to influence Lassa virus binding to cell entry receptor \u03b1-dystroglycan (Shrivastava-Ranjan et al. 2016 ).", [["cell", "ANATOMY", 73, 77], ["N-glycans", "GENE_OR_GENE_PRODUCT", 7, 16], ["Lassa virus", "ORGANISM", 50, 61], ["cell", "CELL", 73, 77], ["N-glycans", "PROTEIN", 7, 16], ["Lassa virus", "SPECIES", 50, 61], ["Mature N-glycans", "TREATMENT", 0, 16], ["Lassa virus binding", "PROBLEM", 50, 69]]], ["In addition, specific N-glycans on HIV-1 have been shown to affect CD4 receptor binding on T cells or regulate coreceptor usage (Nakayama et al. 1998; Pollakis et al. 2001; Francois and Balzarini 2011; Lombardi et al. 2015) .", [["T cells", "ANATOMY", 91, 98], ["HIV-1", "ORGANISM", 35, 40], ["CD4 receptor", "GENE_OR_GENE_PRODUCT", 67, 79], ["T cells", "CELL", 91, 98], ["N-glycans", "PROTEIN", 22, 31], ["CD4 receptor", "PROTEIN", 67, 79], ["T cells", "CELL_TYPE", 91, 98], ["HIV-1", "SPECIES", 35, 40], ["HIV-1", "SPECIES", 35, 40]]], ["Systemic functional analysis of HIV-1 gp160 potential N-glycosylation sites has identified a number of additional glycosites affecting infectivity ).", [["N", "CHEMICAL", 54, 55], ["HIV-1", "ORGANISM", 32, 37], ["gp160", "ORGANISM", 38, 43], ["HIV-1 gp160 potential N-glycosylation sites", "DNA", 32, 75], ["HIV-1", "SPECIES", 32, 37], ["HIV-1", "SPECIES", 32, 37], ["Systemic functional analysis", "TEST", 0, 28], ["HIV", "TEST", 32, 35], ["glycosylation sites", "PROBLEM", 56, 75]]], ["In addition, a certain N-glycan on HIV-1 gp41 was shown to have a consistent effect in several viral strains (Mathys and Balzarini 2014) .", [["HIV-1", "ORGANISM", 35, 40], ["gp41", "ORGANISM", 41, 45], ["HIV-1 gp41", "PROTEIN", 35, 45], ["HIV-1", "SPECIES", 35, 40], ["HIV-1", "SPECIES", 35, 40], ["HIV", "TEST", 35, 38], ["several viral strains", "PROBLEM", 87, 108], ["several", "OBSERVATION_MODIFIER", 87, 94], ["viral strains", "OBSERVATION", 95, 108]]], ["Specific sialylated N-glycans on VZV gB have been identified that are important for interaction with myelin-associated glycoprotein and crucial for cell-cell fusion (Suenaga et al. 2015) , and sialylation of virions in general was shown to affect entry of HSV-1 (Teuton and Brandt 2007) .", [["cell", "ANATOMY", 148, 152], ["cell", "ANATOMY", 153, 157], ["N-glycans", "GENE_OR_GENE_PRODUCT", 20, 29], ["VZV gB", "ORGANISM", 33, 39], ["myelin", "GENE_OR_GENE_PRODUCT", 101, 107], ["cell", "CELL", 148, 152], ["cell", "CELL", 153, 157], ["HSV-1", "ORGANISM", 256, 261], ["VZV gB", "PROTEIN", 33, 39], ["myelin-associated glycoprotein", "PROTEIN", 101, 131], ["VZV gB", "SPECIES", 33, 39], ["HSV-1", "SPECIES", 256, 261], ["VZV gB", "PROBLEM", 33, 39], ["myelin", "TEST", 101, 107], ["associated glycoprotein", "PROBLEM", 108, 131], ["cell-cell fusion", "TREATMENT", 148, 164], ["HSV", "TEST", 256, 259]]], ["Similarly, specific N-linked glycans on HSV-2 gB influenced viral entry (Luo et al. 2015 ).", [["N", "CHEMICAL", 20, 21], ["HSV-2 gB", "ORGANISM", 40, 48], ["N-linked glycans", "PROTEIN", 20, 36], ["HSV-2 gB", "PROTEIN", 40, 48], ["HSV-2 gB", "SPECIES", 40, 48], ["HSV", "TEST", 40, 43]]], ["An N-glycosylation site on IAV HA has also been shown to affect viral entry indirectly by modulating the avidity and specificity for sialosides (Wu et al. 2017 ).", [["IAV HA", "ORGANISM", 27, 33], ["N-glycosylation site", "PROTEIN", 3, 23], ["An N-glycosylation site", "PROBLEM", 0, 23], ["IAV HA", "PROBLEM", 27, 33], ["N-glycosylation", "OBSERVATION", 3, 18], ["IAV", "OBSERVATION", 27, 30]]], ["Finally, distinct putative N-glycosylation site mutations on HCV E1 and E2 resulted in diminished entry and altered CD81 binding (Goffard et al. 2005; Falkowska et al. 2007; Helle et al. 2010) .Attachment and entryIn contrast to the rather well documented roles of N-linked glycans, there are very few known examples, where specific O-glycans participate in virus-host interaction.", [["E2", "CHEMICAL", 72, 74], ["N", "CHEMICAL", 27, 28], ["N", "CHEMICAL", 265, 266], ["O", "CHEMICAL", 333, 334], ["HCV E1", "ORGANISM", 61, 67], ["E2", "GENE_OR_GENE_PRODUCT", 72, 74], ["CD81", "GENE_OR_GENE_PRODUCT", 116, 120], ["O-glycans", "GENE_OR_GENE_PRODUCT", 333, 342], ["N-glycosylation site", "DNA", 27, 47], ["CD81", "PROTEIN", 116, 120], ["N-linked glycans", "PROTEIN", 265, 281], ["O-glycans", "PROTEIN", 333, 342], ["HCV", "SPECIES", 61, 64], ["glycosylation site mutations", "PROBLEM", 29, 57], ["HCV E1 and E2", "TREATMENT", 61, 74], ["diminished entry", "PROBLEM", 87, 103], ["altered CD81 binding", "PROBLEM", 108, 128], ["diminished", "OBSERVATION_MODIFIER", 87, 97], ["entry", "OBSERVATION_MODIFIER", 98, 103], ["CD81 binding", "OBSERVATION", 116, 128]]], ["Among these, two sialylated Oglycans on HSV-1 gB have been identified that determine binding to cellular receptor paired immunoglobulin-like type 2 receptor \u03b1 residing on immune cells (Wang et al. 2009; Arii et al. 2010; Bagdonaite et al. 2015) .", [["cellular", "ANATOMY", 96, 104], ["immune cells", "ANATOMY", 171, 183], ["Oglycans", "GENE_OR_GENE_PRODUCT", 28, 36], ["HSV-1 gB", "ORGANISM", 40, 48], ["cellular", "CELL", 96, 104], ["immunoglobulin-like type 2 receptor \u03b1", "GENE_OR_GENE_PRODUCT", 121, 158], ["immune cells", "CELL", 171, 183], ["HSV-1 gB", "PROTEIN", 40, 48], ["cellular receptor paired immunoglobulin-like type 2 receptor \u03b1", "PROTEIN", 96, 158], ["immune cells", "CELL_TYPE", 171, 183], ["HSV-1", "SPECIES", 40, 45], ["HSV-1", "SPECIES", 40, 45], ["HSV", "TEST", 40, 43], ["cellular receptor paired immunoglobulin", "TEST", 96, 135]]], ["In addition, HSV-1 O-glycans are involved in a few other aspects of viral binding to the host cell, as deletion of the densely O-glycosylated region of attachment factor gC affects both the binding affinity to the cell surface, and the release of progeny virus via modulation of interactions with cell surface glycosaminoglycans (Altgarde et al. 2015) .", [["cell", "ANATOMY", 94, 98], ["cell surface", "ANATOMY", 214, 226], ["cell surface", "ANATOMY", 297, 309], ["O", "CHEMICAL", 127, 128], ["HSV-1", "ORGANISM", 13, 18], ["O-glycans", "GENE_OR_GENE_PRODUCT", 19, 28], ["host cell", "CELL", 89, 98], ["gC", "GENE_OR_GENE_PRODUCT", 170, 172], ["cell surface", "CELLULAR_COMPONENT", 214, 226], ["progeny virus", "ORGANISM", 247, 260], ["cell", "CELL", 297, 301], ["densely O-glycosylated region", "PROTEIN", 119, 148], ["attachment factor gC", "PROTEIN", 152, 172], ["HSV-1", "SPECIES", 13, 18], ["HSV", "TEST", 13, 16], ["viral binding", "PROBLEM", 68, 81], ["attachment factor gC affects", "PROBLEM", 152, 180], ["cell surface glycosaminoglycans", "TREATMENT", 297, 328], ["viral binding", "OBSERVATION", 68, 81], ["host cell", "OBSERVATION", 89, 98], ["densely", "OBSERVATION_MODIFIER", 119, 126]]], ["Another example includes the carbohydrate-dependent binding of filoviruses to the macrophage galactose lectin that is known to recognize GalNAc-O-glycans (Takada et al. 2004) .", [["carbohydrate", "CHEMICAL", 29, 41], ["galactose", "CHEMICAL", 93, 102], ["GalNAc", "CHEMICAL", 137, 143], ["O", "CHEMICAL", 144, 145], ["filoviruses", "GENE_OR_GENE_PRODUCT", 63, 74], ["macrophage", "CELL", 82, 92], ["galactose lectin", "GENE_OR_GENE_PRODUCT", 93, 109], ["GalNAc-O-glycans", "SIMPLE_CHEMICAL", 137, 153], ["filoviruses", "PROTEIN", 63, 74], ["macrophage galactose lectin", "PROTEIN", 82, 109], ["the macrophage galactose lectin", "TEST", 78, 109], ["GalNAc", "TEST", 137, 143]]], ["In hepatitis C virus, the mutation of several putative O-glycosites has also been shown to decrease HCV E2 affinity for CD81, suggesting that O-glycans might be of a more general importance in mediating interaction with host cells (Falkowska et al. 2007) .", [["cells", "ANATOMY", 225, 230], ["hepatitis C", "DISEASE", 3, 14], ["E2", "CHEMICAL", 104, 106], ["hepatitis C virus", "ORGANISM", 3, 20], ["O-glycosites", "SIMPLE_CHEMICAL", 55, 67], ["E2", "GENE_OR_GENE_PRODUCT", 104, 106], ["CD81", "GENE_OR_GENE_PRODUCT", 120, 124], ["O-glycans", "GENE_OR_GENE_PRODUCT", 142, 151], ["host cells", "CELL", 220, 230], ["O-glycosites", "PROTEIN", 55, 67], ["CD81", "PROTEIN", 120, 124], ["host cells", "CELL_TYPE", 220, 230], ["hepatitis C virus", "SPECIES", 3, 20], ["hepatitis C virus", "SPECIES", 3, 20], ["HCV", "SPECIES", 100, 103], ["hepatitis C virus", "PROBLEM", 3, 20], ["HCV E2 affinity", "PROBLEM", 100, 115], ["CD81", "PROBLEM", 120, 124], ["hepatitis", "OBSERVATION", 3, 12]]], ["O-glycoproteomic analysis of Hendra virus glycoprotein G has recently sprouted the first, to the best of our knowledge, systematic functional analysis of known O-glycosylation sites, revealing a multitude of functions including attachment and entry to host cells (Colgrave et al. 2012; Stone et al. 2016) .", [["cells", "ANATOMY", 257, 262], ["O", "CHEMICAL", 160, 161], ["Hendra virus", "ORGANISM", 29, 41], ["glycoprotein G", "GENE_OR_GENE_PRODUCT", 42, 56], ["host cells", "CELL", 252, 262], ["Hendra virus glycoprotein G", "PROTEIN", 29, 56], ["O-glycosylation sites", "PROTEIN", 160, 181], ["host cells", "CELL_TYPE", 252, 262], ["Hendra virus", "SPECIES", 29, 41], ["Hendra virus", "SPECIES", 29, 41], ["glycoproteomic analysis", "TEST", 2, 25], ["Hendra virus glycoprotein G", "TREATMENT", 29, 56], ["systematic functional analysis", "TEST", 120, 150], ["known O-glycosylation sites", "PROBLEM", 154, 181]]], ["Importantly, most of the functions could also be identified in analogous O-glycosites of a closely related Nipah virus (Stone et al. 2016) .", [["Nipah virus", "DISEASE", 107, 118], ["Nipah virus", "ORGANISM", 107, 118], ["Nipah virus", "SPECIES", 107, 118], ["Nipah virus", "SPECIES", 107, 118], ["glycosites", "PROBLEM", 75, 85], ["a closely related Nipah virus", "PROBLEM", 89, 118], ["Nipah virus", "OBSERVATION", 107, 118]]], ["Interestingly, only in Nipah virus a single O-glycosite significantly affected Ephrin B2 receptor binding (Stone et al. 2016 ).", [["O-glycosite", "CHEMICAL", 44, 55], ["O-glycosite", "CHEMICAL", 44, 55], ["Nipah virus", "ORGANISM", 23, 34], ["O-glycosite", "SIMPLE_CHEMICAL", 44, 55], ["Ephrin B2 receptor", "GENE_OR_GENE_PRODUCT", 79, 97], ["Ephrin B2 receptor", "PROTEIN", 79, 97], ["Nipah virus", "SPECIES", 23, 34], ["Nipah virus", "SPECIES", 23, 34], ["Nipah virus", "PROBLEM", 23, 34], ["Nipah virus", "OBSERVATION", 23, 34]]], ["This is an important example of conserved O-glycan function between closely related viruses, and presents intriguing possibilities in the light of recently identified consistent O-glycosylation patterns of several herpesviruses.", [["O", "CHEMICAL", 42, 43], ["O", "CHEMICAL", 178, 179], ["herpesviruses", "ORGANISM", 214, 227], ["closely related viruses", "PROBLEM", 68, 91], ["several herpesviruses", "PROBLEM", 206, 227], ["viruses", "OBSERVATION", 84, 91], ["several", "OBSERVATION_MODIFIER", 206, 213], ["herpesviruses", "OBSERVATION", 214, 227]]], ["Besides confirming the HSV-1 O-glycosites involved in binding PILR\u03b1 in vitro, a few other O-glycosites residing in protein regions expected to influence HSV-1 attachment via cell entry receptors nectin-1 and HVEM (Carfi et al. 2001; Krummenacher et al. 2005; Heldwein et al. 2006; Di Giovine et al. 2011; Gallagher et al. 2014) , or VZV attachment to receptor insulin degrading enzyme (Berarducci et al. 2010) were identified (Bagdonaite et al. 2015 .", [["cell", "ANATOMY", 174, 178], ["O", "CHEMICAL", 90, 91], ["HSV-1", "ORGANISM", 23, 28], ["PILR\u03b1", "GENE_OR_GENE_PRODUCT", 62, 67], ["HSV-1", "GENE_OR_GENE_PRODUCT", 153, 158], ["cell", "CELL", 174, 178], ["nectin-1", "GENE_OR_GENE_PRODUCT", 195, 203], ["HVEM", "GENE_OR_GENE_PRODUCT", 208, 212], ["VZV", "ORGANISM", 333, 336], ["insulin", "GENE_OR_GENE_PRODUCT", 360, 367], ["HSV-1 O-glycosites", "DNA", 23, 41], ["PILR\u03b1", "PROTEIN", 62, 67], ["O-glycosites", "PROTEIN", 90, 102], ["protein regions", "PROTEIN", 115, 130], ["nectin", "PROTEIN", 195, 201], ["HVEM", "PROTEIN", 208, 212], ["receptor insulin degrading enzyme", "PROTEIN", 351, 384], ["HSV-1", "SPECIES", 23, 28], ["HSV-1", "SPECIES", 153, 158], ["VZV", "SPECIES", 333, 336], ["the HSV", "TEST", 19, 26], ["glycosites", "PROBLEM", 31, 41], ["HSV", "TEST", 153, 156], ["nectin", "TEST", 195, 201], ["VZV attachment to receptor insulin", "TREATMENT", 333, 367]]], ["This is another example how MS-based approaches combined with structural knowledge can help narrow down a list of O-glycosite candidates for focused studies.", [["O", "CHEMICAL", 114, 115], ["O-glycosite", "SIMPLE_CHEMICAL", 114, 125], ["focused studies", "TEST", 141, 156]]], ["In conclusion, glycans on viral entry proteins are widely used for modulation of receptor binding and entry, with both N-linked and O-linked glycans having the capacity to affect the interaction (Figure 2, top left panel) .", [["N", "CHEMICAL", 119, 120], ["O", "CHEMICAL", 132, 133], ["viral entry proteins", "PROTEIN", 26, 46], ["N-linked and O-linked glycans", "PROTEIN", 119, 148], ["viral entry proteins", "TEST", 26, 46], ["receptor binding", "PROBLEM", 81, 97], ["the capacity", "PROBLEM", 156, 168]]], ["In some cases, though, it seems to be an effect of conformational stability, rather than direct interaction (Stone et al. 2016 ).Assembly and exitSpecific N-glycosites have been identified, that are important for glycoprotein secretion and viral particle formation in some viruses, including Zika virus, hepatitis viruses B and C (HBV and HCV), HSV-2 and HIV-1 (Fournillier et al. 2001; Falkowska et al. 2007; Helle et al. 2010; Ito et al. 2010; Wang et al. 2013; Luo et al. 2015; Mossenta et al. 2017) .", [["hepatitis viruses B", "DISEASE", 304, 323], ["glycoprotein", "GENE_OR_GENE_PRODUCT", 213, 225], ["Zika virus", "ORGANISM", 292, 302], ["hepatitis viruses B and C (HBV", "ORGANISM", 304, 334], ["HCV", "ORGANISM", 339, 342], ["HSV-2", "ORGANISM", 345, 350], ["HIV-1", "ORGANISM", 355, 360], ["exitSpecific N-glycosites", "PROTEIN", 142, 167], ["glycoprotein", "PROTEIN", 213, 225], ["Zika virus", "SPECIES", 292, 302], ["HSV-2", "SPECIES", 345, 350], ["HIV-1", "SPECIES", 355, 360], ["Zika virus", "SPECIES", 292, 302], ["hepatitis viruses", "SPECIES", 304, 321], ["HBV", "SPECIES", 331, 334], ["HCV", "SPECIES", 339, 342], ["HSV-2", "SPECIES", 345, 350], ["HIV-1", "SPECIES", 355, 360], ["exitSpecific N-glycosites", "PROBLEM", 142, 167], ["glycoprotein secretion", "PROBLEM", 213, 235], ["viral particle formation", "PROBLEM", 240, 264], ["some viruses", "PROBLEM", 268, 280], ["Zika virus", "PROBLEM", 292, 302], ["hepatitis viruses B and C (HBV", "PROBLEM", 304, 334], ["HCV", "TEST", 339, 342], ["HSV", "TEST", 345, 348], ["HIV", "PROBLEM", 355, 358], ["viral particle", "OBSERVATION", 240, 254], ["some viruses", "OBSERVATION", 268, 280], ["hepatitis viruses", "OBSERVATION", 304, 321]]], ["A few N-glycosites on influenza A virus neuraminidase have been shown to affect protein activity and viral particle release (Wu et al. 2017) .", [["influenza A virus", "ORGANISM", 22, 39], ["neuraminidase", "ORGANISM", 40, 53], ["influenza A virus neuraminidase", "SPECIES", 22, 53], ["influenza A virus", "SPECIES", 22, 39], ["A few N-glycosites", "PROBLEM", 0, 18], ["influenza A virus neuraminidase", "PROBLEM", 22, 53], ["few", "OBSERVATION_MODIFIER", 2, 5]]], ["Also, it is well documented that N-linked glycosylation of alphaherpesvirus envelope proteins is required for trafficking to the cell surface and viral particle egress (Norrild and Pedersen 1982; Montalvo et al. 1985; Luo et al. 2015; Suenaga et al. 2015) .", [["cell surface", "ANATOMY", 129, 141], ["N", "CHEMICAL", 33, 34], ["alphaherpesvirus envelope proteins", "GENE_OR_GENE_PRODUCT", 59, 93], ["cell surface", "CELLULAR_COMPONENT", 129, 141], ["alphaherpesvirus envelope proteins", "PROTEIN", 59, 93], ["alphaherpesvirus envelope proteins", "TREATMENT", 59, 93], ["viral particle", "OBSERVATION", 146, 160]]], ["In particular, complex-type N-glycans are required for robust egress ).", [["N-glycans", "GENE_OR_GENE_PRODUCT", 28, 37], ["complex-type N-glycans", "TREATMENT", 15, 37]]], ["In varicella zoster virus the role of potential O-glycosylation sites has also been addressed by site-directed mutagenesis.", [["varicella zoster", "DISEASE", 3, 19], ["O", "CHEMICAL", 48, 49], ["varicella zoster virus", "ORGANISM", 3, 25], ["O-glycosylation sites", "DNA", 48, 69], ["varicella zoster virus", "SPECIES", 3, 25], ["varicella zoster virus", "SPECIES", 3, 25], ["varicella zoster virus", "PROBLEM", 3, 25], ["potential O-glycosylation sites", "TREATMENT", 38, 69], ["varicella", "OBSERVATION", 3, 12], ["zoster virus", "OBSERVATION", 13, 25]]], ["Several glycosites were found to affect cell surface expression of the protein.", [["cell surface", "ANATOMY", 40, 52], ["cell", "CELL", 40, 44], ["Several glycosites", "PROBLEM", 0, 18], ["glycosites", "OBSERVATION", 8, 18]]], ["However, such an approach is too laborious for analysis of all potential O-glycosylation sites, given the lack of conserved sequence motifs for O-glycosylation (Suenaga et al. 2015) .", [["O", "CHEMICAL", 73, 74], ["O", "CHEMICAL", 144, 145], ["O-glycosylation sites", "DNA", 73, 94], ["analysis", "TEST", 47, 55], ["all potential O-glycosylation sites", "PROBLEM", 59, 94]]], ["As a more targeted approach, site-directed mutagenesis of some of the O-glycosites on Hendra virus glycoprotein G, identified via an O-glycoproteomic approach, affected the incorporation of glycoprotein F into pseudotyped virions.", [["virions", "ANATOMY", 222, 229], ["O", "CHEMICAL", 70, 71], ["O", "CHEMICAL", 133, 134], ["Hendra virus", "ORGANISM", 86, 98], ["glycoprotein G", "GENE_OR_GENE_PRODUCT", 99, 113], ["glycoprotein F", "GENE_OR_GENE_PRODUCT", 190, 204], ["pseudotyped", "ORGANISM", 210, 221], ["O-glycosites", "PROTEIN", 70, 82], ["Hendra virus glycoprotein G", "PROTEIN", 86, 113], ["glycoprotein F", "PROTEIN", 190, 204], ["Hendra virus", "SPECIES", 86, 98], ["Hendra virus", "SPECIES", 86, 98], ["Hendra virus glycoprotein G", "TREATMENT", 86, 113], ["an O-glycoproteomic approach", "TREATMENT", 130, 158], ["pseudotyped virions", "PROBLEM", 210, 229], ["pseudotyped virions", "OBSERVATION", 210, 229]]], ["This suggests that the O-glycans might be required for protein-protein interaction (Stone et al. 2016) .", [["O", "CHEMICAL", 23, 24], ["O-glycans", "GENE_OR_GENE_PRODUCT", 23, 32], ["the O-glycans", "TREATMENT", 19, 32], ["protein-protein interaction", "PROBLEM", 55, 82]]], ["Similarly, in HIV gp120 O-glycosylation of a conserved threonine that is crucial for the association with gp41 has recently been shown to enhance infectivity and incorporation of gp120 into virions, though the virus maintains normal functionality in the absence of the O-glycan (Termini et al. 2017) .Assembly and exitIn conclusion, manipulation of glycans or glycosylation sites seems to affect both viruses that use direct budding and those using exocytosis.", [["virions", "ANATOMY", 190, 197], ["threonine", "CHEMICAL", 55, 64], ["threonine", "CHEMICAL", 55, 64], ["O", "CHEMICAL", 269, 270], ["HIV gp120", "ORGANISM", 14, 23], ["threonine", "AMINO_ACID", 55, 64], ["gp41", "GENE_OR_GENE_PRODUCT", 106, 110], ["gp120", "GENE_OR_GENE_PRODUCT", 179, 184], ["HIV gp120", "PROTEIN", 14, 23], ["gp41", "PROTEIN", 106, 110], ["gp120", "PROTEIN", 179, 184], ["glycosylation sites", "PROTEIN", 360, 379], ["HIV", "SPECIES", 14, 17], ["HIV", "SPECIES", 14, 17], ["HIV gp120 O-glycosylation", "TREATMENT", 14, 39], ["a conserved threonine", "TREATMENT", 43, 64], ["gp41", "PROBLEM", 106, 110], ["incorporation of gp120 into virions", "PROBLEM", 162, 197], ["the virus", "PROBLEM", 206, 215], ["manipulation of glycans", "TREATMENT", 333, 356], ["glycosylation sites", "PROBLEM", 360, 379], ["both viruses", "PROBLEM", 396, 408], ["direct budding", "PROBLEM", 418, 432], ["normal functionality", "OBSERVATION", 226, 246], ["viruses", "OBSERVATION", 401, 408]]], ["It is therefore likely that glycans affect many different aspects of viral particle formation (Figure 2 , bottom right panel), possibly through an indirect consequence of disrupted trafficking of glycoproteins that are required for virus formation (Stone et al. 2016; Mossenta et al. 2017 ).Viral spread and innate immunityDifferent viruses employ various spread mechanisms both systemically and within the site of infection, including cell-cell fusion, transmigration and neuroinvasion.", [["cell", "ANATOMY", 436, 440], ["cell", "ANATOMY", 441, 445], ["infection", "DISEASE", 415, 424], ["neuroinvasion", "DISEASE", 473, 486], ["cell", "CELL", 436, 440], ["cell", "CELL", 441, 445], ["glycoproteins", "PROTEIN", 196, 209], ["glycans affect", "PROBLEM", 28, 42], ["viral particle formation", "PROBLEM", 69, 93], ["bottom right panel", "TEST", 106, 124], ["disrupted trafficking of glycoproteins", "PROBLEM", 171, 209], ["virus formation", "PROBLEM", 232, 247], ["Viral spread", "PROBLEM", 291, 303], ["Different viruses", "PROBLEM", 323, 340], ["infection", "PROBLEM", 415, 424], ["cell-cell fusion", "TREATMENT", 436, 452], ["transmigration", "PROBLEM", 454, 468], ["neuroinvasion", "PROBLEM", 473, 486], ["therefore likely", "UNCERTAINTY", 6, 22], ["viral particle formation", "OBSERVATION", 69, 93], ["infection", "OBSERVATION", 415, 424], ["cell fusion", "OBSERVATION", 441, 452], ["transmigration", "OBSERVATION_MODIFIER", 454, 468], ["neuroinvasion", "OBSERVATION_MODIFIER", 473, 486]]], ["Viruses often take advantage of components of the innate immune system to target the cell type of interest at distant locations.", [["cell", "ANATOMY", 85, 89], ["cell", "CELL", 85, 89], ["Viruses", "PROBLEM", 0, 7], ["the innate immune system", "TREATMENT", 46, 70]]], ["Glycans play an important role in these mechanisms (Figure 2 , bottom left panel).", [["Glycans", "GENE_OR_GENE_PRODUCT", 0, 7], ["Glycans", "PROTEIN", 0, 7], ["Glycans", "TREATMENT", 0, 7]]], ["In the deadly Hendra virus the globular head region of glycoprotein G is important for binding to the entry receptors Ephrin B2/B3.", [["head region", "ANATOMY", 40, 51], ["Hendra virus", "ORGANISM", 14, 26], ["glycoprotein G", "GENE_OR_GENE_PRODUCT", 55, 69], ["Ephrin B2", "GENE_OR_GENE_PRODUCT", 118, 127], ["B3", "GENE_OR_GENE_PRODUCT", 128, 130], ["globular head region", "PROTEIN", 31, 51], ["glycoprotein G", "PROTEIN", 55, 69], ["entry receptors", "PROTEIN", 102, 117], ["Ephrin B2", "PROTEIN", 118, 127], ["B3", "PROTEIN", 128, 130], ["Hendra virus", "SPECIES", 14, 26], ["Hendra virus", "SPECIES", 14, 26], ["glycoprotein G", "TREATMENT", 55, 69], ["deadly", "OBSERVATION_MODIFIER", 7, 13], ["Hendra virus", "OBSERVATION", 14, 26], ["globular", "ANATOMY_MODIFIER", 31, 39], ["head", "ANATOMY", 40, 44], ["B3", "ANATOMY", 128, 130]]], ["Mutation of Nglycosylation sites in the globular head of glycoprotein G increased cell-cell fusion, whereas removal of a glycosite in the stalk region of Hendra glycoprotein G abolished cell-cell fusion (Bradel-Tretheway et al. 2015) .", [["head", "ANATOMY", 49, 53], ["cell", "ANATOMY", 82, 86], ["cell", "ANATOMY", 87, 91], ["stalk region", "ANATOMY", 138, 150], ["cell", "ANATOMY", 186, 190], ["cell", "ANATOMY", 191, 195], ["globular head of glycoprotein G", "GENE_OR_GENE_PRODUCT", 40, 71], ["cell", "CELL", 82, 86], ["cell", "CELL", 87, 91], ["Hendra glycoprotein G", "GENE_OR_GENE_PRODUCT", 154, 175], ["cell", "CELL", 186, 190], ["cell", "CELL", 191, 195], ["Nglycosylation sites", "DNA", 12, 32], ["glycoprotein G", "PROTEIN", 57, 71], ["stalk region", "PROTEIN", 138, 150], ["Hendra glycoprotein G", "PROTEIN", 154, 175], ["Mutation of Nglycosylation sites", "PROBLEM", 0, 32], ["glycoprotein G increased cell-cell fusion", "TREATMENT", 57, 98], ["removal", "TREATMENT", 108, 115], ["a glycosite in the stalk region", "TREATMENT", 119, 150], ["Hendra glycoprotein", "TREATMENT", 154, 173], ["cell-cell fusion", "TREATMENT", 186, 202], ["globular", "ANATOMY_MODIFIER", 40, 48], ["head", "ANATOMY", 49, 53], ["increased cell-cell fusion", "OBSERVATION", 72, 98], ["stalk", "ANATOMY_MODIFIER", 138, 143], ["cell fusion", "OBSERVATION", 191, 202]]], ["In case of O-glycans, however, removal of distinct O-glycosites within a cluster in the stalk region resulted in both hypo-and hyperfusogenic phenotypes (Stone et al. 2016) , and neither N-nor O-glycosite mutants exhibited impaired receptor binding (Bradel-Tretheway et al. 2015; Stone et al. 2016) .", [["stalk region", "ANATOMY", 88, 100], ["O", "CHEMICAL", 11, 12], ["O", "CHEMICAL", 51, 52], ["N", "CHEMICAL", 187, 188], ["O", "CHEMICAL", 193, 194], ["O-glycans", "SIMPLE_CHEMICAL", 11, 20], ["O-glycosite", "SIMPLE_CHEMICAL", 193, 204], ["O-glycosites", "PROTEIN", 51, 63], ["O-glycosite mutants", "PROTEIN", 193, 212], ["removal", "TREATMENT", 31, 38], ["glycosites", "PROBLEM", 53, 63], ["a cluster in the stalk region", "PROBLEM", 71, 100], ["both hypo-and hyperfusogenic phenotypes", "PROBLEM", 113, 152], ["glycosite mutants", "PROBLEM", 195, 212], ["impaired receptor binding", "PROBLEM", 223, 248], ["distinct", "OBSERVATION_MODIFIER", 42, 50], ["hyperfusogenic phenotypes", "OBSERVATION", 127, 152], ["Stone", "OBSERVATION", 154, 159]]], ["This suggests that glycans influence other aspects of membrane fusion; possibly by affecting the thermodynamics of conformational changes.", [["membrane", "ANATOMY", 54, 62], ["membrane", "CELLULAR_COMPONENT", 54, 62], ["membrane fusion", "TREATMENT", 54, 69], ["conformational changes", "PROBLEM", 115, 137], ["glycans", "OBSERVATION", 19, 26], ["membrane fusion", "OBSERVATION", 54, 69]]], ["The impact of N-glycans in viral spread has also been demonstrated in in vivo models.", [["N-glycans", "CHEMICAL", 14, 23], ["N-glycans", "GENE_OR_GENE_PRODUCT", 14, 23], ["N-glycans in viral spread", "TREATMENT", 14, 39], ["viral spread", "OBSERVATION", 27, 39]]], ["Interestingly, the glycosylation status of West Nile virus glycoproteins has been associated with neuroinvasiveness, where abolishment of glycosites led to attenuation (Whiteman et al. 2010) .", [["West Nile virus", "ORGANISM", 43, 58], ["West Nile virus glycoproteins", "PROTEIN", 43, 72], ["Nile virus", "SPECIES", 48, 58], ["West Nile virus", "SPECIES", 43, 58], ["West Nile virus glycoproteins", "TREATMENT", 43, 72], ["neuroinvasiveness", "PROBLEM", 98, 115]]], ["Similarly, loss of a N-glycosite on Ross River virus glycoprotein E1 was associated with milder pathogenesis and increased virus clearance in a disease mouse model (Nelson et al. 2016 ).", [["Ross River virus", "ORGANISM", 36, 52], ["glycoprotein E1", "GENE_OR_GENE_PRODUCT", 53, 68], ["mouse", "ORGANISM", 152, 157], ["N-glycosite", "PROTEIN", 21, 32], ["glycoprotein E1", "PROTEIN", 53, 68], ["mouse", "SPECIES", 152, 157], ["Ross River virus", "SPECIES", 36, 52], ["mouse", "SPECIES", 152, 157], ["loss of a N-glycosite", "PROBLEM", 11, 32], ["Ross River virus glycoprotein E1", "TREATMENT", 36, 68], ["milder pathogenesis", "PROBLEM", 89, 108], ["increased virus clearance", "PROBLEM", 113, 138], ["a disease mouse model", "PROBLEM", 142, 163], ["loss", "OBSERVATION_MODIFIER", 11, 15], ["milder", "OBSERVATION_MODIFIER", 89, 95], ["pathogenesis", "OBSERVATION", 96, 108], ["increased", "OBSERVATION_MODIFIER", 113, 122], ["virus clearance", "OBSERVATION", 123, 138]]], ["Finally, specific N-glycosylation patterns on both HA and NA on avian influenza A virus are required for efficient transmission in mammalian models (Park et al. 2016) .", [["NA", "CHEMICAL", 58, 60], ["N", "CHEMICAL", 18, 19], ["HA", "GENE_OR_GENE_PRODUCT", 51, 53], ["avian influenza A virus", "ORGANISM", 64, 87], ["avian influenza A virus", "SPECIES", 64, 87], ["A virus", "SPECIES", 80, 87], ["glycosylation patterns", "PROBLEM", 20, 42], ["both HA", "PROBLEM", 46, 53], ["NA on avian influenza A virus", "PROBLEM", 58, 87]]], ["A more direct role of glycans emerges from the viral exploitation of innate immune receptors as a helping hand during establishing the viral infection.", [["hand", "ANATOMY", 106, 110], ["viral infection", "DISEASE", 135, 150], ["hand", "ORGANISM_SUBDIVISION", 106, 110], ["innate immune receptors", "PROTEIN", 69, 92], ["innate immune receptors", "TREATMENT", 69, 92], ["the viral infection", "PROBLEM", 131, 150], ["viral", "OBSERVATION_MODIFIER", 135, 140], ["infection", "OBSERVATION", 141, 150]]], ["Such innate immune receptors and other secreted glycan binding proteins present on infected host cells or antigen presenting cells are naturally the first line of defense against invading pathogens.", [["cells", "ANATOMY", 97, 102], ["antigen presenting cells", "ANATOMY", 106, 130], ["host cells", "CELL", 92, 102], ["antigen presenting cells", "CELL", 106, 130], ["innate immune receptors", "PROTEIN", 5, 28], ["secreted glycan binding proteins", "PROTEIN", 39, 71], ["infected host cells", "CELL_TYPE", 83, 102], ["antigen presenting cells", "CELL_TYPE", 106, 130], ["Such innate immune receptors", "TREATMENT", 0, 28], ["other secreted glycan binding proteins", "PROBLEM", 33, 71], ["infected host cells", "PROBLEM", 83, 102], ["antigen presenting cells", "PROBLEM", 106, 130], ["invading pathogens", "PROBLEM", 179, 197], ["host cells", "OBSERVATION", 92, 102]]], ["For instance, secreted Ctype lectins, ficolin-2 and mannose-binding lectin, inhibit HCV entry into hepatocytes (Brown et al. 2010; Zhao et al. 2014 ).", [["hepatocytes", "ANATOMY", 99, 110], ["mannose", "CHEMICAL", 52, 59], ["Ctype lectins", "GENE_OR_GENE_PRODUCT", 23, 36], ["ficolin-2", "GENE_OR_GENE_PRODUCT", 38, 47], ["mannose-binding lectin", "GENE_OR_GENE_PRODUCT", 52, 74], ["HCV", "ORGANISM", 84, 87], ["hepatocytes", "CELL", 99, 110], ["Ctype lectins", "PROTEIN", 23, 36], ["ficolin-2 and mannose-binding lectin", "PROTEIN", 38, 74], ["hepatocytes", "CELL_TYPE", 99, 110], ["HCV", "SPECIES", 84, 87], ["secreted Ctype lectins", "TEST", 14, 36], ["ficolin", "TEST", 38, 45], ["hepatocytes", "ANATOMY", 99, 110]]], ["However, these carbohydrate binding proteins can convey both protective and deleterious effects during viral infection, which are exploited by viruses to enter host cells.", [["cells", "ANATOMY", 165, 170], ["viral infection", "DISEASE", 103, 118], ["carbohydrate", "CHEMICAL", 15, 27], ["carbohydrate binding proteins", "GENE_OR_GENE_PRODUCT", 15, 44], ["host cells", "CELL", 160, 170], ["carbohydrate binding proteins", "PROTEIN", 15, 44], ["host cells", "CELL_TYPE", 160, 170], ["these carbohydrate binding proteins", "PROBLEM", 9, 44], ["viral infection", "PROBLEM", 103, 118], ["viral infection", "OBSERVATION", 103, 118], ["host cells", "OBSERVATION", 160, 170]]], ["For example, secreted galectin-1 promotes entry of Nipah virus into endothelial cells by bridging viral and cellular glycans, when the glycan binding proteins are present during initial phases of infection.", [["endothelial cells", "ANATOMY", 68, 85], ["cellular", "ANATOMY", 108, 116], ["infection", "DISEASE", 196, 205], ["galectin-1", "GENE_OR_GENE_PRODUCT", 22, 32], ["Nipah virus", "ORGANISM", 51, 62], ["endothelial cells", "CELL", 68, 85], ["cellular", "CELL", 108, 116], ["glycan binding proteins", "GENE_OR_GENE_PRODUCT", 135, 158], ["secreted galectin-1", "PROTEIN", 13, 32], ["endothelial cells", "CELL_TYPE", 68, 85], ["glycan binding proteins", "PROTEIN", 135, 158], ["Nipah virus", "SPECIES", 51, 62], ["Nipah virus", "SPECIES", 51, 62], ["secreted galectin", "TEST", 13, 30], ["Nipah virus into endothelial cells", "PROBLEM", 51, 85], ["bridging viral and cellular glycans", "PROBLEM", 89, 124], ["the glycan binding proteins", "PROBLEM", 131, 158], ["infection", "PROBLEM", 196, 205], ["Nipah virus", "OBSERVATION", 51, 62], ["endothelial cells", "OBSERVATION", 68, 85], ["cellular glycans", "OBSERVATION", 108, 124], ["infection", "OBSERVATION", 196, 205]]], ["In contrast, galectin-1 inhibits viral spread, when added postinfection (Garner et al. 2015) .", [["galectin-1", "GENE_OR_GENE_PRODUCT", 13, 23], ["galectin-1", "PROTEIN", 13, 23], ["galectin", "TEST", 13, 21], ["viral spread", "PROBLEM", 33, 45]]], ["Galectin-1 has also been shown to promote HIV-1 infection by crosslinking the viral particles and cell entry receptors, whereas influenza virus infection was inhibited (St-Pierre et al. 2011; Yang et al. 2011) .", [["cell", "ANATOMY", 98, 102], ["Galectin-1", "CHEMICAL", 0, 10], ["HIV-1 infection", "DISEASE", 42, 57], ["influenza virus infection", "DISEASE", 128, 153], ["Galectin-1", "GENE_OR_GENE_PRODUCT", 0, 10], ["HIV-1", "ORGANISM", 42, 47], ["cell", "CELL", 98, 102], ["influenza virus", "ORGANISM", 128, 143], ["Galectin-1", "PROTEIN", 0, 10], ["cell entry receptors", "PROTEIN", 98, 118], ["HIV-1", "SPECIES", 42, 47], ["influenza virus", "SPECIES", 128, 143], ["HIV-1", "SPECIES", 42, 47], ["Galectin", "TEST", 0, 8], ["HIV-1 infection", "PROBLEM", 42, 57], ["crosslinking the viral particles", "PROBLEM", 61, 93], ["cell entry receptors", "PROBLEM", 98, 118], ["influenza virus infection", "PROBLEM", 128, 153], ["infection", "OBSERVATION", 48, 57], ["viral particles", "OBSERVATION", 78, 93]]], ["As already mentioned, several viruses specifically use C-type lectin receptors for entry or transmission.", [["C-type lectin receptors", "GENE_OR_GENE_PRODUCT", 55, 78], ["C-type lectin receptors", "PROTEIN", 55, 78], ["several viruses", "PROBLEM", 22, 37], ["viruses", "OBSERVATION", 30, 37]]], ["Ebola virus utilizes an array of different C-type lectins, such as L-SIGN, DC-SIGN and LSECtin, for entry into various cell types (Lennemann et al. 2014) .", [["cell", "ANATOMY", 119, 123], ["Ebola", "DISEASE", 0, 5], ["Ebola virus", "ORGANISM", 0, 11], ["C-type lectins", "GENE_OR_GENE_PRODUCT", 43, 57], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 67, 73], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 75, 82], ["LSECtin", "GENE_OR_GENE_PRODUCT", 87, 94], ["cell", "CELL", 119, 123], ["C-type lectins", "PROTEIN", 43, 57], ["L", "PROTEIN", 67, 68], ["SIGN", "PROTEIN", 69, 73], ["DC", "PROTEIN", 75, 77], ["SIGN", "PROTEIN", 78, 82], ["LSECtin", "PROTEIN", 87, 94], ["Ebola virus", "SPECIES", 0, 11], ["Ebola virus", "SPECIES", 0, 11], ["Ebola virus", "PROBLEM", 0, 11], ["different C-type lectins", "PROBLEM", 33, 57], ["LSECtin", "TREATMENT", 87, 94]]], ["HIV-1 uses DC-SIGN on dendritic cells for migration to T cells (Hong et al. 2002) .", [["DC", "ANATOMY", 11, 13], ["dendritic cells", "ANATOMY", 22, 37], ["T cells", "ANATOMY", 55, 62], ["HIV-1", "ORGANISM", 0, 5], ["DC-SIGN", "CELL", 11, 18], ["dendritic cells", "CELL", 22, 37], ["T cells", "CELL", 55, 62], ["DC", "CELL_TYPE", 11, 13], ["SIGN", "PROTEIN", 14, 18], ["dendritic cells", "CELL_TYPE", 22, 37], ["T cells", "CELL_TYPE", 55, 62], ["HIV-1", "SPECIES", 0, 5], ["HIV-1", "SPECIES", 0, 5], ["HIV", "PROBLEM", 0, 3], ["dendritic cells", "PROBLEM", 22, 37], ["dendritic cells", "OBSERVATION", 22, 37]]], ["Although it is not entirely clear how the balance between antigen presentation and transmission is maintained, it has been proposed that homogeneous high-mannose type N-glycans enhance antigen presentation and virus degradation compared to intrinsically heterogeneous gp120 N-glycosylation (van Montfort et al. 2011) .", [["mannose", "CHEMICAL", 154, 161], ["antigen", "GENE_OR_GENE_PRODUCT", 58, 65], ["antigen", "GENE_OR_GENE_PRODUCT", 185, 192], ["virus degradation", "PROBLEM", 210, 227], ["not entirely", "UNCERTAINTY", 15, 27], ["clear", "OBSERVATION", 28, 33], ["homogeneous", "OBSERVATION_MODIFIER", 137, 148], ["high", "OBSERVATION_MODIFIER", 149, 153]]], ["Interestingly, HIV-1 has also been shown to exploit sialic-acid binding lectin Siglec-1 for more efficient entry into macrophages, likewise promoting the existence of complex-type N-glycans on viral particles (Zou et al. 2011) .", [["macrophages", "ANATOMY", 118, 129], ["sialic-acid", "CHEMICAL", 52, 63], ["sialic-acid", "CHEMICAL", 52, 63], ["HIV-1", "ORGANISM", 15, 20], ["sialic-acid binding lectin Siglec-1", "GENE_OR_GENE_PRODUCT", 52, 87], ["macrophages", "CELL", 118, 129], ["sialic-acid binding lectin Siglec-1", "PROTEIN", 52, 87], ["macrophages", "CELL_TYPE", 118, 129], ["HIV-1", "SPECIES", 15, 20], ["HIV-1", "SPECIES", 15, 20], ["sialic", "TEST", 52, 58], ["viral particles", "TREATMENT", 193, 208]]], ["In a similar context, we have demonstrated, VZV (Bagdonaite et al. 2016) , HCMV ) and EBV .", [["VZV", "ORGANISM", 44, 47], ["HCMV", "ORGANISM", 75, 79], ["EBV", "ORGANISM", 86, 89], ["VZV", "SPECIES", 44, 47], ["HCMV", "SPECIES", 75, 79], ["EBV", "SPECIES", 86, 89], ["VZV", "PROBLEM", 44, 47], ["HCMV", "PROBLEM", 75, 79], ["EBV", "PROBLEM", 86, 89], ["EBV", "ANATOMY", 86, 89]]], ["Protein backbones are depicted as broken black lines, where spaces represent gaps in the alignment.", [["broken black lines", "CELL_LINE", 34, 52], ["Protein backbones", "TREATMENT", 0, 17], ["broken black lines", "PROBLEM", 34, 52], ["backbones", "ANATOMY_MODIFIER", 8, 17], ["broken", "OBSERVATION_MODIFIER", 34, 40], ["black lines", "OBSERVATION", 41, 52], ["gaps", "OBSERVATION_MODIFIER", 77, 81], ["alignment", "OBSERVATION_MODIFIER", 89, 98]]], ["Individual alignments were drawn to scale (indicated below each graph).", [["Individual alignments", "TEST", 0, 21], ["scale", "TEST", 36, 41]]], ["Sequence conservation is indicated above the aligned sequences for each set, and is represented by a greyscale barcode that maps to the clustal alignment score, as shown in the legend.", [["aligned sequences", "DNA", 45, 62], ["greyscale barcode", "DNA", 101, 118], ["Sequence conservation", "TEST", 0, 21]]], ["In brief, for the clustal alignment score, an asterisk indicates positions with fully conserved residues, a colon indicates conservation of amino acids with strongly similar properties, whereas a period indicates conservation of amino acids with weakly similar properties.", [["colon", "ANATOMY", 108, 113], ["amino acids", "CHEMICAL", 140, 151], ["amino acids", "CHEMICAL", 229, 240], ["amino acids", "CHEMICAL", 140, 151], ["amino acids", "CHEMICAL", 229, 240], ["colon", "ORGAN", 108, 113], ["amino acids", "AMINO_ACID", 140, 151], ["amino acids", "AMINO_ACID", 229, 240], ["the clustal alignment score", "TEST", 14, 41], ["amino acids", "TREATMENT", 140, 151], ["amino acids", "TREATMENT", 229, 240], ["colon", "ANATOMY", 108, 113]]], ["Predicted signal peptides and transmembrane regions are shaded in pink and blue, respectively.", [["transmembrane", "ANATOMY", 30, 43], ["transmembrane regions", "PROTEIN", 30, 51], ["Predicted signal peptides and transmembrane regions", "PROBLEM", 0, 51], ["signal peptides", "OBSERVATION", 10, 25], ["transmembrane", "OBSERVATION_MODIFIER", 30, 43], ["regions", "OBSERVATION_MODIFIER", 44, 51], ["shaded", "OBSERVATION_MODIFIER", 56, 62], ["pink", "OBSERVATION_MODIFIER", 66, 70], ["blue", "OBSERVATION_MODIFIER", 75, 79]]], ["Unambiguous O-glycosylation sites are shown as yellow squares, whereas ambiguous sites are marked as yellow lines within the protein backbone, where the number below indicates the number of glycosites.", [["Unambiguous O-glycosylation sites", "TREATMENT", 0, 33], ["yellow squares", "PROBLEM", 47, 61], ["ambiguous sites", "PROBLEM", 71, 86], ["O-glycosylation sites", "OBSERVATION", 12, 33], ["marked", "OBSERVATION_MODIFIER", 91, 97], ["yellow lines", "OBSERVATION", 101, 113], ["backbone", "OBSERVATION_MODIFIER", 133, 141]]], ["An ambiguous O-glycosylation site from our previous publication (Bagdonaite et al. 2015 , HSV-1 gB 109-123 (HexHexNAc)) was omitted from the graph, as we cannot exclude the possibility it could be part of an elongated structure on an adjacent site.", [["site", "ANATOMY", 243, 247], ["HSV-1 gB 109-123", "CHEMICAL", 90, 106], ["O-", "CHEMICAL", 13, 15], ["An ambiguous O-glycosylation site", "PROBLEM", 0, 33], ["HSV", "TEST", 90, 93], ["gB", "TEST", 96, 98], ["an elongated structure on an adjacent site", "PROBLEM", 205, 247], ["elongated", "OBSERVATION_MODIFIER", 208, 217], ["structure", "OBSERVATION", 218, 227]]], ["Reference strain sequences were used for HSV-2, VZV and EBV due to incomplete or unavailable annotation of investigated strains.", [["HSV-2", "ORGANISM", 41, 46], ["VZV", "ORGANISM", 48, 51], ["EBV", "ORGANISM", 56, 59], ["HSV-2", "SPECIES", 41, 46], ["VZV", "SPECIES", 48, 51], ["EBV", "SPECIES", 56, 59], ["Reference strain sequences", "TEST", 0, 26], ["HSV", "TEST", 41, 44], ["VZV", "PROBLEM", 48, 51], ["EBV", "PROBLEM", 56, 59], ["investigated strains", "PROBLEM", 107, 127]]], ["HSV-1-human herpes simplex virus type 1 (strain 17), HSV-2-human herpes simplex virus type 2 (strain HG52), VZV-varicella-zoster virus (strain Dumas), HCMV-human cytomegalovirus (strain Towne), EBV-Epstein-Barr virus (strain AG876).Viral spread and innate immunityNiemann et al. Paramyxoviridae Pneumovirus (\u2212)ssRNA Lambert and Pons (1983) ; Gruber and Levine (1985) Gruber and Levine (1985) c Lambert and Pons (1983) Lambert Bernstein et al. (1994) that very early chemokine-mediated immune response to HSV-2 infection of the vaginal mucosa in mice relies on the presence of elongated O-linked glycans on the viral particles (Iversen et al. 2016) .", [["vaginal mucosa", "ANATOMY", 527, 541], ["herpes simplex", "DISEASE", 12, 26], ["herpes simplex virus", "DISEASE", 65, 85], ["VZV-varicella-zoster", "DISEASE", 108, 128], ["HCMV-human cytomegalovirus", "DISEASE", 151, 177], ["infection", "DISEASE", 510, 519], ["O", "CHEMICAL", 586, 587], ["HSV-1-", "ORGANISM", 0, 6], ["human herpes simplex virus type 1", "ORGANISM", 6, 39], ["strain 17", "ORGANISM", 41, 50], ["HSV-2-", "ORGANISM", 53, 59], ["human herpes simplex virus type 2", "ORGANISM", 59, 92], ["strain HG52", "ORGANISM", 94, 105], ["VZV-varicella-zoster virus", "ORGANISM", 108, 134], ["strain Dumas", "ORGANISM", 136, 148], ["HCMV", "ORGANISM", 151, 155], ["human", "ORGANISM", 156, 161], ["cytomegalovirus", "ORGANISM", 162, 177], ["strain Towne", "ORGANISM", 179, 191], ["EBV-Epstein-Barr virus", "ORGANISM", 194, 216], ["strain AG876", "ORGANISM", 218, 230], ["HSV-2", "ORGANISM", 504, 509], ["vaginal mucosa", "MULTI-TISSUE_STRUCTURE", 527, 541], ["mice", "ORGANISM", 545, 549], ["chemokine", "PROTEIN", 466, 475], ["O-linked glycans", "PROTEIN", 586, 602], ["HSV-1-", "SPECIES", 0, 6], ["human", "SPECIES", 6, 11], ["herpes simplex virus type 1", "SPECIES", 12, 39], ["HSV-2-", "SPECIES", 53, 59], ["human", "SPECIES", 59, 64], ["herpes simplex virus", "SPECIES", 65, 85], ["VZV-", "SPECIES", 108, 112], ["varicella-zoster virus", "SPECIES", 112, 134], ["HCMV-", "SPECIES", 151, 156], ["human", "SPECIES", 156, 161], ["cytomegalovirus", "SPECIES", 162, 177], ["Towne", "SPECIES", 186, 191], ["HSV-2", "SPECIES", 504, 509], ["mice", "SPECIES", 545, 549], ["HSV-1", "SPECIES", 0, 5], ["human herpes simplex virus type 1", "SPECIES", 6, 39], ["HSV-2-human herpes simplex virus type 2", "SPECIES", 53, 92], ["HG52", "SPECIES", 101, 105], ["VZV-varicella-zoster virus", "SPECIES", 108, 134], ["Dumas", "SPECIES", 143, 148], ["HCMV-human cytomegalovirus", "SPECIES", 151, 177], ["Towne", "SPECIES", 186, 191], ["EBV-Epstein-Barr virus", "SPECIES", 194, 216], ["HSV-2", "SPECIES", 504, 509], ["mice", "SPECIES", 545, 549], ["HSV", "TEST", 0, 3], ["human herpes simplex virus type", "TEST", 6, 37], ["strain", "TEST", 41, 47], ["HSV", "TEST", 53, 56], ["human herpes simplex virus type", "PROBLEM", 59, 90], ["strain HG52", "TEST", 94, 105], ["VZV", "PROBLEM", 108, 111], ["varicella", "PROBLEM", 112, 121], ["zoster virus (strain Dumas", "PROBLEM", 122, 148], ["HCMV", "PROBLEM", 151, 155], ["human cytomegalovirus (strain Towne", "PROBLEM", 156, 191], ["EBV", "PROBLEM", 194, 197], ["Barr virus", "PROBLEM", 206, 216], ["Viral spread", "PROBLEM", 232, 244], ["HSV", "PROBLEM", 504, 507], ["2 infection of the vaginal mucosa", "PROBLEM", 508, 541], ["elongated O-linked glycans", "PROBLEM", 576, 602], ["varicella", "ANATOMY", 112, 121], ["zoster virus", "OBSERVATION", 122, 134], ["Barr virus", "OBSERVATION", 206, 216], ["infection", "OBSERVATION", 510, 519], ["vaginal mucosa", "ANATOMY", 527, 541], ["viral particles", "OBSERVATION_MODIFIER", 610, 625]]], ["Although truncation of O-glycans might benefit the virus in escaping the early recognition by the host, elongated O-glycans are essential for viral replication (Bagdonaite et al. 2015; Iversen et al. 2016) .", [["O-glycans", "GENE_OR_GENE_PRODUCT", 23, 32], ["O-glycans", "GENE_OR_GENE_PRODUCT", 114, 123], ["O-glycans", "PROTEIN", 23, 32], ["truncation of O-glycans", "PROBLEM", 9, 32], ["the virus", "PROBLEM", 47, 56], ["viral replication", "PROBLEM", 142, 159]]], ["Various carbohydrate structures from many bacteria and parastic worms are known to elicit robust innate immune responses via toll-like and other receptors (Rabinovich and Toscano 2009; Prasanphanich et al. 2013) .", [["carbohydrate", "CHEMICAL", 8, 20], ["parastic worms", "ORGANISM", 55, 69], ["toll", "PROTEIN", 125, 129], ["worms", "SPECIES", 64, 69], ["Various carbohydrate structures", "PROBLEM", 0, 31], ["many bacteria and parastic worms", "PROBLEM", 37, 69], ["carbohydrate structures", "OBSERVATION", 8, 31], ["many", "OBSERVATION_MODIFIER", 37, 41], ["bacteria", "OBSERVATION", 42, 50]]], ["It is only conceivable that analogous carbohydrate-mediated mechanisms could exist for early detection of viral infections, but have not been described in detail.Adaptive immunityDuring evolution, the immune system has developed redundant and fine-tuned mechanisms to identify and eliminate invading pathogens, including viruses.", [["immune system", "ANATOMY", 201, 214], ["viral infections", "DISEASE", 106, 122], ["carbohydrate", "CHEMICAL", 38, 50], ["carbohydrate", "SIMPLE_CHEMICAL", 38, 50], ["analogous carbohydrate-mediated mechanisms", "PROBLEM", 28, 70], ["viral infections", "PROBLEM", 106, 122], ["Adaptive immunityDuring evolution", "TREATMENT", 162, 195], ["invading pathogens", "PROBLEM", 291, 309], ["viruses", "PROBLEM", 321, 328], ["viral", "OBSERVATION_MODIFIER", 106, 111], ["infections", "OBSERVATION", 112, 122]]], ["In turn, viruses continuously adapted to counteract or take advantage of the host's defense mechanisms, which is an ongoing battle.", [["viruses", "PROBLEM", 9, 16], ["viruses", "OBSERVATION", 9, 16]]], ["Glycans on viral glycoproteins have dual roles in virus-host interplay (Figure 2, top right panel) .", [["Glycans", "GENE_OR_GENE_PRODUCT", 0, 7], ["Glycans", "PROTEIN", 0, 7], ["viral glycoproteins", "PROTEIN", 11, 30], ["viral glycoproteins", "TREATMENT", 11, 30]]], ["On one hand, glycans can be part of the immune determinants themselves, but on the other hand glycans can mask the antigenic protein epitopes from recognition (Alexander and Elder 1984) .", [["antigenic protein epitopes", "PROTEIN", 115, 141]]], ["Accumulating structural evidence suggests that glycans cover large surface areas of viral envelope proteins providing steric hindrance and physical shielding of vulnerable sites Walls et al. 2016; Beniac and Booth 2017) .", [["surface", "ANATOMY", 67, 74], ["viral envelope proteins", "PROTEIN", 84, 107], ["Accumulating structural evidence", "PROBLEM", 0, 32], ["glycans", "PROBLEM", 47, 54], ["large surface areas", "PROBLEM", 61, 80], ["viral envelope proteins", "TREATMENT", 84, 107], ["steric hindrance", "TREATMENT", 118, 134], ["physical shielding of vulnerable sites", "TREATMENT", 139, 177], ["large", "OBSERVATION_MODIFIER", 61, 66], ["surface", "OBSERVATION_MODIFIER", 67, 74], ["viral envelope", "OBSERVATION", 84, 98]]], ["Both N-and O-linked glycans can mask immunogenic B-cell epitopes, and, in some cases also determine or influence immunogenicity (Sodora et al. 1989; Hobman et al. 1991; Fournillier et al. 2001; Falkowska et al. 2007; Helle et al. 2010; Wang et al. 2013; Bradel-Tretheway et al. 2015) .", [["B-cell", "ANATOMY", 49, 55], ["N", "CHEMICAL", 5, 6], ["O", "CHEMICAL", 11, 12], ["O-linked glycans", "SIMPLE_CHEMICAL", 11, 27], ["B-cell", "CELL", 49, 55], ["immunogenic B-cell epitopes", "PROTEIN", 37, 64], ["cell epitopes", "OBSERVATION", 51, 64]]], ["N-glycans covering structured domains and functional regions often confer protection from neutralization (Helle et al. 2010; Wang et al. 2013; Bradel-Tretheway et al. 2015; Wu et al. 2017) .", [["N-glycans", "GENE_OR_GENE_PRODUCT", 0, 9], ["glycans covering structured domains and functional regions", "PROBLEM", 2, 60]]], ["As an example, systemic functional analysis of N-glycosites in HCV revealed that protective N-linked glycans were mainly situated around the CD81 binding site on the HCV envelope glycoprotein E2 (Helle et al. 2010) .", [["N", "CHEMICAL", 92, 93], ["HCV", "ORGANISM", 63, 66], ["CD81", "GENE_OR_GENE_PRODUCT", 141, 145], ["N-glycosites", "PROTEIN", 47, 59], ["CD81 binding site", "DNA", 141, 158], ["HCV envelope glycoprotein E2", "PROTEIN", 166, 194], ["HCV", "SPECIES", 63, 66], ["HCV", "SPECIES", 166, 169], ["systemic functional analysis", "TEST", 15, 43], ["glycosites", "PROBLEM", 49, 59], ["HCV", "PROBLEM", 63, 66], ["protective N-linked glycans", "PROBLEM", 81, 108], ["CD81 binding", "OBSERVATION", 141, 153]]], ["In other cases, removal of specific N-linked glycans can alter the local antigenic landscape and broaden the immune response rather than simply uncovering underlying epitopes (Fournillier et al. 2001; Wang et al. 2013) .", [["N", "CHEMICAL", 36, 37], ["N-linked glycans", "PROTEIN", 36, 52], ["epitopes", "PROTEIN", 166, 174], ["removal", "TREATMENT", 16, 23], ["specific N-linked glycans", "TREATMENT", 27, 52]]], ["In contrast, mutation of seemingly unrelated N-glycosites can reduce the sensitivity to neutralization at distant epitopes , highlighting the role of N-glycans on maintaining protein structure.", [["N-glycosites", "CHEMICAL", 45, 57], ["N-glycans", "GENE_OR_GENE_PRODUCT", 150, 159], ["N-glycosites", "PROTEIN", 45, 57], ["N-glycans", "PROTEIN", 150, 159], ["glycosites", "TREATMENT", 47, 57], ["the sensitivity", "PROBLEM", 69, 84], ["neutralization at distant epitopes", "PROBLEM", 88, 122]]], ["In conclusion, mutation of potential N-glycosylation sites can result in unpredicted effects on protein (Table I) .", [["N", "CHEMICAL", 37, 38], ["N-glycosylation sites", "PROTEIN", 37, 58], ["Table I", "PROTEIN", 105, 112], ["potential N-glycosylation sites", "TREATMENT", 27, 58]]], ["The glycan chains presented on the generic viral particles are of illustrative manner and do not represent the glycoprofiles of individual viruses.", [["The glycan chains", "TREATMENT", 0, 17], ["individual viruses", "PROBLEM", 128, 146], ["glycan chains", "OBSERVATION", 4, 17]]], ["Likewise, the glycan structures shown to interact with specific glycan binding molecules represent the most likely type of structure (high mannose or complex type) based on known carbohydrate binding specificities, unless specified otherwise in individual studies defining the interactions or glycoprofiling/glycoproteomic studies of the viruses in question.", [["mannose", "CHEMICAL", 139, 146], ["carbohydrate", "CHEMICAL", 179, 191], ["mannose", "SIMPLE_CHEMICAL", 139, 146], ["glycan binding molecules", "PROTEIN", 64, 88], ["known carbohydrate binding specificities", "PROBLEM", 173, 213], ["individual studies", "TEST", 245, 263], ["glycoprofiling", "TREATMENT", 293, 307], ["glycoproteomic studies", "TEST", 308, 330], ["most likely type", "OBSERVATION_MODIFIER", 103, 119]]], ["In the bottom right panel, the viruses are grouped according to the predominant mode of exit within the individual families.", [["the viruses", "PROBLEM", 27, 38], ["bottom", "ANATOMY_MODIFIER", 7, 13], ["right", "ANATOMY_MODIFIER", 14, 19], ["panel", "ANATOMY", 20, 25], ["viruses", "OBSERVATION", 31, 38]]], ["Virus abbreviations as in Table I .", [["Virus", "ORGANISM", 0, 5], ["Virus abbreviations", "PROBLEM", 0, 19]]], ["Monosaccharide symbols follow the SNFG (Symbol Nomenclature for Glycans) system (PMID 26,543,186, Glycobiology 25: 1323 -1324 , 2015 .Adaptive immunityconformation and molecular dynamics, which differentially affect neutralization by antibodies, and are not explained solely by epitope recovery.", [["Monosaccharide", "CHEMICAL", 0, 14], ["SNFG", "DNA", 34, 38], ["antibodies", "PROTEIN", 234, 244], ["Monosaccharide symbols", "TEST", 0, 22], ["Adaptive immunityconformation", "TREATMENT", 134, 163]]], ["Site-specific N-glycosylation has also been reported to affect cellular immunity to HCV E1, where deletion of specific glycans enhanced recognition by cytotoxic T cells (Liu et al. 2007) .Adaptive immunityDense O-glycosylation of viral proteins has been widely described to provide \"bulk\" shielding from host immunity, and protect from antibody neutralization (Machiels et al. 2011; Kropff et al. 2012 ).", [["cellular", "ANATOMY", 63, 71], ["cytotoxic T cells", "ANATOMY", 151, 168], ["N", "CHEMICAL", 14, 15], ["cellular", "CELL", 63, 71], ["HCV E1", "ORGANISM", 84, 90], ["cytotoxic T cells", "CELL", 151, 168], ["cytotoxic T cells", "CELL_TYPE", 151, 168], ["viral proteins", "PROTEIN", 230, 244], ["HCV", "SPECIES", 84, 87], ["glycosylation", "TREATMENT", 16, 29], ["HCV E1", "TREATMENT", 84, 90], ["Adaptive immunity", "TREATMENT", 188, 205], ["Dense O-glycosylation of viral proteins", "PROBLEM", 205, 244], ["antibody neutralization", "TEST", 336, 359], ["glycosylation", "OBSERVATION", 213, 226], ["viral proteins", "OBSERVATION", 230, 244]]], ["Besides shielding select immunodominant epitopes (Machiels et al. 2011) , highly O-glycosylated mucin-like domains, such as those found in Ebola and Marburg viruses, have been suggested to physically hinder the interaction between virus-infected cells and immune cells (Francica et al. 2010; Noyori et al. 2013) .", [["cells", "ANATOMY", 246, 251], ["immune cells", "ANATOMY", 256, 268], ["mucin", "GENE_OR_GENE_PRODUCT", 96, 101], ["Ebola", "ORGANISM", 139, 144], ["Marburg viruses", "ORGANISM", 149, 164], ["cells", "CELL", 246, 251], ["immune cells", "CELL", 256, 268], ["immunodominant epitopes", "PROTEIN", 25, 48], ["O-glycosylated mucin-like domains", "PROTEIN", 81, 114], ["virus-infected cells", "CELL_TYPE", 231, 251], ["immune cells", "CELL_TYPE", 256, 268], ["Marburg viruses", "SPECIES", 149, 164], ["glycosylated mucin", "PROBLEM", 83, 101], ["Ebola", "PROBLEM", 139, 144], ["Marburg viruses", "PROBLEM", 149, 164], ["infected cells", "PROBLEM", 237, 251], ["immune cells", "PROBLEM", 256, 268]]], ["Conversely, the deletion of the Ebola virus mucin-like domain decreased the immune response in mice, although it did not have an effect on immunogenicity in vitro (Dowling et al. 2007 ).", [["Ebola virus", "ORGANISM", 32, 43], ["mucin", "GENE_OR_GENE_PRODUCT", 44, 49], ["mice", "ORGANISM", 95, 99], ["Ebola virus mucin-like domain", "PROTEIN", 32, 61], ["Ebola virus", "SPECIES", 32, 43], ["mice", "SPECIES", 95, 99], ["Ebola virus", "SPECIES", 32, 43], ["mice", "SPECIES", 95, 99], ["the Ebola virus mucin", "PROBLEM", 28, 49], ["immune response", "OBSERVATION", 76, 91]]], ["Finally, O-glycans not only shield, but in some cases can be presented as part of neo-epitopes when elongation of the glycans is prevented.", [["O-glycans", "GENE_OR_GENE_PRODUCT", 9, 18], ["O-glycans", "PROTEIN", 9, 18], ["O-glycans", "TREATMENT", 9, 18]]], ["As an example, several O-glycosylated immunodominant B-cell epitopes have been reported for HSV-2 and EBV, by probing O-glycopeptides with sera of infected patients, suggesting that the glycan moiety can be recognized by B-cells (Clo et al. 2012; D'Arrigo et al. 2013) .Adaptive immunityIn the context of epitope shielding and immune recognition of viruses, it might be of importance that RNA viruses, such as influenza virus, HIV-1 and HCV, intrinsically have a very high mutation rate, thus minimizing the effect of adaptive immune response (Sanjuan et al. 2010; Anjum et al. 2013; Lauring et al. 2013; Lynch et al. 2015) .", [["B-cell", "ANATOMY", 53, 59], ["sera", "ANATOMY", 139, 143], ["B-cells", "ANATOMY", 221, 228], ["influenza virus", "DISEASE", 410, 425], ["B-cell", "CELL", 53, 59], ["HSV-2", "ORGANISM", 92, 97], ["EBV", "ORGANISM", 102, 105], ["O-glycopeptides", "GENE_OR_GENE_PRODUCT", 118, 133], ["sera", "ORGANISM_SUBSTANCE", 139, 143], ["patients", "ORGANISM", 156, 164], ["B-cells", "CELL", 221, 228], ["influenza virus", "ORGANISM", 410, 425], ["HIV-1", "ORGANISM", 427, 432], ["HCV", "ORGANISM", 437, 440], ["O-glycosylated immunodominant B-cell epitopes", "PROTEIN", 23, 68], ["B-cells", "CELL_TYPE", 221, 228], ["patients", "SPECIES", 156, 164], ["influenza virus", "SPECIES", 410, 425], ["HIV-1", "SPECIES", 427, 432], ["HSV-2", "SPECIES", 92, 97], ["EBV", "SPECIES", 102, 105], ["influenza virus", "SPECIES", 410, 425], ["HIV-1", "SPECIES", 427, 432], ["HCV", "SPECIES", 437, 440], ["glycosylated immunodominant B-cell epitopes", "PROBLEM", 25, 68], ["HSV", "TEST", 92, 95], ["EBV", "PROBLEM", 102, 105], ["glycopeptides", "TREATMENT", 120, 133], ["the glycan moiety", "PROBLEM", 182, 199], ["Adaptive immunity", "TREATMENT", 270, 287], ["epitope shielding", "PROBLEM", 305, 322], ["immune recognition of viruses", "PROBLEM", 327, 356], ["RNA viruses", "PROBLEM", 389, 400], ["influenza virus", "PROBLEM", 410, 425], ["HIV", "PROBLEM", 427, 430], ["HCV", "PROBLEM", 437, 440], ["a very high mutation rate", "PROBLEM", 461, 486], ["adaptive immune response", "TREATMENT", 518, 542], ["cell epitopes", "OBSERVATION", 55, 68], ["epitope shielding", "OBSERVATION", 305, 322], ["viruses", "OBSERVATION", 349, 356], ["viruses", "OBSERVATION", 393, 400]]], ["Early on it was observed that the highest amino acid substitution rates occurred in antigenic regions of envelope glycoproteins, including such mutations that changed the number and position of glycosylation sites (Krystal et al. 1983; Skehel et al. 1984; Wei et al. 2003) .", [["amino acid", "CHEMICAL", 42, 52], ["amino acid", "CHEMICAL", 42, 52], ["amino acid", "AMINO_ACID", 42, 52], ["antigenic regions", "PROTEIN", 84, 101], ["envelope glycoproteins", "PROTEIN", 105, 127], ["glycosylation sites", "PROTEIN", 194, 213], ["the highest amino acid substitution rates", "TREATMENT", 30, 71], ["envelope glycoproteins", "TREATMENT", 105, 127], ["such mutations", "PROBLEM", 139, 153], ["glycosylation sites", "TREATMENT", 194, 213], ["acid substitution", "OBSERVATION", 48, 65], ["envelope glycoproteins", "OBSERVATION", 105, 127]]], ["Due to high density of glycans in such regions, some of the carbohydrate chains are not fully processed resulting in exposure of immature structures as seen in the mannose patch of HIV gp120 (Doores, Bonomelli et al. 2010) .", [["carbohydrate", "CHEMICAL", 60, 72], ["mannose", "CHEMICAL", 164, 171], ["carbohydrate chains", "GENE_OR_GENE_PRODUCT", 60, 79], ["HIV gp120", "ORGANISM", 181, 190], ["carbohydrate chains", "PROTEIN", 60, 79], ["HIV gp120", "PROTEIN", 181, 190], ["HIV", "SPECIES", 181, 184], ["HIV", "SPECIES", 181, 184], ["high density of glycans in such regions", "PROBLEM", 7, 46], ["the carbohydrate chains", "PROBLEM", 56, 79], ["immature structures", "PROBLEM", 129, 148], ["high", "OBSERVATION_MODIFIER", 7, 11], ["density", "OBSERVATION", 12, 19], ["glycans", "OBSERVATION", 23, 30], ["carbohydrate chains", "OBSERVATION", 60, 79], ["immature structures", "OBSERVATION", 129, 148]]], ["Paradoxically, such underprocessed structures are recognized by the immune system, giving rise to broad neutralizing antibodies (bnAbs), with the classical example being 2G12 .", [["immune system", "ANATOMY", 68, 81], ["neutralizing antibodies", "PROTEIN", 104, 127], ["bnAbs", "PROTEIN", 129, 134], ["2G12", "PROTEIN", 170, 174], ["Paradoxically, such underprocessed structures", "PROBLEM", 0, 45], ["broad neutralizing antibodies", "PROBLEM", 98, 127]]], ["In addition, highly conserved glycosylation sites that are directly involved in binding to cell entry receptors or viral interaction partners often become targeted by bnAbs (Rouvinski et al. 2015) .", [["cell", "ANATOMY", 91, 95], ["cell", "CELL", 91, 95], ["cell entry receptors", "PROTEIN", 91, 111], ["highly conserved glycosylation sites", "PROBLEM", 13, 49], ["glycosylation sites", "OBSERVATION", 30, 49]]], ["Interestingly, it has been demonstrated, that the recognition by such bnAbs is largely unaffected by deletion of individual N-glycans within the gp120 mannose patch, mimicking the consequences of intrinsic mutagenesis (Pritchard, Spencer et al. 2015) .", [["mannose", "CHEMICAL", 151, 158], ["bnAbs", "GENE_OR_GENE_PRODUCT", 70, 75], ["N-glycans", "GENE_OR_GENE_PRODUCT", 124, 133], ["bnAbs", "PROTEIN", 70, 75], ["N-glycans", "PROTEIN", 124, 133], ["gp120", "PROTEIN", 145, 150], ["individual N-glycans", "TREATMENT", 113, 133], ["the gp120 mannose patch", "TREATMENT", 141, 164], ["intrinsic mutagenesis", "TREATMENT", 196, 217]]], ["In some cases, however, mutations at distant glycosites may have subtle effects on epitope recognition (Behrens et al. 2016) .", [["mutations at distant glycosites", "PROBLEM", 24, 55]]], ["Similarly, antigenicity of the HBV surface antigen isoform S did not suffer from introduction of additional N-glycosylation sites, and even resulted in stronger and more persistent immune responses (Hyakumura et al. 2015) .", [["N", "CHEMICAL", 108, 109], ["HBV surface antigen", "GENE_OR_GENE_PRODUCT", 31, 50], ["HBV surface antigen isoform S", "PROTEIN", 31, 60], ["N-glycosylation sites", "PROTEIN", 108, 129], ["HBV", "SPECIES", 31, 34], ["the HBV surface antigen", "TEST", 27, 50], ["additional N-glycosylation sites", "TREATMENT", 97, 129]]], ["In contrast, arenaviruses represent very well adapted pathogens where glycan shield density inversely correlates with potency of neutralizing antibodies (Sommerstein et al. 2015) .", [["arenaviruses", "ORGANISM", 13, 25], ["neutralizing antibodies", "PROTEIN", 129, 152], ["arenaviruses", "PROBLEM", 13, 25], ["glycan shield density", "PROBLEM", 70, 91], ["neutralizing antibodies", "PROBLEM", 129, 152]]], ["However, in other instances, over-glycosylation of important functional regions of viral proteins result in better shielding from the immune system at a cost of binding affinity and virus production (Aguilar et al. 2006; Julithe et al. 2014; Lennemann et al. 2014; Lynch et al. 2015) .", [["viral proteins", "PROTEIN", 83, 97], ["viral proteins", "PROBLEM", 83, 97], ["the immune system", "PROBLEM", 130, 147], ["binding affinity", "PROBLEM", 161, 177], ["virus production", "PROBLEM", 182, 198], ["viral proteins", "OBSERVATION", 83, 97]]], ["As a compromise, variable glycosite occupancy can both fulfill the requirement for receptor binding via the nonglycosylated protein, and provide protection via the glycosylated counterpart (Julithe et al. 2014) .Adaptive immunityBeing the components of viral particles exposed to the extracellular environment, viral envelope glycoproteins serve as major targets for vaccine development; however, protein sequence variability within and across strains, high mutation rate, as well as enormous heterogeneity of glycan structures makes it very difficult to identify immunogens evoking universal reactivity.", [["extracellular", "ANATOMY", 284, 297], ["glycosite", "SIMPLE_CHEMICAL", 26, 35], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 284, 297], ["nonglycosylated protein", "PROTEIN", 108, 131], ["viral envelope glycoproteins", "PROTEIN", 311, 339], ["a compromise", "PROBLEM", 3, 15], ["variable glycosite occupancy", "PROBLEM", 17, 45], ["receptor binding", "PROBLEM", 83, 99], ["the nonglycosylated protein", "TREATMENT", 104, 131], ["Adaptive immunity", "TREATMENT", 212, 229], ["viral particles", "PROBLEM", 253, 268], ["viral envelope glycoproteins", "TREATMENT", 311, 339], ["vaccine development", "TREATMENT", 367, 386], ["protein sequence variability", "TEST", 397, 425], ["high mutation rate", "PROBLEM", 453, 471], ["enormous heterogeneity of glycan structures", "PROBLEM", 484, 527], ["universal reactivity", "PROBLEM", 583, 603], ["compromise", "OBSERVATION", 5, 15], ["viral particles", "OBSERVATION", 253, 268]]], ["Various expression systems are used for production of subunit vaccine candidates, such as bacteria, yeast, plant, insect and mammalian cell lines (Cox 2012; Kushnir et al. 2012; Redkiewicz et al. 2014) .", [["cell lines", "ANATOMY", 135, 145], ["yeast", "CELL", 100, 105], ["mammalian cell lines", "CELL", 125, 145], ["mammalian cell lines", "CELL_LINE", 125, 145], ["yeast", "SPECIES", 100, 105], ["yeast", "SPECIES", 100, 105], ["Various expression systems", "PROBLEM", 0, 26], ["subunit vaccine candidates", "TREATMENT", 54, 80], ["bacteria", "PROBLEM", 90, 98], ["yeast", "PROBLEM", 100, 105], ["mammalian cell lines", "TREATMENT", 125, 145], ["cell lines", "OBSERVATION", 135, 145]]], ["While some glycosylation types can be replicated in insect and mammalian cells, yeast cells will not carry out mucin type O-glycosylation and proteins produced in bacterial cells will also lack N-glycans.", [["cells", "ANATOMY", 73, 78], ["yeast cells", "ANATOMY", 80, 91], ["cells", "ANATOMY", 173, 178], ["mammalian cells", "CELL", 63, 78], ["yeast cells", "CELL", 80, 91], ["mucin", "GENE_OR_GENE_PRODUCT", 111, 116], ["bacterial cells", "CELL", 163, 178], ["N-glycans", "GENE_OR_GENE_PRODUCT", 194, 203], ["insect and mammalian cells", "CELL_TYPE", 52, 78], ["yeast cells", "CELL_TYPE", 80, 91], ["mucin type O-glycosylation and proteins", "PROTEIN", 111, 150], ["bacterial cells", "CELL_TYPE", 163, 178], ["N-glycans", "PROTEIN", 194, 203], ["yeast", "SPECIES", 80, 85], ["yeast", "SPECIES", 80, 85], ["some glycosylation types", "PROBLEM", 6, 30], ["mammalian cells", "PROBLEM", 63, 78], ["yeast cells", "PROBLEM", 80, 91], ["glycosylation and proteins", "TREATMENT", 124, 150], ["bacterial cells", "PROBLEM", 163, 178], ["bacterial cells", "OBSERVATION", 163, 178]]], ["Even mammalian expression systems may lack the required glycosyltransferase repertoire to glycosylate relevant sites and build up relevant structures.", [["glycosyltransferase repertoire", "PROTEIN", 56, 86], ["glycosyltransferase repertoire", "TREATMENT", 56, 86]]], ["Although there are many successful examples of vaccines produced in aforementioned systems, there is quite a number of infectious diseases that still lack vaccine coverage due to failure of vaccine candidates to induce adequate and lasting immune responses (Grimm and Ackerman 2013) .", [["vaccines", "TREATMENT", 47, 55], ["infectious diseases", "PROBLEM", 119, 138], ["lack vaccine coverage", "TREATMENT", 150, 171], ["failure of vaccine candidates", "PROBLEM", 179, 208], ["infectious", "OBSERVATION", 119, 129]]], ["Therefore, cell lines closer to the natural host cell type should be explored to more accurately reproduce the overall protein structure, modifications, and exposed antigenic sites for the primed immune system to be able to neutralize the naturally encountered antigen.", [["cell lines", "ANATOMY", 11, 21], ["cell", "ANATOMY", 49, 53], ["cell lines", "CELL", 11, 21], ["cell type", "CELL", 49, 58], ["cell lines", "CELL_LINE", 11, 21], ["cell lines", "TREATMENT", 11, 21], ["exposed antigenic sites", "TREATMENT", 157, 180], ["the primed immune system", "TREATMENT", 185, 209], ["cell lines", "OBSERVATION", 11, 21], ["host cell type", "OBSERVATION", 44, 58], ["protein structure", "OBSERVATION", 119, 136]]], ["In contrast to fast mutating RNA viruses, DNA viruses, including herpesviruses, have relatively stable genomes and rely on other means for counteracting the host's immune system (Sanjuan et al. 2010) .", [["DNA", "CELLULAR_COMPONENT", 42, 45], ["fast mutating RNA viruses", "PROBLEM", 15, 40], ["DNA viruses", "PROBLEM", 42, 53], ["herpesviruses", "PROBLEM", 65, 78], ["stable", "OBSERVATION_MODIFIER", 96, 102], ["genomes", "OBSERVATION", 103, 110]]], ["It is therefore conceivable, that vaccine development should be less challenging for DNA viruses.", [["DNA", "CELLULAR_COMPONENT", 85, 88], ["vaccine development", "TREATMENT", 34, 53], ["DNA viruses", "PROBLEM", 85, 96]]], ["However, most of herpesvirus-targeted subunit vaccines have failed so far.", [["herpesvirus", "ORGANISM", 17, 28], ["herpesvirus", "PROBLEM", 17, 28], ["targeted subunit vaccines", "TREATMENT", 29, 54]]], ["A recently developed HSV-2 vaccine lacking the main neutralizing antibody target is, however, showing great promise in mice.", [["HSV-2", "ORGANISM", 21, 26], ["mice", "ORGANISM", 119, 123], ["mice", "SPECIES", 119, 123], ["HSV-2", "SPECIES", 21, 26], ["mice", "SPECIES", 119, 123], ["HSV-2 vaccine", "TREATMENT", 21, 34], ["great", "OBSERVATION_MODIFIER", 102, 107], ["promise", "OBSERVATION_MODIFIER", 108, 115]]], ["This vaccine evokes production of non-neutralizing antibodies to other envelope glycoproteins on infected cells, stimulating cellular NK cell immunity through engagement of Fc\u03b3 receptors (Petro et al. 2015) .", [["cells", "ANATOMY", 106, 111], ["cellular NK cell", "ANATOMY", 125, 141], ["cells", "CELL", 106, 111], ["cellular NK cell", "CELL", 125, 141], ["Fc\u03b3 receptors", "GENE_OR_GENE_PRODUCT", 173, 186], ["non-neutralizing antibodies", "PROTEIN", 34, 61], ["envelope glycoproteins", "PROTEIN", 71, 93], ["infected cells", "CELL_TYPE", 97, 111], ["Fc\u03b3 receptors", "PROTEIN", 173, 186], ["This vaccine", "TREATMENT", 0, 12], ["non-neutralizing antibodies", "PROBLEM", 34, 61], ["envelope glycoproteins", "PROBLEM", 71, 93], ["infected cells", "TREATMENT", 97, 111], ["stimulating cellular NK cell immunity", "TREATMENT", 113, 150], ["infected cells", "OBSERVATION", 97, 111], ["cellular NK cell immunity", "OBSERVATION", 125, 150]]], ["In conclusion, glycans on viral envelope glycoproteins have a tremendous impact on recognition by the host, and glycosylation heterogeneity makes it very difficult to identify universal vaccine candidates.", [["viral envelope glycoproteins", "PROTEIN", 26, 54], ["viral envelope glycoproteins", "TREATMENT", 26, 54], ["glycosylation heterogeneity", "PROBLEM", 112, 139], ["universal vaccine candidates", "TREATMENT", 176, 204]]], ["While experimental evidence is key, development of accurate bioinformatic tools to predict glycosylation and likely mutation patterns would be of big value for vaccine research.", [["glycosylation", "TREATMENT", 91, 104], ["mutation patterns", "PROBLEM", 116, 133], ["vaccine research", "TREATMENT", 160, 176]]], ["This should become possible once a substantial number of viral strains are sequenced and analyzed for glycan modifications in native contexts.Roles of glycosylation on viral protein complex formationWhile N-linked glycans situated on structural domains often shield functionally important protein regions from antibody neutralization, stem region N-glycans can affect glycoprotein stability and proteinprotein interactions.", [["stem region", "ANATOMY", 335, 346], ["N", "CHEMICAL", 205, 206], ["glycoprotein", "GENE_OR_GENE_PRODUCT", 368, 380], ["proteinprotein", "GENE_OR_GENE_PRODUCT", 395, 409], ["viral protein complex", "PROTEIN", 168, 189], ["N-linked glycans", "PROTEIN", 205, 221], ["structural domains", "PROTEIN", 234, 252], ["protein regions", "PROTEIN", 289, 304], ["viral strains", "PROBLEM", 57, 70], ["glycan modifications in native contexts", "PROBLEM", 102, 141], ["glycosylation on viral protein complex", "PROBLEM", 151, 189], ["linked glycans", "PROBLEM", 207, 221], ["antibody neutralization", "TREATMENT", 310, 333], ["glycoprotein stability", "PROBLEM", 368, 390], ["proteinprotein interactions", "PROBLEM", 395, 422], ["viral strains", "OBSERVATION", 57, 70]]], ["For example, the mutations in the N-glycosite localized to the stem region of the Hendra virus glycoprotein G affected the conformation of the molecule, leading to increased oligomerization and interaction with its viral binding partner (Bradel-Tretheway et al. 2015) .", [["stem region", "ANATOMY", 63, 74], ["N-glycosite", "CHEMICAL", 34, 45], ["N", "CHEMICAL", 34, 35], ["Hendra virus", "ORGANISM", 82, 94], ["glycoprotein G", "GENE_OR_GENE_PRODUCT", 95, 109], ["N-glycosite", "PROTEIN", 34, 45], ["Hendra virus glycoprotein G", "PROTEIN", 82, 109], ["Hendra virus", "SPECIES", 82, 94], ["Hendra virus", "SPECIES", 82, 94], ["the mutations", "PROBLEM", 13, 26], ["the N-glycosite", "TREATMENT", 30, 45], ["the Hendra virus glycoprotein G", "TREATMENT", 78, 109], ["increased oligomerization", "PROBLEM", 164, 189], ["stem", "ANATOMY_MODIFIER", 63, 67], ["region", "ANATOMY_MODIFIER", 68, 74], ["Hendra virus", "ANATOMY", 82, 94], ["increased", "OBSERVATION_MODIFIER", 164, 173], ["oligomerization", "OBSERVATION", 174, 189]]], ["Moreover, the stalk mutation had similar effects in a closely related Nipah virus (Bradel-Tretheway et al. 2015) .", [["Nipah virus", "DISEASE", 70, 81], ["Nipah virus", "ORGANISM", 70, 81], ["Nipah virus", "SPECIES", 70, 81], ["Nipah virus", "SPECIES", 70, 81], ["the stalk mutation", "PROBLEM", 10, 28], ["a closely related Nipah virus", "PROBLEM", 52, 81], ["Nipah virus", "OBSERVATION", 70, 81]]], ["In Hepatitis C Virus, disruption of specific N-glycosites in the two highly N-glycosylated envelope glycoproteins E1 and E2 results in formation of unproductive E1-E2 heterodimers (Meunier et al. 1999; Goffard et al. 2005; Orlova et al. 2015) , whereas specific O-glycosites on Hendra virus protein G have been shown to affect association with protein F (Stone et al. 2016) , suggesting both types of glycans can carry out similar functions.", [["Hepatitis C Virus", "DISEASE", 3, 20], ["E2", "CHEMICAL", 121, 123], ["E2", "CHEMICAL", 164, 166], ["N", "CHEMICAL", 76, 77], ["Hepatitis C Virus", "ORGANISM", 3, 20], ["E2", "GENE_OR_GENE_PRODUCT", 121, 123], ["E1-E2", "GENE_OR_GENE_PRODUCT", 161, 166], ["O-glycosites", "SIMPLE_CHEMICAL", 262, 274], ["Hendra virus", "ORGANISM", 278, 290], ["protein G", "GENE_OR_GENE_PRODUCT", 291, 300], ["N-glycosites", "PROTEIN", 45, 57], ["N-glycosylated envelope glycoproteins", "PROTEIN", 76, 113], ["E1", "PROTEIN", 114, 116], ["E1", "PROTEIN", 161, 163], ["E2 heterodimers", "PROTEIN", 164, 179], ["O-glycosites", "PROTEIN", 262, 274], ["Hendra virus protein G", "PROTEIN", 278, 300], ["protein F", "PROTEIN", 344, 353], ["Hendra virus", "SPECIES", 278, 290], ["Hepatitis C Virus", "SPECIES", 3, 20], ["Hendra virus", "SPECIES", 278, 290], ["Hepatitis C Virus", "PROBLEM", 3, 20], ["disruption of specific N-glycosites", "PROBLEM", 22, 57], ["glycosylated envelope glycoproteins E1", "TREATMENT", 78, 116], ["unproductive E1-E2 heterodimers", "TREATMENT", 148, 179], ["glycosites", "PROBLEM", 264, 274], ["Hendra virus protein G", "TREATMENT", 278, 300], ["Hepatitis", "OBSERVATION", 3, 12], ["unproductive", "OBSERVATION_MODIFIER", 148, 160]]], ["Similarly, Oglycosites have been found in regions of varicella zoster virus gE, important for interaction with partner gI ), but the glycan specific functions are yet to be uncovered.Induction of host glycosylation machineryIn addition to hijacking host glycosylation machinery for modification of viral proteins, certain viruses induce changes in the expression levels of host glycosyltransferases.", [["varicella zoster", "DISEASE", 53, 69], ["Oglycosites", "GENE_OR_GENE_PRODUCT", 11, 22], ["varicella zoster virus gE", "ORGANISM", 53, 78], ["gI", "GENE_OR_GENE_PRODUCT", 119, 121], ["Oglycosites", "PROTEIN", 11, 22], ["gE", "PROTEIN", 76, 78], ["partner gI", "PROTEIN", 111, 121], ["viral proteins", "PROTEIN", 298, 312], ["host glycosyltransferases", "PROTEIN", 373, 398], ["varicella zoster virus", "SPECIES", 53, 75], ["varicella zoster virus gE", "SPECIES", 53, 78], ["Oglycosites", "PROBLEM", 11, 22], ["varicella zoster virus gE", "PROBLEM", 53, 78], ["host glycosylation machinery", "TREATMENT", 196, 224], ["hijacking host glycosylation machinery", "TREATMENT", 239, 277], ["viral proteins", "PROBLEM", 298, 312], ["certain viruses", "PROBLEM", 314, 329], ["host glycosyltransferases", "TREATMENT", 373, 398], ["varicella", "OBSERVATION_MODIFIER", 53, 62], ["zoster", "OBSERVATION", 63, 69], ["viral proteins", "OBSERVATION", 298, 312]]], ["For example, it is documented that herpesviruses induce expression of host fucosyltransferases leading to expression of sLe x or Le y antigens (Nystrom et al. 2007; Norden et al. 2013 Norden et al. , 2017 .", [["herpesviruses", "ORGANISM", 35, 48], ["fucosyltransferases", "GENE_OR_GENE_PRODUCT", 75, 94], ["sLe x", "GENE_OR_GENE_PRODUCT", 120, 125], ["Le y antigens", "GENE_OR_GENE_PRODUCT", 129, 142], ["host fucosyltransferases", "PROTEIN", 70, 94], ["sLe x", "PROTEIN", 120, 125], ["Le y antigens", "PROTEIN", 129, 142], ["host fucosyltransferases", "PROBLEM", 70, 94], ["sLe x or Le y antigens", "PROBLEM", 120, 142]]], ["In addition, HSV-1 and HSV-2 infection lead to changes in gene expression related to glycosphingolipid synthesis (Miyaji et al. 2016) .", [["infection", "DISEASE", 29, 38], ["HSV-1", "ORGANISM", 13, 18], ["HSV-2", "ORGANISM", 23, 28], ["glycosphingolipid", "SIMPLE_CHEMICAL", 85, 102], ["HSV-1", "SPECIES", 13, 18], ["HSV-2", "SPECIES", 23, 28], ["HSV-1", "SPECIES", 13, 18], ["HSV-2", "SPECIES", 23, 28], ["HSV", "TEST", 13, 16], ["HSV", "PROBLEM", 23, 26], ["2 infection", "PROBLEM", 27, 38], ["changes in gene expression", "PROBLEM", 47, 73], ["glycosphingolipid synthesis", "PROBLEM", 85, 112], ["infection", "OBSERVATION", 29, 38]]], ["Also, in the case of HCV, it has been demonstrated that the total glycoprofile of HCV-infected hepatoma cells was shifted towards more fucosylated, sialylated, and in general complex N-glycans .", [["hepatoma cells", "ANATOMY", 95, 109], ["HCV", "ORGANISM", 21, 24], ["HCV", "ORGANISM", 82, 85], ["hepatoma cells", "CELL", 95, 109], ["N-glycans", "GENE_OR_GENE_PRODUCT", 183, 192], ["HCV-infected hepatoma cells", "CELL_LINE", 82, 109], ["HCV", "SPECIES", 21, 24], ["HCV", "SPECIES", 82, 85], ["HCV", "PROBLEM", 21, 24], ["HCV", "PROBLEM", 82, 85], ["infected hepatoma cells", "PROBLEM", 86, 109], ["HCV", "OBSERVATION", 21, 24], ["infected", "OBSERVATION_MODIFIER", 86, 94], ["hepatoma cells", "OBSERVATION", 95, 109]]], ["Another example includes HBV that has been shown to upregulate mannosidases, which supports increased glycan processing ).", [["HBV", "ORGANISM", 25, 28], ["mannosidases", "GENE_OR_GENE_PRODUCT", 63, 75], ["mannosidases", "PROTEIN", 63, 75], ["HBV", "SPECIES", 25, 28], ["HBV", "PROBLEM", 25, 28], ["increased glycan processing", "PROBLEM", 92, 119], ["increased", "OBSERVATION_MODIFIER", 92, 101]]], ["In the case of influenza A virus, induction of the isoform, GalNAc-T3, has been detected in infected respiratory epithelial cells, possibly increasing O-glycosylation of airway mucins .", [["respiratory epithelial cells", "ANATOMY", 101, 129], ["airway mucins", "ANATOMY", 170, 183], ["influenza A virus", "DISEASE", 15, 32], ["GalNAc-T3", "CHEMICAL", 60, 69], ["GalNAc", "CHEMICAL", 60, 66], ["O", "CHEMICAL", 151, 152], ["influenza A virus", "ORGANISM", 15, 32], ["GalNAc-T3", "GENE_OR_GENE_PRODUCT", 60, 69], ["respiratory epithelial cells", "CELL", 101, 129], ["airway mucins", "GENE_OR_GENE_PRODUCT", 170, 183], ["infected respiratory epithelial cells", "CELL_TYPE", 92, 129], ["influenza A virus", "SPECIES", 15, 32], ["influenza A virus", "SPECIES", 15, 32], ["influenza A virus", "PROBLEM", 15, 32], ["GalNAc", "TEST", 60, 66], ["infected respiratory epithelial cells", "PROBLEM", 92, 129], ["airway mucins", "PROBLEM", 170, 183], ["influenza", "OBSERVATION", 15, 24], ["infected", "OBSERVATION_MODIFIER", 92, 100], ["respiratory epithelial cells", "OBSERVATION", 101, 129], ["possibly", "UNCERTAINTY", 131, 139], ["increasing", "OBSERVATION_MODIFIER", 140, 150], ["airway mucins", "OBSERVATION", 170, 183]]], ["The changes in expression levels of host carbohydrate active enzymes can either hint towards requirements for specific structures for functionality, or highlight the demand for increased glycosylation capacity to support viral glycoprotein glycosylation.PerspectivesIt has long been known that glycosylation of viral envelope proteins is essential for infectivity and affects immune recognition.", [["carbohydrate", "CHEMICAL", 41, 53], ["carbohydrate active enzymes", "GENE_OR_GENE_PRODUCT", 41, 68], ["carbohydrate active enzymes", "PROTEIN", 41, 68], ["viral glycoprotein", "PROTEIN", 221, 239], ["viral envelope proteins", "PROTEIN", 311, 334], ["The changes in expression levels", "PROBLEM", 0, 32], ["host carbohydrate active enzymes", "TEST", 36, 68], ["increased glycosylation capacity", "PROBLEM", 177, 209], ["viral glycoprotein glycosylation", "TREATMENT", 221, 253], ["glycosylation of viral envelope proteins", "TREATMENT", 294, 334], ["infectivity", "PROBLEM", 352, 363]]], ["Surprisingly, few clinical applications have been developed using this knowledge, and glycosylation has rarely been considered in vaccine design.", [["glycosylation", "TREATMENT", 86, 99], ["few", "OBSERVATION_MODIFIER", 14, 17]]], ["However, awareness is increasing and more and more studies are addressing the need of relevant glycosylation in vaccine formulations Go et al. 2017) .", [["relevant glycosylation in vaccine formulations", "TREATMENT", 86, 132], ["increasing", "OBSERVATION_MODIFIER", 22, 32]]], ["The rapidly evolving analytical methods now allow precise characterization of the location and structure of both N-and O-linked glycosylation on viruses.", [["N", "CHEMICAL", 113, 114], ["O", "CHEMICAL", 119, 120], ["rapidly", "OBSERVATION_MODIFIER", 4, 11]]], ["Likewise, the advancement of glycobiology and gene editing techniques offers ample opportunities to investigate the functional roles of glycan structures and specific sites.", [["glycobiology and gene editing techniques", "TREATMENT", 29, 69]]], ["Unreliable prediction of O-glycosylation have discouraged site-specific analysis of O-glycosylation in viruses, but now the structural information obtained by high throughput glycoproteomic approaches as well as bioinformatic analysis of glycosylation patterns can serve as a resource for defining targets for such studies.", [["O", "CHEMICAL", 25, 26], ["O", "CHEMICAL", 84, 85], ["glycosylation", "TREATMENT", 27, 40], ["specific analysis", "TEST", 63, 80], ["glycosylation in viruses", "PROBLEM", 86, 110], ["high throughput glycoproteomic approaches", "TREATMENT", 159, 200], ["bioinformatic analysis", "TEST", 212, 234], ["glycosylation patterns", "TREATMENT", 238, 260], ["such studies", "TEST", 310, 322]]], ["In addition, the knowledge base can be used for addressing the role of O-glycosylation for antigenicity and immunogenicity of subunit vaccine candidates.", [["O", "CHEMICAL", 71, 72], ["glycosylation", "TREATMENT", 73, 86], ["antigenicity", "PROBLEM", 91, 103], ["subunit vaccine candidates", "TREATMENT", 126, 152]]], ["Currently it is difficult to obtain site occupancy information at a proteome-wide scale, but soon this will be possible with optimized targeted glycoproteomics strategies.", [["targeted glycoproteomics strategies", "TREATMENT", 135, 170]]], ["Accumulating evidence suggest that O-glysosylation of viruses play important roles in various aspects of virus biology.", [["O", "CHEMICAL", 35, 36], ["O-glysosylation of viruses", "PROBLEM", 35, 61], ["viruses", "OBSERVATION", 54, 61]]], ["The advent of readily available and robust genome engineering tools provides opportunities to investigate these findings in more detail and map the structural requirements for O-glycan structures on the virus and potential interaction partners on epithelial cells by using glycoengineered cell libraries (Radhakrishnan et al. 2014; Yang et al. 2015) .", [["epithelial cells", "ANATOMY", 247, 263], ["cell", "ANATOMY", 289, 293], ["O", "CHEMICAL", 176, 177], ["epithelial cells", "CELL", 247, 263], ["glycoengineered cell", "CELL", 273, 293], ["epithelial cells", "CELL_TYPE", 247, 263], ["the virus", "PROBLEM", 199, 208], ["epithelial cells", "PROBLEM", 247, 263]]], ["The challenge is, however, to apply such knowledge for clinical purposes.PerspectivesSince viral glycosylation is orchestrated by the capacity of the host cell, general glycosylation inhibitors are of limited use due to toxicity.", [["cell", "ANATOMY", 155, 159], ["toxicity", "DISEASE", 220, 228], ["cell", "CELL", 155, 159], ["clinical purposes", "TEST", 55, 72], ["viral glycosylation", "TREATMENT", 91, 110], ["general glycosylation inhibitors", "TREATMENT", 161, 193], ["toxicity", "PROBLEM", 220, 228], ["viral glycosylation", "OBSERVATION", 91, 110], ["host cell", "OBSERVATION", 150, 159]]], ["It is therefore important to identify structural determinants of combinatorial self-and nonself-nature for safe targeting of viral glycans and boosting antiviral immunity.ConclusionsEnveloped viruses have long been known to hijack the host cell's glycosylation machinery for glycosylation of viral proteins.", [["cell", "ANATOMY", 240, 244], ["host cell", "CELL", 235, 244], ["viral proteins", "PROTEIN", 292, 306], ["viral glycans", "TREATMENT", 125, 138], ["boosting antiviral immunity", "TREATMENT", 143, 170], ["glycosylation machinery", "TREATMENT", 247, 270], ["viral proteins", "PROBLEM", 292, 306], ["viral proteins", "OBSERVATION", 292, 306]]], ["The development and advancement of mass spectrometry techniques have paid a tremendous contribution to the characterization of precise location and structure of glycans decorating the viral envelope proteins, and revealed substantial heterogeneity of glycan structures and site occupancy.", [["viral envelope proteins", "PROTEIN", 184, 207], ["advancement of mass spectrometry techniques", "TREATMENT", 20, 63], ["the viral envelope proteins", "TEST", 180, 207], ["substantial heterogeneity of glycan structures", "PROBLEM", 222, 268], ["site occupancy", "PROBLEM", 273, 287], ["mass", "OBSERVATION", 35, 39], ["tremendous", "OBSERVATION_MODIFIER", 76, 86], ["viral envelope", "OBSERVATION", 184, 198], ["substantial", "OBSERVATION_MODIFIER", 222, 233], ["heterogeneity", "OBSERVATION", 234, 247], ["glycan structures", "OBSERVATION", 251, 268], ["site occupancy", "OBSERVATION", 273, 287]]], ["Moreover, glycan density, as well as N-to Oglycan ratio, varies greatly among different classes of viruses, with some being highly glycosylated, and others having only a few glycan chains.", [["N-to Oglycan", "GENE_OR_GENE_PRODUCT", 37, 49], ["glycan chains", "PROTEIN", 174, 187], ["viruses", "PROBLEM", 99, 106], ["glycan density", "OBSERVATION", 10, 24], ["viruses", "OBSERVATION", 99, 106], ["highly", "OBSERVATION_MODIFIER", 124, 130], ["glycosylated", "OBSERVATION", 131, 143], ["few", "OBSERVATION_MODIFIER", 170, 173], ["glycan chains", "OBSERVATION", 174, 187]]], ["Accumulating site-directed mutagenesis data suggests that individual glycosites play diverse important roles in virus biology.", [["glycosites", "GENE_OR_GENE_PRODUCT", 69, 79], ["Accumulating site", "PROBLEM", 0, 17], ["directed mutagenesis data", "TEST", 18, 43], ["individual glycosites", "PROBLEM", 58, 79]]], ["Moreover, glycans heavily contribute to the overall structure of the glycoprotein, epitope accessibility, and, in some cases, directly affect immune recognition.", [["glycoprotein", "PROTEIN", 69, 81], ["epitope", "PROTEIN", 83, 90]]], ["While there are some examples where carbohydrate moieties directly participate in interactions, in many cases disrupted biological functions are results of impaired protein structure, localization or function.", [["carbohydrate", "CHEMICAL", 36, 48], ["carbohydrate moieties", "SIMPLE_CHEMICAL", 36, 57], ["carbohydrate moieties", "PROBLEM", 36, 57], ["impaired protein structure", "PROBLEM", 156, 182]]], ["Failure to develop universal vaccines for multiple viruses such as HIV-1, HCV and HSV suggest that comprehensive knowledge of structure and immunogenicity of viral envelope proteins in relevant biological systems is needed to achieve desired immune responses.", [["HIV-1", "ORGANISM", 67, 72], ["HCV", "ORGANISM", 74, 77], ["HSV", "ORGANISM", 82, 85], ["viral envelope proteins", "PROTEIN", 158, 181], ["HIV-1", "SPECIES", 67, 72], ["HIV-1", "SPECIES", 67, 72], ["HCV", "SPECIES", 74, 77], ["HSV", "SPECIES", 82, 85], ["Failure", "PROBLEM", 0, 7], ["universal vaccines", "TREATMENT", 19, 37], ["multiple viruses", "PROBLEM", 42, 58], ["HIV", "PROBLEM", 67, 70], ["HCV", "PROBLEM", 74, 77], ["HSV", "PROBLEM", 82, 85], ["viral envelope proteins", "PROBLEM", 158, 181], ["viruses", "OBSERVATION", 51, 58]]], ["While the location and function of N-linked glycans have been very well characterized for many viruses, discovery of O-glycosites has been neglected due to the nature of O-glycan synthesis and analytical difficulties.", [["O-glycosites", "CHEMICAL", 117, 129], ["N", "CHEMICAL", 35, 36], ["O", "CHEMICAL", 170, 171], ["O-glycosites", "SIMPLE_CHEMICAL", 117, 129], ["O-glycan", "SIMPLE_CHEMICAL", 170, 178], ["N-linked glycans", "PROTEIN", 35, 51], ["N-linked glycans", "PROBLEM", 35, 51], ["many viruses", "PROBLEM", 90, 102], ["glycosites", "PROBLEM", 119, 129], ["analytical difficulties", "PROBLEM", 193, 216], ["viruses", "OBSERVATION", 95, 102]]], ["We have developed techniques to globally address site-specific O-glycosylation of enveloped viruses and revealed unprecedented magnitude of O-glycosylation in herpesviruses.", [["O", "CHEMICAL", 63, 64], ["O", "CHEMICAL", 140, 141], ["herpesviruses", "ORGANISM", 159, 172], ["enveloped viruses", "PROBLEM", 82, 99], ["glycosylation in herpesviruses", "PROBLEM", 142, 172]]], ["We argue that the contribution of O-glycans needs to be addressed for vaccine development in order to have a complete picture of post-translational modifications affecting the protein function and immunogenicity.", [["O-glycans", "GENE_OR_GENE_PRODUCT", 34, 43], ["O-glycans", "TREATMENT", 34, 43], ["vaccine development", "TREATMENT", 70, 89], ["post-translational modifications", "PROBLEM", 129, 161]]], ["It is hoped that the data summarized in this review will ignite more interest in viral O-glycosylation, and give rise to focused studies leading to a better understanding of virus biology and improved means to prevent and combat the associated infections.", [["infections", "DISEASE", 244, 254], ["O", "CHEMICAL", 87, 88], ["glycosylation", "TREATMENT", 89, 102], ["focused studies", "TEST", 121, 136], ["the associated infections", "PROBLEM", 229, 254], ["infections", "OBSERVATION", 244, 254]]]], "59b270a8f43274cb9c68e16cac2ea6af110c452c": [["In vivo Luciferase Expression Live imaging displaying luciferase activity was taken using IVIS Lumina optical imaging system at 1, 3, 7, 15, and 41 weeks after lentiviral vector injection.", [["luciferase", "GENE_OR_GENE_PRODUCT", 54, 64], ["lentiviral", "ORGANISM", 160, 170], ["luciferase", "PROTEIN", 54, 64], ["Live imaging", "TEST", 30, 42], ["luciferase activity", "TEST", 54, 73], ["Lumina optical imaging system", "TEST", 95, 124], ["lentiviral vector injection", "TREATMENT", 160, 187]]], ["Images were displayed in luminescence surface radiance (p/sec/cm 2 /sr) with the color scale set at 5x10 4 -1x10 6 as minimum and maximum, respectively, with an exception in lower right panel where levels of luciferase expression in CC065 and CC013 were low and therefore low scale 1x10 4 -1x10 5 was used alongside with high scale 5x10 4 -1x10 6 .", [["luciferase", "GENE_OR_GENE_PRODUCT", 208, 218], ["CC065", "CELL", 233, 238], ["CC013", "CANCER", 243, 248], ["luciferase", "PROTEIN", 208, 218], ["CC065", "CELL_LINE", 233, 238], ["CC013", "CELL_LINE", 243, 248], ["Images", "TEST", 0, 6], ["luminescence surface radiance", "TEST", 25, 54], ["the color scale", "TEST", 77, 92], ["luciferase expression", "TEST", 208, 229], ["CC013", "TEST", 243, 248], ["lower", "ANATOMY_MODIFIER", 174, 179], ["right", "ANATOMY_MODIFIER", 180, 185], ["luciferase expression", "OBSERVATION", 208, 229], ["low", "OBSERVATION_MODIFIER", 254, 257], ["low", "OBSERVATION_MODIFIER", 272, 275]]], ["Liver-specific luciferase activity in the marked (red ellipse) regions of interest (ROI) was quantified.", [["Liver", "ANATOMY", 0, 5], ["Liver", "ORGAN", 0, 5], ["luciferase", "GENE_OR_GENE_PRODUCT", 15, 25], ["luciferase", "PROTEIN", 15, 25], ["specific", "OBSERVATION_MODIFIER", 6, 14], ["luciferase activity", "OBSERVATION", 15, 34], ["marked", "OBSERVATION_MODIFIER", 42, 48], ["red ellipse", "OBSERVATION", 50, 61]]], ["Pathology Assessment of Liver and Spleen H&E stained sections of liver and spleen tissues of six animals from four strains (CC028/GeniUnc, liver tissues from animals #1, and #2; CC013/GeniUnc, liver tissues from animals #1 and #5; CC024/GeniUnc, liver tissue from animal #1; CC035/Unc, spleen tissue from animal #5).", [["Liver", "ANATOMY", 24, 29], ["Spleen", "ANATOMY", 34, 40], ["sections", "ANATOMY", 53, 61], ["liver", "ANATOMY", 65, 70], ["spleen tissues", "ANATOMY", 75, 89], ["strains", "ANATOMY", 115, 122], ["GeniUnc", "ANATOMY", 130, 137], ["liver tissues", "ANATOMY", 139, 152], ["GeniUnc", "ANATOMY", 184, 191], ["liver tissues", "ANATOMY", 193, 206], ["GeniUnc", "ANATOMY", 237, 244], ["liver tissue", "ANATOMY", 246, 258], ["CC035/Unc", "ANATOMY", 275, 284], ["spleen tissue", "ANATOMY", 286, 299], ["Liver", "ORGAN", 24, 29], ["Spleen H&E", "MULTI-TISSUE_STRUCTURE", 34, 44], ["liver", "ORGAN", 65, 70], ["spleen tissues", "TISSUE", 75, 89], ["GeniUnc", "CELL", 130, 137], ["liver tissues", "TISSUE", 139, 152], ["CC013", "ORGANISM", 178, 183], ["GeniUnc", "CELL", 184, 191], ["liver tissues", "TISSUE", 193, 206], ["CC024", "ORGANISM", 231, 236], ["GeniUnc", "CELL", 237, 244], ["liver tissue", "TISSUE", 246, 258], ["CC035", "ORGANISM", 275, 280], ["Unc", "CELL", 281, 284], ["spleen tissue", "MULTI-TISSUE_STRUCTURE", 286, 299], ["Pathology Assessment", "TEST", 0, 20], ["four strains", "TEST", 110, 122], ["CC028", "TEST", 124, 129], ["CC013", "TEST", 178, 183], ["CC024", "TEST", 231, 236], ["CC035", "TEST", 275, 280], ["Liver", "ANATOMY", 24, 29], ["Spleen", "ANATOMY", 34, 40], ["liver", "ANATOMY", 65, 70], ["spleen", "ANATOMY", 75, 81], ["liver", "ANATOMY", 139, 144], ["liver", "ANATOMY", 193, 198], ["liver", "ANATOMY", 246, 251], ["spleen", "ANATOMY", 286, 292]]], ["Microscopic histopathological analysis revealed: CC028/GeniUnc#1, mononuclear chronic periportal infiltrate in the liver tissues; CC028/GeniUnc#2, mononuclear chronic periportal infiltrate in the liver tissues; CC013/GeniUnc#1, mononuclear chronic periportal infiltrate and granuloma with central hepatocellular death & area with eosinophilic droplets; CC013/GeniUnc#5, mononuclear chronic periportal infiltrate and presumed granuloma with central hepatocellular death; CC024/GeniUnc#1, mononuclear neoplasia-likely lymphoma or leukemia; CC035/Unc#5, likely mononuclear neoplasia (lymphoma) in spleen tissue.", [["periportal infiltrate", "ANATOMY", 86, 107], ["liver tissues", "ANATOMY", 115, 128], ["periportal infiltrate", "ANATOMY", 167, 188], ["liver tissues", "ANATOMY", 196, 209], ["periportal infiltrate", "ANATOMY", 248, 269], ["granuloma", "ANATOMY", 274, 283], ["hepatocellular", "ANATOMY", 297, 311], ["eosinophilic droplets", "ANATOMY", 330, 351], ["periportal infiltrate", "ANATOMY", 390, 411], ["granuloma", "ANATOMY", 425, 434], ["hepatocellular", "ANATOMY", 448, 462], ["mononuclear neoplasia", "ANATOMY", 487, 508], ["lymphoma", "ANATOMY", 516, 524], ["leukemia", "ANATOMY", 528, 536], ["mononuclear neoplasia", "ANATOMY", 558, 579], ["lymphoma", "ANATOMY", 581, 589], ["spleen tissue", "ANATOMY", 594, 607], ["granuloma", "DISEASE", 274, 283], ["hepatocellular death", "DISEASE", 297, 317], ["granuloma", "DISEASE", 425, 434], ["hepatocellular death", "DISEASE", 448, 468], ["mononuclear neoplasia-likely lymphoma", "DISEASE", 487, 524], ["leukemia", "DISEASE", 528, 536], ["mononuclear neoplasia", "DISEASE", 558, 579], ["lymphoma", "DISEASE", 581, 589], ["liver tissues", "TISSUE", 115, 128], ["GeniUnc#2", "CELL", 136, 145], ["liver tissues", "TISSUE", 196, 209], ["GeniUnc#1", "CELL", 217, 226], ["periportal infiltrate", "PATHOLOGICAL_FORMATION", 248, 269], ["granuloma", "PATHOLOGICAL_FORMATION", 274, 283], ["hepatocellular", "CANCER", 297, 311], ["granuloma", "PATHOLOGICAL_FORMATION", 425, 434], ["hepatocellular", "CANCER", 448, 462], ["mononuclear neoplasia-likely lymphoma", "CANCER", 487, 524], ["leukemia", "CANCER", 528, 536], ["mononuclear neoplasia", "CANCER", 558, 579], ["lymphoma", "CANCER", 581, 589], ["spleen tissue", "TISSUE", 594, 607], ["Microscopic histopathological analysis", "TEST", 0, 38], ["CC028", "TEST", 49, 54], ["GeniUnc", "TEST", 55, 62], ["mononuclear chronic periportal infiltrate in the liver tissues", "PROBLEM", 66, 128], ["CC028", "TEST", 130, 135], ["GeniUnc", "TEST", 136, 143], ["mononuclear chronic periportal infiltrate in the liver tissues", "PROBLEM", 147, 209], ["CC013", "TEST", 211, 216], ["GeniUnc", "TEST", 217, 224], ["mononuclear chronic periportal infiltrate", "PROBLEM", 228, 269], ["granuloma", "PROBLEM", 274, 283], ["central hepatocellular death", "PROBLEM", 289, 317], ["eosinophilic droplets", "PROBLEM", 330, 351], ["CC013", "TEST", 353, 358], ["mononuclear chronic periportal infiltrate", "PROBLEM", 370, 411], ["granuloma", "PROBLEM", 425, 434], ["central hepatocellular death", "PROBLEM", 440, 468], ["CC024", "TEST", 470, 475], ["GeniUnc", "TEST", 476, 483], ["mononuclear neoplasia", "PROBLEM", 487, 508], ["lymphoma", "PROBLEM", 516, 524], ["leukemia", "PROBLEM", 528, 536], ["mononuclear neoplasia (lymphoma) in spleen tissue", "PROBLEM", 558, 607], ["chronic", "OBSERVATION_MODIFIER", 78, 85], ["periportal", "ANATOMY", 86, 96], ["infiltrate", "OBSERVATION", 97, 107], ["liver", "ANATOMY", 115, 120], ["mononuclear", "OBSERVATION_MODIFIER", 147, 158], ["chronic", "OBSERVATION_MODIFIER", 159, 166], ["periportal", "ANATOMY", 167, 177], ["infiltrate", "OBSERVATION", 178, 188], ["liver", "ANATOMY", 196, 201], ["mononuclear", "OBSERVATION_MODIFIER", 228, 239], ["chronic", "OBSERVATION_MODIFIER", 240, 247], ["periportal", "ANATOMY", 248, 258], ["infiltrate", "OBSERVATION", 259, 269], ["granuloma", "OBSERVATION", 274, 283], ["central", "ANATOMY_MODIFIER", 289, 296], ["hepatocellular", "ANATOMY", 297, 311], ["eosinophilic droplets", "OBSERVATION", 330, 351], ["mononuclear", "OBSERVATION_MODIFIER", 370, 381], ["chronic", "OBSERVATION_MODIFIER", 382, 389], ["periportal", "ANATOMY", 390, 400], ["infiltrate", "OBSERVATION", 401, 411], ["presumed", "UNCERTAINTY", 416, 424], ["granuloma", "OBSERVATION", 425, 434], ["central", "OBSERVATION_MODIFIER", 440, 447], ["hepatocellular death", "OBSERVATION", 448, 468], ["mononuclear neoplasia", "OBSERVATION", 487, 508], ["likely", "UNCERTAINTY", 509, 515], ["lymphoma", "OBSERVATION", 516, 524], ["leukemia", "OBSERVATION", 528, 536], ["likely", "UNCERTAINTY", 551, 557], ["mononuclear neoplasia", "OBSERVATION", 558, 579], ["lymphoma", "OBSERVATION", 581, 589], ["spleen", "ANATOMY", 594, 600], ["tissue", "ANATOMY_MODIFIER", 601, 607]]], ["Sectioned images were taken using 200X and 400X magnifications, and displayed with scale bar in micron.", [["Sectioned images", "TEST", 0, 16]]], ["(1)", [["(1)", "CHEMICAL", 0, 3]]]]}